0001193125-23-142049.txt : 20230511 0001193125-23-142049.hdr.sgml : 20230511 20230511161831 ACCESSION NUMBER: 0001193125-23-142049 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IonQ, Inc. CENTRAL INDEX KEY: 0001824920 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 852992192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39694 FILM NUMBER: 23911323 BUSINESS ADDRESS: STREET 1: 4505 CAMPUS DRIVE CITY: COLLEGE PARK STATE: MD ZIP: 20740 BUSINESS PHONE: (301) 298-7997 MAIL ADDRESS: STREET 1: 4505 CAMPUS DRIVE CITY: COLLEGE PARK STATE: MD ZIP: 20740 FORMER COMPANY: FORMER CONFORMED NAME: dMY Technology Group, Inc. III DATE OF NAME CHANGE: 20200915 10-Q 1 d246263d10q.htm 10-Q 10-Q
Table of Contents
falseQ10001824920--12-31MDIncludes money market funds associated with the Company’s overnight investment sweep account and collateralizing letters of credit. 0001824920 2023-01-01 2023-03-31 0001824920 2022-01-01 2022-03-31 0001824920 2023-03-31 0001824920 2020-08-31 0001824920 2019-11-30 0001824920 2022-12-31 0001824920 2022-01-01 2022-12-31 0001824920 2023-05-04 0001824920 2021-09-01 2021-09-30 0001824920 2021-12-31 0001824920 2022-03-31 0001824920 ionq:BilledAccountsReceivableMember 2023-03-31 0001824920 ionq:UnbilledAccountsReceivableMember 2023-03-31 0001824920 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001824920 ionq:QuantumComputingSystemMember 2023-03-31 0001824920 ionq:MachineryEquipmentFurnitureAndFixturesMember 2023-03-31 0001824920 us-gaap:ComputerEquipmentMember 2023-03-31 0001824920 ionq:UMDAndDukeMember 2023-03-31 0001824920 ionq:PublicWarrantsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-03-31 0001824920 ionq:AccountingStandardsCodification606Member 2023-03-31 0001824920 ionq:TwoThousandsAndTwentyOneEquityIncentivePlanMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:CommonClassAMember ionq:PublicWarrantsMember srt:MinimumMember ionq:RedemptionPriceTwoMember 2023-03-31 0001824920 us-gaap:CommonClassAMember ionq:PublicWarrantsMember ionq:RedemptionPriceOneMember srt:MinimumMember 2023-03-31 0001824920 us-gaap:CommonClassAMember ionq:PublicWarrantsMember ionq:RedemptionPriceTwoMember 2023-03-31 0001824920 ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceOneMember 2023-03-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:ShortTermInvestmentsMember ionq:CorporateNotesAndBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:ShortTermInvestmentsMember ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ionq:CorporateNotesAndBondsMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2023-03-31 0001824920 us-gaap:OtherLongTermInvestmentsMember ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0001824920 us-gaap:MunicipalBondsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0001824920 us-gaap:MunicipalBondsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember 2023-03-31 0001824920 ionq:CapitalizedCommissionsMember 2023-03-31 0001824920 ionq:DukeMember 2023-03-31 0001824920 ionq:BilledAccountsReceivableMember 2022-12-31 0001824920 ionq:UnbilledAccountsReceivableMember 2022-12-31 0001824920 ionq:MachineryEquipmentFurnitureAndFixturesMember 2022-12-31 0001824920 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001824920 ionq:QuantumComputingSystemMember 2022-12-31 0001824920 us-gaap:ComputerEquipmentMember 2022-12-31 0001824920 ionq:UMDAndDukeMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ionq:CorporateNotesAndBondsMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember ionq:CorporateNotesAndBondsMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001824920 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:OtherLongTermInvestmentsMember ionq:CorporateNotesAndBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:OtherLongTermInvestmentsMember ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:OtherLongTermInvestmentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:OtherLongTermInvestmentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:OtherLongTermInvestmentsMember us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001824920 us-gaap:MunicipalBondsMember 2022-12-31 0001824920 ionq:CorporateNotesAndBondsMember 2022-12-31 0001824920 us-gaap:CommercialPaperMember 2022-12-31 0001824920 ionq:CashAndMoneyMarketFundsMember 2022-12-31 0001824920 ionq:CapitalizedCommissionsMember 2022-12-31 0001824920 ionq:DukeMember 2022-12-31 0001824920 ionq:UMDAndDukeMember 2023-01-01 2023-03-31 0001824920 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001824920 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001824920 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001824920 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001824920 ionq:PublicWarrantsMember 2023-01-01 2023-03-31 0001824920 ionq:UnvestedCommonStockMember 2023-01-01 2023-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001824920 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001824920 ionq:TwoThousandsAndFifteenEquityIncentivePlanMember 2023-01-01 2023-03-31 0001824920 ionq:CapitalizedStockbasedCompensationIntangiblesAndFixedAssetsMember 2023-01-01 2023-03-31 0001824920 ionq:StockbasedCompensationNetOfAmountsCapitalizedMember 2023-01-01 2023-03-31 0001824920 ionq:QuantumComputingSystemMember 2023-01-01 2023-03-31 0001824920 srt:MaximumMember ionq:MachineryEquipmentFurnitureAndFixturesMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember ionq:MachineryEquipmentFurnitureAndFixturesMember 2023-01-01 2023-03-31 0001824920 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-01-01 2023-03-31 0001824920 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-03-31 0001824920 ionq:OptionAgreementMember 2023-01-01 2023-03-31 0001824920 ionq:DukeMember ionq:OptionAgreementMember 2023-01-01 2023-03-31 0001824920 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001824920 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember 2023-01-01 2023-03-31 0001824920 us-gaap:RevenueFromRightsConcentrationRiskMember srt:MinimumMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-03-31 0001824920 ionq:InternallyDevelopedSoftwareCostsMember 2023-01-01 2023-03-31 0001824920 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-01-01 2023-03-31 0001824920 ionq:NonConvertibleDebtSecuritiesMember srt:MinimumMember 2023-01-01 2023-03-31 0001824920 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001824920 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001824920 ionq:EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001824920 ionq:PublicWarrantsMember 2023-01-01 2023-03-31 0001824920 us-gaap:CommonClassAMember ionq:PublicWarrantsMember ionq:RedemptionPriceTwoMember 2023-01-01 2023-03-31 0001824920 us-gaap:CommonClassAMember ionq:PublicWarrantsMember ionq:RedemptionPriceOneMember 2023-01-01 2023-03-31 0001824920 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:US 2023-01-01 2023-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001824920 us-gaap:SalesRevenueNetMember 2023-01-01 2023-03-31 0001824920 ionq:UMDMember 2023-01-01 2023-03-31 0001824920 ionq:CapitalizedCommissionsMember 2023-01-01 2023-03-31 0001824920 ionq:DukeMember 2023-01-01 2023-03-31 0001824920 ionq:AccountingStandardsCodification606Member 2023-01-01 2023-03-31 0001824920 srt:MaximumMember ionq:TwoThousandsAndTwentyOneEquityIncentivePlanMember 2023-01-01 2023-03-31 0001824920 ionq:UMDAndDukeMember 2022-01-01 2022-03-31 0001824920 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001824920 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001824920 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001824920 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001824920 ionq:PublicWarrantsMember 2022-01-01 2022-03-31 0001824920 ionq:UnvestedCommonStockMember 2022-01-01 2022-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001824920 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001824920 ionq:CapitalizedStockbasedCompensationIntangiblesAndFixedAssetsMember 2022-01-01 2022-03-31 0001824920 ionq:StockbasedCompensationNetOfAmountsCapitalizedMember 2022-01-01 2022-03-31 0001824920 ionq:DukeMember ionq:OptionAgreementMember 2022-01-01 2022-03-31 0001824920 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001824920 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001824920 ionq:InternallyDevelopedSoftwareCostsMember 2022-01-01 2022-03-31 0001824920 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-03-31 0001824920 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0001824920 ionq:QuantumComputerSystemsMember 2022-01-01 2022-03-31 0001824920 us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0001824920 ionq:CapitalizedCommissionsMember 2022-01-01 2022-03-31 0001824920 ionq:DukeMember 2022-01-01 2022-03-31 0001824920 ionq:UniversityOfMarylandMember us-gaap:CommonStockMember ionq:AmendedLicenseAgreementMember 2021-02-01 2021-02-01 0001824920 ionq:AmendedLicenseAgreementMember ionq:UniversityOfMarylandMember 2021-02-01 0001824920 ionq:AmendedOptionAgreementMember us-gaap:CommonStockMember ionq:DukeMember 2020-01-01 2020-12-31 0001824920 ionq:PublicWarrantsMember 2021-09-30 0001824920 ionq:UMDMember 2021-09-30 0001824920 ionq:TwoThousandsAndTwentyOneEquityIncentivePlanMember 2023-01-01 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001824920 ionq:EmployeeStockPurchasePlanMember 2021-08-31 0001824920 ionq:EmployeeStockPurchasePlanMember 2021-08-31 2021-08-31 0001824920 ionq:UMDMember 2022-07-31 2022-07-31 0001824920 ionq:UniversityOfMarylandMember ionq:OptionAgreementMember 2016-01-01 2016-12-31 0001824920 ionq:OptionAgreementMember ionq:UniversityOfMarylandMember 2016-12-31 0001824920 us-gaap:PatentsMember ionq:OptionAgreementMember ionq:InitialPatentsReceivedMember ionq:UniversityOfMarylandAndDukeMember 2016-07-01 2016-07-31 0001824920 ionq:UMDMember 2021-09-01 2021-09-30 0001824920 us-gaap:CommonStockMember 2022-12-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001824920 us-gaap:RetainedEarningsMember 2022-12-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001824920 us-gaap:CommonStockMember 2023-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001824920 us-gaap:RetainedEarningsMember 2023-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001824920 us-gaap:CommonStockMember 2021-12-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001824920 us-gaap:RetainedEarningsMember 2021-12-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001824920 us-gaap:CommonStockMember 2022-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001824920 us-gaap:RetainedEarningsMember 2022-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 iso4217:USD xbrli:shares xbrli:pure utr:Year utr:Day iso4217:USD xbrli:shares ionq:Segment ionq:Customers
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the quarterly period ended March 31, 2023
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
                
to
                
Commission File
No. 001-39694
 
 
IONQ, INC.
(Exact name of registrant as specified in its charter)
 
 
 
 
Delaware
 
85-2992192
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
4505 Campus Drive
College Park, MD 20740
(301)
298-7997
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common stock, par value $0.0001 per share Warrants, each exercisable for one share of common stock for $11.50 per share
 
IONQ
IONQ WS
 
The New York Stock Exchange
The New York Stock Exchange
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T(§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule12b-2of
the Exchange Act.
 
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
     Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the Registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act):    Yes  ☐    No  
As of May 4, 2023, there were 201,028,320 shares of common stock, par value $0.0001 per share, issued and outstanding.
 
 
 


Table of Contents

IONQ, INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

 

PART 1-FINANCIAL INFORMATION

     1  

Item 1. Unaudited Financial Statements

     1  

Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022

     1  

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022

     2  

Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2023 and 2022

     3  

Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2023 and 2022

     4  

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022

     5  

Notes to Condensed Consolidated Financial Statements

     6  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     22  

Item 3. Quantitative and Qualitative Disclosures About Market Risk

     30  

Item 4. Controls and Procedures

     30  

PART II—OTHER INFORMATION

     31  

Item 1. Legal Proceedings

     31  

Item 1A. Risk Factors

     32  

Item 6. Exhibits

     73  

SIGNATURES

  

WHERE YOU CAN FIND MORE INFORMATION

Investors and others should note that we announce material financial information to our investors using our investor relations website at investors.ionq.com, press releases, filings with the U.S. Securities and Exchange Commission (“SEC”) and public conference calls and webcasts. We also use IonQ’s blog and the following social media channels as a means of disclosing information about the company, our products and services, our planned financials and other announcements and attendance at upcoming investor and industry conferences, and other matters. This is in compliance with our disclosure obligations under Regulation FD:

 

   

IonQ Company Blog (https://ionq.com/resources/learn)

 

   

IonQ LinkedIn Page (https://www.linkedin.com/company/ionq.co)

 

   

IonQ Twitter Account (https://twitter.com/ionq_inc)

 

   

IonQ YouTube Account (https://www.youtube.com/@ionq_inc)

Information posted through these social media channels may be deemed material. Accordingly, in addition to reviewing our press releases, SEC filings, public conference calls and webcasts, investors should monitor IonQ’s blog and our other social media channels. The information we post through these channels is not part of this Quarterly Report on Form 10-Q. The channel list on how to connect with us may be updated from time to time and is available on our investor relations website.


Table of Contents
P1Y
PART
1-FINANCIAL
INFORMATION
Item 1. Unaudited Financial Statements
IONQ, INC.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share data)
 
    
March 31,
   
December 31,
 
    
2023
   
2022
 
Assets
                
Current assets:
                
Cash and cash equivalents
   $ 51,901     $ 44,367  
Short-term investments
     335,966       311,430  
Accounts receivable
     1,837       3,292  
Prepaid expenses and other current assets
     12,638       12,539  
    
 
 
   
 
 
 
Total current assets
     402,342       371,628  
Long-term investments
     137,646       182,001  
Property and equipment, net
     26,488       26,014  
Operating lease
right-of-use
assets
     5,796       3,753  
Intangible assets, net
     10,051       8,944  
Goodwill
     742       742  
Other noncurrent assets
     4,857       4,910  
    
 
 
   
 
 
 
Total Assets
  
$
587,922
 
 
$
597,992
 
    
 
 
   
 
 
 
Liabilities and Stockholders’ Equity
                
Current liabilities:
                
Accounts payable
   $ 3,597     $ 3,055  
Accrued expenses
     9,414       6,655  
Current portion of operating lease liabilities
     610       591  
Unearned revenue
     6,294       8,729  
Current portion of stock option early exercise liabilities
     945       1,130  
    
 
 
   
 
 
 
Total current liabilities
     20,860       20,160  
Operating lease liabilities, net of current portion
     5,624       3,459  
Unearned revenue, net of current portion
     954       1,201  
Stock option early exercise liabilities, net of current portion
     741       839  
Warrant liabilities
     7,429       3,819  
Other noncurrent liabilities
     77       303  
    
 
 
   
 
 
 
Total liabilities
   $ 35,685     $ 29,781  
Commitments and contingencies (see Note 8)
                
Stockholders’ Equity:
                
Common stock $0.0001 par value; 1,000,000,000 shares authorized; 200,122,686 and 199,862,123 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
     20       20  
Additional
paid-in
capital
     779,286       769,848  
Accumulated deficit
     (221,640     (194,302
Accumulated other comprehensive loss
     (5,429     (7,355
    
 
 
   
 
 
 
Total stockholders’ equity
     552,237       568,211  
    
 
 
   
 
 
 
Total Liabilities and Stockholders’ Equity
  
$
587,922
 
 
$
597,992
 
    
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
1

IONQ, INC.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)
 
    
Three Months Ended
March 31,
 
    
2023
   
2022
 
Revenue
   $ 4,285     $ 1,953  
Costs and expenses:
                
Cost of revenue (excluding depreciation and amortization)
     1,036       568  
Research and development
     16,233       7,338  
Sales and marketing
     2,667       1,871  
General and administrative
     10,581       9,194  
Depreciation and amortization
     1,791       1,266  
    
 
 
   
 
 
 
Total operating costs and expenses
  
 
32,308
 
 
 
20,237
 
    
 
 
   
 
 
 
Loss from operations
  
 
(28,023
 
 
(18,284
Change in fair value of warrant liabilities
     (3,610     13,448  
Interest income, net
     4,231       608  
Other income (expense), net
     64       1  
    
 
 
   
 
 
 
Loss before benefit for income taxes
  
 
(27,338
 
 
(4,227
Benefit for income taxes
                        
    
 
 
   
 
 
 
Net loss
  
$
(27,338
 
$
(4,227
    
 
 
   
 
 
 
Net loss per share attributable to common stockholders—basic and diluted
   $ (0.14   $ (0.02
    
 
 
   
 
 
 
Weighted average shares used in computing net loss per share attributable to common
stockholders—basic and diluted
     200,112,855       196,183,247  
    
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
2

IONQ, INC.
Condensed Consolidated Statements of Comprehensive Loss
(unaudited)
(in thousands)
 
    
Three Months Ended
March 31,
 
    
2023
   
2022
 
Net loss
   $ (27,338   $ (4,227
Other comprehensive income (loss), net of reclassification adjustments:
                
Change in unrealized gain (loss) on
available-for-sale
securities, net
     1,926       (4,540
    
 
 
   
 
 
 
Total other comprehensive income (loss)
     1,926       (4,540
    
 
 
   
 
 
 
Total comprehensive loss
  
$
(25,412
 
$
(8,767
    
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
3

IONQ, INC.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(unaudited)
(in thousands, except share data)
 
    
Stockholders’ Equity
 
    
Common Stock
    
Additional
Paid-in

Capital
    
Accumulated
Deficit
   
Accumulated
Other
Comprehensive
Loss
   
Total
Stockholders’
Equity
 
    
Shares
    
Amount
                           
Balance, December 31, 2022
  
 
199,862,123
 
  
$
20
 
  
$
769,848
 
  
$
(194,302
 
$
(7,355
 
$
568,211
 
Net loss
     —          —          —          (27,338     —         (27,338
Other comprehensive income
     —          —          —          —         1,926       1,926  
Stock options exercised
     131,492        —          52        —         —         52  
Vesting of restricted common stock
     125,341        —          282        —         —         282  
Issuance of common stock from the settlement of restricted stock units
     3,730        —          —          —         —         —    
Stock-based compensation
     —          —          9,104        —         —         9,104  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance, March 31, 2023
  
 
200,122,686
 
  
$
20
 
  
$
779,286
 
  
$
(221,640
 
$
(5,429
 
$
552,237
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
 
    
Stockholders’ Equity
 
    
Common Stock
    
Additional
Paid-in

Capital
    
Accumulated
Deficit
   
Accumulated
Other
Comprehensive
Loss
   
Total
Stockholders’
Equity
 
    
Shares
    
Amount
                           
Balance, December 31, 2021
  
 
195,630,975
 
  
$
19
 
  
$
737,150
 
  
$
(145,791
 
$
(148
 
$
591,230
 
Net loss
     —          —          —          (4,227     —         (4,227
Other comprehensive loss
     —          —          —          —         (4,540     (4,540
Stock options exercised
     453,225        1        131        —         —         132  
Vesting of restricted common stock
     139,511        —          316        —         —         316  
Issuance of common stock from the settlement of restricted stock units
     168,750        —          —          —         —         —    
Stock-based compensation
     —          —          6,848        —         —         6,848  
Warrants exercised
     1,487        —          24        —         —         24  
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance, March 31, 2022
  
 
196,393,948
 
  
$
20
 
  
$
744,469
 
  
$
(150,018
 
$
(4,688
 
$
589,783
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
4
IONQ, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
 
  
Three Months Ended
March 31,
 
 
  
2023
 
  
2022
 
Cash flows from operating activities:
  
  
Net loss
   $ (27,338
)
   $ (4,227
Adjustments to reconcile net loss to net cash used in operating activities:
                 
Depreciation and amortization
     1,791        1,266  
Non-cash
research and development arrangements
     130        130  
Stock-based compensation
     10,268        6,672  
Change in fair value of warrant liabilities
     3,610        (13,448
Other, net
     (1,570 )      (490
Changes in operating assets and liabilities:
                 
Accounts receivable
     2,044        138  
Prepaid expenses and other current assets
     (939 )      1,516  
Accounts payable
     728        (291
Accrued expenses
     920        1,571  
Unearned revenue
     (3,271 )      (1,058
Other assets and liabilities
     (188 )      (103
    
 
 
    
 
 
 
Net cash used in operating activities
     (13,815 )      (8,324
Cash flows from investing activities:
                 
Purchases of property and equipment
     (1,185 )      (2,672
Capitalized software development costs
     (843 )      (457
Intangible asset acquisition costs
     (318 )      (134
Purchases of
available-for-sale
securities
     (64,430 )      (311,235
Maturities and sales of
available-for-sale
securities
     88,091        10,400  
    
 
 
    
 
 
 
Net cash provided by (used in) investing activities
     21,315        (304,098
Cash flows from financing activities:
                 
Proceeds from stock options exercised
     52        132  
Other financing, net
     (18      16  
    
 
 
    
 
 
 
Net cash provided by financing activities
     34        148  
    
 
 
    
 
 
 
Net change in cash, cash equivalents and restricted cash
     7,534        (312,274
Cash, cash equivalents and restricted cash at the beginning of the period
     46,367        399,025  
    
 
 
    
 
 
 
Cash, cash equivalents and restricted cash at the end of the period
   $ 53,901      $ 86,751  
    
 
 
    
 
 
 
Supplemental disclosures of
non-cash
investing and financing transactions:
                 
Property and equipment purchases in accounts payable and accrued expenses
   $ 153      $ 1,007  
Intangible asset purchases in accounts payable and accrued expenses
     216        86  
Operating lease
right-of-use
assets subject to lease liability
     2,239            
Noncash reclassification of warrant liabilities to equity upon exercise
               8  
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
5

IONQ, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
1. DESCRIPTION OF BUSINESS
IonQ, Inc. (“IonQ” or “the Company”), formerly known as dMY Technology Group, Inc. III (“dMY”), was incorporated in the state of Delaware in September 2020 and formed as a special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. IonQ Quantum, Inc. (formerly known as IonQ, Inc., and referred to as “Legacy IonQ” herein), was incorporated in the state of Delaware in September 2015 and is headquartered in College Park, Maryland.
On March 7, 2021, Legacy IonQ entered into an Agreement and Plan of Merger (the “Merger Agreement”) with dMY and Ion Trap Acquisition Inc. (“Merger Sub”), a direct, wholly owned subsidiary of dMY. Pursuant to the Merger Agreement, on September 30, 2021 (“the Closing Date”), the Merger Sub was merged with and into Legacy IonQ with Legacy IonQ continuing as the surviving corporation following the Merger, becoming a wholly owned subsidiary of dMY and the separate corporate existence of the Merger Sub ceased (the “Business Combination”). Commensurate with the Business Combination, dMY changed its name to IonQ, Inc. and Legacy IonQ changed its name to IonQ Quantum, Inc.
Unless otherwise indicated, references in this Quarterly Report on Form
10-Q
to the “Company” and “IonQ” refer to the consolidated operations of IonQ, Inc. subsequent to the Business Combination. References to “dMY” refer to the company prior to the consummation of the Business Combination and references to “Legacy IonQ” refer to IonQ, Inc. prior to the consummation of the Business Combination.
IonQ is engaged in quantum computing and develops general-purpose quantum computing systems designed to solve some of the world’s most complex problems, and transform business, society, and the planet for the better. To operate the quantum computing systems, the Company has developed custom hardware, custom firmware, and an operating system to orchestrate the quantum computers.
Business Combination
While the legal acquirer in the Merger Agreement is dMY, for financial accounting and reporting purposes under accounting principles generally accepted in the United States of America (“U.S. GAAP”), Legacy IonQ is the accounting acquirer and the merger is accounted for as a “reverse recapitalization” (i.e., a capital transaction involving the issuance of stock by dMY for the stock of Legacy IonQ).
For accounting purposes, the Business Combination was treated as the equivalent of Legacy IonQ issuing stock for the net assets of dMY, accompanied by a recapitalization. The net assets of dMY are stated at historical cost, and no goodwill or other intangible assets were recorded. Because Legacy IonQ was deemed the accounting acquirer in the Business Combination, the historical financial statements of Legacy IonQ are the historical financial statements of the Company upon the consummation of the Business Combination. As a result, the condensed consolidated financial statements included in this report reflect: (i) the historical operating results of Legacy IonQ prior to the Business Combination; (ii) the combined results of dMY and Legacy IonQ following the close of the Business Combination on September 30, 2021; and (iii) the assets and liabilities of Legacy IonQ stated at their historical cost.
In accordance with guidance applicable to these circumstances, the equity structure has been retroactively restated in all comparative periods to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Legacy IonQ’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy IonQ convertible redeemable preferred stock and warrants and Legacy IonQ common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination. Legacy IonQ’s convertible redeemable preferred stock and warrants previously classified as mezzanine equity were retroactively adjusted, converted into common stock, and reclassified to permanent equity because of the reverse recapitalization. All exercise prices for stock options and customer warrants have similarly been retroactively restated to reflect the exchange ratio established in the Business Combination.
Segment Reporting
The Company operates as
one
operating segment as its chief executive officer, who is the chief operating decision maker, reviews financial information on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Significant Accounting Policies
The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022, and the notes thereto are included in the Company’s Annual Report on Form
10-K
(the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below.
Basis of Preparation
The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP as determined by the Financial Accounting Standards Board (“FASB”). Such condensed consolidated financial statements include the accounts of IonQ and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
 
6

Unaudited Interim Financial Information
The interim condensed consolidated financial statements included in this Quarterly Report on Form
10-Q
have been prepared by the Company and are unaudited, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures contained in this Quarterly Report on Form
10-Q
comply with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for a quarterly report and are adequate to make the information presented not misleading. The interim condensed consolidated financial statements included herein reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022, included in the Annual Report. The condensed consolidated statements of operations and the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2023, are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023, or thereafter. All references to March 31, 2023 and 2022, in the notes to the condensed consolidated financial statements are unaudited.
Emerging Growth Company
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies.
The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
The Company remains an emerging growth company until the earliest of (i) December 31, 2025, (ii) the last day of the fiscal year in which the Company has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the Company is deemed to be a large accelerated filer, which means the market value of the Company’s common stock that is held by
non-affiliates
exceeds $700.0 million as of the prior June 30th or (iv) the date on which the Company has issued more than $1.0 billion in
non-convertible
debt securities during the prior three-year period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP and the rules and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes.
Significant estimates and judgments are inherent in the analysis and measurement of items including, but not limited to: revenue recognition, capitalization of internally developed software and quantum computing costs, useful lives of long-lived assets, and fair value of
available-for-sale
securities. Management bases its estimates and assumptions on historical experience, expectations, forecasts, and on various other factors that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ and be affected by changes in those estimates.
Fair Value Measurements
The Company evaluates the fair value of certain assets and liabilities using the fair value hierarchy. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
 
   
Level 1—Observable inputs, which include quoted prices in active markets;
 
   
Level 2—Observable inputs other than the quoted prices in active markets that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs such as broker quotes, benchmark yield curves, credit spreads and market interest rates for similar securities that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
 
   
Level 3—Unobservable inputs that are supported by little or no market activity and that are based on management’s assumptions, including fair value measurements determined using pricing models, discounted cash flow methodologies or similar techniques.
The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the total fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability.
 
7

Assets and liabilities that are measured at fair value on a
non-recurring
basis include property and equipment, intangible assets, and goodwill. The Company recognizes these items at fair value when they are considered to be impaired or upon initial recognition when acquired through a business combination or an asset acquisition. The fair value of these assets and liabilities are determined with valuation techniques using the best information available and may include quoted market prices, market comparables and discounted cash flow models.
Due to their short-term nature, the carrying amounts reported in the Company’s condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include cash in banks, checking deposits, money market funds, and commercial paper. The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Restricted cash collateralizing letters of credit is included in other noncurrent assets in the condensed consolidated balance sheets. The Company issues letters of credits in the ordinary course of business, including for lease arrangements. As of both March 31, 2023 and December 31, 2022, letters of credit totaling 
$2.0 million were outstanding.
The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Cash and cash equivalents
   $ 51,901      $ 44,367  
Restricted cash
     2,000        2,000  
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows
   $ 53,901      $ 46,367  
    
 
 
    
 
 
 
Accounts Receivable and Allowance for Credit Losses
Accounts receivable are
non-interest
bearing and represent amounts billed and currently due from customers at the gross invoiced amount as well as unbilled amounts related to unconditional rights for consideration to be received for services performed but not yet invoiced. A receivable is recorded when the Company has an unconditional right to receive payment. Accounts receivable consists of the following at (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Billed accounts receivable
   $ 1,001      $ 1,150  
Unbilled accounts receivable
     836        2,142  
    
 
 
    
 
 
 
Total accounts receivable
   $ 1,837      $ 3,292  
    
 
 
    
 
 
 
On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance for credit losses. This assessment is based on management’s evaluation of relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the receivable.
The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022.
Materials and Supplies
Materials and supplies are carried at average cost and recorded in prepaid expenses and other current assets in the condensed consolidated balance sheets. Materials and supplies used in the production of quantum computing systems to be made commercially available are capitalized to property and equipment when installed. Materials and supplies used for maintenance or research and development efforts are expensed when consumed. The Company capitalized $0.8 million of materials and supplies to property and equipment for the three months ended March 31, 2023.
Investments
Management determines the appropriate classification of investments at the time of purchase based upon management’s intent with regard to such investments. The Company primarily invests in debt securities and classifies its investments as
available-for-sale
at the time of purchase if they are available to support either current or future operations. This classification is
re-evaluated
at each balance sheet date. Investments not considered cash equivalents, with remaining contractual maturities of one year or less from the balance sheet date are classified as short-term investments, and those with remaining contractual maturities greater than one year from the balance sheet date are classified as long-term investments. All investments are recorded at their estimated fair value, and any unrealized gains and losses are recorded in accumulated other comprehensive loss. Realized gains and losses on sales and maturities of investments are determined based on the specific identification method and are recognized in the condensed consolidated statements of operations in other income (expense), net. Accrued interest receivable on available-for-sale investments is recorded in the condensed consolidated balance sheet in prepaid expenses and other current assets. As of
March 31, 2023
and December 31, 2022, accrued interest receivable was $1.8 million and $1.7 million, respectively.
 
8

The Company performs periodic evaluations to determine whether any declines in the fair value of investments below amortized cost are credit losses or impairments. The evaluation consists of qualitative and quantitative factors regarding the severity of the unrealized loss, as well as the Company’s ability and intent to hold the investments until a forecasted recovery occurs. Declines in fair value are considered to be credit losses if they are related to deterioration in credit risk or are considered impairments if it is likely that the underlying securities will be sold prior to a full recovery of their cost basis. Credit losses and impairments are determined based on the specific identification method and
are
reported in other income (expense), net in the condensed consolidated statements of operations.
Property and Equipment, Net
Property and equipment, net is stated at cost less accumulated depreciation. Historical cost of fixed assets is the cost as of the date acquired. Hardware and labor costs associated with the building of quantum computing systems are capitalized. Costs
to
maintain quantum computing systems are expensed as incurred.
Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows:
 
Computer equipment and acquired computer software    35 years
Machinery, equipment, furniture and fixtures    57 years
Quantum computing systems    3 years
Leasehold improvements    Shorter of the lease term or the estimated useful life of the related asset
Effective October 1, 2022, the Company revised the accounting useful life of quantum computing systems, which was determined to be a change in accounting estimate and is being applied prospectively. This change in accounting estimate is not material for the three months ended March 31, 2023. The estimated useful life for quantum computing systems was previously 2 years.
Leases
The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease
right-of-use
(“ROU”) assets and current operating lease liabilities and operating lease liabilities, net of current portion on the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has no financing lease arrangements. The Company recognizes lease expense for its operating leases on a straight-line basis over the term of the lease.
The Company records a ROU asset and lease liability in connection with its operating leases. The Company’s lease portfolio is comprised primarily of real estate leases, which are accounted for as operating leases. The Company elected the practical expedient to not separate lease and
non-lease
components for all leases.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future minimum lease payments, including the impact of any lease incentives, as applicable, over the lease term. Amendments to a lease are assessed to determine if it represents a lease modification or a separate contract. Lease modifications are reassessed as of the effective date of the modification using an incremental borrowing rate based on the information available at the commencement date. For modified leases the Company also reassesses the lease classification as of the effective date of the modification.
The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate, because the interest rate implicit in the Company’s leases is not readily determinable. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located.
The Company’s lease terms include periods under options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company considers contractual-based factors such as the nature and terms of the renewal or termination, asset-based factors such as physical location of the asset and entity-based factors such as the importance of the leased asset to the Company’s operations to determine the lease term. The Company generally uses the base
non-cancelable
lease term when determining the ROU assets and lease liabilities.
Capitalized Internally Developed Software
Capitalized internally developed software, which is included in intangible assets, net, consists of costs to purchase and develop internal-use software, which the Company primarily uses to provide services to its customers. The costs to purchase and develop internal-use software are capitalized from the time that the preliminary project stage is completed, and it is considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Any costs incurred during subsequent efforts to upgrade and enhance the functionality of the software are also capitalized. Once this software is ready for its intended use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is typically assessed to be three years. During the three months ended March 31, 2023 and 2022, the Company capitalized $
1.3 million and $0.5 million in
internal-use
software costs, respectively. The Company amortized $0.5 million and $0.3 million of capitalized internally developed software costs during the three months ended March 31, 2023 and 2022, respectively.
Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment and other long-term assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent the carrying amount of the underlying asset exceeds its fair value. No impairment loss was recognized for the three months ended March 31, 2023 or 2022.
 
9

Warrant Liabilities
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and
is then re-valued
upon exercise or at each reporting date for the unexercised warrants, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The warrants of dMY assumed in the Business Combination are classified as liabilities and remeasured at each reporting period (as more fully described in Note 10). The determination of the fair value of the warrant liabilities may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are
classified as non-current liabilities as
their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Revenue Recognition
The Company derives revenue from providing access to its quantum-computing-as-a-service (“QCaaS”), consulting services related to
co-developing
algorithms on the quantum computing systems, and from contracts associated with the design, development, and construction of specialized quantum computing systems together with related services. The Company applies the provisions of the FASB Accounting Standards Update (“ASU”), Revenue from Contracts with Customers (“ASC 606”), and all related applicable guidance. The core principle of ASC 606 is that an entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
To support this core principle, the Company applies the following five step approach:
 
1.
Identify the contract with the customer
 
2.
Identify the performance obligations
 
3.
Determine the transaction price
 
4.
Allocate the transaction price to the performance obligations
 
5.
Recognize revenue when (or as) the entity satisfies a performance obligation
The Company has determined that its QCaaS contracts represent a combined, stand-ready performance obligation to provide access to its quantum computing systems together with related maintenance and support. The transaction price may consist of a variable fee based on usage of its quantum computing systems or a fixed fee for a minimum volume of usage to be made available over a defined period of access. Fixed fee arrangements may also include a variable component whereby customers pay an amount for usage over contractual minimums contained in the contracts. The Company has determined that contracts that contain consulting services related
to co-developing quantum
computing algorithms and the ability to use its quantum computing systems to run such algorithms represent a combined performance obligation that is satisfied over-time with revenue recognized based on the efforts incurred to date relative to the total expected effort. For contracts with a fixed transaction price, the fixed fee is recognized on a straight-line basis over the access period or associated measure of progress for the Company’s consulting services contracts. For contracts without fixed fees, variable usage fees are billed and recognized during the period of such usage.
Certain of the Company’s contracts contain multiple performance obligations, most commonly in contracts for specialized quantum computing systems together with related maintenance and support. Such contracts may also include access to the Company’s QCaaS. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. When there are multiple performance obligations in a contract, the Company allocates the transaction price to each performance obligation based on its standalone selling price when available. We determine standalone selling price based on the observable price of a product or service when we sell the products or services separately in similar circumstances and to similar customers. When the standalone selling price is not known, due to it being either highly variable or uncertain, the Company allocates the transaction price using the residual approach.
Performance obligations are satisfied over time if the customer receives the benefits as we perform the work, if the customer controls the asset as it is being produced (continuous transfer of control), or if the product being produced for the customer has no alternative use and we have a contractual right to payment for performance to date. Revenue is recognized on performance obligations satisfied over time based on the efforts incurred to date relative to the total expected effort.
For the three months ended March 31, 2023 and 2022, all of the revenue recognized by the Company was recognized based on transfer of service over time. There were no revenues recognized at a point in time. In arrangements with cloud service providers, the cloud service provider is considered the customer and IonQ does not have any contractual relationships with the cloud service providers’ end users. For these arrangements, revenue is recognized at the amount charged to the cloud service provider and does not reflect any
mark-up
to the end user.
The Company may enter into multiple contracts with a single counterparty at or near the same time. The Company will combine contracts and account for them as a single contract when one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) consideration to be paid in one contract depends on the price or performance of the other contract; and (iii) goods or services promised are a single performance obligation. Consideration payable to a customer includes cash amounts that an entity pays, or expects to pay, to the customer. For arrangements that contain consideration payable to a customer, the Company uses judgment in determining whether such payments are a reduction of the transaction price or a payment to the customer for a distinct good or service.
The variable fees associated with the QCaaS are generally billed a month in arrears. Customers also have the ability to make advance payments. If a contract exists under ASC 606, advance payments are recorded as a contract liability until services are delivered or obligations are met and revenue is earned. Contract liabilities to be recognized in the succeeding
12-month
period are classified as current and the remaining amounts are classified as
non-current
liabilities in the Company’s condensed consolidated balance sheets.
 
10

As of March 31, 2023, approximately $30.4 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for
non-cancelable
contracts, including both funded (firm orders for which funding has been both authorized and appropriated by the customer) and unfunded (firm orders for which funding has not been appropriated) orders. The Company expects approximately 60% of the remaining performance obligations to be recognized as revenue within the next twelve months.
The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands):
 
    
Total
 
Balance as of December 31, 2022
   $ 9,930  
Revenue recognized
     (3,446
New deferrals, net
     764  
    
 
 
 
Balance as of March 31, 2023
   $ 7,248  
    
 
 
 
For contractual arrangements where consideration is paid
up-front,
the transfer of the quantum computing services is completed at the discretion of the customer as the customer chooses to use the services starting from the date of contract inception. As such, the
up-front
payment of consideration does not represent a significant financing component.
Assets Recognized from Costs to Obtain a Contract
Sales commissions paid to employees and third parties are considered incremental costs to obtain a contract with a customer. These costs are capitalized in the period a customer contract is executed and are amortized as an expense consistent with the transfer of the goods or services to the customer. Capitalized costs are recorded in prepaid expenses and other current assets and other noncurrent assets in the condensed consolidated balance sheets. Applying the practical expedient, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets is one year or less. As of March 31, 2023 and December 31, 2022, total capitalized costs were $0.9 million and $1.0 million, respectively. Amortization expense was $0.1 million and zero for the three months ended March 31, 2023 and 2022, respectively.
Stock-Based Compensation
The Company measures and records the expense related to stock-based awards based on the fair value of those awards as determined on the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes-Merton (“Black- Scholes”) option-pricing model to determine the fair value of stock awards and the estimated fair value for stock options. The Black-Scholes option- pricing model requires the use of subjective assumptions, which determine the fair value of share-based awards, including the fair value of the Company’s common stock, the option’s expected term, the price volatility of the underlying common stock, risk-free interest rates, and the expected dividend yield of the common stock. The assumptions used to determine the fair value of the stock awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. The Company records forfeitures as they occur.
Stock-based compensation cost for restricted stock units is measured based on the fair value of the Company’s common stock on the grant date. For awards with a performance-based vesting condition, the Company records stock-based compensation cost if it is probable that the performance condition will be achieved.
The Company records stock-based compensation expense for incentive compensation liabilities based on estimated payments to employees for which the Company expects to settle the liability by granting restricted stock units. For these awards, stock-based compensation expense is accrued commencing at the service inception date, which generally precedes the grant date, through the end of the requisite service period.
The Company obtained third-party valuations to estimate the fair value of its common stock for awards granted prior to the Business Combination, for purposes of measuring stock-based compensation expense. The third-party valuations were prepared using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants (“AICPA”) Accounting &Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, investments, and trade accounts receivable. The Company maintains the majority of its cash, cash equivalents, restricted cash and investments with two financial institutions. The Company’s deposits routinely exceed amounts guaranteed by the Federal Deposit Insurance Corporation. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to limited credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors.
The Company’s accounts receivable are derived from customers primarily located in the U.S. The Company performs periodic evaluations of its customers’ financial condition and generally does not require its customers to provide collateral or other security to support accounts receivable and maintains an allowance for credit losses. Credit losses historically have not been material.
Significant customers are those that represent more than 10% of the Company’s total revenue. The Company’s revenue was primarily from three significant customers for the three months ended March 31, 2023, and from two significant customers for the three months ended March 31, 2022.
 
11
Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock during the period, plus common stock equivalents, outstanding during the period. If the Company reports a net loss, the computation of diluted loss per share excludes the effect of dilutive common stock equivalents, as their effect would be antidilutive.
The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Numerator:
                 
Net loss attributable to common stockholders
   $ (27,338    $ (4,227
Denominator:
                 
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted
     200,112,855        196,183,247  
Net loss per share attributable to common stockholders—basic and diluted
   $ (0.14    $ (0.02
In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted stock units, unvested common stock (including unvested restricted common stock) and warrants are excluded and diluted loss per share is equal to basic loss per share. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:
 
    
Three Months Ended
March 31
 
    
2023
    
2022
 
Common stock options outstanding
     24,499,968        21,108,390  
Warrants to purchase common stock
     8,301,202        8,301,202  
Public warrants
     5,231,486        5,232,471  
Unvested restricted stock units
     9,077,343        1,310,471  
Unvested common stock
     842,454        1,351,261  
    
 
 
    
 
 
 
Total
  
 
47,952,453
 
  
 
37,303,795
 
    
 
 
    
 
 
 
Recently Adopted Accounting Standards
In June 2016, the FASB issued ASU
2016-13,
Financial Instruments—Credit Losses, along with various updates and improvements. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the first quarter of 2023, and it did not have a material effect on the condensed consolidated financial statements and related disclosures.
Recently Issued Accounting Standards Not Yet Adopted
In August 2020, the FASB issued ASU
2020-06,
Debt, Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic
815-40)
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its consolidated financial statements and related disclosures.
 
12

3. CASH, CASH EQUIVALENTS, RESTRICTED CASH AND INVESTMENTS
The following table summarizes the Company’s unrealized gains and losses and estimated fair value of cash, cash equivalents, restricted cash and investments in
available-for-sale
securities recorded in the condensed consolidated balance sheets (in thousands):
 
    
AS OF MARCH 31, 2023
    
AS OF DECEMBER 31, 2022
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
   
Estimated
Fair
Value
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
   
Estimated
Fair Value
 
Cash and money market funds
   $ 51,012      $         $        $ 51,012      $ 46,367      $         $        $ 46,367  
Commercial paper
     121,151        2        (198     120,955        130,141                  (443     129,698  
Corporate notes and bonds
     263,876        106        (4,761     259,221        277,184        19        (5,993     271,210  
Municipal bonds
     9,935                  (213     9,722        9,905                  (273     9,632  
US government and agency
     86,968        88        (453     86,603        83,556        23        (688     82,891  
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Total cash, cash equivalents, restricted cash and investments
  
$
532,942
 
  
$
196
 
  
$
(5,625
 
$
527,513
 
  
$
547,153
 
  
$
42
 
  
$
(7,397
 
$
539,798
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Unrealized losses related to investments were primarily a result of interest rate fluctuations. The following table presents information about the Company’s investments in available-for-sale securities with gross unrealized losses and the length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2023 (in thousands).
 
 
  
As of March 31, 2023
 
 
  
Less than 12 Months
 
 
12 Months or Longer
 
 
Total
 
 
  
Fair Value
 
  
Gross Unrealized
Losses
 
 
Fair Value
 
  
Gross Unrealized
Losses
 
 
Fair Value
 
  
Gross Unrealized
Loses
 
Commercial paper
  
$
75,326
 
  
$
(198
)
 
 
$
  
 
  
$
 
  
 
 
$
75,326
 
  
$
(198
)
 
Corporate notes and bonds
  
 
91,968
 
  
 
(1,237
)
 
 
 
138,518
 
  
 
(3,524
 
 
230,486
 
  
 
(4,761
)
 
Municipal bonds
  
 
4,951
 
  
 
(31
 
 
4,771
 
  
 
(182
 
 
9,722
 
  
 
(213
US government and agency
  
 
29,124
 
  
 
(83
 
 
12,123
 
  
 
(370
 
 
41,247
 
  
 
(453
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
Total
  
$
201,369
 
  
$
(1,549
 
$
155,412
 
  
$
(4,076
 
$
356,781
 
  
$
(5,625
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
There were no securities in a gross unrealized loss position for greater than 12 months as of December 31, 2022.
The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022. The Company does not intend or believe it is more likely than not, that it will be required to sell the investments in an unrealized loss position before the recovery of the associated amortized cost basis.
The estimated fair value of the Company’s cash, cash equivalents, restricted cash and investments in
available-for-sale
securities as of March 31, 2023, aggregated by investment category and classified by contractual maturity date, is as follows (in thousands):
 
    
1 Year
or Less
    
1 Year
or Greater
    
Total
 
Cash and money market funds
   $ 49,012      $ 2,000      $ 51,012  
Commercial paper
     120,955                  120,955  
Corporate notes and bonds
     148,350        110,871        259,221  
Municipal bonds
     9,722                  9,722  
US government and agency
     59,828        26,775        86,603  
    
 
 
    
 
 
    
 
 
 
Total
  
$
387,867
 
  
$
139,646
 
  
$
527,513
 
    
 
 
    
 
 
    
 
 
 
 
13

4. FAIR VALUE MEASUREMENTS
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (in thousands):
 
    
Fair Value Measured as of
March 31, 2023:
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Cash, cash equivalents and restricted cash:
                                   
Cash and money market funds
(1)
   $ 51,012      $ —        $ —        $ 51,012  
Commercial paper
     —          2,889        —          2,889  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash
     51,012        2,889        —          53,901  
    
 
 
    
 
 
    
 
 
    
 
 
 
Short-term investments:
                                   
Commercial paper
     —          118,066        —          118,066  
Corporate notes and bonds
     —          148,350        —          148,350  
Municipal bonds
     —          9,722                 9,722  
US government and agency
     —          59,828        —          59,828  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total short-term investments
     —          335,966        —          335,966  
    
 
 
    
 
 
    
 
 
    
 
 
 
Long-term investments:
                                   
Corporate notes and bonds
     —          110,871        —          110,871  
US government and agency
     —          26,775        —          26,775  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total long-term investments
     —          137,646        —          137,646  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Assets
   $ 51,012      $ 476,501      $ —        $ 527,513  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Public warrants
   $ 7,429      $ —        $ —        $ 7,429  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Fair Value Measured as of
December 31, 2022:
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Cash, cash equivalents and restricted cash:
                                   
Cash and money market funds
(1)
   $ 46,367      $ —        $ —        $ 46,367  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash
     46,367                  —          46,367  
    
 
 
    
 
 
    
 
 
    
 
 
 
Short-term investments:
                                   
Commercial paper
     —          129,698        —          129,698  
Corporate notes and bonds
     —          120,447        —          120,447  
Municipal bonds
     —          4,911                 4,911  
US government and agency
     —          56,374        —          56,374  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total short-term investments
     —          311,430        —          311,430  
    
 
 
    
 
 
    
 
 
    
 
 
 
Long-term investments:
                                   
Corporate notes and bonds
     —          150,763        —          150,763  
Municipal bonds
     —          4,721        —          4,721  
US government and agency
     —          26,517        —          26,517  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total long-term investments
     —          182,001        —          182,001  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Assets
   $ 46,367      $ 493,431      $ —        $ 539,798  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Public warrants
   $ 3,819      $ —        $ —        $ 3,819  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
(1)
Includes money market funds associated with the Company’s overnight investment sweep account and collateralized letter of credit.
Transfers to/from Levels 1, 2 and 3 are r
ec
ognized at the beginning of the reporting period. There were no transfers between levels during the period. On March 31, 2023, the closing trading price of the public warrants was $1.42 per warrant.
14
 

5. PROPERTY AND EQUIPMENT, NET
Property and equipment, net is composed of the following (in thousands):
 
 
  
March 31,
 
  
December 31,
 
 
  
2023
 
  
2022
 
Computer equipment and acquired computer software
   $ 2,707      $ 2,407  
Machinery, equipment, furniture and fixtures
     7,747        7,506  
Leasehold improvements
     1,193        1,132  
Quantum computing systems
     23,532        22,430  
    
 
 
    
 
 
 
Gross property and equipment
  
 
35,179
 
  
 
33,475
 
Less: accumulated depreciation
     (8,691
  
  (7,461
    
 
 
    
 
 
 
Property and equipment, net
  
$
26,488
 
  
$
26,014
 
    
 
 
    
 
 
 
Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.2 million and $1.0 million, respectively.
6. AGREEMENTS WITH UNIVERSITY OF MARYLAND AND DUKE UNIVERSITY
Exclusive License Agreement
The Company entered into an exclusive license agreement (“License Agreement”) in July 2016 with the University of Maryland (“UMD”) and Duke University (“Duke”). The License Agreement grants to the Company an exclusive, perpetual license (“Initial Patents”) to certain patents,
know-how
and other intellectual property utilized in
trapped-ion
quantum computing systems. The license granted to the Company is exclusive for all patents (and
non-exclusive
for other types of intellectual property), subject to certain governmental rights and retained rights by UMD and Duke and other
non-profit
institutions to use and practice the Licensed Patents (as defined below) and technology for internal research and other
non-profit
purposes. In exchange for the Initial Patents, UMD and Duke received an aggregate of 142,886
 shares of common stock after giving effect to the recapitalization. 
On February 1, 2021, the Company and UMD executed two amendments to the License Agreement granting exclusive rights to license additional intellectual property in exchange for a total of 
257,198
 shares of common stock after giving effect to the recapitalization. Management evaluated the amendments and concluded that the arrangements qualify as equity-classified instruments and recorded an intangible asset and additional paid-in capital based on the fair value of the shares at the date the amendments were executed of $
1.6 million. The shares for each executed amendment were issued during the year ended December 31, 2021.
Exclusive Option Agreements
The Company also entered into an exclusive option agreement (“Option Agreement”) with each of UMD and Duke in 2016 whereby on the anniversary of the effective date of the License Agreement for a period of 5
 years, the Company has the right to exclusively license additional intellectual property developed by UMD and Duke (the “Additional Patents” and together with the Initial Patents, the “Licensed Patents”) by exercising an annual option and issuing shares of common stock each to Duke and UMD in consideration for the Additional Patents. The amount issued to UMD and Duke pursuant to the option over the 5-year term was equal to an aggregate of 
642,995
 shares of common stock to each university after giving effect to the recapitalization. The Company may elect not to exercise the option if there was not a minimum number of intellectual property developed in a given year and then the Option Agreement would 
extend another year.
In December 2020, the Company amended its option agreement with Duke, and under this amendment, the Company issued 1,214,317
 shares of common stock after giving effect to the recapitalization, to Duke in consideration for research and development services through July 15, 2026. Under the terms of the amended Option Agreement, the issuance of shares is a nonrefundable upfront payment in exchange for research and development services by Duke whereby the Company will obtain rights to any potential future intellectual property developed during the term. As such, the fair value of the shares of common stock was recorded as a prepaid expense and is being amortized over the term of the arrangement as services are received. The Company recognized $
0.1 million of research and development expense related to the agreement with Duke during each of the three months ended March 31, 2023 and 2022.
The useful life of the Licensed Patents derived from the License Agreement and the Option Agreement is the remaining legal life at the time of acquisition. The value of the Licensed Patents is based on the fair value of the common stock given as consideration on the effective date of each agreement and exercise of option. The asset is amortized over the useful life of the Licensed Patents.
 
15

7. OTHER BALANCE SHEET ACCOUNTS
Accrued expenses are composed of the following (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Accrued salaries and other payroll liabilities
   $ 6,597      $ 4,935  
Accrued professional services
     1,283        678  
Accrued equipment and services liabilities for research and development
     611        489  
Accrued expenses—other
     923        553  
    
 
 
    
 
 
 
Total accrued expenses
  
$
9,414
 
  
$
6,655
 
    
 
 
    
 
 
 
8. COMMITMENTS AND CONTINGENCIES
Warranties and Indemnification
The Company’s commercial services are typically warranted to perform in a manner consistent with general industry standards that are reasonably applicable and materially in accordance with the Company’s documentation under normal use and circumstances.
The Company’s arrangements generally include certain provisions for indemnifying customers against liabilities if its products or services infringe third-party intellectual property rights. To date, the Company has not incurred any material costs as a result of such obligations and has not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements.
Stockholder Lawsuit
In May 2022, a securities class action complaint captioned
Leacock v. IonQ, Inc. et al
., Case No.
8:22-cv-01306,
was filed by a stockholder of the Company in the United States District Court for the District of Maryland (the “Leacock Litigation”) against the Company and certain of the Company’s current officers. In June 2022, a securities class action complaint captioned
Fisher v. IonQ, Inc
., Case No.
8:22-cv-01306-DLB
(the “Fisher Litigation”) was filed by a stockholder against the Company and certain of the Company’s current officers (“IonQ Defendants”). Both the Leacock Litigation and Fisher Litigation, which have been consolidated into a single action, allege violations of Section 10(b) of the Exchange Act, and Rule
10b-5
promulgated thereunder, and Section 20(a) of the Exchange Act and seek damages. In September 2022, the Court appointed lead plaintiffs and counsel for lead plaintiffs, and ordered lead plaintiffs to file a consolidated amended complaint. The consolidated amended complaint was filed on November 22, 2022. As part of the consolidated amended complaint, certain members of the Company’s board of directors as well as other dMY-related defendants (“Additional Defendants”) have been added as defendants to the case. On February 7, 2023, the IonQ Defendants and the Additional Defendants each filed a motion to dismiss the consolidated amended complaint. Both the IonQ Defendants and Additional Defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the associated suit.
Glatt Litigation
On January 12, 2021, dMY Technology Group, Inc. II, dMY Sponsor II, LLC, dMY, and dMY Sponsor III, LLC (“Sponsor”) accepted service of a lawsuit where they were named as counterclaim defendants in an underlying action by and between GTY Technology Holdings, Inc. (“GTY”), dMY Technology Holdings Inc., dMY Sponsor, LLC, dMY Sponsor II, LLC, dMY Technology Group Inc. II, dMY and Sponsor (collectively “dMY Defendants”) and Carter Glatt (“Glatt”) and Captains Neck Holdings LLC (“Captains Neck”), an entity of which Mr. Glatt is a member. The underlying lawsuit, filed by dMY Technology Group, Inc. and dMY Sponsor, LLC, seeks a declaratory judgment that Glatt and Captains Neck are not entitled to membership units of dMY Sponsor LLC, which was formed by Harry L. You, the
co-founder
and former President and Chief Financial Officer of GTY when Glatt was still working at GTY. The underlying lawsuit contains claims arising from Glatt’s termination of employment from GTY, including theft and misappropriation of confidential GTY information, breach of contract, breach of the duties of loyalty and fiduciary duty and conversion. Glatt responded to the underlying lawsuit by adding members of the Sponsor and officers of dMY as additional counterclaim defendants (collectively with the dMY Defendants Glatt and Captains Neck, the “Counterclaim Defendants”) and adding Dune Acquisition Holdings LLC, a newly formed special purpose acquisition company, as a counterclaimant and asserting claims for breach of contract, fraudulent misrepresentation, negligent misrepresentation, tortious interference with business relations, quantum meruit and unjust enrichment. dMY, and now the Company, has never employed Glatt and has no business agreements with him. The Counterclaim Defendants have denied the claims against them and have filed a motion to dismiss the suit. Although the outcome of this matter cannot be predicted with certainty and the impact of the final resolution of this matter on the Company’s results of operations in a particular subsequent reporting period is not known, management does not believe that the resolution of this matter will have a material adverse effect on the Company’s future consolidated financial position, future results of operations or cash flows.
9. WARRANT TRANSACTION AGREEMENT
In November 2019, contemporaneously with a revenue arrangement, the Company entered into a contract, pursuant to which the Company agreed to issue to a customer warrants to acquire shares of Legacy IonQ Series
B-1
preferred stock (the “Warrant Shares”), subject to certain vesting events. Upon closing of the Business Combination, these warrants exercisable for Legacy IonQ Series
B-1
preferred stock were assumed by the Company and converted into a warrant to purchase shares of common stock. Except as specifically provided in the Merger Agreement, the Warrant Shares will have the same terms and be subject to the same conditions (including applicable vesting conditions) as set forth in the Legacy IonQ warrant agreement. As of March 31, 2023, the contract allows for the customer to acquire up to 8,301,202 shares of common stock in the Company.
As the Warrant Shares were issued in connection with an existing commercial agreement with a customer, the value of the Warrant Shares was determined to be consideration payable to the customer and consequently is treated as a reduction to revenue recognized under the corresponding revenue arrangement.
 
16

Approximately 6.5% of the Warrant Shares vested and became immediately exercisable in August 2020. The fair value of the vested Warrant Shares was amortized over time as the related customer revenue was earned and was fully amortized as of December 31, 2021. The remaining Warrant Shares will vest and become exercisable upon satisfaction of certain milestones based on revenue generated under the commercial agreement with the customer, to the extent certain prepayments are made by the customer. The exercise price
for
the Warrant Shares is $1.38 per share and the warrant is exercisable through November 2029. The fair value of the Warrant Shares at the date of issuance was determined to be $8.7 million.
10. WARRANT LIABILITIES
The Company assumed 7,500,000 public warrants on September 30, 2021 as part of the Business Combination. As of March 31, 2023, there were 5,231,486 public warrants to purchase common stock outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per share.
Public warrants
The public warrants may be exercised on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering of dMY; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their public warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The public warrants became exercisable on November 17, 2021.
Redemption of warrants when the price per share of common stock equals or exceeds $18.00:
Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash:
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within
30-trading day
period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.
Redemption of warrants for when the price per share of common stock equals or exceeds $10.00:
Once the warrants become exercisable, the Company may redeem the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value (as defined within the warrant agreement) of the common stock except as otherwise described within the warrant agreement; and upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of common stock equals or exceeds $10.00 per public share (as adjusted) for any 20 trading days within
the 30-trading day
period ending three trading days before the Company sends notice of redemption to the warrant holders.
No
 public warrants had been redeemed by the Company as of March 31, 2023. 
11. STOCK-BASED COMPENSATION
Equity Incentive Plans
The Company has a 2015 Equity Incentive Plan (the “2015 Plan”), which provided for the grant of share-based compensation to certain officers, directors, employees, consultants, and advisors. Upon the closing of the Business Combination, no further awards were made pursuant to the 2015 Plan and all outstanding Legacy IonQ stock options under the 2015 Plan were assumed by the Company. Each Legacy IonQ stock option issued and outstanding immediately prior to the Business Combination was converted into an option to purchase shares of common stock of the Company equal to the product of (a) the number of shares of Legacy IonQ common stock subject to such Legacy IonQ stock option agreement immediately prior to the Business Combination and (b) the exchange ratio at an exercise price equal to the (i) the exercise price per share of such Legacy IonQ stock option divided by (ii) the exchange ratio. Such stock options will continue to be governed by the terms of the 2015 Plan and the stock option agreements thereunder, until such outstanding options are exercised or until they terminate or expire by their terms. For awards granted under the 2015 Plan, vesting generally occurs over four to five years from the date of grant.
In August 2021, the Company’s board of directors adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which was subsequently approved by the Company’s stockholders in September 2021, and became effective upon the closing of the Business Combination. The 2021 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSU”), performance awards and other forms of awards to employees, directors, and consultants. The number of shares of the Company’s common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each year, beginning on January 1, 2022, and continuing through and including January 1, 2031, by 5% of the Fully Diluted Common Stock (as defined in the 2021 Plan) outstanding on December 31 of the preceding year, or a lesser number of shares
 
17

determined by the Company’s board of directors prior to such increase. As of January 1, 2023, the number of shares reserved for issuance under the 2021 Plan increased by 13,587,593. For awards granted under the 2021 Plan, vesting terms range from one to four years from the date of grant. As of March 31, 2023, the Company had
37,279,201
 shares available for grant under the 2021 Plan.
Under both equity incentive plans, all options granted have a contractual term of 10 years.
Stock Options
The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option- pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option.
Expected Volatility
—As the Company was privately held until 2021 and there has been limited history of a public market for its common stock prior to closing the Business Combination, the expected volatility is based on the average historical stock price volatility of comparable publicly-traded companies in its industry peer group, financial, and market capitalization data.
Expected Term
—The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding.
The Company has estimated the expected term of its employee awards using the SAB Topic 14 Simplified Method allowed by the FASB and SEC, for calculating expected term as it has limited historical exercise data to provide a reasonable basis upon which to otherwise estimate expected term. Certain of the Company’s options began vesting prior to the grant date, in which case the Company uses the remaining vesting term at the grant date in the expected term calculation.
Risk-Free Interest Rate
—The Company estimates its risk-free interest rate by using the yield on actively traded
on-inflation-indexed
U.S. treasury securities with contract maturities equal to the expected term.
Dividend Yield
—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero.
Fair Value of Underlying Common Stock
—For options granted under the 2015 Plan, because the Company’s common stock was not yet publicly traded on the date of grant, the Company estimated the fair value of common stock prior to closing the Business Combination. The board of directors considered numerous objective and subjective factors to determine the fair value of the Company’s common stock at each meeting in which awards were approved. The factors considered included, but were not limited to: (i) the results of contemporaneous independent third-party valuations of the Company’s common stock; (ii) the prices, rights, preferences, and privileges of Legacy IonQ’s previously Convertible Redeemable Preferred Stock relative to those of its common stock; (iii) the lack of marketability of the Company’s common stock; (iv) actual operating and financial results; (v) current business conditions and projections; (vi) the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company, given prevailing market conditions; and (vii) precedent transactions involving the Company’s shares. For options granted under the 2021 Plan, the Company utilizes the closing stock price on the date of grant as the fair value of the common stock underlying such options.
The assumptions used to estimate the fair value of stock options granted during the three months ended March 31, 2023 and 2022, are as follows:
 
    
Three Months Ended
March 31,
 
    
2023
   
2022
 
Risk-free interest rate
            1.76
Expected term (in years)
     —         5.63  
Expected volatility
            77.48
Dividend yield
              
The stock option activity is summarized in the following table:
 
    
Number of
Option
Shares
    
Weighted
Average
Exercise
Price
    
Weighted
Average
Remaining
Contractual
Term (Years)
    
Aggregate
Intrinsic
Value
(in millions)
 
Outstanding as of December 31, 2022
     24,716,270      $ 2.19        7.32      $ 49.69  
Granted
                                     
Exercised
     (131,492      0.40                    
Cancelled/ Forfeited
     (296,628      1.58                    
    
 
 
                            
Outstanding as of March 31, 2023
     24,288,150      $ 2.21        7.09      $ 108.06  
    
 
 
                            
Exercisable as of March 31, 2023
     12,571,954      $ 0.96        7.27      $ 67.93  
Exercisable and expected to vest as of March 31, 2023
     24,288,150      $ 2.21        7.09      $ 108.06  
 
18

The following table summarizes additional information on stock option grants, vesting and exercises (in millions, except per share amounts):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Total intrinsic value of options exercised
   $ 0.8      $ 5.7  
Aggregate grant-date fair value of options vested
   $ 3.3      $ 2.2  
Weighted-average grant date fair value per share for options granted
   $         $ 12.87  
Early Exercised Stock Options
As of March 31, 2023 and December 31, 2022, there were 779,787 and 905,128 shares, respectively, subject to repurchase related to stock options early exercised and unvested. As of March 31, 2023 and December 31, 2022, the Company recorded a liability related to these shares subject to repurchase in the amount of $1.7 million and $2.0 million, respectively, in its condensed consolidated balance sheets. 
Restricted Stock Units
The RSU activity is summarized in the following table:
 
    
Number of
RSUs
    
Weighted
Average
Grant
Date Fair
Value
    
Weighted
Average
Remaining
Contractual
Term (Years)
    
Aggregate
Fair Value
(in millions)
 
Outstanding as of December 31, 2022
     9,320,045      $ 7.02        3.21      $ 65.38  
Granted
                                     
Vested
     (524,711      8.39                    
Forfeited
     (235,613      5.04                    
    
 
 
                            
Outstanding as of March 31, 2023
     8,559,721      $ 6.99        2.99      $ 59.79  
    
 
 
                            
Expected to vest after March 31, 2023
     8,518,721      $ 6.96        3.01      $ 59.26  
Stock-Based Compensation Expense
Total stock-based compensation expense for stock option awards and RSU awards, which are included in the condensed consolidated financial statements, is as follows (in thousands):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Cost of revenue
   $ 349      $ 104  
Research and development
     5,280        1,698  
Sales and marketing
     764        73  
General and administrative
     3,875        4,797  
    
 
 
    
 
 
 
Stock-based compensation, net of amounts capitalized
     10,268        6,672  
Capitalized stock-based compensation—Intangibles and fixed assets
     619        176  
    
 
 
    
 
 
 
Total stock-based compensation
   $ 10,887      $ 6,848  
    
 
 
    
 
 
 
Unrecognized Stock-Based Compensation
A summary of our remaining unrecognized compensation expense and the weighted-average remaining amortization period as of March 31, 2023, related to our
non-vested
stock options and RSU awards is presented below (in millions, except time period amounts):
 
    
Unrecognized
Expense
    
Weighted-
Average
Amortization
Period (Years)
 
Restricted stock units
   $ 54.7        1.5  
Stock options
   $ 40.6        1.5  
Employee Stock Purchase Plan
In August 2021, the Company’s board of directors adopted the Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders in September 2021, and became effective upon the closing of the Business Combination. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The number of shares of common stock initially reserved for issuance under the ESPP was 5,354,000 shares. The ESPP provides for an annual increase on January 1 of each year, beginning on January 1, 2022, and continuing through and including January 1, 2031, equal to the lesser of (i) 1% of the fully diluted shares of common stock outstanding on the last day of the prior fiscal year, (ii) 10,708,000 shares, or (iii) a lesser number of shares determined by the Company’s board of directors prior to such increase. The board of directors elected not to approve the annual increase of ESPP shares on January 1, 2023.
 
19

Under the terms of the ESPP, eligible employees can elect to acquire shares of the Company’s common stock through periodic payroll deductions during a series of offering periods. Purchases under the ESPP are affected on the last business day of each offering period at a 15% discount to the lower of closing price on that day or the closing price on the first day of the offering period. As of March 31, 2023, no shares of common stock had been issued under the ESPP and no offering period had been set by the board of directors.
12. INCOME TAXES
The Company had no provision for income taxes in any period presented. The effective tax rate for each period differs from the statutory rate primarily as a result of not recognizing a deferred tax asset for losses due to having a full valuation allowance against deferred tax assets.
The realization of tax benefits of deferred tax assets is dependent upon future levels of taxable income, of an appropriate character, in the periods the items are expected to be deductible or taxable. Based on the available objective evidence, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets as of March 31, 2023, and December 31, 2022. The Company intends to maintain the remaining valuation allowance until sufficient positive evidence exists to support a reversal of, or decrease in, the valuation allowance.
13. LEASES
The Company has two operating leases for its facilities in College Park, Maryland, and Bothell, Washington. The College Park, Maryland facility is used for research and development and corporate functions and is leased from UMD. Refer to Note 14 for further information. The Bothell, Washington, facility is used for manufacturing, research and development and general office space. Both leases expire in 2030. As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term was 7.3 years and 7.9
 years, respectively, and the weighted-average discount rate 
was 9.8%
and
11.9
%,
respectively.
The Bothell, Washington facility lease includes a landlord-provided tenant improvement allowance to offset a portion of the costs of the construction of leasehold improvements. The Company determined that the leasehold improvements will be Company-owned, and as such, reflected the lease incentive as a reduction of lease payments used to measure the operating lease liability and ROU asset as of the lease commencement date.
The components of lease cost were as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Operating lease cost
(1)
                 
Fixed lease cost
   $ 360      $ 191  
Short-term cost
     43        6  
    
 
 
    
 
 
 
Total operating lease cost
   $ 403      $ 197  
 
(1)
The lease costs are reflected in the condensed consolidated statements of operations as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Cost of revenue
   $ 14      $ 14  
Research and development
     172        146  
Sales and marketing
     13        7  
General and administrative
     204        30  
    
 
 
    
 
 
 
Total
   $ 403      $ 197  
    
 
 
    
 
 
 
Supplemental cash flow and other information related to operating leases was as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Cash payments included in the measurement of operating lease liabilities
   $ 166      $ 161  
As of March 31, 2023, maturities of operating lease liabilities are as follows (in thousands):
 
 
  
Amount
 
Year Ending December 31,
  
2023
   $ 559  
2024
     1,831  
2025
     2,309  
2026
     2,378  
2027
     2,449  
Thereafter
     6,385  
    
 
 
 
Total lease payments
     15,911  
Less: imputed interest
     (4,795)  
Less: lease incentives
     (4,882)  
    
 
 
 
Present value of operating lease liabilities
   $ 6,234  
    
 
 
 
 
20

14. RELATED PARTY TRANSACTIONS
Transactions with UMD and Duke
As described in Note 6, the Company entered into a License Agreement and Option Agreement with UMD and Duke whereby the Company, in the normal course of business, has licensed certain intellectual property and, in the case of the amendments to the Option Agreements, has purchased research and development services. The Company considers these agreements to be related party transactions because the Company’s
Co-founder
and Chief Technology Officer serves as a professor at Duke and the Company’s
Co-founder
and Chief Scientist served as a professor at UMD. During 2021, the Company’s Chief Scientist moved to Duke and each, in their role as professors at Duke, are leading the research subject to the License Agreement and Option Agreement with Duke as of March 31, 2023.
In addition, the Company has an operating lease for office space with UMD, which expires in 2030. Under the lease, for each of the three months ended March 31, 2023 and 2022, the Company incurred fixed lease costs of $0.2 million and made lease payments of $0.2 million. Future minimum lease payments as of March 31, 2023, are $6.2 million. As of March 31, 2023 and December 31, 2022, the remaining lease term was 7.7 years and 7.9 years, respectively. As of both March 31, 2023, and December 31, 2022, the weighted-average discount rate was 11.9%.
In September 2021, the Company entered into a contract with UMD to provide certain quantum computing services and facility access (the “UMD Quantum Agreement”) related to the National Quantum Lab at UMD in exchange for payments totaling $14.0 million over three years. Over the term of the contract, the Company estimates that it will make payments to UMD of approximately $1.4 million, including a contribution of $1.0 million to establish the IonQ Endowed Professorship in the College of Computer, Mathematical and Natural Sciences at UMD. The pledge and other estimated payments to UMD will not be an exchange for distinct goods or services under the provisions of ASC 606 and therefore are considered a reduction of the transaction price for the UMD Quantum Agreement. The transaction price is currently estimated at $12.6 million, reflecting this reduction.
In July 2022, the Company entered into an agreement to provide customized quantum computing hardware to UMD for a transaction price of $0.7 million.
The Company’s results from transactions with related parties, as reflected in the condensed consolidated statements of operations are detailed below. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Revenue
   $ 992      $ 992  
Cost of revenue
     13        14  
Research and development ($130 and $130 attributable to Duke)
     275        271  
Sales and marketing ($10 and zero attributable to Duke)
     20        32  
General and administrative
     47        29  
The Company has the following balances related to transactions with related parties, as reflected in the condensed consolidated balance sheets. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Assets
                 
Prepaid expenses and other current assets ($520 and $520 attributable to Duke)
   $ 525      $ 529  
Operating lease
right-of-use
asset
     3,680        3,753  
Other noncurrent assets ($1,195 and $1,325 attributable to Duke)
     1,195        1,325  
Liabilities
                 
Accounts payable
     81        29  
Accrued expenses
     88            
Current operating lease liabilities
     610        591  
Unearned revenue
     2,448        3,514  
Non-current
operating lease liabilities
     3,393        3,459  
15. GEOGRAPHIC INFORMATION
Revenue generated for customers located in the United States was approximately 86% and 87% of revenue for the three months ended March 31, 2023 and 2022, respectively.
 
21


Table of Contents
Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve substantial risks and uncertainties. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believes,” “expects,” “intends,” “estimates,” “projects,” “anticipates,” “will,” “plan,” “may,” “should,” or similar language are intended to identify forward-looking statements.

It is routine for our internal projections and expectations to change throughout the year, and any forward-looking statements based upon these projections or expectations may change prior to the end of the next quarter or year. Readers of this Quarterly Report on Form 10-Q are cautioned not to place undue reliance on any such forward-looking statements. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties are identified under “Risk Factors” in Item 1A herein and in our other filings with the Securities and Exchange Commission (the “SEC”). All forward-looking statements included herein are made only as of the date hereof. Unless otherwise required by law, we do not undertake, and specifically disclaim, any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise after the date of such statement.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, and our audited consolidated financial statements and related notes for the year ended December 31, 2022, filed with the SEC on March 30, 2023. Unless the context otherwise requires, the terms “IonQ,” “Legacy IonQ” “we,” “us,” “our” and similar terms refer to IonQ Quantum, Inc. prior to the consummation of the Business Combination and IonQ, Inc. and its wholly owned subsidiaries after the consummation of the Business Combination. References to “dMY” refer to the predecessor company prior to the consummation of the Business Combination.

Overview

We are developing quantum computers designed to solve some of the world’s most complex problems, and transform business, society and the planet for the better. We believe that our proprietary technology, our architecture, and the technology exclusively available to us through license agreements will offer us advantages both in terms of research and development, as well as the commercial value of our intended product offerings.

Today, we sell access to several quantum computers of various qubit capacities and are in the process of researching and developing technologies for quantum computers with increasing computational capabilities. We currently make access to our quantum computers available via three major cloud platforms, Amazon Web Services’ (“AWS”) Amazon Braket, Microsoft’s Azure Quantum and Google’s Cloud Marketplace, and also to select customers via our own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (“QCaaS”).

We supplement our QCaaS offering with professional services focused on assisting our customers in applying quantum computing to their businesses. We also expect to sell full quantum computing systems to customers, either over the cloud or for local access.

We are still in the early stages of commercial growth. Since our inception we have incurred significant operating losses. Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful development and further commercialization of our quantum computing systems. Our net losses were $27.3 million and $4.2 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, we had an accumulated deficit of $221.6 million. We expect to continue to incur significant losses for the foreseeable future as we prioritize reaching the technical milestones necessary to achieve an increasingly higher number of stable qubits and higher levels of fidelity than presently exists—prerequisites for quantum computing to reach broad quantum advantage.

 

22


Table of Contents

Business and Technical Highlights

 

   

We signed a contract with the United Emirates Quantum Research Center - Technology Innovation Institute to explore how quantum computing can give the nation a competitive edge.

 

   

In collaboration with Fidelity Center for Applied Technology, or FCAT, we were proud to announce new work in the field of Quantum Monte Carlo. This newest accomplishment focuses on speeding up Monte Carlo simulations, a widely-used statistical analysis method in finance, science, and engineering.

 

   

We launched a partnership with BearingPoint, a global management and technology consulting firm, to bolster their growing quantum team in Europe.

 

   

We achieved 29 #AQ on IonQ Forte, our latest world-class quantum system, reaching our most significant 2023 technical goal seven months ahead of our technical roadmap. This is a 16x increase in computational power, measured by useful computational space for running algorithms, compared to IonQ Aria with 25 #AQ.

 

   

We completed construction of IonQ Aria 2, a second Aria-class quantum computer. This new machine will join IonQ Aria 1 on the public cloud this quarter.

 

   

We published research results on modeling human cognition using quantum hardware in the peer-reviewed scientific journal, Entropy. This is the first output of work we initiated a year ago on quantum artificial intelligence, or quantum AI.

 

   

We hired Pat Tang as Vice President of Research and Development. Pat brings over 23 years of technology experience, most recently as Vice President of Engineering at Amazon’s Lab126.

Impact of the Macroeconomic Climate on Our Business

The recent trends towards rising inflation may materially adversely affect our business and corresponding financial position and cash flows. Inflationary factors, interest rates and overhead costs may adversely affect our operating results. Rising interest and inflation rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue to rise) on our operating costs, including our labor, due to supply chain constraints, consequences associated with bank failures and the Russia-Ukraine war, and employee availability and wage increases, which may result in additional stress on our working capital resources.

The Merger Agreement

On March 7, 2021, Legacy IonQ, dMY and Ion Trap Acquisition Inc. (the “Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, at the closing, the Merger Sub was merged with and into Legacy IonQ, with Legacy IonQ continuing as the surviving corporation following the merger, being a wholly owned subsidiary of dMY and the separate corporate existence of the Merger Sub ceased (the “Business Combination”). Commensurate with the Business Combination, dMY changed its name to IonQ, Inc. and Legacy IonQ changed its name to IonQ Quantum, Inc. IonQ became the successor registrant with the SEC, meaning that Legacy IonQ’s financial statements for previous periods will be disclosed in the registrant’s future periodic reports filed with the SEC.

Key Components of Results of Operations

Revenue

We have generated limited revenues since our inception. We derive revenue from providing access to QCaaS, consulting services related to co-developing algorithms on our quantum computing systems, and from contracts associated with the design, development, and construction of specialized quantum computing systems together with related services. In arrangements with the cloud service providers, the cloud service provider is considered the customer and we do not have any contractual relationships with the cloud service providers’ end users.

We have determined that our QCaaS contracts represent a combined, stand-ready performance obligation to provide access to our quantum computing systems together with related maintenance and support. The transaction price generally includes a variable fee based on usage of our quantum computing systems and may include a fixed fee for a minimum volume of usage to be made available over a defined period of access. Fixed fee arrangements may also include a variable component whereby customers pay an amount for usage over contractual minimums contained in the contracts. We have determined that contracts that contain consulting services related to co-developing quantum computing algorithms and the ability to use our quantum computing systems to run such algorithms represent a combined performance obligation that is satisfied over-time with revenue recognized based on the efforts incurred to date relative to the total expected effort.

Certain of our contracts contain multiple performance obligations, most commonly in contracts for specialized quantum computing systems together with related maintenance and support. Such contracts may also include access to our QCaaS. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. When there are multiple performance obligations in a contract, we allocate the transaction price to each performance obligation based on its standalone selling price when available. We determine standalone selling price based on the observable price of a product or service when we sell the products or services separately in similar circumstances and to similar customers. When the standalone selling price is not known, due to it being either highly variable or uncertain, we allocate the transaction price using the residual approach.

For contracts with a fixed transaction price, the fixed fee is recognized on a straight-line basis over the access period or associated measure of progress for our consulting services contracts. For contracts without fixed fees, variable usage fees are billed and recognized during the period of such usage. Performance obligations are satisfied over-time if the customer receives the benefits as we perform the work, if the customer controls the asset as it is being produced (continuous transfer of control), or if the product being produced for the customer has no alternative use and we have a contractual right to payment for performance to date. Revenue is recognized on performance obligations satisfied over time based on the efforts incurred to date relative to the total expected effort.

We are currently focused on marketing our QCaaS and consulting services and have entered into, and are continuing to enter into, new contracts with customers. We have also engaged with certain prospects who are interested in purchasing entire quantum computers, either over the cloud or for local access.

Operating Costs and Expenses

Cost of revenue

Cost of revenue primarily consists of expenses related to delivering our services, including personnel-related expenses, allocated facility and other costs for customer facing functions, and costs associated with maintaining our in-service quantum computing systems to ensure proper calibration as well as costs incurred for maintaining the cloud on which the QCaaS resides. Cost of revenue also includes hardware costs for construction of specialized quantum computing systems. Personnel-related expenses include salaries, benefits, and stock-based compensation. Cost of revenue excludes depreciation and amortization related to our quantum computing systems and related software.

 

23


Table of Contents

Research and development

Research and development expenses consist of personnel-related expenses, including salaries, benefits and stock-based compensation, and allocated facility and other costs for our research and development functions. Unlike a standard computer, design and development efforts continue throughout the useful life of our quantum computing systems to ensure proper calibration and optimal functionality. Research and development expenses also include purchased hardware and software costs related to quantum computing systems constructed for research purposes that are not probable of providing future economic benefit and have no alternate future use as well as costs associated with third-party research and development arrangements.

Sales and marketing

Sales and marketing expenses consist of personnel-related expenses, including salaries, benefits and stock-based compensation, costs for direct advertising, marketing and promotional expenditures and allocated facility and other costs for our sales and marketing functions. We expect to continue to make the necessary sales and marketing investments to enable us to increase our market penetration and expand our customer base.

General and administrative

General and administrative expenses consist of personnel-related expenses, including salaries, benefits and stock-based compensation, and allocated facility and other costs for our corporate, executive, finance, and other administrative functions. General and administrative expenses also include expenses for outside professional services, including legal, auditing and accounting services, recruitment expenses, information technology, travel expenses, certain non-income taxes, insurance, and other administrative expenses.

We expect our general and administrative expenses to increase for the foreseeable future as we scale headcount with the growth of our business, and as a result of operating as a public company, including compliance with the rules and regulations of the SEC, NYSE, legal, audit, additional insurance expenses, investor relations activities, and other administrative and professional services. As a result, we expect that our general and administrative expenses will increase in absolute dollars but may fluctuate as a percentage of total revenue over time.

Depreciation and amortization

Depreciation and amortization expense results from depreciation and amortization of our property and equipment, including our quantum computing systems, and intangible assets that are recognized over their estimated lives.

Nonoperating Costs and Expenses

Change in fair value of warrant liabilities

The change in fair value of warrant liabilities consists of mark-to-market fair value adjustments recorded associated with the public warrants assumed as part of the Business Combination.

Interest income, net

Interest income, net consists of income earned on our money market funds and other available-for-sale investments.

Other income (expense), net

Other income (expense), net consists of realized losses on our available-for-sale investments and certain other expenses.

 

 

24


Table of Contents

Results of Operations

The following table sets forth our statements of operations for the periods indicated:

 

     Three Months Ended
March 31,
 
     2023      2022  
  

 

 

    

 

 

 
     (in thousands)  

Revenue

   $ 4,285      $ 1,953  

Costs and expenses:

     

Cost of revenue (excluding depreciation and amortization)(1)

     1,036        568  

Research and development (1)

     16,233        7,338  

Sales and marketing(1)

     2,667        1,871  

General and administrative(1)

     10,581        9,194  

Depreciation and amortization

     1,791        1,266  
  

 

 

    

 

 

 

Total operating costs and expenses

     32,308        20,237  
  

 

 

    

 

 

 

Loss from operations

     (28,023      (18,284

Change in fair value of warrant liabilities

     (3,610      13,448  

Interest income, net

     4,231        608  

Other income (expense), net

     64        1  
  

 

 

    

 

 

 

Loss before benefit for income taxes

     (27,338      (4,227

Benefit for income taxes

     —          —    
  

 

 

    

 

 

 

Net loss

   $ (27,338    $ (4,227
  

 

 

    

 

 

 

 

(1)

Cost of revenue, research and development, sales and marketing, and general and administrative expenses for the periods include stock-based compensation expense as follows:

 

     Three Months Ended
March 31,
 
     2023      2022  
  

 

 

    

 

 

 
     (in thousands)  

Cost of revenue

   $ 349      $ 104  

Research and development

     5,280        1,698  

Sales and marketing

     764        73  

General and administrative

     3,875        4,797  

Comparison of the Three Months Ended March 31, 2023 and 2022

Revenue

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Revenue

   $ 4,285      $ 1,953      $ 2,332        119

Revenue increased by $2.3 million, or 119%, to $4.3 million for the three months ended March 31, 2023, from $2.0 million for the three months ended March 31, 2022. The increase was primarily driven by new revenue contracts under which we provided services during the three months ended March 31, 2023.

Cost of revenue

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Cost of revenue (excluding depreciation and amortization)

   $ 1,036      $ 568      $ 468        82

Cost of revenue increased by $0.5 million, or 82%, to $1.0 million for the three months ended March 31, 2023, from $0.6 million for the three months ended March 31, 2022. The increase was driven primarily by the increase in labor costs to service contracts for the three months ended March 31, 2023.

 

 

25


Table of Contents

Research and development

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Research and development

   $ 16,233      $ 7,338      $ 8,895        121

Research and development expense increased by $8.9 million, or 121%, to $16.2 million for the three months ended March 31, 2023, from $7.3 million for the three months ended March 31, 2022. The increase was primarily driven by a $7.7 million increase in payroll-related expenses, including an increase in stock-based compensation of $3.6 million, as a result of increased headcount and a $0.6 million increase in professional service costs to support research and development initiatives.

Sales and marketing

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Sales and marketing

   $ 2,667      $ 1,871      $ 796        43

Sales and marketing expense increased by $0.8 million, or 43%, to $2.7 million for the three months ended March 31, 2023, from $1.9 million for the three months ended March 31, 2022. The increase was primarily due to an increase of $0.6 million of payroll-related expenses as a result of increased headcount, and increased costs to promote our services and other marketing initiatives of approximately $0.2 million.

General and administrative

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

General and administrative

   $ 10,581      $ 9,194      $ 1,387        15

General and administrative expenses increased by $1.4 million, or 15%, to $10.6 million for the three months ended March 31, 2023, from $9.2 million for the three months ended March 31, 2022. The increase was primarily driven by an increase of $2.3 million in payroll-related expenses, including an increase in stock-based compensation of $1.3 million, due to increased headcount, offset by a decrease of $2.2 million in one-time stock-based compensation costs incurred in the three months ended March 31, 2022. The remaining increase is primarily due to an increase of $1.2 million in professional services fees as we scale our business as a public company.

Depreciation and amortization

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Depreciation and amortization

   $ 1,791      $ 1,266      $ 525        41

Depreciation and amortization expenses increased by $0.5 million, or 41%, to $1.8 million for the three months ended March 31, 2023, from $1.3 million for the three months ended March 31, 2022. The increase was primarily driven by an increase of $0.2 million due to amortization of capitalized internally developed software and an increase of $0.1 million in depreciation expense associated with capitalized quantum computing system costs.

Change in fair value of warrant liabilities

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Change in fair value of warrant liabilities

   $ (3,610    $ 13,448      $ (17,058      (127 )% 

The change in fair value of warrant liabilities decreased by $17.1 million, or 127%, to a loss of $3.6 million for the three months ended March 31, 2023, from a gain of $13.4 million for the three months ended March 31, 2022. The decrease was primarily due to mark-to-market adjustments based on changes in the trading price for the public warrants.

 

 

26


Table of Contents

Interest income, net

 

     Three Months Ended
March 31,
     $
Change
     %
Change
 
     2023      2022                
  

 

 

    

 

 

       
     (in thousands)                

Interest income, net

   $ 4,231      $ 608      $ 3,623        596

Interest income, net increased by $3.6 million, or 596%, to $4.2 million for the three months ended March 31, 2023, from $0.6 million for the three months ended March 31, 2022. The increase was primarily driven by interest income earned on our cash equivalents and available-for-sale investments due to higher interest rates.

Liquidity and Capital Resources

As of March 31, 2023, we had cash, cash equivalents and available-for-sale securities of $525.5 million. Excluded from our available liquidity is $2.0 million of restricted cash, which is recorded in other noncurrent assets in our condensed consolidated balance sheets. We believe that our cash, cash equivalents and investments as of March 31, 2023, will be sufficient to meet our working capital and capital expenditure needs for the next 12 months. We believe we will meet longer term expected future cash requirements and obligations through a combination of cash flows from operating activities and available funds from our cash, cash equivalents and investment balances. However, this determination is based upon internal projections and is subject to changes in market and business conditions. We have incurred significant losses since our inception and as of March 31, 2023, we had an accumulated deficit of $221.6 million. During the three months ended March 31, 2023, we incurred net losses of $27.3 million. We expect to incur significant losses and higher operating expenses for the foreseeable future.

Future Funding Requirements

We expect our principal sources of liquidity will continue to be our cash, cash equivalents and investments and any additional capital we may obtain through additional equity or debt financings. Our future capital requirements will depend on many factors, including investments in growth and technology. We may, in the future, enter into arrangements to acquire or invest in complementary businesses, services, and technologies, which may require us to seek additional equity or debt financing.

Our primary uses of cash and investments are to fund our operations as we continue to grow our business. We require a significant amount of cash for expenditures as we invest in ongoing research and development and commercialization of our products. Until such time as we can generate significant revenue from commercializing our quantum computing technology, if ever, we expect to finance our liquidity needs through our cash, cash equivalents and investments, as well as equity or debt financings or other capital sources, including potential collaborations and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Rising interest and inflation rates present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our quantum computing technology on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our quantum computing development efforts. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled “Risk Factors.”

Other than operating expenses and our continued investment in our quantum computers, cash requirements for fiscal year 2023 are expected to consist primarily of capital expenditures for corporate facilities.

Our material cash requirements as of March 31, 2023, include operating lease commitments, including the lease of our headquarters in College Park, Maryland and our manufacturing and office space in Bothell, Washington. As of March 31, 2023, we have total operating lease obligations of $15.9 million, with $0.9 million payable within 12 months.

Cash flows

The following table summarizes our cash flows for the period indicated:

 

     Three Months Ended
March 31,
 
     2023      2022  
  

 

 

    

 

 

 
     (in thousands)  

Net cash used in operating activities

   $ (13,815)      $ (8,324

Net cash provided by (used in) investing activities

     21,315        (304,098

Net cash provided by financing activities

     34        148  

 

27


Table of Contents

Cash flows from operating activities

Our cash flows from operating activities are significantly affected by the growth of our business, primarily related to research and development, sales and marketing, and general and administrative activities. Our operating cash flows are also affected by our working capital needs to support growth in personnel-related expenditures and fluctuations in accounts payable and other current assets and liabilities.

Net cash used in operating activities during the three months ended March 31, 2023, was $13.8 million, resulting primarily from a net loss of $27.3 million, adjusted for non-cash activity, primarily related to the loss recorded as a result of mark-to-market activity for our public warrants, stock-based compensation and other working capital activities. The increase in net cash used in operations from the prior year period was primarily related to increased research and development activities, increased compensation costs as a result of hiring personnel and increased costs incurred as a public company.

Net cash used in operating activities during the three months ended March 31, 2022, was $8.3 million, resulting primarily from a net loss of $4.2 million, adjusted for non-cash activity, primarily related to the loss recorded as a result of mark-to-market activity for our public and private warrants, stock-based compensation and offering costs associated with warrants, as well as other working capital activities. The increase in net cash used in operations from the prior year period was primarily related to increased research and development activities, increased compensation costs as a result of hiring personnel and increased costs incurred as a public company.

Cash flows from investing activities

Net cash provided by investing activities during the three months ended March 31, 2023, was $21.3 million, primarily resulting from cash received from sales and maturities of available-for-sale investments of $88.1 million, offset by purchases of available-for-sale securities of $64.4 million and additions of $1.2 million to property and equipment primarily related to the development of our quantum computing systems.

Net cash used in investing activities during the three months ended March 31, 2022, was $304.1 million, primarily resulting from purchases of available-for-sale securities of $311.2 million, additions of $2.7 million to property and equipment primarily related to the development of our quantum computing systems, offset by cash received from maturities of available-for-sale investments of $10.4 million.

Cash flows from financing activities

Net cash provided by financing activities during the three months ended March 31, 2023, was less than $0.1 million, primarily resulting from proceeds from stock options exercised.

Net cash provided by financing activities during the three months ended March 31, 2022, was $0.1 million primarily resulting from proceeds from stock options exercised.

Critical Accounting Estimates

This discussion and analysis of financial condition and results of operations is based upon the Company’s condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities. We also make estimates and assumptions on revenue generated and reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

There have been no material changes to our critical accounting estimates from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report.

Critical accounting estimates are defined as those reflective of significant judgments, estimates and uncertainties, which may result in materially different results under different assumptions and conditions. Within our Annual Report on Form 10-K, we have disclosed our critical accounting estimates that we believe to have the greatest potential impact on our consolidated financial statements. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results.

Recently Issued and Adopted Accounting Standards

See Note 2, Summary of Significant Accounting Policies, in the notes to our condensed consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.

Emerging Growth Company Status and Smaller Reporting Company Status

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. During the extended transition period, it may be difficult or impossible to compare our financial results with the financial results of another public company that complies with public company effective dates for accounting standard updates because of the potential differences in accounting standards used.

 

28


Table of Contents

We will remain an emerging growth company under the JOBS Act until the earliest of (a) December 31, 2025, (b) the last date of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (c) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th or (d) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the previous three-year period.

We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

 

29


Table of Contents
Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk related to changes in interest rates and concentration of credit. For a discussion of quantitative and qualitative disclosures about market risk, see Item 7A of Part II of our Annual Report. No material changes related to our market risks have occurred since December 31, 2022.

 

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2023, our disclosure controls and procedures were effective at a reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

30


Table of Contents

PART II—OTHER INFORMATION

 

Item 1.

Legal Proceedings.

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Future litigation may be necessary to defend ourselves. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

In May 2022, a securities class action complaint captioned Leacock v. IonQ, Inc. et al., Case No. 8:22-cv-01306, was filed by a stockholder of the Company in the United States District Court for the District of Maryland (the “Leacock Litigation”) against the Company and certain of the Company’s current officers. In June 2022, a securities class action complaint captioned Fisher v. IonQ, Inc., Case No. 8:22-cv-01306-DLB (the “Fisher Litigation”) was filed by a stockholder of the Company and certain of the Company’s current officers (“IonQ Defendants”). Both the Leacock Litigation and Fisher Litigation, which have been consolidated into a single action, allege violations of Section 10(b) of the Exchange Act, and Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act and seek damages. In September 2022, the Court appointed lead plaintiffs and counsel for lead plaintiffs, and ordered lead plaintiffs to file a consolidated amended complaint. The consolidated amended complaint was filed on November 22, 2022. As part of the consolidated amended complaint, certain members of the Company’s Board of Directors as well as other dMY-related defendants (the “Additional Defendants”) have been added as defendants to the case. On February 7, 2023, the IonQ Defendants and the Additional Defendants each filed a motion to dismiss the consolidated amended complaint. Both the IonQ Defendants and the Additional Defendants believe that the allegations in the various complaints are without merit and intend to defend the matters vigorously.

On March 2, 2023, we filed a petition in the Delaware Court of Chancery pursuant to Section 205 of the Delaware General Corporation Law, which permits the Court of Chancery, in its discretion, to validate potentially defective corporate acts. The petition sought an order of the Chancery Court validating and declaring effective (i) our Second Amended and Restated Certificate of Incorporation dated September 30, 2021 (the “A&R COI”), including its filing and effectiveness, as of the date and time that it was originally filed with the Delaware Secretary of State and (ii) all shares of our capital stock issued in reliance on the validity and effectiveness of the A&R COI as of the date and time of the original issuance of such shares. Although we believe the A&R COI and all shares issued under it were valid and effective at all relevant times, a recent decision of the Court of Chancery created uncertainty regarding the approval of the A&R COI by our stockholders in February 2021. On March 17, 2023, the Court of Chancery entered the requested order. In addition, at no point prior to March 17, 2023 had we issued or reserved for issuance shares in excess of the predecessor certificate of incorporation of the Company.

Please refer to Note 8, Commitments and Contingencies, to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further details on current legal proceedings.

 

31


Table of Contents
Item 1A.

Risk Factors.

RISK FACTORS

Investing in our securities involves a high degree of risk. Before you make a decision to buy our securities, you should carefully consider the risks and uncertainties described below together with all of the other information contained in this Quarterly Report on Form 10-Q. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.

Summary Risk Factors

Our business is subject to a number of risks of which you should be aware before making a decision to invest in our securities. These risks include, among others, the following:

 

   

We are an early-stage company and have a limited operating history, which makes it difficult to forecast our future results of operations.

 

   

We have a history of operating losses and expect to incur significant expenses and continuing losses for the foreseeable future.

 

   

We may not be able to scale our business quickly enough to meet customer and market demand, which could result in lower profitability or cause us to fail to execute on our business strategies.

 

   

We may not manage our growth effectively.

 

   

Our management has limited experience in operating a public company.

 

   

Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate.

 

32


Table of Contents
   

Even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all.

 

   

Our operating and financial results forecast relies in large part upon assumptions and analyses we developed. If these assumptions or analyses prove to be incorrect, our actual operating results may be materially different from our forecasted results.

 

   

We may need additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be sure that additional financing will be available.

 

   

We have not produced a scalable quantum computer and face significant barriers in our attempts to produce quantum computers.

 

   

The quantum computing industry is competitive on a global scale and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers.

 

   

Even if we are successful in developing quantum computing systems and executing our strategy, competitors in the industry may achieve technological breakthroughs that render our quantum computing systems obsolete or inferior to other products.

 

   

We may be unable to reduce the cost per qubit, which may prevent us from pricing our quantum systems competitively.

 

   

The quantum computing industry is in its early stages and volatile, and if it does not develop, if it develops slower than we expect, if it develops in a manner that does not require use of our quantum computing solutions, if it encounters negative publicity or if our solution does not drive commercial engagement, the growth of our business will be harmed.

 

   

If our computers fail to achieve a broad quantum advantage, our business, financial condition and future prospects may be harmed.

 

   

We could suffer disruptions, outages, defects and other performance and quality problems with our quantum computing systems or with the public cloud and internet infrastructure on which they rely.

 

   

We have and may continue to face supply chain issues that could delay the introduction of our product and negatively impact our business and operating results.

 

   

If we cannot successfully execute on our strategy or achieve our objectives in a timely manner, our business, financial condition and results of operations could be harmed.

 

   

Our products may not achieve market success, but will still require significant costs to develop.

 

   

We are highly dependent on our co-founders, and our ability to attract and retain senior management and other key employees is critical to our success.

 

   

We may not be able to accurately estimate the future supply and demand for our quantum computers, which could result in a variety of inefficiencies in our business and hinder our ability to generate revenue.

 

   

Our systems depend on the use of a particular isotope of an atomic element that provides qubits for our ion trap technology. If we are unable to procure these isotopically enriched atomic samples, or are unable to do so on a timely and cost-effective basis, and in sufficient quantities, we may incur significant costs or delays, which could negatively affect our operations and business.

 

   

If our quantum computing systems are not compatible with some or all industry-standard software and hardware in the future, our business could be harmed.

 

   

If we are unable to maintain our current strategic partnerships or we are unable to develop future collaborative partnerships, our future growth and development could be negatively impacted.

 

33


Table of Contents
   

Our business depends on our customers’ abilities to implement useful quantum algorithms and sufficient quantum resources for their business.

 

   

Our future growth and success depend in part on our ability to sell effectively to government entities and large enterprises.

 

   

Contracts with government and state agencies are subject to a number of challenges and risks.

 

   

Our future growth and success depend on our ability to sell effectively to large customers.

 

   

Contracts with government and state agencies are subject to a number of challenges and risks.

 

   

If our information technology systems, data, or physical facilities where our quantum computers are stored, or those of third parties upon which we rely, are or were compromised, we could experience adverse business consequences resulting from such compromise.

 

   

Unfavorable conditions in our industry or the global economy, could limit our ability to grow our business and negatively affect our results of operations.

 

   

Government actions and regulations, such as tariffs and trade protection measures, may limit our ability to obtain products from our suppliers.

 

   

Because our success depends, in part, on our ability to expand sales internationally, our business will be susceptible to risks associated with international operations.

 

   

Licensing of intellectual property is of critical importance to our business.

 

   

If we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected. Moreover, our trade secrets could be compromised, which could cause us to lose the competitive advantage resulting from these trade secrets.

 

   

We may face patent infringement and other intellectual property claims that could be costly to defend, result in injunctions and significant damage awards or other costs and limit our ability to use certain key technologies in the future or require development of non-infringing products, services, or technologies.

 

   

Some of our in-licensed intellectual property, including the intellectual property licensed from the University of Maryland and Duke University, has been conceived or developed through government-funded research and thus may be subject to federal regulations providing for certain rights for the U.S. government or imposing certain obligations on us and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers.

Risks Related to Our Financial Condition and Status as an Early Stage Company

We are an early stage company and have a limited operating history, which makes it difficult to forecast our future results of operations.

As a result of our limited operating history, our ability to accurately forecast our future results of operations is limited and subject to a number of uncertainties, including our ability to plan for and model future growth. Our ability to generate revenues will largely be dependent on our ability to develop and produce quantum computers with increasing numbers of algorithmic qubits. As a result, our scalable business model has not been formed and our technical roadmap may not be realized as quickly as expected, or even at all. The development of our scalable business model will likely require the incurrence of a substantially higher level of costs than incurred to date, while our revenues will not substantially increase until more powerful, scalable computers are produced, which requires a number of technological advancements that may not occur on the currently anticipated

 

34


Table of Contents

timetable or at all. As a result, our historical results should not be considered indicative of our future performance. Further, in future periods, our growth could slow or decline for a number of reasons, including but not limited to slowing demand for our service offerings, increased competition, changes to technology, inability to scale up our technology, a decrease in the growth of the overall market, or our failure, for any reason, to continue to take advantage of growth opportunities.

We have also encountered, and will continue to encounter, risks and uncertainties frequently experienced by growing companies in rapidly changing industries. If our assumptions regarding these risks and uncertainties and our future growth are incorrect or change, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations, and our business could suffer. Our success as a business ultimately relies upon fundamental research and development breakthroughs in the coming years and decade. There is no certainty these research and development milestones will be achieved as quickly as expected, or even at all.

We have a history of operating losses and expect to incur significant expenses and continuing losses for the foreseeable future.

We have historically experienced net losses from operations. For the three months ended March 31, 2023, we incurred a loss from operations of $28.0 million. As of March 31, 2023, we had an accumulated deficit of $221.6 million. We believe that we will continue to incur losses each year until at least the time we begin significant production and delivery of our quantum computers, which is not expected to occur until 2025, at the earliest, and may occur later, or never. Even with significant production, such production may never become profitable.

We expect the rate at which we will incur operating losses to be significantly higher in future periods as we, among other things, continue to incur significant expenses in connection with the design, development and construction of our quantum computers, and as we expand our research and development activities, invest in manufacturing capabilities, build up inventories of components for our quantum computers, increase our sales and marketing activities, develop our distribution infrastructure, and increase our general and administrative functions to support our growing operations and costs of being a public company. We may find that these efforts are more expensive than we currently anticipate or that these efforts may not result in revenues, which would further increase our losses. If we are unable to achieve and/or sustain profitability, or if we are unable to achieve the growth that we expect from these investments, it could have a material effect on our business, financial condition or results of operations. Our business model is unproven and may never allow us to cover our costs.

We may not be able to scale our business quickly enough to meet customer and market demand, which could result in lower profitability or cause us to fail to execute on our business strategies.

In order to grow our business, we will need to continually evolve and scale our business and operations to meet customer and market demand. Quantum computing technology has never been sold at large-scale commercial levels. Evolving and scaling our business and operations places increased demands on our management as well as our financial and operational resources to:

 

   

effectively manage organizational change;

 

   

design scalable processes;

 

   

accelerate and/or refocus research and development activities;

 

   

expand manufacturing, supply chain and distribution capacity;

 

   

increase sales and marketing efforts;

 

   

broaden customer-support and services capabilities;

 

   

maintain or increase operational efficiencies;

 

35


Table of Contents
   

scale support operations in a cost-effective manner;

 

   

implement appropriate operational and financial systems; and

 

   

maintain effective financial disclosure controls and procedures.

Commercial production of quantum computers may never occur. We have no experience in producing large quantities of our products and are currently constructing advanced generations of our products. As noted above, there are significant technological and logistical challenges associated with developing, producing, marketing, selling and distributing products in the advanced technology industry, including our products, and we may not be able to resolve all of the difficulties that may arise in a timely or cost-effective manner, or at all. We may not be able to cost-effectively manage production at a scale or quality consistent with customer demand in a timely or economical manner.

Our ability to scale is dependent also upon components we must source from the optical, electronics and semiconductor industries. Shortages or supply interruptions in any of these components will adversely impact our ability to deliver revenues.

The stability of ion traps may prove poorer than hoped, or more difficult to manufacture. It may also prove more difficult or even impossible to reliably entangle/connect ion traps together. Both of these factors would adversely impact scalability and costs of the ion trap system.

If commercial production of our quantum computers commences, our products may contain defects in design and manufacture that may cause them to not perform as expected or that may require repair, recalls and design changes. Our quantum computers are inherently complex and incorporate technology and components that have not been used for other applications and that may contain defects and errors, particularly when first introduced. We have a limited frame of reference from which to evaluate the long-term performance of our products. There can be no assurance that we will be able to detect and fix any defects in our quantum computers prior to the sale to potential consumers. If our products fail to perform as expected, customers may delay deliveries, terminate further orders or initiate product recalls, each of which could adversely affect our sales and brand and could adversely affect our business, prospects and results of operations.

If we cannot evolve and scale our business and operations effectively, we may not be able to execute our business strategies in a cost-effective manner and our business, financial condition, profitability and results of operations could be adversely affected.

We may not manage growth effectively.

If we fail to manage growth effectively, our business, results of operations and financial condition could be harmed. We anticipate that a period of significant expansion will be required to address potential growth. This expansion will place a significant strain on our management, operational and financial resources. Expansion will require significant cash investments and management resources and there is no guarantee that they will generate additional sales of our products or services, or that we will be able to avoid cost overruns or be able to hire additional personnel to support them. In addition, we will also need to ensure our compliance with regulatory requirements in various jurisdictions applicable to the sale, installation and servicing of our products. To manage the growth of our operations and personnel, we must establish appropriate and scalable operational and financial systems, procedures and controls and establish and maintain a qualified finance, administrative and operations staff. We may be unable to acquire the necessary capabilities and personnel required to manage growth or to identify, manage and exploit potential strategic relationships and market opportunities.

Our management has limited experience in operating a public company.

Our executive officers have limited experience in the management of a publicly traded company. Our management team may not successfully or effectively manage reporting obligations under federal securities laws. Their limited experience in dealing with the increasingly complex laws pertaining to public companies could be a

 

36


Table of Contents

significant disadvantage in that it is likely that an increasing amount of their time may be devoted to these activities, which will result in less time being devoted to our management and growth. The development and implementation of the standards and controls necessary for us to achieve the level of accounting standards required of a public company in the United States may require costs greater than expected. It is possible that we will be required to expand our employee base and hire additional employees to support our operations as a public company, which will increase our operating costs in future periods.

Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate.

Market opportunity estimates and growth forecasts, including those we have generated, are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. The variables that go into the calculation of our market opportunity are subject to change over time, and there is no guarantee that any particular number or percentage of companies covered by our market opportunity estimates will purchase our products at all or generate any particular level of revenue for us. In addition, alternatives to quantum computing may present themselves and if they did, could substantially reduce the market for quantum computing services. Any expansion in our market depends on a number of factors, including the cost, performance, and perceived value associated with quantum computing solutions.

The methodology and assumptions used to estimate market opportunities may differ materially from the methodologies and assumptions previously used to estimate the total addressable market. To estimate the size of our market opportunities and our growth rates, we have relied on market reports by leading research and consulting firms. These estimates of the total addressable market and growth forecasts are subject to significant uncertainty, are based on assumptions and estimates that may not prove to be accurate and are based on data published by third parties that we have not independently verified. Advances in classical computing may prove more robust for longer than currently anticipated. This could adversely affect the timing of any quantum advantage being achieved, if at all.

Even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all.

Our success will depend upon our ability to expand, scale our operations, and increase our sales capability. Even if the market in which we compete meets the size estimates and growth forecasted, our business could fail to grow at similar rates, if at all.

Our growth is dependent upon our ability to successfully scale up manufacturing of our products in sufficient quantity and quality, in a timely or cost-effective manner. Our growth is also dependent upon our ability to successfully market and sell quantum computing technology. We do not have experience with the mass distribution and sale of quantum computing technology. Our growth and long-term success will depend upon the development of our sales and delivery capabilities.

Unforeseen issues associated with scaling up and constructing quantum computing technology at commercially viable levels, and selling our technology, could negatively impact our business, financial condition and results of operations.

Moreover, because of our unique technology, our customers will require particular support and service functions, some of which are not currently available. If we experience delays in adding such support capacity or servicing our customers efficiently, or experience unforeseen issues with the reliability of our technology, it could overburden our servicing and support capabilities. Similarly, increasing the number of our customers, products or services, for example by entering into government contracts and expanding to new geographies, has required and may continue to require us to rapidly increase the availability of these services. Failure to adequately support and service our customers may inhibit our growth and ability to expand computing targets globally. There can be no assurance that our projections on which such targets are based will prove accurate or that the pace of growth or coverage of our customer infrastructure network will meet customer expectations. Failure to grow at rates similar to that of the quantum computing industry may adversely affect our operating results and ability to effectively compete within the industry.

 

37


Table of Contents

Our operating and financial results forecast relies in large part upon assumptions and analyses we have developed. If these assumptions or analyses prove to be incorrect, our actual operating results may be materially different from our forecasted results.

Our projected financial and operating information reflect current estimates of future performance, which may never occur. Whether actual operating and financial results and business developments will be consistent with our expectations and assumptions as reflected in our forecasts depends on a number of factors, many of which are outside our control, including, but not limited to:

 

   

success and timing of development activity;

 

   

customer acceptance of our quantum computing systems;

 

   

breakthroughs in classical computing or other computing technologies that could eliminate the advantages of quantum computing systems rendering them less practical to customers;

 

   

competition, including from established and future competitors;

 

   

whether we can obtain sufficient capital to sustain and grow our business;

 

   

our ability to manage our growth;

 

   

our ability to retain existing key management, integrate recent hires and attract, retain and motivate qualified personnel; and

 

   

the overall strength and stability of domestic and international economies.

Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, financial condition and results of operations.

We may need additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be sure that additional financing will be available.

Our business and our future plans for expansion are capital-intensive and the specific timing of cash inflows and outflows may fluctuate substantially from period to period. Our operating plan may change because of factors currently unknown, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financings may result in dilution to our stockholders, issuance of securities with priority as to liquidation and dividend and other rights more favorable than common stock, imposition of debt covenants and repayment obligations or other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe that we have sufficient funds for current or future operating plans. Weakness and volatility in capital markets and the economy, in general or as a result of bank failures or macroeconomic conditions such as rising inflation and interest rates, could limit our access to capital markets and increase our costs of borrowing. There can be no assurance that financing will be available to us on favorable terms, or at all. The inability to obtain financing when needed may make it more difficult for us to operate our business or implement our growth plans.

 

38


Table of Contents

Our ability to use net operating loss carryforwards and other tax attributes may be limited.

We have incurred losses during our history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, if at all. As of December 31, 2022, we had U.S. federal and state net operating loss carryforwards of approximately $96.3 million and $69.5 million, respectively.

Our net operating loss carryforwards are subject to review and possible adjustment by the IRS, and state tax authorities. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), our federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our stock. An “ownership change” pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including changes in connection with our Business Combination with dMY or other transactions. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our Business Combination with dMY or other transactions, or any resulting limitations on our ability to utilize our net operating loss carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future income tax liability and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our net operating loss carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.

 

39


Table of Contents

Risks Related to Our Business and Industry

We have not produced a scalable quantum computer and face significant barriers in our attempts to produce quantum computers. If we cannot successfully overcome those barriers, our business will be negatively impacted and could fail.

Producing quantum computers is a difficult undertaking. There are significant engineering challenges that we must overcome to build our quantum computers. We are still in the development stage and face significant challenges in completing development of our quantum computers and in producing quantum computers in commercial volumes. Some of the development challenges that could prevent the introduction of our quantum computers include, but are not limited to, failure to find scalable ways to flexibly manipulate qubits, failure to transition quantum systems to leverage low-cost, commodity optical technology, and failure to realize multicore quantum computer technology.

Additional development challenges we face include:

 

   

gate fidelity, error correction and miniaturization may not commercialize from the lab and scale as hoped or at all;

 

   

it could prove more challenging and take materially longer than expected to operate parallel gates within a single ion trap and maintain gate fidelity;

 

   

the photonic interconnect between ion traps could prove more challenging and take longer to perfect than currently expected. This would limit our ability to scale to a sufficiently large number of algorithmic qubits in a single system;

 

   

it could take longer to tune the qubits in a single ion trap, as well as preserve the stability of the qubits within a trap as we seek to maximize the total number of qubits within one trap;

 

   

the gate speed in our technology could prove more difficult to improve than expected; and

 

   

the scaling of fidelity with qubit number could prove poorer than expected, limiting our ability to achieve larger algorithmic qubits.

In addition, we will need to develop the manufacturing process necessary to make these quantum computers in high volume. We have not yet validated a manufacturing process or acquired the tools or processes necessary to produce high volumes of our quantum computers that meet all commercial requirements. If we are not able to overcome these manufacturing hurdles in building our quantum computers, our business is likely to fail.

Even if we complete development and achieve volume production of our quantum computers, if the cost, performance characteristics or other specifications of the quantum computer fall short of our projections, our business, financial condition and results of operations would be adversely affected.

The quantum computing industry is competitive on a global scale and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers.

The markets in which we operate are rapidly evolving and highly competitive. As these markets continue to mature and new technologies and competitors enter such markets, we expect competition to intensify. Our current competitors include:

 

   

large, well-established tech companies that generally compete in all of our markets, including Google, Microsoft, Amazon, Intel and IBM;

 

   

countries such as China, Russia, Canada, Australia and the United Kingdom, and those in the European Union and we believe additional countries in the future;

 

   

less-established public and private companies with competing technology, including companies located outside the United States; and

 

   

new or emerging entrants seeking to develop competing technologies.

 

40


Table of Contents

We compete based on various factors, including technology, performance, multi-cloud availability, brand recognition and reputation, customer support and differentiated capabilities, including ease of administration and use, scalability and reliability, data governance and security. Many of our competitors have substantially greater brand recognition, customer relationships, and financial, technical and other resources, including an experienced sales force and sophisticated supply chain management. They may be able to respond more effectively than us to new or changing opportunities, technologies, standards, customer requirements and buying practices. In addition, many countries are focused on developing quantum computing solutions either in the private or public sector and may subsidize quantum computers, which may make it difficult for us to compete. Many of these competitors do not face the same challenges we do in growing our business. In addition, other competitors might be able to compete with us by bundling their other products in a way that does not allow us to offer a competitive solution.

Additionally, we must be able to achieve our objectives in a timely manner or quantum computing may lose ground to competitors, including competing technologies. Because there are a large number of market participants, including certain sovereign nations, focused on developing quantum computing technology, we must dedicate significant resources to achieving any technical objectives on the timelines established by our management team. Any failure to achieve objectives in a timely manner could adversely affect our business, operating results and financial condition.

For all of these reasons, competition may negatively impact our ability to maintain and grow consumption of our platform or put downward pressure on our prices and gross margins, any of which could materially harm our reputation, business, results of operations, and financial condition.

An element of our business is currently dependent upon our relationship with our cloud providers. There are no assurances that we will be able to commercialize quantum computers from our relationships with cloud providers.

We currently offer our QCaaS on public clouds provided by AWS’s Amazon Braket, Microsoft’s Azure Quantum, and the Google Cloud Marketplace. The companies that own these public clouds have internal quantum computing efforts that are competitive to our technology. There is risk that one or more of these public cloud providers could use their respective control of their public clouds to embed innovations or privileged interoperating capabilities in competing products, bundle competing products, provide us with unfavorable pricing, leverage their public cloud customer relationships to exclude us from opportunities, and treat us and our customers differently with respect to terms and conditions or regulatory requirements than they would treat their similarly situated customers. Further, they have the resources to acquire or partner with existing and emerging providers of competing technology and thereby accelerate adoption of those competing technologies. All of the foregoing could make it difficult or impossible for us to provide products and services that compete favorably with those of the public cloud providers.

Any material change in our contractual and other business relationships with our public cloud providers could result in harm to our brand and reputation and reduced use of our systems, which could have a material adverse effect on our business, financial condition and results of operations.

Even if we are successful in developing quantum computing systems and executing our strategy, competitors in the industry may achieve technological breakthroughs that render our quantum computing systems obsolete or inferior to other products.

Our continued growth and success depend on our ability to innovate and develop quantum computing technology in a timely manner and effectively market these products. Without timely innovation and development, our quantum computing solutions could be rendered obsolete or less competitive by changing customer preferences or because of the introduction of a competitor’s newer technologies. We believe that many

 

41


Table of Contents

competing technologies will require a technological breakthrough in one or more problems related to science, fundamental physics or manufacturing. While it is uncertain whether such technological breakthroughs will occur in the next several years, that does not preclude the possibility that such technological breakthroughs could eventually occur. Any technological breakthroughs that render our technology obsolete or inferior to other products could have a material effect on our business, financial condition or results of operations.

We may be unable to reduce the cost per qubit, which may prevent us from pricing our quantum systems competitively.

Our projections are dependent on the cost per qubit decreasing over the next several years as our quantum computers advance. These cost projections are based on economies of scale due to demand for our computer systems, technological innovation and negotiations with third-party parts suppliers. If these cost savings do not materialize, the cost per qubit may be higher than projected, making our quantum computing solution less competitive than those produced by our competitors, which could have a material effect on our business, financial condition or results of operations.

The quantum computing industry is in its early stages and volatile, and if it does not develop, if it develops slower than we expect, if it develops in a manner that does not require use of our quantum computing solutions, if it encounters negative publicity or if our solution does not drive commercial engagement, the growth of our business will be harmed.

The nascent market for quantum computers is still rapidly evolving, characterized by rapidly changing technologies, competitive pricing and competitive factors, evolving government regulation and industry standards, and changing customer demands and behaviors. If the market for quantum computers in general does not develop as expected, or develops more slowly than expected, our business, prospects, financial condition and operating results could be harmed.

In addition, our growth and future demand for our products is highly dependent upon the adoption by developers and customers of quantum computers, as well as on our ability to demonstrate the value of quantum computing to our customers. Delays in future generations of our quantum computers or technical failures at other quantum computing companies could limit market acceptance of our solution. Negative publicity concerning our solution or the quantum computing industry as a whole could limit market acceptance of our solution. We believe quantum computing will solve many large-scale problems. However, such problems may never be solvable by quantum computing technology. If our clients and partners do not perceive the benefits of our solution, or if our solution does not drive member engagement, then our market may not develop at all, or it may develop slower than we expect. If any of these events occur, it could have a material adverse effect on our business, financial condition or results of operations. If progress towards quantum advantage ever slows relative to expectations, it could adversely impact revenues and customer confidence to continue to pay for testing, access and “quantum readiness.” This would harm or even eliminate revenues in the period before quantum advantage.

If our computers fail to achieve a broad quantum advantage, our business, financial condition and future prospects may be harmed.

Quantum advantage refers to the moment when a quantum computer can compute faster than traditional computers, while quantum supremacy is achieved once quantum computers are powerful enough to complete calculations that traditional supercomputers cannot perform at all. Broad quantum advantage is when quantum advantage is seen in many applications and developers prefer quantum computers to a traditional computer. No current quantum computers, including our quantum hardware, have reached a broad quantum advantage, and they may never reach such advantage. Achieving a broad quantum advantage will be critical to the success of any quantum computing company, including us. However, achieving quantum advantage would not necessarily lead to commercial viability of the technology that accomplished such advantage, nor would it mean that such system could outperform classical computers in tasks other than the one used to determine a quantum advantage.

 

42


Table of Contents

Quantum computing technology, including broad quantum advantage, may take decades to be realized, if ever. If we cannot develop quantum computers that have quantum advantage, customers may not continue to purchase our products and services. If other companies’ quantum computers reach a broad quantum advantage prior to the time ours reaches such capabilities, it could lead to a loss of customers. If any of these events occur, it could have a material adverse effect on our business, financial condition or results of operations.

We could suffer disruptions, outages, defects and other performance and quality problems with our quantum computing systems or with the public cloud and internet infrastructure on which they rely.

Our business depends on our quantum computing systems to be available. We have experienced, and may in the future further experience, disruptions, outages, defects and other performance and quality problems with our systems. We have also experienced, and may in the future further experience, disruptions, outages, defects and other performance and quality problems with the public cloud and internet infrastructure on which our systems rely. These problems can be caused by a variety of factors, including failed introductions of new functionality, vulnerabilities and defects in proprietary and open-source software, hardware components, human error or misconduct, capacity constraints, design limitations or denial of service attacks or other security-related incidents. We do not have a contractual right with our public cloud providers that compensates us for any losses due to availability interruptions in the public cloud.

Any disruptions, outages, defects and other performance and quality problems with our quantum computing system or with the public cloud and internet infrastructure on which it relies, could result in reduced use of our systems, increased expenses, including service credit obligations, and harm to our brand and reputation, any of which could have a material adverse effect on our business, financial condition and results of operations.

We have and may continue to face supply chain issues that could delay the introduction of our product and negatively impact our business and operating results.

We are reliant on third-party suppliers for components necessary to develop and manufacture our quantum computing solutions. As our business grows, we must continue to scale and adapt our supply chain or it could have an adverse impact on our business. Any of the following factors (and others) could have an adverse impact on the availability of these components necessary to our business:

 

   

our inability to enter into agreements with suppliers on commercially reasonable terms, or at all;

 

   

difficulties of suppliers ramping up their supply of materials to meet our requirements;

 

   

a significant increase in the price of one or more components, including due to industry consolidation occurring within one or more component supplier markets or as a result of decreased production capacity at manufacturers;

 

   

any reductions or interruption in supply, including disruptions on our global supply chain as a result of the global chip shortage, or the Russia-Ukraine war and any indirect effects thereof;

 

   

financial problems of either manufacturers or component suppliers;

 

   

significantly increased freight charges, or raw material costs and other expenses associated with our business;

 

   

other factors beyond our control or that we do not presently anticipate, could also affect our suppliers’ ability to deliver components to us on a timely basis;

 

   

a failure to develop our supply chain management capabilities and recruit and retain qualified professionals;

 

   

a failure to adequately authorize procurement of inventory by our contract manufacturers; or

 

   

a failure to appropriately cancel, reschedule, or adjust our requirements based on our business needs.

 

43


Table of Contents

We have experienced supply chain issues in the past as a result of COVID-19. If any of the aforementioned factors were to materialize, it could cause us to delay or halt production of our quantum computing solutions and/or entail higher manufacturing costs, any of which could materially adversely affect our business, operating results, and financial condition and could materially damage customer relationships.

If we cannot successfully execute on our strategy, including in response to changing customer needs and new technologies and other market requirements, or achieve our objectives in a timely manner, our business, financial condition and results of operations could be harmed.

The quantum computing market is characterized by rapid technological change, changing user requirements, uncertain product lifecycles and evolving industry standards. We believe that the pace of innovation will continue to accelerate as technology changes and different approaches to quantum computing mature on a broad range of factors, including system architecture, error correction, performance and scale, ease of programming, user experience, markets addressed, types of data processed, and data governance and regulatory compliance. Our future success depends on our ability to continue to innovate and increase customer adoption of our quantum computer. If we are unable to enhance our quantum computing system to keep pace with these rapidly evolving customer requirements, or if new technologies emerge that are able to deliver competitive products at lower prices, more efficiently, with better functionality, more conveniently, or more securely than our platform, our business, financial condition and results of operations could be adversely affected.

Our products may not achieve market success, but will still require significant costs to develop.

We believe that we must continue to dedicate significant resources to our research and development efforts before knowing whether there will be market acceptance of our quantum computing technologies. Furthermore, the technology for our products is new, and the performance of these products is uncertain. Our quantum computing technologies could fail to attain sufficient market acceptance, if at all, for many reasons, including:

 

   

pricing and the perceived value of our systems relative to its cost;

 

   

delays in releasing quantum computers with sufficient performance and scale to the market;

 

   

failure to produce products of consistent quality that offer functionality comparable or superior to existing or new products;

 

   

ability to produce products fit for their intended purpose;

 

   

failures to accurately predict market or customer demands;

 

   

defects, errors or failures in the design or performance of our quantum computing systems;

 

   

negative publicity about the performance or effectiveness of our systems;

 

   

strategic reaction of companies that market competitive products; and

 

   

the introduction or anticipated introduction of competing technology.

To the extent we are unable to effectively develop and market a quantum computing system to address these challenges and attain market acceptance, our business, operating results and financial condition may be adversely affected.

 

44


Table of Contents

We are highly dependent on our co-founders, and our ability to attract and retain senior management and other key employees, such as quantum physicists and other key technical employees, is critical to our success. If we fail to retain talented, highly-qualified senior management, engineers and other key employees or attract them when needed, such failure could negatively impact our business.

Our future success is highly dependent on our ability to attract and retain our executive officers, key employees and other qualified personnel, including our co-founders, Jungsang Kim, our Chief Technology Officer, and Christopher Monroe, our Chief Scientist. As we build our brand and become more well known, there is increased risk that competitors or other companies may seek to hire our personnel. The loss of the services provided by these individuals will adversely impact the achievement of our business strategy. These individuals could leave our employment at any time, as they are “at will” employees. A loss of one of our co-founders, a member of senior management, or an engineer or other key employee particularly to a competitor, could also place us at a competitive disadvantage. Effective succession planning is also important to our long-term success. Failure to ensure effective transfer of knowledge and smooth transitions involving key employees could hinder our strategic planning and execution.

Our future success also depends on our continuing ability to attract, develop, motivate and retain highly qualified and skilled employees. The market for highly skilled workers and leaders in the quantum computing industry is extremely competitive. In particular, hiring qualified personnel specializing in engineering, software development and sales, as well as other technical staff and research and development personnel is critical to our business and the development of our quantum computing systems. Some of these professionals are hard to find and we may encounter significant competition in our efforts to hire them. Many of the other companies with which we compete for qualified personnel have greater financial and other resources than we do. The effective operation of our supply chain, including the acquisition of critical components and materials, the development of our quantum computing technologies, the commercialization of our quantum computing technologies and the effective operation of our managerial and operating systems all depend upon our ability to attract, train and retain qualified personnel in the aforementioned specialties. Additionally, changes in immigration and work permit laws and regulations or the administration or interpretation of such laws or regulations could impair our ability to attract and retain highly qualified employees. If we cannot attract, train and retain qualified personnel, including our co-founders, in this competitive environment, we may experience delays in the development of our quantum computing technologies and be otherwise unable to develop and grow our business as projected, or even at all.

We may not be able to accurately estimate the future supply and demand for our quantum computers, which could result in a variety of inefficiencies in our business and hinder our ability to generate revenue. If we fail to accurately predict our manufacturing requirements, we could incur additional costs or experience delays.

It is difficult to predict our future revenues and appropriately budget for our expenses, and we may have limited insight into trends that may emerge and affect our business. We anticipate being required to provide forecasts of our demand to our current and future suppliers prior to the scheduled delivery of products to potential customers. Currently, there is very little historical basis for making judgments on the demand for our quantum computers or our ability to develop, manufacture, and deliver quantum computers, or our profitability, if any, in the future. If we overestimate our requirements, our suppliers may have excess inventory, which indirectly would increase our costs. If we underestimate our requirements, our suppliers may have inadequate inventory, which could interrupt manufacturing of our products and result in delays in shipments and revenues. In addition, lead times for materials and components that our suppliers order may vary significantly and depend on factors such as the specific supplier, contract terms and demand for each component at a given time. If we fail to order sufficient quantities of product components in a timely manner, the delivery of quantum computers and related compute time to our potential customers could be delayed, which would harm our business, financial condition and operating results.

 

45


Table of Contents

Our systems depend on the use of a particular isotope of an atomic element that provides qubits for our ion trap technology. If we are unable to procure these isotopically enriched atomic samples, or are unable to do so on a timely and cost-effective basis, and in sufficient quantities, we may incur significant costs or delays, which could negatively affect our operations and business.

There are limited suppliers to sources of isotopically enriched materials that may be necessary for the production of our ion trap technology. We currently purchase such materials through the National Isotope Development Center managed by the U.S. Department of Energy Isotope Program. We do not have any supplier agreements with the U.S. Department of Energy, and purchase the materials through a standard ordering process. While we are currently looking to engage additional suppliers, there is no guarantee we will be able to establish or maintain relationships with such additional suppliers on terms satisfactory to us. Reliance on any single supplier increases the risks associated with being unable to obtain the necessary atomic samples because the supplier may have laboratory constraints, can be subject to unanticipated shutdowns and/or may be affected by natural disasters and other catastrophic events. Some of these factors may be completely out of our and our suppliers’ control. Failure to acquire sufficient quantities of the necessary isotopically enriched atomic samples in a timely or cost-effective manner could materially harm our business.

If our quantum computing systems are not compatible with some or all industry-standard software and hardware in the future, our business could be harmed.

Programming for quantum computing requires unique tools, software, hardware, and development environments. We have focused our efforts on creating quantum computing hardware, the operating system for such hardware and a suite of low-level software programs that optimize execution of quantum algorithms on our hardware. Further up the software stack, we rely on third parties to create higher level quantum programming languages, SDKs, and application libraries. Such third-party software and programming is essential to operating our quantum computing products and services. Our quantum computing solutions are designed today to be compatible with most major quantum SDKs, including Qiskit, Cirq, Q# QDK, and OpenQASM, all of which are open source. If a proprietary (not open source) software toolset became the standard for quantum application development in the future by a competitor, usage of our hardware might be limited as a result, which would have a negative impact on us. Similarly, if a piece of hardware or other quantum tool became a necessary component for quantum computing (for instance, quantum networking) and we cannot integrate with it (as we have thus far), the result might have a negative impact on us and our anticipated growth.

If our customers are unable to achieve compatibility between other software and hardware and our hardware, it could impact our relationships with such customers or with customers, generally, if the incompatibility is more widespread. In addition, the mere announcement of an incompatibility problem relating to our products with higher level software tools could cause us to suffer reputational harm and/or lead to a loss of customers. Any adverse impacts from the incompatibility of our quantum computing solutions could adversely affect our business, operating results and financial condition.

If we are unable to maintain our current strategic partnerships or we are unable to develop future collaborative partnerships, our future growth and development could be negatively impacted.

We have entered into, and may enter into, strategic partnerships to develop and commercialize our current and future research and development programs with other companies to accomplish one or more of the following:

 

   

obtain expertise in relevant markets;

 

   

obtain sales and marketing services or support;

 

   

obtain equipment and facilities;

 

   

develop relationships with potential future customers; and

 

   

generate revenue.

 

46


Table of Contents

We may not be successful in establishing or maintaining suitable partnerships, and we may not be able to negotiate collaboration agreements having terms satisfactory to us, or at all. Failure to make or maintain these arrangements or a delay or failure in a collaborative partner’s performance under any such arrangements could harm our business and financial condition.

Our business depends on our customers’ abilities to implement useful quantum algorithms and sufficient quantum resources for their business. If they are unable to do so due to the nature of their algorithmic challenge or other technical or personnel dilemmas, our growth may be negatively impacted.

We have entered into, and may enter into, contracts, partnerships and other arrangements with customers to develop, test and run quantum algorithms specific to their business. The success of these contracts and partnerships is dependent on our customer’s ability to implement useful and scalable algorithms for their portfolio. These arrangements are also dependent on the availability of time and resources to develop and optimize these algorithms. The development and optimization of these algorithms is reliant on employing sufficient talent familiar with quantum computing, a unique skill that requires special training and education. If the market fails to train a sufficient number of engineers, researchers and other key quantum personnel, our customers may not find sufficient talent to partner with us to solve these problems. To the extent our customers are unable to effectively develop or utilize resources to advance algorithmic-use cases, our business, operating results and financial condition may be adversely impacted.

Our future growth and success depends in part on our ability to sell effectively to government entities and large enterprises.

Our customers and potential customers include domestic and international government agencies and large enterprises. Therefore, our future success will depend on our ability to effectively sell our products to such customers. Sales to these end-customers involve risks that may not be present (or that are present to a lesser extent) with sales to non-governmental agencies or smaller customers. These risks include, but are not limited to, (i) increased purchasing power and leverage held by such customers in negotiating contractual arrangements with us and (ii) longer sales cycles and the associated risk that substantial time and resources may be spent on a potential end-customer that elects not to purchase our solutions. Sales to government agencies are typically under fixed fee development contracts, which involve additional risks. In addition, government contracts generally include the ability of government agencies to terminate early which, if exercised, would result in a lower contract value and lower than anticipated revenues generated by such arrangement. Additionally, such government contracts may suspend us from doing business with foreign governments or prevent us from selling our products in certain countries.

Government agencies and large organizations often undertake a significant evaluation process that results in a lengthy sales cycle. Our contracts with government agencies are typically structured in phases, with each phase subject to satisfaction of certain conditions. As a result, the actual scope of work performed pursuant to any such contracts, in addition to related contract revenue, could be less than total contract value. In addition, product purchases by such organizations are frequently subject to budget constraints, multiple approvals and unanticipated administrative, processing and other delays. Finally, these organizations typically have longer implementation cycles, require greater product functionality and scalability, require a broader range of services, demand that vendors take on a larger share of risks, require acceptance provisions that can lead to a delay in revenue recognition and expect greater payment flexibility. All of these factors can add further risk to business conducted with these potential customers and could lead to lower revenue results than originally anticipated.

Additionally, changes in government defense spending could have adverse consequences on our financial position, results of operations and business. Certain current contracts and our anticipated future revenues from the U.S. government are expected to result from contracts awarded under various U.S. government programs. Cost cutting, including through consolidation and elimination of duplicative organizations, has become a major initiative for certain departments within the U.S. government. The funding of our programs is subject to the overall U.S. government budget and appropriation decisions and processes, which are driven by numerous factors, including geo-political events and macroeconomic conditions. The overall level of U.S. defense spending increased in recent years for numerous reasons.

 

47


Table of Contents

Significant reduction in defense spending could have long-term consequences for our size and structure. In addition, reduction in government priorities and requirements could impact the funding, or the timing of funding, of our programs, which could negatively impact our results of operations and financial condition.

Contracts with domestic and international government and state agencies are subject to a number of challenges and risks.

Contracts with domestic and international government and state agencies are subject to a number of challenges and risks. The bidding process for government contracts can be highly competitive, expensive and time-consuming, often requiring significant upfront time and expense without any assurance that these efforts will generate revenue.

We also must comply with both local and international laws and regulations relating to the formation, administration, and performance of contracts, which provide public sector customers rights, many of which are not typically found in commercial contracts. For example, in 2021, the U.S. House of Representatives introduced the Quantum Cybersecurity Preparedness Act, signaling fresh focus on the need for U.S. investment in quantum computing—both to protect against quantum-powered attacks from foreign actors and to develop quantum computing strength on the domestic front. In May 2022, the Biden administration announced directives to support U.S. leadership in quantum computing, and in September 2022, the National Security Administration (NSA) shared guidance on the importance of cybersecurity readiness against would-be adversaries developing quantum systems. Any changes to government regulations as a result of this demonstrated focus on quantum computing could affect our ability to enter into, or the profitability of, contracts with government entities.

In addition, our perceived relationship with the U.S. government could adversely affect our business prospects in certain non-U.S. geographies or with certain non-U.S. governments. Conversely, our perceived relationship with non-U.S. governments or government entities could adversely affect our business prospects with the U.S. government.

Accordingly, our business, financial condition, results of operations, and growth prospects may be adversely affected by certain events or activities, including, but not limited to:

 

   

changes in government fiscal or procurement policies, or decreases in government funding available for procurement of goods and services generally, or for our federal government contracts specifically;

 

   

changes in government programs or applicable requirements;

 

   

restrictions in the grant of personnel security clearances to our employees;

 

   

ability to maintain facility clearances required to perform on classified contracts for U.S. government and foreign government agencies, as applicable;

 

   

changes in the political environment, including before or after a change to the leadership within the government administration, and any resulting uncertainty or changes in policy or priorities and resultant funding;

 

   

changes in the government’s attitude towards us as a company or our technology;

 

   

appeals, disputes, or litigation relating to government procurement, including but not limited to bid protests by unsuccessful bidders on potential or actual awards of contracts to us or our partners by the government;

 

   

the adoption of new laws or regulations or changes to existing laws or regulations;

 

   

budgetary constraints, including automatic reductions as a result of “sequestration” or similar measures and constraints imposed by any lapses in appropriations for the federal government or certain of its departments and agencies;

 

48


Table of Contents
   

influence by, or competition from, third parties with respect to pending, new, or existing contracts with government customers;

 

   

changes in legal obligations or political or social attitudes with respect to security or data privacy issues;

 

   

potential delays or changes in the government appropriations or procurement processes, including as a result of events such as war, incidents of terrorism, natural disasters, and public health concerns; and

 

   

increased or unexpected costs or unanticipated delays caused by other factors outside of our control.

Any such event or activity, among others, could cause governments and governmental agencies to delay or refrain entering into contracts with us and/or purchasing our computers in the future, reduce the size or timing of payment with respect to our services to or purchases from existing or new government customers, or otherwise have an adverse effect on our business, results of operations, financial condition, and growth prospects.

If our information technology systems, data, or physical facilities where our quantum computers are stored, or those of third parties upon which we rely, are or were compromised, we could experience adverse business consequences resulting from such compromise.

In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, “Processing”) personal data and other sensitive information, including intellectual property, proprietary and confidential business data, trade secrets, sensitive third-party data, business plans, transactions, and financial information of our own, our partners, our customers, or other third parties (collectively, “Sensitive Data”).

We and the third parties upon which we rely may process Sensitive Data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats to our information technology systems, data, or physical facilities where our quantum computers are stored, including but not limited to ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our Sensitive Data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. U.S. law enforcement agencies have indicated to us that quantum computing technology is of particular interest to certain threat actors, including nation state and other malicious actors, who may steal our Sensitive Data, including our intellectual property or other proprietary or confidential information, including our trade secrets.

Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state and nation-state-supported actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, and our customers may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to distribute our services.

We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats.

In particular, severe ransomware attacks are becoming increasingly prevalent and could lead to significant interruptions in our operations, loss of Sensitive Data and income, reputational harm, and diversion of funds.

 

49


Table of Contents

Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.

Additionally, we are incorporated into the supply chain of a large number of companies worldwide and, as a result, if our services are compromised, a significant number or, in some instances, all of our customers and their data could be simultaneously affected. The potential liability and associated consequences we could suffer as a result of such a large-scale event could be catastrophic and result in irreparable harm.

Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.

In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. Our platform is built to be accessed through third-party cloud providers, such as AWS’s Amazon Braket, Microsoft’s Azure Quantum, and Google’s Cloud Marketplace, and we rely on these and other third-party service providers and technologies to operate critical business systems to process Sensitive Data in a variety of contexts, including, without limitation, other cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. We may also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third parties’ information security practices is limited. Although we understand our third-party cloud providers have implemented security measures designed to protect against various cybersecurity risks and vulnerabilities, these and other third parties may nevertheless not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised.

Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our Sensitive Data (including proprietary information and intellectual property) or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services.

We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and Sensitive Data.

While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect and remediate vulnerabilities in our information technology systems (including in our services), but we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit vulnerabilities change frequently and, are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but, may not be detected until after a

 

50


Table of Contents

security incident has occurred. These vulnerabilities pose material risks to our business. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. As a result, we may be unable to implement adequate preventative and responsive measures to stop or mitigate security breaches before or while they are occurring.

Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.

If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: exposure of Sensitive Data (including intellectual property or confidential or proprietary information); government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on Processing Sensitive Data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. Our efforts to prevent and overcome these challenges could increase our expenses and may not be successful.

Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.

In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.

Unfavorable conditions in our industry or the global economy, could limit our ability to grow our business and negatively affect our results of operations.

Our results of operations may vary based on the impact of changes in our industry or the global economy on the company or our customers and potential customers. The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, higher interest rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets and any future public health crises could result in similar impacts on the global economy. Similarly, the Russia-Ukraine war has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. Employee salaries and benefits expenses have increased as a result of economic growth, increased demand for business services, increased competition for trained and talented employees, among other wage-inflationary pressures and we cannot assure that they will not continue to rise. In addition, higher inflation also could increase our customers’ operating costs, which could result in reduced budgets for our customers and potentially less demand for our platform and the development of quantum technologies. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.

 

51


Table of Contents

In addition, in challenging economic times, our current or potential future customers may experience cash flow problems and as a result may modify, delay or cancel plans to purchase our products and services. Additionally, if our customers are not successful in generating sufficient revenue or are unable to secure financing, they may not be able to pay, or may delay payment of, accounts receivable due to us. Moreover, our key suppliers may reduce their output or become insolvent, thereby adversely impacting our ability to manufacture our products. Furthermore, uncertain economic conditions may make it more difficult for us to raise funds through borrowings or private or public sales of debt or equity securities. We cannot predict the timing, strength or duration of any economic slowdown, instability or recovery, generally or within any particular industry.

Government actions and regulations, such as tariffs and trade protection measures, may limit our ability to obtain products from our suppliers.

Political challenges between the United States and countries in which our suppliers are located, including China, and changes to trade policies, including tariff rates and customs duties, trade relations between the United States and China and other macroeconomic issues could adversely impact our business. Specifically, United States-China trade relations remain uncertain. The United States administration has announced tariffs on certain products imported into the United States with China as the country of origin, and China has imposed tariffs in response to the actions of the United States. There is also a possibility of future tariffs, trade protection measures or other restrictions imposed on our products or on our customers by the United States, China or other countries that could have a material adverse effect on our business. Our technology may be deemed a matter of national security and as such our customer base may be tightly restricted. We may accept government grants that place restrictions on our ability to operate.

Acquisitions, divestitures, strategic investments and strategic partnerships could disrupt our business and harm our financial condition and operating results.

We have pursued and we may continue to pursue growth opportunities by acquiring complementary businesses, solutions or technologies through strategic transactions, investments or partnerships. The identification of suitable acquisition, strategic investment or strategic partnership candidates can be costly and time consuming and can distract our management team from our current operations. If such strategic transactions require us to seek additional debt or equity financing, we may not be able to obtain such financing on terms favorable to us or at all, and such transactions may adversely affect our liquidity and capital structure. Any strategic transaction might not strengthen our competitive position, may increase some of our risks, and may be viewed negatively by our customers, partners or investors. Even if we successfully complete a strategic transaction, we may not be able to effectively integrate the acquired business, technology, systems, control environment, solutions, personnel or operations into our business. We may experience unexpected changes in how we are required to account for strategic transactions pursuant to accounting principles generally accepted in the United States of America (“U.S. GAAP”) and may not achieve the anticipated benefits of any strategic transaction. We may incur unexpected costs, claims or liabilities that we incur during the strategic transaction or that we assume from the acquired company, or we may discover adverse conditions post acquisition for which we have limited or no recourse.

Risks Related to Our International Expansion and Future Operations

Because our success depends, in part, on our ability to expand sales internationally, our business will be susceptible to risks associated with international operations.

We currently maintain offices and/or have personnel in the United States, Canada, and Israel, and recently expanded operations to Germany. We expect to continue to expand our international operations by developing our sales and operations presence in these and other international markets, which may include opening offices in new jurisdictions. Any additional international expansion efforts that we are undertaking and may undertake may not be successful. In addition, conducting international operations subjects us to new risks, some of which we have not generally faced in the United States or other countries where we currently operate. These risks include, among other things:

 

   

lack of familiarity and burdens of complying with foreign laws, legal standards, privacy and cybersecurity standards, regulatory requirements, tariffs and other barriers, and the risk of penalties to our customers and individual members of management or employees if our practices are deemed to not be in compliance;

 

52


Table of Contents
   

practical difficulties of enforcing intellectual property rights in countries with varying laws and standards and reduced or varied protection for intellectual property rights in some countries;

 

   

an evolving legal framework and additional legal or regulatory requirements for data privacy and cybersecurity, which may necessitate the establishment of systems to maintain data in local markets, requiring us to invest in additional data centers and network infrastructure, and the implementation of additional employee data privacy documentation (including locally compliant data privacy notice and policies), all of which may involve substantial expense and may cause us to need to divert resources from other aspects of our business, all of which may adversely affect our business;

 

   

unexpected changes in regulatory requirements, taxes, trade laws, tariffs, export quotas, custom duties or other trade restrictions;

 

   

difficulties in managing systems integrators and partners;

 

   

increased or unexpected supply chain challenges or delays;

 

   

differing technology standards;

 

   

different pricing environments, longer sales cycles, longer accounts receivable payment cycles and difficulties in collecting accounts receivable;

 

   

increased financial accounting and reporting burdens and complexities;

 

   

difficulties in managing and staffing international operations including the proper classification of independent contractors and other contingent workers, differing employer/employee relationships and local employment laws;

 

   

increased costs involved with recruiting and retaining an expanded employee population outside the United States through cash and equity-based incentive programs and unexpected legal costs and regulatory restrictions in issuing our shares to employees outside the United States;

 

   

global political and regulatory changes that may lead to restrictions on immigration and travel for our employees;

 

   

fluctuations in exchange rates that may decrease the value of our foreign-based revenue or increase the cost of our foreign operations;

 

   

global public health threats or geopolitical events such as the Russia-Ukraine war;

 

   

potentially adverse tax consequences, including the complexities of foreign value added tax (or other tax) systems, restrictions on the repatriation of earnings, and transfer pricing requirements; and

 

   

permanent establishment risks and complexities in connection with international payroll, tax and social security requirements for international employees.

Additionally, operating in international markets also requires significant management attention and financial resources. We cannot be certain that the investment and additional resources required in establishing operations in other countries will produce desired levels of revenue or profitability.

Compliance with laws and regulations applicable to our global operations also substantially increases our cost of doing business in foreign jurisdictions. We have limited experience in marketing, selling and supporting our platform outside of the United States. Our limited experience in operating our business internationally increases the risk that any potential future expansion efforts that we may undertake will not be successful. If we

 

53


Table of Contents

invest substantial time and resources to expand our international operations and are unable to do so successfully, in a timely manner, our business, financial condition, revenues, results of operations or cash flows will suffer. We may be unable to keep current with changes in government requirements as they change from time to time. Failure to comply with these regulations could harm our business. In many countries, it is common for others to engage in business practices that are prohibited by our internal policies and procedures or other regulations applicable to us. Although we have implemented policies and procedures designed to ensure compliance with these laws and policies, there can be no assurance that all of our employees, contractors, partners and agents will comply with these laws and policies. Violations of laws or key control policies by our employees, contractors, partners or agents could result in delays in revenue recognition, financial reporting misstatements, enforcement actions, reputational harm, disgorgement of profits, fines, civil and criminal penalties, damages, injunctions, other collateral consequences or the prohibition of the importation or exportation of our solutions and could harm our business, financial condition, revenues, results of operations or cash flows.

Our international sales and operations subject us to additional risks and costs, including the ability to engage with customers in new geographies and exposure to foreign currency exchange rate fluctuations, that can adversely affect our business, financial condition, revenues, results of operations or cash flows.

We are continuing to expand our international operations as part of our growth strategy. However, there are a variety of risks and costs associated with our international sales and operations, which include making investments prior to the sales or use of quantum computers, the cost of conducting our business internationally and hiring and training international employees and the costs associated with complying with local law. Furthermore, we cannot predict the rate at which our quantum computers will be accepted in international markets by potential customers.

We have a limited sales presence in Germany and Israel; and, as a result, our sales, support and engineering organization outside the United States is substantially smaller than our U.S. sales organization. We believe our ability to attract new customers to subscribe to our platform or to attract existing customers to renew or expand their use of our platform is directly correlated to the level of engagement we obtain with the customer. To the extent we are unable to effectively engage with non-U.S. customers due to our limited sales force capacity, we may be unable to effectively grow in international markets.

As our international operations expand, our exposure to the effects of fluctuations in currency exchange rates grows. While we have primarily transacted with customers in U.S. dollars, historically, we expect to continue to expand the number of transactions with our customers that are denominated in foreign currencies in the future. Additionally, fluctuations in the value of the U.S. dollar and foreign currencies may make our subscriptions more expensive for international customers, which could harm our business. Additionally, we incur expenses for employee compensation and other operating expenses for our non-U.S. employees in the local currency for such locations. Fluctuations in the exchange rates between the U.S. dollar and other currencies could result in an increase to the U.S. dollar equivalent of such expenses. These fluctuations could cause our results of operations to differ from our expectations or the expectations of our investors. Additionally, such foreign currency exchange rate fluctuations could make it more difficult to detect underlying trends in our business and results of operations.

Our international operations may subject us to greater than anticipated tax liabilities.

The amount of taxes we may pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the United States, to our international business activities, changes in tax rates, new or revised tax laws or interpretations of existing tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to any future intercompany arrangement or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position

 

54


Table of Contents

was not sustained, we could be required to pay additional taxes, interest and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a “permanent establishment” under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.

Risks Related to Litigation and Government Regulation

Our business is exposed to risks associated with litigation, investigations and regulatory proceedings.

We may face legal, administrative and regulatory proceedings, claims, demands and/or investigations involving stockholder, consumer, competition and/or other issues relating to our business. Litigation and regulatory proceedings are inherently uncertain, and adverse rulings could occur, including monetary damages, or an injunction stopping us from engaging in certain business practices, or requiring other remedies, such as compulsory licensing of patents. For example, on January 12, 2021, dMY Technology Group, Inc. II, dMY Sponsor II, LLC, dMY and dMY Sponsor III, LLC (“Sponsor”) accepted service of a lawsuit where we are named as counterclaim defendants in an underlying action by and between GTY Technology Holdings, Inc. (“GTY”), dMY Technology Group, Inc. and dMY Sponsor, LLC, dMY Sponsor II, LLC, dMY Technology Group Inc. II, dMY and Sponsor (collectively, “dMY Defendants”) and Carter Glatt (“Glatt”) and Captains Neck Holdings LLC (“Captains Neck”), an entity of which Mr. Glatt is a member. The underlying lawsuit, filed by dMY Technology Group, Inc. and dMY Sponsor, LLC, seeks a declaratory judgment that Glatt and Captains Neck are not entitled to membership units of dMY Sponsor LLC, which was formed by Harry L. You, the co-founder and former President and Chief Financial Officer of GTY when Glatt was still working at GTY. The underlying lawsuit contains claims arising from Glatt’s termination of employment from GTY, including theft and misappropriation of confidential GTY information, breach of contract, breach of the duties of loyalty and fiduciary duty and conversion. Glatt has responded to the underlying lawsuit by adding members of the Sponsor and officers of dMY as additional counterclaim defendants (collectively with the dMY Defendants, Glatt and Captains Neck, the “Counterclaim Defendants”) and adding Dune Acquisition Holdings LLC, a newly formed special purpose acquisition company, as a counterclaimant and asserting claims for breach of contract, fraudulent misrepresentation, negligent misrepresentation, tortious interference with business relations, quantum meruit and unjust enrichment. The Counterclaim Defendants have denied the claims against them and have a motion to dismiss the suit.

In May 2022, a securities class action complaint captioned Leacock v. IonQ, Inc. et al., Case No. 8:22-cv-01306, was filed by a stockholder of the Company in the United States District Court for the District of Maryland (the “Leacock Litigation”) against the Company and certain of the Company’s current officers. In June 2022, a securities class action complaint captioned Fisher v. IonQ, Inc., Case No. 8:22-cv-01306-DLB (the “Fisher Litigation”) was filed by a stockholder against the Company and certain of the Company’s current officers (the “IonQ Defendants”). Both the Leacock Litigation and Fisher Litigation, which have been consolidated into a single action, allege violations of Section 10(b) of the Exchange Act, and Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act and seek damages. In September 2022, the Court appointed lead plaintiffs and counsel for lead plaintiffs, and ordered lead plaintiffs to file a consolidated amended complaint. The consolidated amended complaint was filed on November 22, 2022. As part of the consolidated amended complaint, certain members of the Company’s board of directors (the “Board”) as well as other dMY-related defendants (“Additional Defendants”) have been added as defendants to the case. On February 7, 2023, the IonQ Defendants and the Additional Defendants each filed a motion to dismiss the consolidated amended complaint. Both the IonQ Defendants and the Additional Defendants believe that the allegations in the various complaints are without merit and intend to defend the matters vigorously.

 

55


Table of Contents

These proceedings and any additional investigations, inquiries or litigation by various regulators may harm our reputation regardless of the outcome of any such action. The outcome of any litigation, regardless of its merits, is inherently uncertain. Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management attention and resources, and lead to attempts on the part of other parties to pursue similar claims. Negative perceptions of our business may result in additional regulation, enforcement actions by the government and increased litigation, or harm to our ability to attract or retain customers or strategic partners, any of which may affect our business. Any damage to our reputation, including from publicity from legal proceedings against us or companies that work within our industry, governmental proceedings, unfavorable media coverage or class action could adversely affect our business, financial condition and results of operations.

An unfavorable outcome or settlement or any other legal, administrative and regulatory proceeding may result in a material adverse impact on our business, results of operations, financial position and overall trends. In addition, regardless of the outcome, litigation can be costly, time-consuming, and disruptive to our operations. Any claims or litigation, even if fully indemnified or insured, could damage our reputation and make it more difficult to compete effectively or to obtain adequate insurance in the future. In addition, the laws and regulations our business is subject to are complex and change frequently. We may be required to incur significant expense to comply with changes in, or remedy violations of, these laws and regulations.

Furthermore, while we maintain insurance for certain potential liabilities, such insurance does not cover all types and amounts of potential liabilities and is subject to various exclusions as well as caps on amounts recoverable. Even if we believe a claim is covered by insurance, insurers may dispute our entitlement to recovery for a variety of potential reasons, which may affect the timing and, if the insurers prevail, the amount of our recovery.

We may become subject to product liability claims, which could harm our financial condition and liquidity if we are not able to successfully defend or insure against such claims.

We may become subject to product liability claims, even those without merit, which could harm our business prospects, operating results, and financial condition. We may face inherent risk of exposure to claims in the event our quantum computers do not perform as expected or malfunction. A successful product liability claim against us could require us to pay a substantial monetary award. Moreover, a product liability claim could generate substantial negative publicity about our quantum computers and business and inhibit or prevent commercialization of other future quantum computers, which would have material adverse effects on our brand, business, prospects and operating results. Any insurance coverage might not be sufficient to cover all potential product liability claims. Any lawsuit seeking significant monetary damages either in excess of our coverage, or outside of our coverage, may have a material adverse effect on our reputation, business and financial condition. We may not be able to secure additional product liability insurance coverage on commercially acceptable terms or at reasonable costs when needed, particularly if we do face liability for our products and are forced to make a claim under our policy.

We are subject to requirements relating to environmental and safety regulations and environmental remediation matters, which could adversely affect our business, results of operation and reputation.

We are subject to numerous federal, state and local environmental laws and regulations governing, among other things, solid and hazardous waste storage, treatment and disposal, and remediation of releases of hazardous materials. There are significant capital, operating and other costs associated with compliance with these environmental laws and regulations. Environmental laws and regulations may become more stringent in the future, which could increase costs of compliance or require us to manufacture with alternative technologies and materials.

Federal, state and local authorities also regulate a variety of matters, including, but not limited to, health, safety and permitting in addition to the environmental matters discussed above. New legislation and regulations may require us to make material changes to our operations, resulting in significant increases to the cost of production.

 

56


Table of Contents

Our manufacturing process will have hazards such as but not limited to hazardous materials, machines with moving parts, and high voltage and/or high current electrical systems typical of large manufacturing equipment and related safety incidents. There may be safety incidents that damage machinery or product, slow or stop production, or harm employees. Consequences may include litigation, regulation, fines, increased insurance premiums, mandates to temporarily halt production, workers’ compensation claims, or other actions that impact the company brand, finances, or ability to operate.

Contracts with U.S. government entities subject us to risks, including early termination, audits, investigations, sanctions and penalties.

As part of our business strategy, we have entered into and may enter into additional contracts with state and federal government entities, which subjects our business to statutes and regulations applicable to companies doing business with the government, including the Federal Acquisition Regulation. These government contracts customarily contain provisions that give the government substantial rights and remedies, many of which are not typically found in commercial contracts and which are unfavorable to contractors. For instance, most U.S. government agencies include provisions that allow the government to unilaterally terminate or modify contracts for convenience, and in that event, the counterparty to the contract may generally recover only its incurred or committed costs and settlement expenses and profit on work completed prior to the termination. If the government terminates a contract for default, the defaulting party may be liable for any extra costs incurred by the government in procuring undelivered items from another source.

In addition, government contracts normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:

 

   

specialized disclosure and accounting requirements unique to government contracts;

 

   

financial and compliance audits that may result in potential liability for price adjustments, recoupment of government funds after such funds have been spent, civil and criminal penalties, or administrative sanctions such as suspension or debarment from doing business with the U.S. government;

 

   

public disclosures of certain contract and company information; and

 

   

mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action programs and environmental compliance requirements.

Government contracts are also generally subject to greater scrutiny by the government, which can initiate reviews, audits and investigations regarding our compliance with government contract requirements. In addition, if we fail to comply with government contracting laws, regulations and contract requirements, our contracts may be subject to termination, and we may be subject to financial and/or other liability under our contracts, the Federal Civil False Claims Act (including treble damages and other penalties), or criminal law. In particular, the False Claims Act’s “whistleblower” provisions also allow private individuals, including present and former employees, to sue on behalf of the U.S. government. Any penalties, damages, fines, suspension, or damages could adversely affect our ability to operate our business and our financial results.

We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to adverse business consequences.

Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.

 

57


Table of Contents

In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the California Consumer Privacy Act of 2018 (“CCPA”) applies to personal information of California consumers, business representatives and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. In addition, the California Privacy Rights Act of 2020 (“CPRA”) expands the CCPA’s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law.

Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. Additionally, several states and localities have enacted measures related to the use of artificial intelligence and machine learning in products and services. These developments may further complicate compliance efforts, and may increase legal risk and compliance costs for us, the third parties upon whom we rely, and our customers.

Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union’s General Data Protection Regulation (“EU GDPR”), the United Kingdom’s General Data Protection Regulation (“UK GDPR”), Brazil’s General Data Protection Law (Lei Geral de Proteção de Dados Pessoais, or “LGPD”) (Law No. 13,709/2018), and China’s Personal Information Protection Law (“PIPL”) impose strict requirements for processing personal data.

For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. Additionally, we also target customers in Asia and may be subject to new and emerging data privacy regimes in Asia, including China’s PIPL, Japan’s Act on the Protection of Personal Information, and Singapore’s Personal Data Protection Act.

In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (“EEA”) and the United Kingdom (“UK”) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK’s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigators, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the EU GDPR’s cross-border data transfer limitations.

 

58


Table of Contents

In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the EU GDPR, UK GDPR and CCPA, require our customers to impose specific contractual restrictions on their service providers. Additionally, some of our customers may require us to host personal data locally.

We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.

Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.

We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; interruptions or stoppages in our business operations or data collection; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.

We are subject to U.S. and foreign anti-corruption, anti-bribery and similar laws, and non-compliance with such laws can subject us to criminal or civil liability and harm our business.

We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, and other anti-bribery, and anti-corruption laws in countries in which we conduct activities. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years and are interpreted broadly to generally prohibit companies, their employees, and their third-party intermediaries from authorizing, promising, offering, providing, soliciting, or accepting, directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector. We may engage with partners and third-party intermediaries to market our services and to obtain necessary permits, licenses, and other regulatory approvals. In addition, we or our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, and of our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize such activities. We cannot provide any assurance that all of our employees and agents will not take actions in violation of our policies and applicable law, for which we may be ultimately held responsible.

Detecting, investigating, and resolving actual or alleged violations of anti-corruption laws can require a significant diversion of time, resources, and attention from senior management. In addition, noncompliance with anti-corruption or anti-bribery laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, enforcement actions, fines, damages, other civil or criminal penalties, injunctions, suspension or debarment from contracting with certain persons, reputational harm, adverse media coverage, and other collateral consequences.

 

59


Table of Contents

We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.

Our products and technologies are subject to U.S. export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls. U.S. export control and economic sanctions laws include restrictions or prohibitions on the sale or supply of certain products, technologies, and services to U.S. government embargoed or sanctioned countries, governments, persons and entities. In addition, certain products and technology may be subject to export licensing or approval requirements. Exports of our products and technology must be made in compliance with export control and sanctions laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers.

In addition, changes in our products or technologies or changes in applicable export or import laws and regulations may create delays in the introduction and sale of our products and technologies in international markets or, in some cases, prevent the export or import of our products and technologies to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws and regulations, or change in the countries, governments, persons or technologies targeted by such laws and regulations, could also result in decreased use of our products and technologies, or in our decreased ability to export or sell our products and technologies to existing or potential customers. Any decreased use of our products and technologies or limitation on our ability to export or sell our products and technologies would likely adversely affect our business, financial condition and results of operations.

We expect to incur significant costs in complying with these regulations. Regulations related to quantum computing are currently evolving and we may face additional risks associated with changes to these regulations.

Risks Related to our Intellectual Property

Licensing of intellectual property is of critical importance to our business. For example, we license patents (some of which are foundational patents) and other intellectual property from the University of Maryland and Duke University on an exclusive basis. If the license agreement with these universities terminates, or if any of the other agreements under which we acquired or licensed, or will acquire or license, material intellectual property rights is terminated, we could lose the ability to develop and operate our business.

We are heavily reliant upon licenses to certain patent rights and other intellectual property from third parties that are important or necessary to the development of our products. In particular, our quantum computing technology is dependent on our license agreement with University of Maryland and Duke University. Significant intellectual property developed by our co-founders, Jungsang Kim, our Chief Technology Officer, and Christopher Monroe, our Chief Scientist, has been and is required to be assigned to the Universities as a result of Dr. Kim and Dr. Monroe’s employment by the Universities, and certain such intellectual property is licensed pursuant to the license agreement with the Universities. Pursuant to the license agreement with the universities, we were granted an exclusive, worldwide, royalty-free, sublicenseable license for certain patents, know-how (on a non-exclusive basis) and other intellectual property to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which includes the application of the licensed intellectual property in ion trap quantum computing.

 

60


Table of Contents

Our existing license agreement with the Universities imposes, and we expect that any future license agreements will impose, upon us various commercial and development obligations. If we fail to comply with our obligations under these agreements, or we are subject to an insolvency-related event, the licensor may have the right to terminate these agreements, in which event we would not be able to develop, market or otherwise commercialize products covered by these agreements, including if any of the foregoing were to occur with respect to our license agreement with the Universities. Our business could significantly suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.

Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues, and certain provisions in intellectual property license agreements may be susceptible to multiple interpretations. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:

 

   

the scope of rights granted under the license agreement and other interpretation-related issues;

 

   

whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

 

   

our right to sublicense patent and other rights to third parties;

 

   

our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product and technology, and what activities satisfy those diligence obligations;

 

   

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and the company;

 

   

our right to transfer or assign the license; and

 

   

the effects of termination.

The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could harm our business, financial condition and results of operations. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize our products or technology.

While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the license agreement, we may not be able to do so in a timely manner, at an acceptable cost or at all.

If we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected. Moreover, our trade secrets could be compromised, which could cause us to lose the competitive advantage resulting from these trade secrets.

Our success depends, in significant part, on our ability to obtain, maintain, enforce and defend patents and other intellectual property rights, including trade secrets, with respect to our products and technology and to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights of others. We may not be able to prevent unauthorized use of our intellectual property. We rely upon a combination of the intellectual property protections afforded by patent, copyright, trademark and trade secret

 

61


Table of Contents

laws in the United States and other jurisdictions, as well as license agreements and other contractual protections, to establish, maintain and enforce rights in our proprietary technologies. In addition, we seek to protect our intellectual property rights through nondisclosure and invention assignment agreements with our employees and consultants, and through non-disclosure agreements with business partners and other third parties. Our trade secrets may also be compromised, which could cause us to lose the competitive advantage from such trade secrets. Despite our efforts to protect our proprietary rights, third parties may attempt to copy or otherwise obtain and use our intellectual property. Monitoring unauthorized use of our intellectual property is difficult and costly, and the steps we have taken or will take to prevent misappropriation may not be sufficient. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive and could divert management’s attention, which could harm our business, results of operations and financial condition. In addition, existing intellectual property laws and contractual remedies may afford less protection than needed to safeguard our intellectual property portfolio.

Patent, copyright, trademark and trade secret laws vary significantly throughout the world. A number of foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. Therefore, our intellectual property rights may not be as strong or as easily enforced outside of the United States and efforts to protect against the unauthorized use of our intellectual property rights, technology and other proprietary rights may be more expensive and difficult outside of the United States. Failure to adequately protect our intellectual property rights could result in our competitors using our intellectual property to offer products, potentially resulting in the loss of some of our competitive advantage and a decrease in our revenue, which would adversely affect our business, financial condition and operating results.

Our patent applications may not result in issued patents or our patent rights may be contested, circumvented, invalidated or limited in scope, any of which could have a material adverse effect on our ability to prevent others from interfering with our commercialization of our products.

Our patent applications may not result in issued patents, which may have a material adverse effect on our ability to prevent others from commercially exploiting products similar to ours. The status of patents involves complex legal and factual questions and the breadth of claims allowed is uncertain. As a result, we cannot be certain that the patent applications that we file will result in patents being issued, or that our patents and any patents that may be issued to us will afford protection against competitors with similar technology. Numerous patents and pending patent applications owned by others exist in the fields in which we have developed and are developing our technology. In addition to those who may have patents or patent applications directed to relevant technology with an effective filing date earlier than any of our existing patents or pending patent applications, any of our existing or pending patents may also be challenged by others on the basis that they are otherwise invalid or unenforceable. Furthermore, patent applications filed in foreign countries are subject to laws, rules and procedures that differ from those of the United States, and thus we cannot be certain that foreign patent applications related to issued U.S. patents will be issued.

Even if our patent applications succeed and we are issued patents in accordance with them, it is still uncertain whether these patents will be contested, circumvented, invalidated or limited in scope in the future. The rights granted under any issued patents may not provide us with meaningful protection or competitive advantages, and some foreign countries provide significantly less effective patent enforcement than in the United States. In addition, the claims under any patents that issue from our patent applications may not be broad enough to prevent others from developing technologies that are similar or that achieve results similar to ours. The intellectual property rights of others could also bar us from licensing and exploiting any patents that issue from our pending applications. In addition, patents issued to us may be infringed upon or designed around by others and others may obtain patents that it needs to license or design around, either of which would increase costs and may adversely affect our business, prospects, financial condition and operating results.

 

62


Table of Contents

We may face patent infringement and other intellectual property claims that could be costly to defend, result in injunctions and significant damage awards or other costs (including indemnification of third parties or costly licensing arrangements (if licenses are available at all)) and limit our ability to use certain key technologies in the future or require development of non-infringing products, services, or technologies, which could result in a significant expenditure and otherwise harm our business.

We may become subject to intellectual property disputes. Our success depends, in part, on our ability to develop and commercialize our products, services and technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. However, we may not be aware that our products, services or technologies are infringing, misappropriating or otherwise violating third-party intellectual property rights and such third parties may bring claims alleging such infringement, misappropriation or violation. For example, there may be issued patents of which we are unaware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future products, services or technologies. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future products, services or technologies. Because patent applications can take years to issue and are often afforded confidentiality for some period of time there may currently be pending applications, unknown to us, that later result in issued patents that could cover our current or future products, services or technologies. Lawsuits can be time-consuming and expensive to resolve, and they divert management’s time and attention. Numerous patents and pending patent applications owned by others exist in the fields in which we have developed and are developing our technology. Companies that have developed and are developing technology are often required to defend against litigation claims based on allegations of infringement, misappropriation or other violations of intellectual property rights. Our products, services or technologies may not be able to withstand any third-party claims against their use. In addition, many companies have the capability to dedicate substantially greater resources to enforce their intellectual property rights and to defend claims that may be brought against them. In a patent infringement claim against us, we may assert, as a defense, that we do not infringe the relevant patent claims, that the patent is invalid or both. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents. However, we could be unsuccessful in advancing non-infringement and/or invalidity arguments in our defense. In the United States, issued patents enjoy a presumption of validity, and the party challenging the validity of a patent claim must present clear and convincing evidence of invalidity, which is a high burden of proof. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof. Our patent portfolio may not be large enough to deter patent infringement claims, and our competitors and others may now and in the future have significantly larger and more mature patent portfolios. Any litigation may also involve patent holding companies or other adverse patent owners that have no relevant solution revenue, and therefore, our patent portfolio may provide little or no deterrence as we would not be able to assert our patents against such entities or individuals. If a third party is able to obtain an injunction preventing us from accessing such third-party intellectual property rights, or if we cannot license or develop alternative technology for any infringing aspect of our business, we may be forced to limit or stop sales of our products, services or technologies or cease business activities related to such intellectual property.

Although we carry general liability insurance, our insurance may not cover potential claims of this type or may not be adequate to indemnify us for all liability that may be imposed. We cannot predict the outcome of lawsuits and cannot ensure that the results of any such actions will not have an adverse effect on our business, financial condition or results of operations. Any intellectual property litigation to which we might become a party, or for which we are required to provide indemnification, regardless of the merit of the claim or our defenses, may require us to do one or more of the following:

 

   

cease selling or using solutions or services that incorporate the intellectual property rights that allegedly infringe, misappropriate or violate the intellectual property of a third party;

 

   

make substantial payments for legal fees, settlement payments or other costs or damages;

 

63


Table of Contents
   

obtain a license, which may not be available on reasonable terms or at all, to sell or use the relevant technology;

 

   

redesign the allegedly infringing solutions to avoid infringement, misappropriation or violation, which could be costly, time-consuming or impossible; or

 

   

indemnify organizations using our platform or third-party service providers.

Even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business and operating results. Moreover, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. The occurrence of infringement claims may grow as the market for our products, services and technologies grows. Accordingly, our exposure to damages resulting from infringement claims could increase and this could further exhaust our financial and management resources.

Some of our in-licensed intellectual property, including the intellectual property licensed from the Universities, has been conceived or developed through government-funded research and thus may be subject to federal regulations providing for certain rights for the U.S. government or imposing certain obligations on us, such as a license to the U.S. government under such intellectual property, “march-in” rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers.

Certain intellectual property rights that have been in-licensed pursuant to the license agreement with the Universities have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Patent and Trademark Law Amendment. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention, (2) government action is necessary to meet public health or safety needs or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as “march-in rights”). The U.S. government also has the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the U.S., and the license agreement with the Universities requires that we comply with this requirement. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. To the extent any of our owned or licensed future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.

 

64


Table of Contents

Risks Related to an Investment in our Securities and Other General Matters

The market price of shares of our common stock or public warrants may be volatile, which could cause the value of your investment to decline.

If you purchase shares of our common stock, you may not be able to resell those shares at or above the price you paid. The market price of our common stock may be highly volatile and may fluctuate or decline significantly in response to numerous factors, some of which are beyond our control. The securities markets have experienced and continue to experience significant volatility. Market volatility, as well as general economic, market or political conditions, could reduce the market price of shares of our common stock regardless of our operating performance. Our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including:

 

   

variations in quarterly operating results or dividends, if any, to stockholders;

 

   

additions or departures of key management personnel;

 

   

publication of research reports about our industry;

 

   

rumors and market speculation involving us or other companies in our industry, which may include short seller reports;

 

   

litigation and government investigations;

 

   

changes or proposed changes in laws or regulations or differing interpretations or enforcement of laws or regulations affecting our business;

 

   

adverse market reaction to any indebtedness incurred or securities issued in the future;

 

   

changes in market valuations of similar companies;

 

   

announcements by competitors of significant contracts, acquisitions, dispositions, strategic partnerships, joint ventures, or capital commitments;

 

   

the impact of any future bank failures, public health crises or geopolitical events such as the Russia-Ukraine war; and

 

   

the impact of any of the foregoing on our management, employees, partners, customers, and operating results.

Following periods of volatility in the overall market and the market price of a company’s securities, securities class action litigation has often been instituted against such company. Such litigation could result in substantial costs and a diversion of management’s attention and resources. See also “—Risks Related to Litigation and Government Regulation—Our business is exposed to risks associated with litigation, investigations and regulatory proceedings.”

Short sellers may engage in manipulative activity intended to drive down the market price of our common stock, which could also result in related regulatory and governmental scrutiny, among other effects.

Short selling is the practice of selling securities that the seller does not own but rather has borrowed or intends to borrow from a third party with the intention of later buying lower priced identical securities to return to the lender. Accordingly, it is in the interest of a short seller of our common stock for the price to decline. At any time, short sellers may publish, or arrange for the publication of, opinions or characterizations that are intended to create negative market momentum. Issuers, like us, whose securities have historically had limited trading history or volumes and/or have been susceptible to relatively high volatility levels can be vulnerable to such short seller attacks. Short selling reports can cause increased volatility in an issuer’s stock price, and result in regulatory and governmental inquiries. On May 3, 2022, a short seller report was published about us, which contained certain allegations against us. Any inquiry or formal investigation from a governmental organization or other regulatory body, including any inquiry from the SEC or the U.S. Department of Justice, could result in a material diversion of our management’s time and could have a material adverse effect on our business and results of operations.

 

65


Table of Contents

There may not be an active trading market for our common stock or public warrants, which may make it difficult to sell such securities.

It is possible that an active trading market will not be sustained. This would make it difficult for you to sell shares of our common stock or public warrants at an attractive price or at all.

Our ability to timely raise capital in the future may be limited, or may be unavailable on acceptable terms, if at all. The failure to raise capital when needed could harm our business, operating results and financial condition. Debt or equity issued to raise additional capital may reduce the value of our common stock.

We cannot be certain when or if the operations of our business will generate sufficient cash to fund our ongoing operations or the growth of our business. We intend to make investments to support our current business and may require additional funds to respond to business challenges, including the need to develop or enhance our technology, improve our operating infrastructure or acquire complementary businesses and technologies. Additional financing may not be available on favorable terms, if at all. In addition, we may not be able to access a portion of our existing cash, cash equivalents and investments due to market conditions. For example, on March 10, 2023, the Federal Deposit Insurance Corporation (“FDIC”) took control and was appointed receiver of Silicon Valley Bank (“SVB”). Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition. Additionally, weakness and volatility in capital markets and the economy, in general or as a result of bank failures or macroeconomic conditions such as rising inflation, could limit our access to capital markets and increase our costs of borrowing. If adequate funds are not available on acceptable terms, we may be unable to invest in future growth opportunities, which could harm our business, operating results and financial condition. If we incur debt, the debt holders could have rights senior to holders of our common stock to make claims on our assets. The terms of any debt could restrict our operations, including our ability to pay dividends on our common stock. If we issue additional equity securities, stockholders will experience dilution, and the new equity securities could have rights senior to those of our common stock.

Because the decision to issue securities in the future offering will depend on numerous considerations, including factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future issuances of debt or equity securities. As a result, stockholders will bear the risk of future issuances of debt or equity securities reducing the value of their common stock and diluting their interest.

A small number of stockholders will continue to have substantial control over us, which may limit other stockholders’ ability to influence corporate matters and delay or prevent a third party from acquiring control over us.

As of March 31, 2023, our directors and executive officers of, and beneficial owners of 5% or more of our voting securities and their respective affiliates beneficially own, in the aggregate, approximately 27% of our outstanding common stock. This concentration of ownership may have a negative impact on the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with controlling stockholders. In addition, these stockholders will be able to exercise influence over all matters requiring stockholder approval, including the election of directors and approval of corporate transactions, such as a merger or other sale of us or our assets. This concentration of ownership could limit stockholders’ ability to influence corporate matters and may have the effect of delaying or preventing a change in control, including a merger, consolidation or other business combination, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control, even if that change in control would benefit the other stockholders.

 

66


Table of Contents

There can be no assurance that we will be able to comply with the continued listing standards of the New York Stock Exchange (“NYSE”).

If we fail to satisfy the continued listing requirements of NYSE, such as the corporate governance requirements or the minimum share price requirement, NYSE may take steps to delist our securities. Such a delisting would likely have a negative effect on the price of the securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our securities from dropping below the NYSE minimum share price requirement or prevent future non-compliance with NYSE’s listing requirements. Additionally, if our securities are not listed on, or become delisted from the NYSE, for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if we were quoted or listed on the NYSE or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.

If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of financial reports, and the market price of our common stock may decline.

We are required to maintain internal controls over financial reporting and to report any material weaknesses in such internal controls. The process of designing, implementing, and testing the internal control over financial reporting required to comply with this obligation is time-consuming, costly, and complicated. There can be no assurance that the controls put in place will remain effective or that any additional controls needed will be designed and implemented timely to prevent material misstatements in our consolidated financial statements in future periods. If we identify material weaknesses in our internal control over financial reporting in the future, if we are unable to comply with the requirements of Section 404 of Sarbanes-Oxley Act of 2002 in a timely manner, or if we are unable to assert that our internal control over financial reporting is effective, we will be unable to certify that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline. We could become subject to investigations by the NYSE, the SEC or other regulatory authorities, which could require additional financial and management resources.

If our operating and financial performance in any given period does not meet the guidance provided to the public or the expectations of investment analysts, the market price of our common stock may decline.

We may, but are not obligated to, provide public guidance on our expected operating and financial results for future periods. Any such guidance will consist of forward-looking statements, subject to the risks and uncertainties described in this filing and in our other public filings and public statements. Our actual results may not always be in line with or exceed any guidance we have provided, especially in times of economic uncertainty, such as the current global economic uncertainty being experienced. If, in the future, our operating or financial results for a particular period do not meet any guidance provided or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our common stock may decline as well. Even if we do issue public guidance, there can be no assurance that we will continue to do so in the future.

Our quarterly operating results may fluctuate significantly and could fall below the expectations of securities analysts and investors due several factors, some of which are beyond our control, resulting in a decline in our stock price.

Our quarterly operating results may fluctuate significantly because of several factors, including:

 

   

labor availability and costs for hourly and management personnel;

 

67


Table of Contents
   

profitability of our products, especially in new markets;

 

   

changes in interest rates;

 

   

impairment of long-lived assets;

 

   

macroeconomic conditions, both nationally and locally;

 

   

size and scope of our revenue arrangements with our customers;

 

   

negative publicity relating to products we serve;

 

   

changes in consumer preferences and competitive conditions;

 

   

expansion to new markets; and

 

   

fluctuations in commodity prices.

We will continue to incur significant increased expenses and administrative burdens as a public company, which could negatively impact our business, financial condition and results of operations.

We face increased legal, accounting, insurance, administrative and other costs and expenses as a public company that we did not incur as a private company. Sarbanes-Oxley, including the requirements of Section 404, as well as rules and regulations subsequently implemented by the SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules and regulations promulgated and to be promulgated thereunder, the Public Company Accounting Oversight Board (“PCAOB”) and the securities exchanges, impose additional reporting and other obligations on public companies. Compliance with public company requirements will continue to increase costs and make certain activities more time-consuming. A number of those requirements require us to carry out activities we have not done previously. For example, we adopted new internal controls and disclosure controls and procedures.

If any issues in complying with SEC reporting requirements are identified (for example, if we identify a material weakness or significant deficiency in the internal control over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could harm our reputation or investor perceptions of us. Further, the costs to maintain our director and officer liability insurance may continue to rise to unprecedented levels. Risks associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve on our Board or as executive officers. The additional reporting and other obligations imposed by these rules and regulations will increase legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These increased costs will require us to divert a significant amount of money that could otherwise be used to expand our business and achieve strategic objectives. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs.

We qualify as an emerging growth company as well as a smaller reporting company. The reduced public company reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.

We qualify as an emerging growth company under SEC rules. As an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These provisions include: (1) presenting only two years of audited financial statements; (2) presenting only two years of related selected financial data and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure; (3) an exemption from compliance with the auditor attestation requirement in the assessment of internal control over financial reporting pursuant to Section 404 of Sarbanes-Oxley; (4) not being required to comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements; (5) reduced disclosure obligations regarding executive compensation arrangements in periodic reports, registration statements, and proxy statements; and (6) exemptions

 

68


Table of Contents

from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide will be different than the information that is available with respect to other public companies that are not emerging growth companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and the market price of our common stock may be more volatile. We will remain an emerging growth company until the earliest of: (1) December 31, 2025; (2) the last day of the fiscal year in which we have gross revenue exceeding $1.235 billion; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three year period; and (4) the last day of the year in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the prior June 30th.

Additionally, we qualify as a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of common stock held by non-affiliates exceeds $250 million as of the end of that year’s second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of common stock held by non-affiliates equals or exceeds $700 million as of the end of that year’s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, this may also make comparison of our financial statements with other public companies difficult or impossible.

We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our common stock.

As of March 31, 2023, we had warrants outstanding to purchase an aggregate of 13,532,688 shares of common stock. Pursuant to our employee benefit plans, we may issue an aggregate of up to 42,633,201 shares of common stock, which amount may be subject to increase from time to time. We may also issue additional shares of common stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances.

The issuance of additional shares or other equity securities of equal or senior rank would have the following effects:

 

   

existing stockholders’ proportionate ownership interest in us will decrease;

 

   

the amount of cash available per share, including for payment of dividends, if any, may decrease;

 

   

the relative voting strength of each previously outstanding common stock may be diminished; and

 

   

the market price of our common stock may decline.

There is no guarantee that the public warrants will be in the money, and they may expire worthless.

The exercise price for our public warrants is $11.50 per share of common stock. There is no guarantee that the public warrants will be in the money prior to their expiration, and as such, the public warrants may expire worthless. The public warrants expire on September 30, 2026.

We may amend the terms of the public warrants in a manner that may be adverse to holders with the approval by the holders of at least 50% of the then-outstanding public warrants. As a result, the exercise price of your public warrants could be increased, the exercise period could be shortened and the number of shares of our common stock purchasable upon exercise of a public warrant could be decreased, all without your approval.

 

69


Table of Contents

Our public warrants are issued in registered form under the Warrant Agreement between the warrant agent and us. The Warrant Agreement provides that the terms of the public warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then-outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding public warrants approve of such amendment. Although our ability to amend the terms of the public warrants with the consent of at least 50% of the then-outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the public warrants into cash or stock (at a ratio different than initially provided), shorten the exercise period or decrease the number of shares of our common stock purchasable upon exercise of a public warrant.

We may redeem unexpired public warrants prior to their exercise at a time that is disadvantageous to warrantholders, thereby making such warrants worthless.

We have the ability to redeem outstanding public warrants prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of our common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we give proper notice of such redemption and provided certain other conditions are met. If and when the public warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding public warrants could force you (1) to exercise your public warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (2) to sell your public warrants at the then-current market price when you might otherwise wish to hold your public warrants or (3) to accept the nominal redemption price which, at the time the outstanding public warrants are called for redemption, is likely to be substantially less than the market value of your public warrants.

In addition, we may redeem the public warrants after they become exercisable for a number of shares of common stock determined based on the redemption date and the fair market value of our common stock. Any such redemption may have similar consequences to a cash redemption described above. In addition, such redemption may occur at a time when the public warrants are “out-of-the-money,” in which case, you would lose any potential embedded value from a subsequent increase in the value of our common stock had your public warrants remained outstanding.

We have no current plans to pay cash dividends on our common stock; as a result, stockholders may not receive any return on investment unless they sell their common stock for a price greater than the purchase price.

We have no current plans to pay dividends on our common stock. Any future determination to pay dividends will be made at the discretion of our Board, subject to applicable laws. It will depend on a number of factors, including our financial condition, results of operations, capital requirements, contractual, legal, tax and regulatory restrictions, general business conditions, and other factors that the Board may deem relevant. In addition, the ability to pay cash dividends may be restricted by the terms of debt financing arrangements, as any future debt financing arrangement likely will contain terms restricting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, stockholders may not receive any return on an investment in our common stock unless they sell their shares for a price greater than what they paid for them.

 

70


Table of Contents

Provisions in our organizational documents and certain rules imposed by regulatory authorities may delay or prevent an acquisition by a third party that could otherwise be in the interests of stockholders.

Our second amended and restated certificate of incorporation (“Certificate of Incorporation”) and amended and restated bylaws (“Bylaws”) contain several provisions that may make it more difficult or expensive for a third party to acquire control of us without the approval of the Board. These provisions, which may delay, prevent or deter a merger, acquisition, tender offer, proxy contest, or other transaction that stockholders may consider favorable, include the following:

 

   

a classified board;

 

   

advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at our annual meetings;

 

   

certain limitations on convening special stockholder meetings;

 

   

limiting the persons who may call special meetings of stockholders;

 

   

limiting the ability of stockholders to act by written consent;

 

   

restrictions on business combinations with interested stockholder;

 

   

in certain cases, the approval of holders representing at least 66 2/3% of the total voting power of the shares entitled to vote generally in the election of directors will be required for stockholders to adopt, amend or repeal the Bylaws, or amend or repeal certain provisions of the Certificate of Incorporation;

 

   

no cumulative voting;

 

   

the required approval of holders representing at least 66 2/3% of the total voting power of the shares entitled to vote at an election of the directors to remove directors; and

 

   

the ability of the Board to designate the terms of and issue new series of preferred stock without stockholder approval, which could be used, among other things, to institute a rights plan that would have the effect of significantly diluting the stock ownership of a potential hostile acquirer, likely preventing acquisitions.

These provisions of our Certificate of Incorporation and Bylaws could discourage potential takeover attempts and reduce the price that investors might be willing to pay for shares of our common stock in the future, which could reduce the market price of our common stock.

The provision of our Certificate of Incorporation requiring exclusive venue in the Court of Chancery in the State of Delaware and the federal district courts of the United States for certain types of lawsuits may have the effect of discouraging lawsuits against directors and officers.

Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for:

 

   

any derivative action or proceeding brought on behalf of us;

 

   

any action asserting a claim of breach of fiduciary duty owed by any director, officer, agent or other employee or stockholder to us or our stockholders;

 

   

any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law (the “DGCL”), the Certificate of Incorporation or Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware;

 

   

any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; or

 

   

any action asserting a claim governed by the internal affairs doctrine, in each case subject to such Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. It further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolutions of any complaint asserting a cause of action arising under the Securities Act. The exclusive forum clauses described above shall not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive

 

71


Table of Contents
 

jurisdiction. Although these provisions are expected to benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation have been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action. If so, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition or results of operations.

These provisions of our Certificate of Incorporation and Bylaws could discourage lawsuits against directors and officers, which could reduce the market price of our common stock.

 

72


Table of Contents
Item 6.

Exhibits.

 

(a)

Exhibits.

The exhibits listed below are filed as part of this Quarterly Report on Form 10-Q.

 

               Incorporated by Reference
Exhibit    Description Form         File Number    Exhibit    Filing Date
    2.1+    Agreement and Plan of Merger, dated as of March 7, 2021, by and among dMY Technology Group, Inc. III, IonQ, Inc. and IonQ Trap Acquisition Inc.    8-K    001-39694    2.1    March 8, 2021
    3.1    Amended and Restated Certificate of Incorporation of IonQ, Inc.    8-K    001-39694    3.1    October 4, 2021
    3.2    Amended and Restated Bylaws of IonQ, Inc.    8-K    001-39694    3.2    October 4, 2021
  31.1    Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a- 14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            
  31.2    Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002            
  32.1*    Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            
101.INS    Inline XBRL Instance Document.            
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document.            
101.SCH    Inline XBRL Taxonomy Extension Schema Document.            
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document.            
101.LAB    Inline XBRL Taxonomy Extension Labels Linkbase Document.            
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document.            
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).            

 

+

Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

*

Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.

 

73


Table of Contents

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    IonQ, Inc.
Date: May 11, 2023    

/s/ Peter Chapman

    Name:   Peter Chapman
    Title:   President and Chief Executive Officer
      (Principal Executive Officer)
Date: May 11, 2023    

/s/ Thomas Kramer

    Name:   Thomas Kramer
    Title:   Chief Financial Officer
      (Principal Financial and Accounting Officer)

 

EX-31.1 2 d246263dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Peter Chapman, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of IonQ, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2023

 

/s/ Peter Chapman

Peter Chapman
Chief Executive Officer
(Principal Executive Officer)
EX-31.2 3 d246263dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Thomas Kramer, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of IonQ, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in exchange act rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2023

 

/s/ Thomas Kramer

Thomas Kramer
Chief Financial Officer
(Principal Financial and Accounting Officer)
EX-32.1 4 d246263dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Peter Chapman, Chief Executive Officer of IonQ, Inc. (the “Company”), and Thomas Kramer, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

 

1.

The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

 

2.

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 11th day of May 2023.

 

/s/ Peter Chapman

   

/s/ Thomas Kramer

   

 

       
Peter Chapman     Thomas Kramer
Chief Executive Officer     Chief Financial Officer
EX-101.SCH 5 ionq-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Description of Business link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Property And Equipment, Net link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Agreements With University Of Maryland And Duke University link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Other Balance Sheet Accounts link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Warrant Transaction Agreement link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Warrant Liabilities link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Geographic Information link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Property And Equipment, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Other Balance Sheet Accounts (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Description of Business - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Summary of Significant Accounting Policies - Summary Of a Reconciliation Of Cash And Restricted Cash (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Summary of Significant Accounting Policies - Summary of Loans and Financing Receivable (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Unearned Revenue (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Fair Value Measurements - Summary of fair value measurements on a recurring basis and the level of inputs (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Property And Equipment, Net - Summary Of Property And Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Property And Equipment, Net - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Agreements With University Of Maryland And Duke University - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Other Balance Sheet Accounts - Summary of accrued expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Warrant Transaction Agreement - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Warrant Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Stock-Based Compensation - Summary Of Share Based Payment Award Stock Options Valuation Assumptions (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Stock-Based Compensation - Summary of the Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Stock-Based Compensation - Summary of stock option grants, vesting and exercises (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Stock-Based Compensation - Summary of restricted stock unit ("RSU") activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock (Detail) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation (Detail) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1059 - Disclosure - Leases - Summary Of Components Of Lease Cost (Detail) link:presentationLink link:definitionLink link:calculationLink 1060 - Disclosure - Leases - Summary Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss (Detail) link:presentationLink link:definitionLink link:calculationLink 1061 - Disclosure - Leases - Summary Of Supplemental Cash Flow And Other Information Related To Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1062 - Disclosure - Leases - Summary Of Maturities Of Operating Lease Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1063 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1064 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Detail) link:presentationLink link:definitionLink link:calculationLink 1065 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 1066 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1067 - Disclosure - Geographic Information - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1068 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Alternate link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 ionq-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 ionq-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ionq-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 ionq-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
3 Months Ended
Mar. 31, 2023
May 04, 2023
Entity Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Registrant Name IONQ, INC.  
Entity Central Index Key 0001824920  
Current Fiscal Year End Date --12-31  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-39694  
Entity Tax Identification Number 85-2992192  
Entity Address, Address Line One 4505 Campus Drive  
Entity Address, City or Town College Park  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20740  
City Area Code 301  
Local Phone Number 298-7997  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
Entity Ex Transition Period false  
Entity Common Stock, Shares Outstanding   201,028,320
Warrant [Member]    
Entity Information [Line Items]    
Trading Symbol IONQ WS  
Title of 12(b) Security Warrants, each exercisable for one share of common stock for $11.50 per share  
Security Exchange Name NYSE  
Common Stock [Member]    
Entity Information [Line Items]    
Trading Symbol IONQ  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Security Exchange Name NYSE  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 51,901 $ 44,367
Short-term investments 335,966 311,430
Accounts receivable 1,837 3,292
Prepaid expenses and other current assets 12,638 12,539
Total current assets 402,342 371,628
Long-term investments 137,646 182,001
Property and equipment, net 26,488 26,014
Operating lease right-of-use assets 5,796 3,753
Intangible assets, net 10,051 8,944
Goodwill 742 742
Other noncurrent assets 4,857 4,910
Total Assets 587,922 597,992
Current liabilities:    
Accounts payable 3,597 3,055
Accrued expenses 9,414 6,655
Current portion of operating lease liabilities 610 591
Unearned revenue 6,294 8,729
Current portion of stock option early exercise liabilities 945 1,130
Total current liabilities 20,860 20,160
Operating lease liabilities, net of current portion 5,624 3,459
Unearned revenue, net of current portion 954 1,201
Stock option early exercise liabilities, net of current portion 741 839
Warrant liabilities 7,429 3,819
Other noncurrent liabilities 77 303
Total liabilities 35,685 29,781
Commitments and contingencies (see Note 8)
Stockholders' Equity:    
Common stock $0.0001 par value; 1,000,000,000 shares authorized; 200,122,686 and 199,862,123 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 20 20
Additional paid-in capital 779,286 769,848
Accumulated deficit (221,640) (194,302)
Accumulated other comprehensive loss (5,429) (7,355)
Total stockholders' equity 552,237 568,211
Total Liabilities and Stockholders' Equity $ 587,922 $ 597,992
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 200,122,686 199,862,123
Common stock, shares outstanding 200,122,686 199,862,123
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue $ 4,285 $ 1,953
Costs and expenses:    
Cost of revenue (excluding depreciation and amortization) 1,036 568
Research and development 16,233 7,338
Sales and marketing 2,667 1,871
General and administrative 10,581 9,194
Depreciation and amortization 1,791 1,266
Total operating costs and expenses 32,308 20,237
Loss from operations (28,023) (18,284)
Change in fair value of warrant liabilities (3,610) 13,448
Interest income, net 4,231 608
Other income (expense), net 64 1
Loss before benefit for income taxes (27,338) (4,227)
Benefit for income taxes 0 0
Net loss $ (27,338) $ (4,227)
Net loss per share attributable to common stockholders—basic $ (0.14) $ (0.02)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic 200,112,855 196,183,247
Net loss per share attributable to common stockholders—diluted $ (0.14) $ (0.02)
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted 200,112,855 196,183,247
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net loss $ (27,338) $ (4,227)
Other comprehensive income (loss), net of reclassification adjustments:    
Change in unrealized gain (loss) on available-for-sale securities, net 1,926 (4,540)
Total other comprehensive income (loss) 1,926 (4,540)
Total comprehensive loss $ (25,412) $ (8,767)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income [Member]
Balance at Dec. 31, 2021 $ 591,230 $ 19 $ 737,150 $ (145,791) $ (148)
Balance (in shares) at Dec. 31, 2021   195,630,975      
Net loss (4,227)     (4,227)  
Other comprehensive income loss (4,540)       (4,540)
Stock options exercised 132 $ 1 131    
Stock options exercised (in shares)   453,225      
Vesting of restricted common stock 316   316    
Vesting of restricted common stock (in shares)   139,511      
Issuance of common stock from the settlement of restricted stock units shares   168,750      
Stock-based compensation 6,848   6,848    
Warrants exercised shares   1,487      
Warrants exercised 24   24    
Balance at Mar. 31, 2022 589,783 $ 20 744,469 (150,018) (4,688)
Balance (in shares) at Mar. 31, 2022   196,393,948      
Balance at Dec. 31, 2022 568,211 $ 20 769,848 (194,302) (7,355)
Balance (in shares) at Dec. 31, 2022   199,862,123      
Net loss (27,338)     (27,338)  
Other comprehensive income loss 1,926       1,926
Stock options exercised $ 52   52    
Stock options exercised (in shares) 131,492 131,492      
Vesting of restricted common stock $ 282   282    
Vesting of restricted common stock (in shares)   125,341      
Issuance of common stock from the settlement of restricted stock units shares   3,730      
Stock-based compensation 9,104   9,104    
Balance at Mar. 31, 2023 $ 552,237 $ 20 $ 779,286 $ (221,640) $ (5,429)
Balance (in shares) at Mar. 31, 2023   200,122,686      
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net loss $ (27,338) $ (4,227)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,791 1,266
Non-cash research and development arrangements 130 130
Stock-based compensation 10,268 6,672
Change in fair value of warrant liabilities 3,610 (13,448)
Other, net (1,570) (490)
Changes in operating assets and liabilities:    
Accounts receivable 2,044 138
Prepaid expenses and other current assets (939) 1,516
Accounts payable 728 (291)
Accrued expenses 920 1,571
Unearned revenue (3,271) (1,058)
Other assets and liabilities (188) (103)
Net cash used in operating activities (13,815) (8,324)
Cash flows from investing activities:    
Purchases of property and equipment (1,185) (2,672)
Capitalized software development costs (843) (457)
Intangible asset acquisition costs (318) (134)
Purchases of available-for-sale securities (64,430) (311,235)
Maturities and sales of available-for-sale securities 88,091 10,400
Net cash provided by (used in) investing activities 21,315 (304,098)
Cash flows from financing activities:    
Proceeds from stock options exercised 52 132
Other financing, net (18) 16
Net cash provided by financing activities 34 148
Net change in cash, cash equivalents and restricted cash 7,534 (312,274)
Cash, cash equivalents and restricted cash at the beginning of the period 46,367 399,025
Cash, cash equivalents and restricted cash at the end of the period 53,901 86,751
Supplemental disclosures of non-cash investing and financing transactions:    
Property and equipment purchases in accounts payable and accrued expenses 153 1,007
Intangible asset purchases in accounts payable and accrued expenses 216 86
Operating lease right-of-use assets subject to lease liability 2,239 0
Noncash reclassification of warrant liabilities to equity upon exercise $ 0 $ 8
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business
3 Months Ended
Mar. 31, 2023
Description of Business
1. DESCRIPTION OF BUSINESS
IonQ, Inc. (“IonQ” or “the Company”), formerly known as dMY Technology Group, Inc. III (“dMY”), was incorporated in the state of Delaware in September 2020 and formed as a special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. IonQ Quantum, Inc. (formerly known as IonQ, Inc., and referred to as “Legacy IonQ” herein), was incorporated in the state of Delaware in September 2015 and is headquartered in College Park, Maryland.
On March 7, 2021, Legacy IonQ entered into an Agreement and Plan of Merger (the “Merger Agreement”) with dMY and Ion Trap Acquisition Inc. (“Merger Sub”), a direct, wholly owned subsidiary of dMY. Pursuant to the Merger Agreement, on September 30, 2021 (“the Closing Date”), the Merger Sub was merged with and into Legacy IonQ with Legacy IonQ continuing as the surviving corporation following the Merger, becoming a wholly owned subsidiary of dMY and the separate corporate existence of the Merger Sub ceased (the “Business Combination”). Commensurate with the Business Combination, dMY changed its name to IonQ, Inc. and Legacy IonQ changed its name to IonQ Quantum, Inc.
Unless otherwise indicated, references in this Quarterly Report on Form
10-Q
to the “Company” and “IonQ” refer to the consolidated operations of IonQ, Inc. subsequent to the Business Combination. References to “dMY” refer to the company prior to the consummation of the Business Combination and references to “Legacy IonQ” refer to IonQ, Inc. prior to the consummation of the Business Combination.
IonQ is engaged in quantum computing and develops general-purpose quantum computing systems designed to solve some of the world’s most complex problems, and transform business, society, and the planet for the better. To operate the quantum computing systems, the Company has developed custom hardware, custom firmware, and an operating system to orchestrate the quantum computers.
Business Combination
While the legal acquirer in the Merger Agreement is dMY, for financial accounting and reporting purposes under accounting principles generally accepted in the United States of America (“U.S. GAAP”), Legacy IonQ is the accounting acquirer and the merger is accounted for as a “reverse recapitalization” (i.e., a capital transaction involving the issuance of stock by dMY for the stock of Legacy IonQ).
For accounting purposes, the Business Combination was treated as the equivalent of Legacy IonQ issuing stock for the net assets of dMY, accompanied by a recapitalization. The net assets of dMY are stated at historical cost, and no goodwill or other intangible assets were recorded. Because Legacy IonQ was deemed the accounting acquirer in the Business Combination, the historical financial statements of Legacy IonQ are the historical financial statements of the Company upon the consummation of the Business Combination. As a result, the condensed consolidated financial statements included in this report reflect: (i) the historical operating results of Legacy IonQ prior to the Business Combination; (ii) the combined results of dMY and Legacy IonQ following the close of the Business Combination on September 30, 2021; and (iii) the assets and liabilities of Legacy IonQ stated at their historical cost.
In accordance with guidance applicable to these circumstances, the equity structure has been retroactively restated in all comparative periods to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Legacy IonQ’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy IonQ convertible redeemable preferred stock and warrants and Legacy IonQ common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination. Legacy IonQ’s convertible redeemable preferred stock and warrants previously classified as mezzanine equity were retroactively adjusted, converted into common stock, and reclassified to permanent equity because of the reverse recapitalization. All exercise prices for stock options and customer warrants have similarly been retroactively restated to reflect the exchange ratio established in the Business Combination.
Segment Reporting
The Company operates as
one
operating segment as its chief executive officer, who is the chief operating decision maker, reviews financial information on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2023
Summary of Significant Accounting Policies
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Significant Accounting Policies
The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022, and the notes thereto are included in the Company’s Annual Report on Form
10-K
(the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below.
Basis of Preparation
The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP as determined by the Financial Accounting Standards Board (“FASB”). Such condensed consolidated financial statements include the accounts of IonQ and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
 
Unaudited Interim Financial Information
The interim condensed consolidated financial statements included in this Quarterly Report on Form
10-Q
have been prepared by the Company and are unaudited, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures contained in this Quarterly Report on Form
10-Q
comply with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for a quarterly report and are adequate to make the information presented not misleading. The interim condensed consolidated financial statements included herein reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022, included in the Annual Report. The condensed consolidated statements of operations and the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2023, are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023, or thereafter. All references to March 31, 2023 and 2022, in the notes to the condensed consolidated financial statements are unaudited.
Emerging Growth Company
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies.
The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
The Company remains an emerging growth company until the earliest of (i) December 31, 2025, (ii) the last day of the fiscal year in which the Company has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the Company is deemed to be a large accelerated filer, which means the market value of the Company’s common stock that is held by
non-affiliates
exceeds $700.0 million as of the prior June 30th or (iv) the date on which the Company has issued more than $1.0 billion in
non-convertible
debt securities during the prior three-year period.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP and the rules and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes.
Significant estimates and judgments are inherent in the analysis and measurement of items including, but not limited to: revenue recognition, capitalization of internally developed software and quantum computing costs, useful lives of long-lived assets, and fair value of
available-for-sale
securities. Management bases its estimates and assumptions on historical experience, expectations, forecasts, and on various other factors that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ and be affected by changes in those estimates.
Fair Value Measurements
The Company evaluates the fair value of certain assets and liabilities using the fair value hierarchy. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
 
   
Level 1—Observable inputs, which include quoted prices in active markets;
 
   
Level 2—Observable inputs other than the quoted prices in active markets that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs such as broker quotes, benchmark yield curves, credit spreads and market interest rates for similar securities that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
 
   
Level 3—Unobservable inputs that are supported by little or no market activity and that are based on management’s assumptions, including fair value measurements determined using pricing models, discounted cash flow methodologies or similar techniques.
The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the total fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability.
 
Assets and liabilities that are measured at fair value on a
non-recurring
basis include property and equipment, intangible assets, and goodwill. The Company recognizes these items at fair value when they are considered to be impaired or upon initial recognition when acquired through a business combination or an asset acquisition. The fair value of these assets and liabilities are determined with valuation techniques using the best information available and may include quoted market prices, market comparables and discounted cash flow models.
Due to their short-term nature, the carrying amounts reported in the Company’s condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include cash in banks, checking deposits, money market funds, and commercial paper. The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Restricted cash collateralizing letters of credit is included in other noncurrent assets in the condensed consolidated balance sheets. The Company issues letters of credits in the ordinary course of business, including for lease arrangements. As of both March 31, 2023 and December 31, 2022, letters of credit totaling 
$2.0 million were outstanding.
The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Cash and cash equivalents
   $ 51,901      $ 44,367  
Restricted cash
     2,000        2,000  
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows
   $ 53,901      $ 46,367  
    
 
 
    
 
 
 
Accounts Receivable and Allowance for Credit Losses
Accounts receivable are
non-interest
bearing and represent amounts billed and currently due from customers at the gross invoiced amount as well as unbilled amounts related to unconditional rights for consideration to be received for services performed but not yet invoiced. A receivable is recorded when the Company has an unconditional right to receive payment. Accounts receivable consists of the following at (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Billed accounts receivable
   $ 1,001      $ 1,150  
Unbilled accounts receivable
     836        2,142  
    
 
 
    
 
 
 
Total accounts receivable
   $ 1,837      $ 3,292  
    
 
 
    
 
 
 
On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance for credit losses. This assessment is based on management’s evaluation of relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the receivable.
The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022.
Materials and Supplies
Materials and supplies are carried at average cost and recorded in prepaid expenses and other current assets in the condensed consolidated balance sheets. Materials and supplies used in the production of quantum computing systems to be made commercially available are capitalized to property and equipment when installed. Materials and supplies used for maintenance or research and development efforts are expensed when consumed. The Company capitalized $0.8 million of materials and supplies to property and equipment for the three months ended March 31, 2023.
Investments
Management determines the appropriate classification of investments at the time of purchase based upon management’s intent with regard to such investments. The Company primarily invests in debt securities and classifies its investments as
available-for-sale
at the time of purchase if they are available to support either current or future operations. This classification is
re-evaluated
at each balance sheet date. Investments not considered cash equivalents, with remaining contractual maturities of one year or less from the balance sheet date are classified as short-term investments, and those with remaining contractual maturities greater than one year from the balance sheet date are classified as long-term investments. All investments are recorded at their estimated fair value, and any unrealized gains and losses are recorded in accumulated other comprehensive loss. Realized gains and losses on sales and maturities of investments are determined based on the specific identification method and are recognized in the condensed consolidated statements of operations in other income (expense), net. Accrued interest receivable on available-for-sale investments is recorded in the condensed consolidated balance sheet in prepaid expenses and other current assets. As of
March 31, 2023
and December 31, 2022, accrued interest receivable was $1.8 million and $1.7 million, respectively.
 
The Company performs periodic evaluations to determine whether any declines in the fair value of investments below amortized cost are credit losses or impairments. The evaluation consists of qualitative and quantitative factors regarding the severity of the unrealized loss, as well as the Company’s ability and intent to hold the investments until a forecasted recovery occurs. Declines in fair value are considered to be credit losses if they are related to deterioration in credit risk or are considered impairments if it is likely that the underlying securities will be sold prior to a full recovery of their cost basis. Credit losses and impairments are determined based on the specific identification method and
are
reported in other income (expense), net in the condensed consolidated statements of operations.
Property and Equipment, Net
Property and equipment, net is stated at cost less accumulated depreciation. Historical cost of fixed assets is the cost as of the date acquired. Hardware and labor costs associated with the building of quantum computing systems are capitalized. Costs
to
maintain quantum computing systems are expensed as incurred.
Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows:
 
Computer equipment and acquired computer software    3 – 5 years
Machinery, equipment, furniture and fixtures    5 – 7 years
Quantum computing systems    3 years
Leasehold improvements    Shorter of the lease term or the estimated useful life of the related asset
Effective October 1, 2022, the Company revised the accounting useful life of quantum computing systems, which was determined to be a change in accounting estimate and is being applied prospectively. This change in accounting estimate is not material for the three months ended March 31, 2023. The estimated useful life for quantum computing systems was previously 2 years.
Leases
The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease
right-of-use
(“ROU”) assets and current operating lease liabilities and operating lease liabilities, net of current portion on the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has no financing lease arrangements. The Company recognizes lease expense for its operating leases on a straight-line basis over the term of the lease.
The Company records a ROU asset and lease liability in connection with its operating leases. The Company’s lease portfolio is comprised primarily of real estate leases, which are accounted for as operating leases. The Company elected the practical expedient to not separate lease and
non-lease
components for all leases.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future minimum lease payments, including the impact of any lease incentives, as applicable, over the lease term. Amendments to a lease are assessed to determine if it represents a lease modification or a separate contract. Lease modifications are reassessed as of the effective date of the modification using an incremental borrowing rate based on the information available at the commencement date. For modified leases the Company also reassesses the lease classification as of the effective date of the modification.
The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate, because the interest rate implicit in the Company’s leases is not readily determinable. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located.
The Company’s lease terms include periods under options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company considers contractual-based factors such as the nature and terms of the renewal or termination, asset-based factors such as physical location of the asset and entity-based factors such as the importance of the leased asset to the Company’s operations to determine the lease term. The Company generally uses the base
non-cancelable
lease term when determining the ROU assets and lease liabilities.
Capitalized Internally Developed Software
Capitalized internally developed software, which is included in intangible assets, net, consists of costs to purchase and develop internal-use software, which the Company primarily uses to provide services to its customers. The costs to purchase and develop internal-use software are capitalized from the time that the preliminary project stage is completed, and it is considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Any costs incurred during subsequent efforts to upgrade and enhance the functionality of the software are also capitalized. Once this software is ready for its intended use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is typically assessed to be three years. During the three months ended March 31, 2023 and 2022, the Company capitalized $
1.3 million and $0.5 million in
internal-use
software costs, respectively. The Company amortized $0.5 million and $0.3 million of capitalized internally developed software costs during the three months ended March 31, 2023 and 2022, respectively.
Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment and other long-term assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent the carrying amount of the underlying asset exceeds its fair value. No impairment loss was recognized for the three months ended March 31, 2023 or 2022.
 
Warrant Liabilities
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and
is then re-valued
upon exercise or at each reporting date for the unexercised warrants, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The warrants of dMY assumed in the Business Combination are classified as liabilities and remeasured at each reporting period (as more fully described in Note 10). The determination of the fair value of the warrant liabilities may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are
classified as non-current liabilities as
their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Revenue Recognition
The Company derives revenue from providing access to its quantum-computing-as-a-service (“QCaaS”), consulting services related to
co-developing
algorithms on the quantum computing systems, and from contracts associated with the design, development, and construction of specialized quantum computing systems together with related services. The Company applies the provisions of the FASB Accounting Standards Update (“ASU”), Revenue from Contracts with Customers (“ASC 606”), and all related applicable guidance. The core principle of ASC 606 is that an entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
To support this core principle, the Company applies the following five step approach:
 
1.
Identify the contract with the customer
 
2.
Identify the performance obligations
 
3.
Determine the transaction price
 
4.
Allocate the transaction price to the performance obligations
 
5.
Recognize revenue when (or as) the entity satisfies a performance obligation
The Company has determined that its QCaaS contracts represent a combined, stand-ready performance obligation to provide access to its quantum computing systems together with related maintenance and support. The transaction price may consist of a variable fee based on usage of its quantum computing systems or a fixed fee for a minimum volume of usage to be made available over a defined period of access. Fixed fee arrangements may also include a variable component whereby customers pay an amount for usage over contractual minimums contained in the contracts. The Company has determined that contracts that contain consulting services related
to co-developing quantum
computing algorithms and the ability to use its quantum computing systems to run such algorithms represent a combined performance obligation that is satisfied over-time with revenue recognized based on the efforts incurred to date relative to the total expected effort. For contracts with a fixed transaction price, the fixed fee is recognized on a straight-line basis over the access period or associated measure of progress for the Company’s consulting services contracts. For contracts without fixed fees, variable usage fees are billed and recognized during the period of such usage.
Certain of the Company’s contracts contain multiple performance obligations, most commonly in contracts for specialized quantum computing systems together with related maintenance and support. Such contracts may also include access to the Company’s QCaaS. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. When there are multiple performance obligations in a contract, the Company allocates the transaction price to each performance obligation based on its standalone selling price when available. We determine standalone selling price based on the observable price of a product or service when we sell the products or services separately in similar circumstances and to similar customers. When the standalone selling price is not known, due to it being either highly variable or uncertain, the Company allocates the transaction price using the residual approach.
Performance obligations are satisfied over time if the customer receives the benefits as we perform the work, if the customer controls the asset as it is being produced (continuous transfer of control), or if the product being produced for the customer has no alternative use and we have a contractual right to payment for performance to date. Revenue is recognized on performance obligations satisfied over time based on the efforts incurred to date relative to the total expected effort.
For the three months ended March 31, 2023 and 2022, all of the revenue recognized by the Company was recognized based on transfer of service over time. There were no revenues recognized at a point in time. In arrangements with cloud service providers, the cloud service provider is considered the customer and IonQ does not have any contractual relationships with the cloud service providers’ end users. For these arrangements, revenue is recognized at the amount charged to the cloud service provider and does not reflect any
mark-up
to the end user.
The Company may enter into multiple contracts with a single counterparty at or near the same time. The Company will combine contracts and account for them as a single contract when one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) consideration to be paid in one contract depends on the price or performance of the other contract; and (iii) goods or services promised are a single performance obligation. Consideration payable to a customer includes cash amounts that an entity pays, or expects to pay, to the customer. For arrangements that contain consideration payable to a customer, the Company uses judgment in determining whether such payments are a reduction of the transaction price or a payment to the customer for a distinct good or service.
The variable fees associated with the QCaaS are generally billed a month in arrears. Customers also have the ability to make advance payments. If a contract exists under ASC 606, advance payments are recorded as a contract liability until services are delivered or obligations are met and revenue is earned. Contract liabilities to be recognized in the succeeding
12-month
period are classified as current and the remaining amounts are classified as
non-current
liabilities in the Company’s condensed consolidated balance sheets.
 
As of March 31, 2023, approximately $30.4 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for
non-cancelable
contracts, including both funded (firm orders for which funding has been both authorized and appropriated by the customer) and unfunded (firm orders for which funding has not been appropriated) orders. The Company expects approximately 60% of the remaining performance obligations to be recognized as revenue within the next twelve months.
The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands):
 
    
Total
 
Balance as of December 31, 2022
   $ 9,930  
Revenue recognized
     (3,446
New deferrals, net
     764  
    
 
 
 
Balance as of March 31, 2023
   $ 7,248  
    
 
 
 
For contractual arrangements where consideration is paid
up-front,
the transfer of the quantum computing services is completed at the discretion of the customer as the customer chooses to use the services starting from the date of contract inception. As such, the
up-front
payment of consideration does not represent a significant financing component.
Assets Recognized from Costs to Obtain a Contract
Sales commissions paid to employees and third parties are considered incremental costs to obtain a contract with a customer. These costs are capitalized in the period a customer contract is executed and are amortized as an expense consistent with the transfer of the goods or services to the customer. Capitalized costs are recorded in prepaid expenses and other current assets and other noncurrent assets in the condensed consolidated balance sheets. Applying the practical expedient, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets is one year or less. As of March 31, 2023 and December 31, 2022, total capitalized costs were $0.9 million and $1.0 million, respectively. Amortization expense was $0.1 million and zero for the three months ended March 31, 2023 and 2022, respectively.
Stock-Based Compensation
The Company measures and records the expense related to stock-based awards based on the fair value of those awards as determined on the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes-Merton (“Black- Scholes”) option-pricing model to determine the fair value of stock awards and the estimated fair value for stock options. The Black-Scholes option- pricing model requires the use of subjective assumptions, which determine the fair value of share-based awards, including the fair value of the Company’s common stock, the option’s expected term, the price volatility of the underlying common stock, risk-free interest rates, and the expected dividend yield of the common stock. The assumptions used to determine the fair value of the stock awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. The Company records forfeitures as they occur.
Stock-based compensation cost for restricted stock units is measured based on the fair value of the Company’s common stock on the grant date. For awards with a performance-based vesting condition, the Company records stock-based compensation cost if it is probable that the performance condition will be achieved.
The Company records stock-based compensation expense for incentive compensation liabilities based on estimated payments to employees for which the Company expects to settle the liability by granting restricted stock units. For these awards, stock-based compensation expense is accrued commencing at the service inception date, which generally precedes the grant date, through the end of the requisite service period.
The Company obtained third-party valuations to estimate the fair value of its common stock for awards granted prior to the Business Combination, for purposes of measuring stock-based compensation expense. The third-party valuations were prepared using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants (“AICPA”) Accounting &Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, investments, and trade accounts receivable. The Company maintains the majority of its cash, cash equivalents, restricted cash and investments with two financial institutions. The Company’s deposits routinely exceed amounts guaranteed by the Federal Deposit Insurance Corporation. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to limited credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors.
The Company’s accounts receivable are derived from customers primarily located in the U.S. The Company performs periodic evaluations of its customers’ financial condition and generally does not require its customers to provide collateral or other security to support accounts receivable and maintains an allowance for credit losses. Credit losses historically have not been material.
Significant customers are those that represent more than 10% of the Company’s total revenue. The Company’s revenue was primarily from three significant customers for the three months ended March 31, 2023, and from two significant customers for the three months ended March 31, 2022.
 
Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock during the period, plus common stock equivalents, outstanding during the period. If the Company reports a net loss, the computation of diluted loss per share excludes the effect of dilutive common stock equivalents, as their effect would be antidilutive.
The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Numerator:
                 
Net loss attributable to common stockholders
   $ (27,338    $ (4,227
Denominator:
                 
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted
     200,112,855        196,183,247  
Net loss per share attributable to common stockholders—basic and diluted
   $ (0.14    $ (0.02
In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted stock units, unvested common stock (including unvested restricted common stock) and warrants are excluded and diluted loss per share is equal to basic loss per share. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:
 
    
Three Months Ended
March 31
 
    
2023
    
2022
 
Common stock options outstanding
     24,499,968        21,108,390  
Warrants to purchase common stock
     8,301,202        8,301,202  
Public warrants
     5,231,486        5,232,471  
Unvested restricted stock units
     9,077,343        1,310,471  
Unvested common stock
     842,454        1,351,261  
    
 
 
    
 
 
 
Total
  
 
47,952,453
 
  
 
37,303,795
 
    
 
 
    
 
 
 
Recently Adopted Accounting Standards
In June 2016, the FASB issued ASU
2016-13,
Financial Instruments—Credit Losses, along with various updates and improvements. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the first quarter of 2023, and it did not have a material effect on the condensed consolidated financial statements and related disclosures.
Recently Issued Accounting Standards Not Yet Adopted
In August 2020, the FASB issued ASU
2020-06,
Debt, Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic
815-40)
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its consolidated financial statements and related disclosures.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, Restricted Cash And Investments
3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, Restricted Cash And Investments
3. CASH, CASH EQUIVALENTS, RESTRICTED CASH AND INVESTMENTS
The following table summarizes the Company’s unrealized gains and losses and estimated fair value of cash, cash equivalents, restricted cash and investments in
available-for-sale
securities recorded in the condensed consolidated balance sheets (in thousands):
 
    
AS OF MARCH 31, 2023
    
AS OF DECEMBER 31, 2022
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
   
Estimated
Fair
Value
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
   
Estimated
Fair Value
 
Cash and money market funds
   $ 51,012      $ —        $ —       $ 51,012      $ 46,367      $ —        $ —       $ 46,367  
Commercial paper
     121,151        2        (198     120,955        130,141        —          (443     129,698  
Corporate notes and bonds
     263,876        106        (4,761     259,221        277,184        19        (5,993     271,210  
Municipal bonds
     9,935        —          (213     9,722        9,905        —          (273     9,632  
US government and agency
     86,968        88        (453     86,603        83,556        23        (688     82,891  
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Total cash, cash equivalents, restricted cash and investments
  
$
532,942
 
  
$
196
 
  
$
(5,625
 
$
527,513
 
  
$
547,153
 
  
$
42
 
  
$
(7,397
 
$
539,798
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Unrealized losses related to investments were primarily a result of interest rate fluctuations. The following table presents information about the Company’s investments in available-for-sale securities with gross unrealized losses and the length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2023 (in thousands).
 
 
  
As of March 31, 2023
 
 
  
Less than 12 Months
 
 
12 Months or Longer
 
 
Total
 
 
  
Fair Value
 
  
Gross Unrealized
Losses
 
 
Fair Value
 
  
Gross Unrealized
Losses
 
 
Fair Value
 
  
Gross Unrealized
Loses
 
Commercial paper
  
$
75,326
 
  
$
(198
)
 
 
$
—  
 
  
$
 
—  
 
 
$
75,326
 
  
$
(198
)
 
Corporate notes and bonds
  
 
91,968
 
  
 
(1,237
)
 
 
 
138,518
 
  
 
(3,524
 
 
230,486
 
  
 
(4,761
)
 
Municipal bonds
  
 
4,951
 
  
 
(31
 
 
4,771
 
  
 
(182
 
 
9,722
 
  
 
(213
US government and agency
  
 
29,124
 
  
 
(83
 
 
12,123
 
  
 
(370
 
 
41,247
 
  
 
(453
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
Total
  
$
201,369
 
  
$
(1,549
 
$
155,412
 
  
$
(4,076
 
$
356,781
 
  
$
(5,625
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
There were no securities in a gross unrealized loss position for greater than 12 months as of December 31, 2022.
The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022. The Company does not intend or believe it is more likely than not, that it will be required to sell the investments in an unrealized loss position before the recovery of the associated amortized cost basis.
The estimated fair value of the Company’s cash, cash equivalents, restricted cash and investments in
available-for-sale
securities as of March 31, 2023, aggregated by investment category and classified by contractual maturity date, is as follows (in thousands):
 
    
1 Year
or Less
    
1 Year
or Greater
    
Total
 
Cash and money market funds
   $ 49,012      $ 2,000      $ 51,012  
Commercial paper
     120,955        —          120,955  
Corporate notes and bonds
     148,350        110,871        259,221  
Municipal bonds
     9,722        —          9,722  
US government and agency
     59,828        26,775        86,603  
    
 
 
    
 
 
    
 
 
 
Total
  
$
387,867
 
  
$
139,646
 
  
$
527,513
 
    
 
 
    
 
 
    
 
 
 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Fair Value Measurements
4. FAIR VALUE MEASUREMENTS
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (in thousands):
 
    
Fair Value Measured as of
March 31, 2023:
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Cash, cash equivalents and restricted cash:
                                   
Cash and money market funds
(1)
   $ 51,012      $ —        $ —        $ 51,012  
Commercial paper
     —          2,889        —          2,889  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash
     51,012        2,889        —          53,901  
    
 
 
    
 
 
    
 
 
    
 
 
 
Short-term investments:
                                   
Commercial paper
     —          118,066        —          118,066  
Corporate notes and bonds
     —          148,350        —          148,350  
Municipal bonds
     —          9,722                 9,722  
US government and agency
     —          59,828        —          59,828  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total short-term investments
     —          335,966        —          335,966  
    
 
 
    
 
 
    
 
 
    
 
 
 
Long-term investments:
                                   
Corporate notes and bonds
     —          110,871        —          110,871  
US government and agency
     —          26,775        —          26,775  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total long-term investments
     —          137,646        —          137,646  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Assets
   $ 51,012      $ 476,501      $ —        $ 527,513  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Public warrants
   $ 7,429      $ —        $ —        $ 7,429  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Fair Value Measured as of
December 31, 2022:
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Cash, cash equivalents and restricted cash:
                                   
Cash and money market funds
(1)
   $ 46,367      $ —        $ —        $ 46,367  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash
     46,367        —          —          46,367  
    
 
 
    
 
 
    
 
 
    
 
 
 
Short-term investments:
                                   
Commercial paper
     —          129,698        —          129,698  
Corporate notes and bonds
     —          120,447        —          120,447  
Municipal bonds
     —          4,911                 4,911  
US government and agency
     —          56,374        —          56,374  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total short-term investments
     —          311,430        —          311,430  
    
 
 
    
 
 
    
 
 
    
 
 
 
Long-term investments:
                                   
Corporate notes and bonds
     —          150,763        —          150,763  
Municipal bonds
     —          4,721        —          4,721  
US government and agency
     —          26,517        —          26,517  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total long-term investments
     —          182,001        —          182,001  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Assets
   $ 46,367      $ 493,431      $ —        $ 539,798  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Public warrants
   $ 3,819      $ —        $ —        $ 3,819  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
(1)
Includes money market funds associated with the Company’s overnight investment sweep account and collateralized letter of credit.
Transfers to/from Levels 1, 2 and 3 are r
ec
ognized at the beginning of the reporting period. There were no transfers between levels during the period. On March 31, 2023, the closing trading price of the public warrants was $1.42 per warrant.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Property And Equipment, Net
3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Property And Equipment, Net
5. PROPERTY AND EQUIPMENT, NET
Property and equipment, net is composed of the following (in thousands):
 
 
  
March 31,
 
  
December 31,
 
 
  
2023
 
  
2022
 
Computer equipment and acquired computer software
   $ 2,707      $ 2,407  
Machinery, equipment, furniture and fixtures
     7,747        7,506  
Leasehold improvements
     1,193        1,132  
Quantum computing systems
     23,532        22,430  
    
 
 
    
 
 
 
Gross property and equipment
  
 
35,179
 
  
 
33,475
 
Less: accumulated depreciation
     (8,691
  
  (7,461
    
 
 
    
 
 
 
Property and equipment, net
  
$
26,488
 
  
$
26,014
 
    
 
 
    
 
 
 
Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.2 million and $1.0 million, respectively.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Agreements With University Of Maryland And Duke University
3 Months Ended
Mar. 31, 2023
Agreement Disclosure [Abstract]  
Agreements With University Of Maryland And Duke University
6. AGREEMENTS WITH UNIVERSITY OF MARYLAND AND DUKE UNIVERSITY
Exclusive License Agreement
The Company entered into an exclusive license agreement (“License Agreement”) in July 2016 with the University of Maryland (“UMD”) and Duke University (“Duke”). The License Agreement grants to the Company an exclusive, perpetual license (“Initial Patents”) to certain patents,
know-how
and other intellectual property utilized in
trapped-ion
quantum computing systems. The license granted to the Company is exclusive for all patents (and
non-exclusive
for other types of intellectual property), subject to certain governmental rights and retained rights by UMD and Duke and other
non-profit
institutions to use and practice the Licensed Patents (as defined below) and technology for internal research and other
non-profit
purposes. In exchange for the Initial Patents, UMD and Duke received an aggregate of 142,886
 shares of common stock after giving effect to the recapitalization. 
On February 1, 2021, the Company and UMD executed two amendments to the License Agreement granting exclusive rights to license additional intellectual property in exchange for a total of 
257,198
 shares of common stock after giving effect to the recapitalization. Management evaluated the amendments and concluded that the arrangements qualify as equity-classified instruments and recorded an intangible asset and additional paid-in capital based on the fair value of the shares at the date the amendments were executed of $
1.6 million. The shares for each executed amendment were issued during the year ended December 31, 2021.
Exclusive Option Agreements
The Company also entered into an exclusive option agreement (“Option Agreement”) with each of UMD and Duke in 2016 whereby on the anniversary of the effective date of the License Agreement for a period of 5
 years, the Company has the right to exclusively license additional intellectual property developed by UMD and Duke (the “Additional Patents” and together with the Initial Patents, the “Licensed Patents”) by exercising an annual option and issuing shares of common stock each to Duke and UMD in consideration for the Additional Patents. The amount issued to UMD and Duke pursuant to the option over the 5-year term was equal to an aggregate of 
642,995
 shares of common stock to each university after giving effect to the recapitalization. The Company may elect not to exercise the option if there was not a minimum number of intellectual property developed in a given year and then the Option Agreement would 
extend another year.
In December 2020, the Company amended its option agreement with Duke, and under this amendment, the Company issued 1,214,317
 shares of common stock after giving effect to the recapitalization, to Duke in consideration for research and development services through July 15, 2026. Under the terms of the amended Option Agreement, the issuance of shares is a nonrefundable upfront payment in exchange for research and development services by Duke whereby the Company will obtain rights to any potential future intellectual property developed during the term. As such, the fair value of the shares of common stock was recorded as a prepaid expense and is being amortized over the term of the arrangement as services are received. The Company recognized $
0.1 million of research and development expense related to the agreement with Duke during each of the three months ended March 31, 2023 and 2022.
The useful life of the Licensed Patents derived from the License Agreement and the Option Agreement is the remaining legal life at the time of acquisition. The value of the Licensed Patents is based on the fair value of the common stock given as consideration on the effective date of each agreement and exercise of option. The asset is amortized over the useful life of the Licensed Patents.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Other Balance Sheet Accounts
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Other Balance Sheet Accounts
7. OTHER BALANCE SHEET ACCOUNTS
Accrued expenses are composed of the following (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Accrued salaries and other payroll liabilities
   $ 6,597      $ 4,935  
Accrued professional services
     1,283        678  
Accrued equipment and services liabilities for research and development
     611        489  
Accrued expenses—other
     923        553  
    
 
 
    
 
 
 
Total accrued expenses
  
$
9,414
 
  
$
6,655
 
    
 
 
    
 
 
 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies
8. COMMITMENTS AND CONTINGENCIES
Warranties and Indemnification
The Company’s commercial services are typically warranted to perform in a manner consistent with general industry standards that are reasonably applicable and materially in accordance with the Company’s documentation under normal use and circumstances.
The Company’s arrangements generally include certain provisions for indemnifying customers against liabilities if its products or services infringe third-party intellectual property rights. To date, the Company has not incurred any material costs as a result of such obligations and has not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements.
Stockholder Lawsuit
In May 2022, a securities class action complaint captioned
Leacock v. IonQ, Inc. et al
., Case No.
8:22-cv-01306,
was filed by a stockholder of the Company in the United States District Court for the District of Maryland (the “Leacock Litigation”) against the Company and certain of the Company’s current officers. In June 2022, a securities class action complaint captioned
Fisher v. IonQ, Inc
., Case No.
8:22-cv-01306-DLB
(the “Fisher Litigation”) was filed by a stockholder against the Company and certain of the Company’s current officers (“IonQ Defendants”). Both the Leacock Litigation and Fisher Litigation, which have been consolidated into a single action, allege violations of Section 10(b) of the Exchange Act, and Rule
10b-5
promulgated thereunder, and Section 20(a) of the Exchange Act and seek damages. In September 2022, the Court appointed lead plaintiffs and counsel for lead plaintiffs, and ordered lead plaintiffs to file a consolidated amended complaint. The consolidated amended complaint was filed on November 22, 2022. As part of the consolidated amended complaint, certain members of the Company’s board of directors as well as other dMY-related defendants (“Additional Defendants”) have been added as defendants to the case. On February 7, 2023, the IonQ Defendants and the Additional Defendants each filed a motion to dismiss the consolidated amended complaint. Both the IonQ Defendants and Additional Defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the associated suit.
Glatt Litigation
On January 12, 2021, dMY Technology Group, Inc. II, dMY Sponsor II, LLC, dMY, and dMY Sponsor III, LLC (“Sponsor”) accepted service of a lawsuit where they were named as counterclaim defendants in an underlying action by and between GTY Technology Holdings, Inc. (“GTY”), dMY Technology Holdings Inc., dMY Sponsor, LLC, dMY Sponsor II, LLC, dMY Technology Group Inc. II, dMY and Sponsor (collectively “dMY Defendants”) and Carter Glatt (“Glatt”) and Captains Neck Holdings LLC (“Captains Neck”), an entity of which Mr. Glatt is a member. The underlying lawsuit, filed by dMY Technology Group, Inc. and dMY Sponsor, LLC, seeks a declaratory judgment that Glatt and Captains Neck are not entitled to membership units of dMY Sponsor LLC, which was formed by Harry L. You, the
co-founder
and former President and Chief Financial Officer of GTY when Glatt was still working at GTY. The underlying lawsuit contains claims arising from Glatt’s termination of employment from GTY, including theft and misappropriation of confidential GTY information, breach of contract, breach of the duties of loyalty and fiduciary duty and conversion. Glatt responded to the underlying lawsuit by adding members of the Sponsor and officers of dMY as additional counterclaim defendants (collectively with the dMY Defendants Glatt and Captains Neck, the “Counterclaim Defendants”) and adding Dune Acquisition Holdings LLC, a newly formed special purpose acquisition company, as a counterclaimant and asserting claims for breach of contract, fraudulent misrepresentation, negligent misrepresentation, tortious interference with business relations, quantum meruit and unjust enrichment. dMY, and now the Company, has never employed Glatt and has no business agreements with him. The Counterclaim Defendants have denied the claims against them and have filed a motion to dismiss the suit. Although the outcome of this matter cannot be predicted with certainty and the impact of the final resolution of this matter on the Company’s results of operations in a particular subsequent reporting period is not known, management does not believe that the resolution of this matter will have a material adverse effect on the Company’s future consolidated financial position, future results of operations or cash flows.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Warrant Transaction Agreement
3 Months Ended
Mar. 31, 2023
Warrant Transaction Agreement [Abstract]  
Warrant Transaction Agreement
9. WARRANT TRANSACTION AGREEMENT
In November 2019, contemporaneously with a revenue arrangement, the Company entered into a contract, pursuant to which the Company agreed to issue to a customer warrants to acquire shares of Legacy IonQ Series
B-1
preferred stock (the “Warrant Shares”), subject to certain vesting events. Upon closing of the Business Combination, these warrants exercisable for Legacy IonQ Series
B-1
preferred stock were assumed by the Company and converted into a warrant to purchase shares of common stock. Except as specifically provided in the Merger Agreement, the Warrant Shares will have the same terms and be subject to the same conditions (including applicable vesting conditions) as set forth in the Legacy IonQ warrant agreement. As of March 31, 2023, the contract allows for the customer to acquire up to 8,301,202 shares of common stock in the Company.
As the Warrant Shares were issued in connection with an existing commercial agreement with a customer, the value of the Warrant Shares was determined to be consideration payable to the customer and consequently is treated as a reduction to revenue recognized under the corresponding revenue arrangement.
 
Approximately 6.5% of the Warrant Shares vested and became immediately exercisable in August 2020. The fair value of the vested Warrant Shares was amortized over time as the related customer revenue was earned and was fully amortized as of December 31, 2021. The remaining Warrant Shares will vest and become exercisable upon satisfaction of certain milestones based on revenue generated under the commercial agreement with the customer, to the extent certain prepayments are made by the customer. The exercise price
for
the Warrant Shares is $1.38 per share and the warrant is exercisable through November 2029. The fair value of the Warrant Shares at the date of issuance was determined to be $8.7 million.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Warrant Liabilities
3 Months Ended
Mar. 31, 2023
Warrant Liabilities [Abstract]  
Warrant Liabilities
10. WARRANT LIABILITIES
The Company assumed 7,500,000 public warrants on September 30, 2021 as part of the Business Combination. As of March 31, 2023, there were 5,231,486 public warrants to purchase common stock outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per share.
Public warrants
The public warrants may be exercised on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering of dMY; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their public warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The public warrants became exercisable on November 17, 2021.
Redemption of warrants when the price per share of common stock equals or exceeds $18.00:
Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash:
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within
a 30-trading day
period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.
Redemption of warrants for when the price per share of common stock equals or exceeds $10.00:
Once the warrants become exercisable, the Company may redeem the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value (as defined within the warrant agreement) of the common stock except as otherwise described within the warrant agreement; and upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of common stock equals or exceeds $10.00 per public share (as adjusted) for any 20 trading days within
the 30-trading day
period ending three trading days before the Company sends notice of redemption to the warrant holders.
No
 public warrants had been redeemed by the Company as of March 31, 2023. 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Stock-Based Compensation
11. STOCK-BASED COMPENSATION
Equity Incentive Plans
The Company has a 2015 Equity Incentive Plan (the “2015 Plan”), which provided for the grant of share-based compensation to certain officers, directors, employees, consultants, and advisors. Upon the closing of the Business Combination, no further awards were made pursuant to the 2015 Plan and all outstanding Legacy IonQ stock options under the 2015 Plan were assumed by the Company. Each Legacy IonQ stock option issued and outstanding immediately prior to the Business Combination was converted into an option to purchase shares of common stock of the Company equal to the product of (a) the number of shares of Legacy IonQ common stock subject to such Legacy IonQ stock option agreement immediately prior to the Business Combination and (b) the exchange ratio at an exercise price equal to the (i) the exercise price per share of such Legacy IonQ stock option divided by (ii) the exchange ratio. Such stock options will continue to be governed by the terms of the 2015 Plan and the stock option agreements thereunder, until such outstanding options are exercised or until they terminate or expire by their terms. For awards granted under the 2015 Plan, vesting generally occurs over four to five years from the date of grant.
In August 2021, the Company’s board of directors adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which was subsequently approved by the Company’s stockholders in September 2021, and became effective upon the closing of the Business Combination. The 2021 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSU”), performance awards and other forms of awards to employees, directors, and consultants. The number of shares of the Company’s common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each year, beginning on January 1, 2022, and continuing through and including January 1, 2031, by 5% of the Fully Diluted Common Stock (as defined in the 2021 Plan) outstanding on December 31 of the preceding year, or a lesser number of shares
determined by the Company’s board of directors prior to such increase. As of January 1, 2023, the number of shares reserved for issuance under the 2021 Plan increased by 13,587,593. For awards granted under the 2021 Plan, vesting terms range from one to four years from the date of grant. As of March 31, 2023, the Company had
37,279,201
 shares available for grant under the 2021 Plan.
Under both equity incentive plans, all options granted have a contractual term of 10 years.
Stock Options
The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option- pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option.
Expected Volatility
—As the Company was privately held until 2021 and there has been limited history of a public market for its common stock prior to closing the Business Combination, the expected volatility is based on the average historical stock price volatility of comparable publicly-traded companies in its industry peer group, financial, and market capitalization data.
Expected Term
—The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding.
The Company has estimated the expected term of its employee awards using the SAB Topic 14 Simplified Method allowed by the FASB and SEC, for calculating expected term as it has limited historical exercise data to provide a reasonable basis upon which to otherwise estimate expected term. Certain of the Company’s options began vesting prior to the grant date, in which case the Company uses the remaining vesting term at the grant date in the expected term calculation.
Risk-Free Interest Rate
—The Company estimates its risk-free interest rate by using the yield on actively traded
on-inflation-indexed
U.S. treasury securities with contract maturities equal to the expected term.
Dividend Yield
—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero.
Fair Value of Underlying Common Stock
—For options granted under the 2015 Plan, because the Company’s common stock was not yet publicly traded on the date of grant, the Company estimated the fair value of common stock prior to closing the Business Combination. The board of directors considered numerous objective and subjective factors to determine the fair value of the Company’s common stock at each meeting in which awards were approved. The factors considered included, but were not limited to: (i) the results of contemporaneous independent third-party valuations of the Company’s common stock; (ii) the prices, rights, preferences, and privileges of Legacy IonQ’s previously Convertible Redeemable Preferred Stock relative to those of its common stock; (iii) the lack of marketability of the Company’s common stock; (iv) actual operating and financial results; (v) current business conditions and projections; (vi) the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company, given prevailing market conditions; and (vii) precedent transactions involving the Company’s shares. For options granted under the 2021 Plan, the Company utilizes the closing stock price on the date of grant as the fair value of the common stock underlying such options.
The assumptions used to estimate the fair value of stock options granted during the three months ended March 31, 2023 and 2022, are as follows:
 
    
Three Months Ended
March 31,
 
    
2023
   
2022
 
Risk-free interest rate
     —       1.76
Expected term (in years)
     —         5.63  
Expected volatility
     —       77.48
Dividend yield
     —       —  
The stock option activity is summarized in the following table:
 
    
Number of
Option
Shares
    
Weighted
Average
Exercise
Price
    
Weighted
Average
Remaining
Contractual
Term (Years)
    
Aggregate
Intrinsic
Value
(in millions)
 
Outstanding as of December 31, 2022
     24,716,270      $ 2.19        7.32      $ 49.69  
Granted
     —          —                      
Exercised
     (131,492      0.40                    
Cancelled/ Forfeited
     (296,628      1.58                    
    
 
 
                            
Outstanding as of March 31, 2023
     24,288,150      $ 2.21        7.09      $ 108.06  
    
 
 
                            
Exercisable as of March 31, 2023
     12,571,954      $ 0.96        7.27      $ 67.93  
Exercisable and expected to vest as of March 31, 2023
     24,288,150      $ 2.21        7.09      $ 108.06  
 
The following table summarizes additional information on stock option grants, vesting and exercises (in millions, except per share amounts):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Total intrinsic value of options exercised
   $ 0.8      $ 5.7  
Aggregate grant-date fair value of options vested
   $ 3.3      $ 2.2  
Weighted-average grant date fair value per share for options granted
   $ —        $ 12.87  
Early Exercised Stock Options
As of March 31, 2023 and December 31, 2022, there were 779,787 and 905,128 shares, respectively, subject to repurchase related to stock options early exercised and unvested. As of March 31, 2023 and December 31, 2022, the Company recorded a liability related to these shares subject to repurchase in the amount of $1.7 million and $2.0 million, respectively, in its condensed consolidated balance sheets. 
Restricted Stock Units
The RSU activity is summarized in the following table:
 
    
Number of
RSUs
    
Weighted
Average
Grant
Date Fair
Value
    
Weighted
Average
Remaining
Contractual
Term (Years)
    
Aggregate
Fair Value
(in millions)
 
Outstanding as of December 31, 2022
     9,320,045      $ 7.02        3.21      $ 65.38  
Granted
     —          —                      
Vested
     (524,711      8.39                    
Forfeited
     (235,613      5.04                    
    
 
 
                            
Outstanding as of March 31, 2023
     8,559,721      $ 6.99        2.99      $ 59.79  
    
 
 
                            
Expected to vest after March 31, 2023
     8,518,721      $ 6.96        3.01      $ 59.26  
Stock-Based Compensation Expense
Total stock-based compensation expense for stock option awards and RSU awards, which are included in the condensed consolidated financial statements, is as follows (in thousands):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Cost of revenue
   $ 349      $ 104  
Research and development
     5,280        1,698  
Sales and marketing
     764        73  
General and administrative
     3,875        4,797  
    
 
 
    
 
 
 
Stock-based compensation, net of amounts capitalized
     10,268        6,672  
Capitalized stock-based compensation—Intangibles and fixed assets
     619        176  
    
 
 
    
 
 
 
Total stock-based compensation
   $ 10,887      $ 6,848  
    
 
 
    
 
 
 
Unrecognized Stock-Based Compensation
A summary of our remaining unrecognized compensation expense and the weighted-average remaining amortization period as of March 31, 2023, related to our
non-vested
stock options and RSU awards is presented below (in millions, except time period amounts):
 
    
Unrecognized
Expense
    
Weighted-
Average
Amortization
Period (Years)
 
Restricted stock units
   $ 54.7        1.5  
Stock options
   $ 40.6        1.5  
Employee Stock Purchase Plan
In August 2021, the Company’s board of directors adopted the Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders in September 2021, and became effective upon the closing of the Business Combination. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The number of shares of common stock initially reserved for issuance under the ESPP was 5,354,000 shares. The ESPP provides for an annual increase on January 1 of each year, beginning on January 1, 2022, and continuing through and including January 1, 2031, equal to the lesser of (i) 1% of the fully diluted shares of common stock outstanding on the last day of the prior fiscal year, (ii) 10,708,000 shares, or (iii) a lesser number of shares determined by the Company’s board of directors prior to such increase. The board of directors elected not to approve the annual increase of ESPP shares on January 1, 2023.
 
Under the terms of the ESPP, eligible employees can elect to acquire shares of the Company’s common stock through periodic payroll deductions during a series of offering periods. Purchases under the ESPP are affected on the last business day of each offering period at a 15% discount to the lower of closing price on that day or the closing price on the first day of the offering period. As of March 31, 2023, no shares of common stock had been issued under the ESPP and no offering period had been set by the board of directors.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Mar. 31, 2023
Income Taxes
12. INCOME TAXES
The Company had no provision for income taxes in any period presented. The effective tax rate for each period differs from the statutory rate primarily as a result of not recognizing a deferred tax asset for losses due to having a full valuation allowance against deferred tax assets.
The realization of tax benefits of deferred tax assets is dependent upon future levels of taxable income, of an appropriate character, in the periods the items are expected to be deductible or taxable. Based on the available objective evidence, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets as of March 31, 2023, and December 31, 2022. The Company intends to maintain the remaining valuation allowance until sufficient positive evidence exists to support a reversal of, or decrease in, the valuation allowance.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Leases
13. LEASES
The Company has two operating leases for its facilities in College Park, Maryland, and Bothell, Washington. The College Park, Maryland facility is used for research and development and corporate functions and is leased from UMD. Refer to Note 14 for further information. The Bothell, Washington, facility is used for manufacturing, research and development and general office space. Both leases expire in 2030. As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term was 7.3 years and 7.9
 years, respectively, and the weighted-average discount rate 
was 9.8%
and
11.9
%,
respectively.
The Bothell, Washington facility lease includes a landlord-provided tenant improvement allowance to offset a portion of the costs of the construction of leasehold improvements. The Company determined that the leasehold improvements will be Company-owned, and as such, reflected the lease incentive as a reduction of lease payments used to measure the operating lease liability and ROU asset as of the lease commencement date.
The components of lease cost were as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Operating lease cost
(1)
                 
Fixed lease cost
   $ 360      $ 191  
Short-term cost
     43        6  
    
 
 
    
 
 
 
Total operating lease cost
   $ 403      $ 197  
 
(1)
The lease costs are reflected in the condensed consolidated statements of operations as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Cost of revenue
   $ 14      $ 14  
Research and development
     172        146  
Sales and marketing
     13        7  
General and administrative
     204        30  
    
 
 
    
 
 
 
Total
   $ 403      $ 197  
    
 
 
    
 
 
 
Supplemental cash flow and other information related to operating leases was as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Cash payments included in the measurement of operating lease liabilities
   $ 166      $ 161  
As of March 31, 2023, maturities of operating lease liabilities are as follows (in thousands):
 
 
  
Amount
 
Year Ending December 31,
  
2023
   $ 559  
2024
     1,831  
2025
     2,309  
2026
     2,378  
2027
     2,449  
Thereafter
     6,385  
    
 
 
 
Total lease payments
     15,911  
Less: imputed interest
     (4,795)  
Less: lease incentives
     (4,882)  
    
 
 
 
Present value of operating lease liabilities
   $ 6,234  
    
 
 
 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
3 Months Ended
Mar. 31, 2023
Related Party Transaction [Line Items]  
Related Party Transactions
14. RELATED PARTY TRANSACTIONS
Transactions with UMD and Duke
As described in Note 6, the Company entered into a License Agreement and Option Agreement with UMD and Duke whereby the Company, in the normal course of business, has licensed certain intellectual property and, in the case of the amendments to the Option Agreements, has purchased research and development services. The Company considers these agreements to be related party transactions because the Company’s
Co-founder
and Chief Technology Officer serves as a professor at Duke and the Company’s
Co-founder
and Chief Scientist served as a professor at UMD. During 2021, the Company’s Chief Scientist moved to Duke and each, in their role as professors at Duke, are leading the research subject to the License Agreement and Option Agreement with Duke as of March 31, 2023.
In addition, the Company has an operating lease for office space with UMD, which expires in 2030. Under the lease, for each of the three months ended March 31, 2023 and 2022, the Company incurred fixed lease costs of $0.2 million and made lease payments of $0.2 million. Future minimum lease payments as of March 31, 2023, are $6.2 million. As of March 31, 2023 and December 31, 2022, the remaining lease term was 7.7 years and 7.9 years, respectively. As of both March 31, 2023, and December 31, 2022, the weighted-average discount rate was 11.9%.
In September 2021, the Company entered into a contract with UMD to provide certain quantum computing services and facility access (the “UMD Quantum Agreement”) related to the National Quantum Lab at UMD in exchange for payments totaling $14.0 million over three years. Over the term of the contract, the Company estimates that it will make payments to UMD of approximately $1.4 million, including a contribution of $1.0 million to establish the IonQ Endowed Professorship in the College of Computer, Mathematical and Natural Sciences at UMD. The pledge and other estimated payments to UMD will not be an exchange for distinct goods or services under the provisions of ASC 606 and therefore are considered a reduction of the transaction price for the UMD Quantum Agreement. The transaction price is currently estimated at $12.6 million, reflecting this reduction.
In July 2022, the Company entered into an agreement to provide customized quantum computing hardware to UMD for a transaction price of $0.7 million.
The Company’s results from transactions with related parties, as reflected in the condensed consolidated statements of operations are detailed below. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Revenue
   $ 992      $ 992  
Cost of revenue
     13        14  
Research and development ($130 and $130 attributable to Duke)
     275        271  
Sales and marketing ($10 and zero attributable to Duke)
     20        32  
General and administrative
     47        29  
The Company has the following balances related to transactions with related parties, as reflected in the condensed consolidated balance sheets. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Assets
                 
Prepaid expenses and other current assets ($520 and $520 attributable to Duke)
   $ 525      $ 529  
Operating lease
right-of-use
asset
     3,680        3,753  
Other noncurrent assets ($1,195 and $1,325 attributable to Duke)
     1,195        1,325  
Liabilities
                 
Accounts payable
     81        29  
Accrued expenses
     88        —    
Current operating lease liabilities
     610        591  
Unearned revenue
     2,448        3,514  
Non-current
operating lease liabilities
     3,393        3,459  
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Geographic Information
3 Months Ended
Mar. 31, 2023
Geographic Areas, Revenues from External Customers [Abstract]  
Geographic Information
15. GEOGRAPHIC INFORMATION
Revenue generated for customers located in the United States was approximately 86% and 87% of revenue for the three months ended March 31, 2023 and 2022, respectively.
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2023
Significant Accounting Policies
Significant Accounting Policies
The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022, and the notes thereto are included in the Company’s Annual Report on Form
10-K
(the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below.
Basis of Preparation
Basis of Preparation
The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP as determined by the Financial Accounting Standards Board (“FASB”). Such condensed consolidated financial statements include the accounts of IonQ and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Unaudited Interim Financial Information
Unaudited Interim Financial Information
The interim condensed consolidated financial statements included in this Quarterly Report on Form
10-Q
have been prepared by the Company and are unaudited, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures contained in this Quarterly Report on Form
10-Q
comply with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for a quarterly report and are adequate to make the information presented not misleading. The interim condensed consolidated financial statements included herein reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022, included in the Annual Report. The condensed consolidated statements of operations and the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2023, are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023, or thereafter. All references to March 31, 2023 and 2022, in the notes to the condensed consolidated financial statements are unaudited.
Emerging Growth Company
Emerging Growth Company
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies.
The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
The Company remains an emerging growth company until the earliest of (i) December 31, 2025, (ii) the last day of the fiscal year in which the Company has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the Company is deemed to be a large accelerated filer, which means the market value of the Company’s common stock that is held by
non-affiliates
exceeds $700.0 million as of the prior June 30th or (iv) the date on which the Company has issued more than $1.0 billion in
non-convertible
debt securities during the prior three-year period.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP and the rules and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes.
Significant estimates and judgments are inherent in the analysis and measurement of items including, but not limited to: revenue recognition, capitalization of internally developed software and quantum computing costs, useful lives of long-lived assets, and fair value of
available-for-sale
securities. Management bases its estimates and assumptions on historical experience, expectations, forecasts, and on various other factors that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ and be affected by changes in those estimates.
Fair Value Measurements
Fair Value Measurements
The Company evaluates the fair value of certain assets and liabilities using the fair value hierarchy. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
 
   
Level 1—Observable inputs, which include quoted prices in active markets;
 
   
Level 2—Observable inputs other than the quoted prices in active markets that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs such as broker quotes, benchmark yield curves, credit spreads and market interest rates for similar securities that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
 
   
Level 3—Unobservable inputs that are supported by little or no market activity and that are based on management’s assumptions, including fair value measurements determined using pricing models, discounted cash flow methodologies or similar techniques.
The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the total fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability.
 
Assets and liabilities that are measured at fair value on a
non-recurring
basis include property and equipment, intangible assets, and goodwill. The Company recognizes these items at fair value when they are considered to be impaired or upon initial recognition when acquired through a business combination or an asset acquisition. The fair value of these assets and liabilities are determined with valuation techniques using the best information available and may include quoted market prices, market comparables and discounted cash flow models.
Due to their short-term nature, the carrying amounts reported in the Company’s condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses.
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include cash in banks, checking deposits, money market funds, and commercial paper. The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Restricted cash collateralizing letters of credit is included in other noncurrent assets in the condensed consolidated balance sheets. The Company issues letters of credits in the ordinary course of business, including for lease arrangements. As of both March 31, 2023 and December 31, 2022, letters of credit totaling 
$2.0 million were outstanding.
The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Cash and cash equivalents
   $ 51,901      $ 44,367  
Restricted cash
     2,000        2,000  
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows
   $ 53,901      $ 46,367  
    
 
 
    
 
 
 
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses
Accounts receivable are
non-interest
bearing and represent amounts billed and currently due from customers at the gross invoiced amount as well as unbilled amounts related to unconditional rights for consideration to be received for services performed but not yet invoiced. A receivable is recorded when the Company has an unconditional right to receive payment. Accounts receivable consists of the following at (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Billed accounts receivable
   $ 1,001      $ 1,150  
Unbilled accounts receivable
     836        2,142  
    
 
 
    
 
 
 
Total accounts receivable
   $ 1,837      $ 3,292  
    
 
 
    
 
 
 
On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance for credit losses. This assessment is based on management’s evaluation of relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the receivable.
The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022.
Materials and Supplies
Materials and Supplies
Materials and supplies are carried at average cost and recorded in prepaid expenses and other current assets in the condensed consolidated balance sheets. Materials and supplies used in the production of quantum computing systems to be made commercially available are capitalized to property and equipment when installed. Materials and supplies used for maintenance or research and development efforts are expensed when consumed. The Company capitalized $0.8 million of materials and supplies to property and equipment for the three months ended March 31, 2023.
Investments
Investments
Management determines the appropriate classification of investments at the time of purchase based upon management’s intent with regard to such investments. The Company primarily invests in debt securities and classifies its investments as
available-for-sale
at the time of purchase if they are available to support either current or future operations. This classification is
re-evaluated
at each balance sheet date. Investments not considered cash equivalents, with remaining contractual maturities of one year or less from the balance sheet date are classified as short-term investments, and those with remaining contractual maturities greater than one year from the balance sheet date are classified as long-term investments. All investments are recorded at their estimated fair value, and any unrealized gains and losses are recorded in accumulated other comprehensive loss. Realized gains and losses on sales and maturities of investments are determined based on the specific identification method and are recognized in the condensed consolidated statements of operations in other income (expense), net. Accrued interest receivable on available-for-sale investments is recorded in the condensed consolidated balance sheet in prepaid expenses and other current assets. As of
March 31, 2023
and December 31, 2022, accrued interest receivable was $1.8 million and $1.7 million, respectively.
 
The Company performs periodic evaluations to determine whether any declines in the fair value of investments below amortized cost are credit losses or impairments. The evaluation consists of qualitative and quantitative factors regarding the severity of the unrealized loss, as well as the Company’s ability and intent to hold the investments until a forecasted recovery occurs. Declines in fair value are considered to be credit losses if they are related to deterioration in credit risk or are considered impairments if it is likely that the underlying securities will be sold prior to a full recovery of their cost basis. Credit losses and impairments are determined based on the specific identification method and
are
reported in other income (expense), net in the condensed consolidated statements of operations.
Property and Equipment, Net
Property and Equipment, Net
Property and equipment, net is stated at cost less accumulated depreciation. Historical cost of fixed assets is the cost as of the date acquired. Hardware and labor costs associated with the building of quantum computing systems are capitalized. Costs
to
maintain quantum computing systems are expensed as incurred.
Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows:
 
Computer equipment and acquired computer software    3 – 5 years
Machinery, equipment, furniture and fixtures    5 – 7 years
Quantum computing systems    3 years
Leasehold improvements    Shorter of the lease term or the estimated useful life of the related asset
Effective October 1, 2022, the Company revised the accounting useful life of quantum computing systems, which was determined to be a change in accounting estimate and is being applied prospectively. This change in accounting estimate is not material for the three months ended March 31, 2023. The estimated useful life for quantum computing systems was previously 2 years.
Leases
Leases
The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease
right-of-use
(“ROU”) assets and current operating lease liabilities and operating lease liabilities, net of current portion on the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has no financing lease arrangements. The Company recognizes lease expense for its operating leases on a straight-line basis over the term of the lease.
The Company records a ROU asset and lease liability in connection with its operating leases. The Company’s lease portfolio is comprised primarily of real estate leases, which are accounted for as operating leases. The Company elected the practical expedient to not separate lease and
non-lease
components for all leases.
ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future minimum lease payments, including the impact of any lease incentives, as applicable, over the lease term. Amendments to a lease are assessed to determine if it represents a lease modification or a separate contract. Lease modifications are reassessed as of the effective date of the modification using an incremental borrowing rate based on the information available at the commencement date. For modified leases the Company also reassesses the lease classification as of the effective date of the modification.
The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate, because the interest rate implicit in the Company’s leases is not readily determinable. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located.
The Company’s lease terms include periods under options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company considers contractual-based factors such as the nature and terms of the renewal or termination, asset-based factors such as physical location of the asset and entity-based factors such as the importance of the leased asset to the Company’s operations to determine the lease term. The Company generally uses the base
non-cancelable
lease term when determining the ROU assets and lease liabilities.
Capitalized Internally Developed Software
Capitalized Internally Developed Software
Capitalized internally developed software, which is included in intangible assets, net, consists of costs to purchase and develop internal-use software, which the Company primarily uses to provide services to its customers. The costs to purchase and develop internal-use software are capitalized from the time that the preliminary project stage is completed, and it is considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Any costs incurred during subsequent efforts to upgrade and enhance the functionality of the software are also capitalized. Once this software is ready for its intended use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is typically assessed to be three years. During the three months ended March 31, 2023 and 2022, the Company capitalized $
1.3 million and $0.5 million in
internal-use
software costs, respectively. The Company amortized $0.5 million and $0.3 million of capitalized internally developed software costs during the three months ended March 31, 2023 and 2022, respectively.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
Long-lived assets, such as property and equipment and other long-term assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent the carrying amount of the underlying asset exceeds its fair value. No impairment loss was recognized for the three months ended March 31, 2023 or 2022.
Warrant Liabilities
Warrant Liabilities
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and
is then re-valued
upon exercise or at each reporting date for the unexercised warrants, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The warrants of dMY assumed in the Business Combination are classified as liabilities and remeasured at each reporting period (as more fully described in Note 10). The determination of the fair value of the warrant liabilities may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are
classified as non-current liabilities as
their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Revenue Recognition
Revenue Recognition
The Company derives revenue from providing access to its quantum-computing-as-a-service (“QCaaS”), consulting services related to
co-developing
algorithms on the quantum computing systems, and from contracts associated with the design, development, and construction of specialized quantum computing systems together with related services. The Company applies the provisions of the FASB Accounting Standards Update (“ASU”), Revenue from Contracts with Customers (“ASC 606”), and all related applicable guidance. The core principle of ASC 606 is that an entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
To support this core principle, the Company applies the following five step approach:
 
1.
Identify the contract with the customer
 
2.
Identify the performance obligations
 
3.
Determine the transaction price
 
4.
Allocate the transaction price to the performance obligations
 
5.
Recognize revenue when (or as) the entity satisfies a performance obligation
The Company has determined that its QCaaS contracts represent a combined, stand-ready performance obligation to provide access to its quantum computing systems together with related maintenance and support. The transaction price may consist of a variable fee based on usage of its quantum computing systems or a fixed fee for a minimum volume of usage to be made available over a defined period of access. Fixed fee arrangements may also include a variable component whereby customers pay an amount for usage over contractual minimums contained in the contracts. The Company has determined that contracts that contain consulting services related
to co-developing quantum
computing algorithms and the ability to use its quantum computing systems to run such algorithms represent a combined performance obligation that is satisfied over-time with revenue recognized based on the efforts incurred to date relative to the total expected effort. For contracts with a fixed transaction price, the fixed fee is recognized on a straight-line basis over the access period or associated measure of progress for the Company’s consulting services contracts. For contracts without fixed fees, variable usage fees are billed and recognized during the period of such usage.
Certain of the Company’s contracts contain multiple performance obligations, most commonly in contracts for specialized quantum computing systems together with related maintenance and support. Such contracts may also include access to the Company’s QCaaS. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. When there are multiple performance obligations in a contract, the Company allocates the transaction price to each performance obligation based on its standalone selling price when available. We determine standalone selling price based on the observable price of a product or service when we sell the products or services separately in similar circumstances and to similar customers. When the standalone selling price is not known, due to it being either highly variable or uncertain, the Company allocates the transaction price using the residual approach.
Performance obligations are satisfied over time if the customer receives the benefits as we perform the work, if the customer controls the asset as it is being produced (continuous transfer of control), or if the product being produced for the customer has no alternative use and we have a contractual right to payment for performance to date. Revenue is recognized on performance obligations satisfied over time based on the efforts incurred to date relative to the total expected effort.
For the three months ended March 31, 2023 and 2022, all of the revenue recognized by the Company was recognized based on transfer of service over time. There were no revenues recognized at a point in time. In arrangements with cloud service providers, the cloud service provider is considered the customer and IonQ does not have any contractual relationships with the cloud service providers’ end users. For these arrangements, revenue is recognized at the amount charged to the cloud service provider and does not reflect any
mark-up
to the end user.
The Company may enter into multiple contracts with a single counterparty at or near the same time. The Company will combine contracts and account for them as a single contract when one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) consideration to be paid in one contract depends on the price or performance of the other contract; and (iii) goods or services promised are a single performance obligation. Consideration payable to a customer includes cash amounts that an entity pays, or expects to pay, to the customer. For arrangements that contain consideration payable to a customer, the Company uses judgment in determining whether such payments are a reduction of the transaction price or a payment to the customer for a distinct good or service.
The variable fees associated with the QCaaS are generally billed a month in arrears. Customers also have the ability to make advance payments. If a contract exists under ASC 606, advance payments are recorded as a contract liability until services are delivered or obligations are met and revenue is earned. Contract liabilities to be recognized in the succeeding
12-month
period are classified as current and the remaining amounts are classified as
non-current
liabilities in the Company’s condensed consolidated balance sheets.
 
As of March 31, 2023, approximately $30.4 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for
non-cancelable
contracts, including both funded (firm orders for which funding has been both authorized and appropriated by the customer) and unfunded (firm orders for which funding has not been appropriated) orders. The Company expects approximately 60% of the remaining performance obligations to be recognized as revenue within the next twelve months.
The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands):
 
    
Total
 
Balance as of December 31, 2022
   $ 9,930  
Revenue recognized
     (3,446
New deferrals, net
     764  
    
 
 
 
Balance as of March 31, 2023
   $ 7,248  
    
 
 
 
For contractual arrangements where consideration is paid
up-front,
the transfer of the quantum computing services is completed at the discretion of the customer as the customer chooses to use the services starting from the date of contract inception. As such, the
up-front
payment of consideration does not represent a significant financing component.
Assets Recognized from Costs to Obtain a Contract
Sales commissions paid to employees and third parties are considered incremental costs to obtain a contract with a customer. These costs are capitalized in the period a customer contract is executed and are amortized as an expense consistent with the transfer of the goods or services to the customer. Capitalized costs are recorded in prepaid expenses and other current assets and other noncurrent assets in the condensed consolidated balance sheets. Applying the practical expedient, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets is one year or less. As of March 31, 2023 and December 31, 2022, total capitalized costs were $0.9 million and $1.0 million, respectively. Amortization expense was $0.1 million and zero for the three months ended March 31, 2023 and 2022, respectively.
Stock-Based Compensation
Stock-Based Compensation
The Company measures and records the expense related to stock-based awards based on the fair value of those awards as determined on the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes-Merton (“Black- Scholes”) option-pricing model to determine the fair value of stock awards and the estimated fair value for stock options. The Black-Scholes option- pricing model requires the use of subjective assumptions, which determine the fair value of share-based awards, including the fair value of the Company’s common stock, the option’s expected term, the price volatility of the underlying common stock, risk-free interest rates, and the expected dividend yield of the common stock. The assumptions used to determine the fair value of the stock awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. The Company records forfeitures as they occur.
Stock-based compensation cost for restricted stock units is measured based on the fair value of the Company’s common stock on the grant date. For awards with a performance-based vesting condition, the Company records stock-based compensation cost if it is probable that the performance condition will be achieved.
The Company records stock-based compensation expense for incentive compensation liabilities based on estimated payments to employees for which the Company expects to settle the liability by granting restricted stock units. For these awards, stock-based compensation expense is accrued commencing at the service inception date, which generally precedes the grant date, through the end of the requisite service period.
The Company obtained third-party valuations to estimate the fair value of its common stock for awards granted prior to the Business Combination, for purposes of measuring stock-based compensation expense. The third-party valuations were prepared using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants (“AICPA”) Accounting &Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.
Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, investments, and trade accounts receivable. The Company maintains the majority of its cash, cash equivalents, restricted cash and investments with two financial institutions. The Company’s deposits routinely exceed amounts guaranteed by the Federal Deposit Insurance Corporation. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to limited credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors.
The Company’s accounts receivable are derived from customers primarily located in the U.S. The Company performs periodic evaluations of its customers’ financial condition and generally does not require its customers to provide collateral or other security to support accounts receivable and maintains an allowance for credit losses. Credit losses historically have not been material.
Significant customers are those that represent more than 10% of the Company’s total revenue. The Company’s revenue was primarily from three significant customers for the three months ended March 31, 2023, and from two significant customers for the three months ended March 31, 2022.
Earnings (Loss) Per Share
Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock during the period, plus common stock equivalents, outstanding during the period. If the Company reports a net loss, the computation of diluted loss per share excludes the effect of dilutive common stock equivalents, as their effect would be antidilutive.
The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Numerator:
                 
Net loss attributable to common stockholders
   $ (27,338    $ (4,227
Denominator:
                 
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted
     200,112,855        196,183,247  
Net loss per share attributable to common stockholders—basic and diluted
   $ (0.14    $ (0.02
In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted stock units, unvested common stock (including unvested restricted common stock) and warrants are excluded and diluted loss per share is equal to basic loss per share. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:
 
    
Three Months Ended
March 31
 
    
2023
    
2022
 
Common stock options outstanding
     24,499,968        21,108,390  
Warrants to purchase common stock
     8,301,202        8,301,202  
Public warrants
     5,231,486        5,232,471  
Unvested restricted stock units
     9,077,343        1,310,471  
Unvested common stock
     842,454        1,351,261  
    
 
 
    
 
 
 
Total
  
 
47,952,453
 
  
 
37,303,795
 
    
 
 
    
 
 
 
Recently Issued Accounting Standards Not Yet Adopted
Recently Issued Accounting Standards Not Yet Adopted
In August 2020, the FASB issued ASU
2020-06,
Debt, Debt with Conversion and Other Options (Subtopic
470-20)
and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic
815-40)
Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its consolidated financial statements and related disclosures.
Recently Adopted Accounting Standards
Recently Adopted Accounting Standards
In June 2016, the FASB issued ASU
2016-13,
Financial Instruments—Credit Losses, along with various updates and improvements. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the first quarter of 2023, and it did not have a material effect on the condensed consolidated financial statements and related disclosures.
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2023
Summary Of a Reconciliation Of Cash And Restricted Cash
The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Cash and cash equivalents
   $ 51,901      $ 44,367  
Restricted cash
     2,000        2,000  
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows
   $ 53,901      $ 46,367  
    
 
 
    
 
 
 
Summary of Loans and Financing Receivable Accounts receivable consists of the following at (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Billed accounts receivable
   $ 1,001      $ 1,150  
Unbilled accounts receivable
     836        2,142  
    
 
 
    
 
 
 
Total accounts receivable
   $ 1,837      $ 3,292  
    
 
 
    
 
 
 
Summary of Property Plant And Equipment Useful Life
Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows:
 
Computer equipment and acquired computer software    3 – 5 years
Machinery, equipment, furniture and fixtures    5 – 7 years
Quantum computing systems    3 years
Leasehold improvements    Shorter of the lease term or the estimated useful life of the related asset
Summary of Changes in Unearned Revenue
The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands):
 
    
Total
 
Balance as of December 31, 2022
   $ 9,930  
Revenue recognized
     (3,446
New deferrals, net
     764  
    
 
 
 
Balance as of March 31, 2023
   $ 7,248  
    
 
 
 
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Numerator:
                 
Net loss attributable to common stockholders
   $ (27,338    $ (4,227
Denominator:
                 
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted
     200,112,855        196,183,247  
Net loss per share attributable to common stockholders—basic and diluted
   $ (0.14    $ (0.02
Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive:
 
    
Three Months Ended
March 31
 
    
2023
    
2022
 
Common stock options outstanding
     24,499,968        21,108,390  
Warrants to purchase common stock
     8,301,202        8,301,202  
Public warrants
     5,231,486        5,232,471  
Unvested restricted stock units
     9,077,343        1,310,471  
Unvested common stock
     842,454        1,351,261  
    
 
 
    
 
 
 
Total
  
 
47,952,453
 
  
 
37,303,795
 
    
 
 
    
 
 
 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, Restricted Cash And Investments (Tables)
3 Months Ended
Mar. 31, 2023
Cash and Cash Equivalents [Abstract]  
Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments
The following table summarizes the Company’s unrealized gains and losses and estimated fair value of cash, cash equivalents, restricted cash and investments in
available-for-sale
securities recorded in the condensed consolidated balance sheets (in thousands):
 
    
AS OF MARCH 31, 2023
    
AS OF DECEMBER 31, 2022
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
   
Estimated
Fair
Value
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
   
Estimated
Fair Value
 
Cash and money market funds
   $ 51,012      $ —        $ —       $ 51,012      $ 46,367      $ —        $ —       $ 46,367  
Commercial paper
     121,151        2        (198     120,955        130,141        —          (443     129,698  
Corporate notes and bonds
     263,876        106        (4,761     259,221        277,184        19        (5,993     271,210  
Municipal bonds
     9,935        —          (213     9,722        9,905        —          (273     9,632  
US government and agency
     86,968        88        (453     86,603        83,556        23        (688     82,891  
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Total cash, cash equivalents, restricted cash and investments
  
$
532,942
 
  
$
196
 
  
$
(5,625
 
$
527,513
 
  
$
547,153
 
  
$
42
 
  
$
(7,397
 
$
539,798
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities
The estimated fair value of the Company’s cash, cash equivalents, restricted cash and investments in
available-for-sale
securities as of March 31, 2023, aggregated by investment category and classified by contractual maturity date, is as follows (in thousands):
 
    
1 Year
or Less
    
1 Year
or Greater
    
Total
 
Cash and money market funds
   $ 49,012      $ 2,000      $ 51,012  
Commercial paper
     120,955        —          120,955  
Corporate notes and bonds
     148,350        110,871        259,221  
Municipal bonds
     9,722        —          9,722  
US government and agency
     59,828        26,775        86,603  
    
 
 
    
 
 
    
 
 
 
Total
  
$
387,867
 
  
$
139,646
 
  
$
527,513
 
    
 
 
    
 
 
    
 
 
 
Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value The following table presents information about the Company’s investments in available-for-sale securities with gross unrealized losses and the length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2023 (in thousands).
 
 
  
As of March 31, 2023
 
 
  
Less than 12 Months
 
 
12 Months or Longer
 
 
Total
 
 
  
Fair Value
 
  
Gross Unrealized
Losses
 
 
Fair Value
 
  
Gross Unrealized
Losses
 
 
Fair Value
 
  
Gross Unrealized
Loses
 
Commercial paper
  
$
75,326
 
  
$
(198
)
 
 
$
—  
 
  
$
 
—  
 
 
$
75,326
 
  
$
(198
)
 
Corporate notes and bonds
  
 
91,968
 
  
 
(1,237
)
 
 
 
138,518
 
  
 
(3,524
 
 
230,486
 
  
 
(4,761
)
 
Municipal bonds
  
 
4,951
 
  
 
(31
 
 
4,771
 
  
 
(182
 
 
9,722
 
  
 
(213
US government and agency
  
 
29,124
 
  
 
(83
 
 
12,123
 
  
 
(370
 
 
41,247
 
  
 
(453
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
Total
  
$
201,369
 
  
$
(1,549
 
$
155,412
 
  
$
(4,076
 
$
356,781
 
  
$
(5,625
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurement (Tables)
3 Months Ended
Mar. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Summary of fair value measurements on a recurring basis and the level of inputs
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (in thousands):
 
    
Fair Value Measured as of
March 31, 2023:
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Cash, cash equivalents and restricted cash:
                                   
Cash and money market funds
(1)
   $ 51,012      $ —        $ —        $ 51,012  
Commercial paper
     —          2,889        —          2,889  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash
     51,012        2,889        —          53,901  
    
 
 
    
 
 
    
 
 
    
 
 
 
Short-term investments:
                                   
Commercial paper
     —          118,066        —          118,066  
Corporate notes and bonds
     —          148,350        —          148,350  
Municipal bonds
     —          9,722                 9,722  
US government and agency
     —          59,828        —          59,828  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total short-term investments
     —          335,966        —          335,966  
    
 
 
    
 
 
    
 
 
    
 
 
 
Long-term investments:
                                   
Corporate notes and bonds
     —          110,871        —          110,871  
US government and agency
     —          26,775        —          26,775  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total long-term investments
     —          137,646        —          137,646  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Assets
   $ 51,012      $ 476,501      $ —        $ 527,513  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Public warrants
   $ 7,429      $ —        $ —        $ 7,429  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
Fair Value Measured as of
December 31, 2022:
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
                                   
Cash, cash equivalents and restricted cash:
                                   
Cash and money market funds
(1)
   $ 46,367      $ —        $ —        $ 46,367  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total cash, cash equivalents and restricted cash
     46,367        —          —          46,367  
    
 
 
    
 
 
    
 
 
    
 
 
 
Short-term investments:
                                   
Commercial paper
     —          129,698        —          129,698  
Corporate notes and bonds
     —          120,447        —          120,447  
Municipal bonds
     —          4,911                 4,911  
US government and agency
     —          56,374        —          56,374  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total short-term investments
     —          311,430        —          311,430  
    
 
 
    
 
 
    
 
 
    
 
 
 
Long-term investments:
                                   
Corporate notes and bonds
     —          150,763        —          150,763  
Municipal bonds
     —          4,721        —          4,721  
US government and agency
     —          26,517        —          26,517  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total long-term investments
     —          182,001        —          182,001  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total Assets
   $ 46,367      $ 493,431      $ —        $ 539,798  
    
 
 
    
 
 
    
 
 
    
 
 
 
Liabilities:
                                   
Public warrants
   $ 3,819      $ —        $ —        $ 3,819  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
(1)
Includes money market funds associated with the Company’s overnight investment sweep account and collateralized letter of credit.
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Property And Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
Summary Of Property And Equipment, Net
Property and equipment, net is composed of the following (in thousands):
 
 
  
March 31,
 
  
December 31,
 
 
  
2023
 
  
2022
 
Computer equipment and acquired computer software
   $ 2,707      $ 2,407  
Machinery, equipment, furniture and fixtures
     7,747        7,506  
Leasehold improvements
     1,193        1,132  
Quantum computing systems
     23,532        22,430  
    
 
 
    
 
 
 
Gross property and equipment
  
 
35,179
 
  
 
33,475
 
Less: accumulated depreciation
     (8,691
  
  (7,461
    
 
 
    
 
 
 
Property and equipment, net
  
$
26,488
 
  
$
26,014
 
    
 
 
    
 
 
 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Other Balance Sheet Accounts (Tables)
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of accrued expenses
Accrued expenses are composed of the following (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Accrued salaries and other payroll liabilities
   $ 6,597      $ 4,935  
Accrued professional services
     1,283        678  
Accrued equipment and services liabilities for research and development
     611        489  
Accrued expenses—other
     923        553  
    
 
 
    
 
 
 
Total accrued expenses
  
$
9,414
 
  
$
6,655
 
    
 
 
    
 
 
 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Summary of Share Based Payment Award Stock Options Valuation Assumptions
The assumptions used to estimate the fair value of stock options granted during the three months ended March 31, 2023 and 2022, are as follows:
 
    
Three Months Ended
March 31,
 
    
2023
   
2022
 
Risk-free interest rate
     —       1.76
Expected term (in years)
     —         5.63  
Expected volatility
     —       77.48
Dividend yield
     —       —  
Summary of the Stock Option Activity
The stock option activity is summarized in the following table:
 
    
Number of
Option
Shares
    
Weighted
Average
Exercise
Price
    
Weighted
Average
Remaining
Contractual
Term (Years)
    
Aggregate
Intrinsic
Value
(in millions)
 
Outstanding as of December 31, 2022
     24,716,270      $ 2.19        7.32      $ 49.69  
Granted
     —          —                      
Exercised
     (131,492      0.40                    
Cancelled/ Forfeited
     (296,628      1.58                    
    
 
 
                            
Outstanding as of March 31, 2023
     24,288,150      $ 2.21        7.09      $ 108.06  
    
 
 
                            
Exercisable as of March 31, 2023
     12,571,954      $ 0.96        7.27      $ 67.93  
Exercisable and expected to vest as of March 31, 2023
     24,288,150      $ 2.21        7.09      $ 108.06  
Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock
Total stock-based compensation expense for stock option awards and RSU awards, which are included in the condensed consolidated financial statements, is as follows (in thousands):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Cost of revenue
   $ 349      $ 104  
Research and development
     5,280        1,698  
Sales and marketing
     764        73  
General and administrative
     3,875        4,797  
    
 
 
    
 
 
 
Stock-based compensation, net of amounts capitalized
     10,268        6,672  
Capitalized stock-based compensation—Intangibles and fixed assets
     619        176  
    
 
 
    
 
 
 
Total stock-based compensation
   $ 10,887      $ 6,848  
    
 
 
    
 
 
 
Summary of stock option grants, vesting and exercises
The following table summarizes additional information on stock option grants, vesting and exercises (in millions, except per share amounts):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Total intrinsic value of options exercised
   $ 0.8      $ 5.7  
Aggregate grant-date fair value of options vested
   $ 3.3      $ 2.2  
Weighted-average grant date fair value per share for options granted
   $ —        $ 12.87  
Summary of restricted stock unit ("RSU") activity
The RSU activity is summarized in the following table:
 
    
Number of
RSUs
    
Weighted
Average
Grant
Date Fair
Value
    
Weighted
Average
Remaining
Contractual
Term (Years)
    
Aggregate
Fair Value
(in millions)
 
Outstanding as of December 31, 2022
     9,320,045      $ 7.02        3.21      $ 65.38  
Granted
     —          —                      
Vested
     (524,711      8.39                    
Forfeited
     (235,613      5.04                    
    
 
 
                            
Outstanding as of March 31, 2023
     8,559,721      $ 6.99        2.99      $ 59.79  
    
 
 
                            
Expected to vest after March 31, 2023
     8,518,721      $ 6.96        3.01      $ 59.26  
Smmary of Unrecognized Stock-Based Compensation
A summary of our remaining unrecognized compensation expense and the weighted-average remaining amortization period as of March 31, 2023, related to our
non-vested
stock options and RSU awards is presented below (in millions, except time period amounts):
 
    
Unrecognized
Expense
    
Weighted-
Average
Amortization
Period (Years)
 
Restricted stock units
   $ 54.7        1.5  
Stock options
   $ 40.6        1.5  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
3 Months Ended
Mar. 31, 2023
Lease, Cost [Abstract]  
Summary of Components of lease cost
The components of lease cost were as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Operating lease cost
(1)
                 
Fixed lease cost
   $ 360      $ 191  
Short-term cost
     43        6  
    
 
 
    
 
 
 
Total operating lease cost
   $ 403      $ 197  
Summary of lease costs are reflected in the Statements of Operations and Comprehensive Loss
(1)
The lease costs are reflected in the condensed consolidated statements of operations as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Cost of revenue
   $ 14      $ 14  
Research and development
     172        146  
Sales and marketing
     13        7  
General and administrative
     204        30  
    
 
 
    
 
 
 
Total
   $ 403      $ 197  
    
 
 
    
 
 
 
Summary of Supplemental cash flow and other information related to operating leases
Supplemental cash flow and other information related to operating leases was as follows (in thousands):
 
    
Three Months Ended

March 31,
 
    
2023
    
2022
 
Cash payments included in the measurement of operating lease liabilities
   $ 166      $ 161  
Summary of maturities of operating lease liabilities
As of March 31, 2023, maturities of operating lease liabilities are as follows (in thousands):
 
 
  
Amount
 
Year Ending December 31,
  
2023
   $ 559  
2024
     1,831  
2025
     2,309  
2026
     2,378  
2027
     2,449  
Thereafter
     6,385  
    
 
 
 
Total lease payments
     15,911  
Less: imputed interest
     (4,795)  
Less: lease incentives
     (4,882)  
    
 
 
 
Present value of operating lease liabilities
   $ 6,234  
    
 
 
 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2023
Related Party Transaction [Line Items]  
Schedule of Related Party Transactions
The Company’s results from transactions with related parties, as reflected in the condensed consolidated statements of operations are detailed below. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):
 
    
Three Months Ended
March 31,
 
    
2023
    
2022
 
Revenue
   $ 992      $ 992  
Cost of revenue
     13        14  
Research and development ($130 and $130 attributable to Duke)
     275        271  
Sales and marketing ($10 and zero attributable to Duke)
     20        32  
General and administrative
     47        29  
The Company has the following balances related to transactions with related parties, as reflected in the condensed consolidated balance sheets. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):
 
    
March 31,
    
December 31,
 
    
2023
    
2022
 
Assets
                 
Prepaid expenses and other current assets ($520 and $520 attributable to Duke)
   $ 525      $ 529  
Operating lease
right-of-use
asset
     3,680        3,753  
Other noncurrent assets ($1,195 and $1,325 attributable to Duke)
     1,195        1,325  
Liabilities
                 
Accounts payable
     81        29  
Accrued expenses
     88        —    
Current operating lease liabilities
     610        591  
Unearned revenue
     2,448        3,514  
Non-current
operating lease liabilities
     3,393        3,459  
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business - Additional Information (Detail)
3 Months Ended
Mar. 31, 2023
Segment
$ / shares
Dec. 31, 2022
$ / shares
Organization Business And Basis Of Presentation [Line Items]    
Common stock, par value | $ / shares $ 0.0001 $ 0.0001
Number of operating segment | Segment 1  
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Summary Of a Reconciliation Of Cash And Restricted Cash (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 51,901 $ 44,367    
Restricted cash 2,000 2,000    
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows $ 53,901 $ 46,367 $ 86,751 $ 399,025
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Summary of Loans and Financing Receivable (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable $ 1,837 $ 3,292
Billed Accounts Receivable [Member]    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 1,001 1,150
Unbilled Accounts Receivable [Member]    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable $ 836 $ 2,142
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail)
3 Months Ended
Mar. 31, 2023
Computer Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Computer Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Machinery Equipment Furniture And Fixtures [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 5 years
Machinery Equipment Furniture And Fixtures [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 7 years
Quantum Computing System [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Useful Life 3 years
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, Plant and Equipment, Estimated Useful Lives Shorter of the lease term or the estimated useful life of the related asset
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Summary of Changes in Unearned Revenue (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Deferred Revenue [Abstract]  
Beginning balance $ 9,930
Revenue recognized (3,446)
New deferrals, net 764
Ending balance $ 7,248
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net loss attributable to common stockholders $ (27,338) $ (4,227)
Denominator:    
Weighted average shares used in computing net loss per share attributable to common stockholders – Basic 200,112,855 196,183,247
Net loss per share attributable to common stockholders - Basic $ (0.14) $ (0.02)
Weighted average shares used in computing net loss per share attributable to common stockholders – Diluted 200,112,855 196,183,247
Net loss per share attributable to common stockholders - Diluted $ (0.14) $ (0.02)
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 47,952,453 37,303,795
Common stock options outstanding    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 24,499,968 21,108,390
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 8,301,202 8,301,202
Public Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 5,231,486 5,232,471
Unvested restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 9,077,343 1,310,471
Unvested common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 842,454 1,351,261
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Additional Information (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Customers
Mar. 31, 2022
USD ($)
Customers
Dec. 31, 2022
USD ($)
Significant Accounting Policies [Line Items]      
Allowance for doubtful accounts $ 0   $ 0
Impairment of Long-Lived Assets to be Disposed of 0 $ 0  
Accrued interest receivable on available-for-sale investments 1,800   1,700
Capitalized materials and supplies 800    
Letters of credit outstanding amount 2,000   2,000
Capitalized Commissions [Member]      
Significant Accounting Policies [Line Items]      
Capitalized contract cost 900   $ 1,000
Capitalized contract cost amortization expense 100 $ 0  
Quantum Computer Systems [Member]      
Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life   2 years  
ASC 606 [Member]      
Significant Accounting Policies [Line Items]      
Revenue, remaining performance obligation, amount $ 30,400    
Percentage Of Remaining Performance Obligation 60.00%    
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation twelve months    
Minimum [Member]      
Significant Accounting Policies [Line Items]      
Market value of the Company's common stock $ 700,000    
Revenues $ 1,235,000    
Revenue Benchmark [Member]      
Significant Accounting Policies [Line Items]      
Number of customers over ten percent benchmark | Customers 3 2  
Revenue Benchmark [Member] | Revenue from Rights Concentration Risk [Member] | Minimum [Member]      
Significant Accounting Policies [Line Items]      
Concentration risk, percentage 10.00%    
Software and Software Development Costs [Member]      
Significant Accounting Policies [Line Items]      
Intangible asset capitalized during period $ 1,300 $ 500  
Finite lived intangible asset, useful life 3 years    
Internally Developed Software [Member]      
Significant Accounting Policies [Line Items]      
Amortization of intangible assets $ 500 $ 300  
Non Convertible Debt Securities [Member] | Minimum [Member]      
Significant Accounting Policies [Line Items]      
Proceeds from Issuance of Debt $ 1,000,000    
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Cash and Cash Equivalents [Line Items]    
Amortized Cost $ 532,942 $ 547,153
Gross Unrealized Gains 196 42
Gross Unrealized Losses (5,625) (7,397)
Estimated Fair Value 527,513 539,798
Cash and money market funds [Member]    
Cash and Cash Equivalents [Line Items]    
Amortized Cost 51,012 46,367
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 51,012 46,367
Commercial Paper [Member]    
Cash and Cash Equivalents [Line Items]    
Amortized Cost 121,151 130,141
Gross Unrealized Gains 2 0
Gross Unrealized Losses (198) (443)
Estimated Fair Value 120,955 129,698
Corporate Notes And Bonds [Member]    
Cash and Cash Equivalents [Line Items]    
Amortized Cost 263,876 277,184
Gross Unrealized Gains 106 19
Gross Unrealized Losses (4,761) (5,993)
Estimated Fair Value 259,221 271,210
Municipal Bonds [Member]    
Cash and Cash Equivalents [Line Items]    
Amortized Cost 9,935 9,905
Gross Unrealized Gains 0 0
Gross Unrealized Losses (213) (273)
Estimated Fair Value 9,722 9,632
US Government Corporations and Agencies Securities [Member]    
Cash and Cash Equivalents [Line Items]    
Amortized Cost 86,968 83,556
Gross Unrealized Gains 88 23
Gross Unrealized Losses (453) (688)
Estimated Fair Value $ 86,603 $ 82,891
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, Restricted Cash And Investments - Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities (Detail)
$ in Thousands
Mar. 31, 2023
USD ($)
Cash and Cash Equivalents [Line Items]  
1 Year or Less $ 387,867
1 Year or Greater 139,646
Total 527,513
Cash and money market funds [Member]  
Cash and Cash Equivalents [Line Items]  
1 Year or Less 49,012
1 Year or Greater 2,000
Total 51,012
Commercial Paper [Member]  
Cash and Cash Equivalents [Line Items]  
1 Year or Less 120,955
1 Year or Greater 0
Total 120,955
Corporate Notes and Bonds [Member]  
Cash and Cash Equivalents [Line Items]  
1 Year or Less 148,350
1 Year or Greater 110,871
Total 259,221
Municipal Bonds [Member]  
Cash and Cash Equivalents [Line Items]  
1 Year or Less 9,722
1 Year or Greater 0
Total 9,722
US government and agency [Member]  
Cash and Cash Equivalents [Line Items]  
1 Year or Less 59,828
1 Year or Greater 26,775
Total $ 86,603
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Detail)
$ in Thousands
Mar. 31, 2023
USD ($)
Debt Securities, Available-for-Sale [Line Items]  
Less than 12 Months, Fair Value $ 201,369
Less than 12 Months, Gross Unrealized Losses (1,549)
12 Months or Longer, Fair value 155,412
12 Months or Longer, Gross Unrealized Losses (4,076)
Total, Fair value 356,781
Total, Gross Unrealized Loses (5,625)
US government and agency  
Debt Securities, Available-for-Sale [Line Items]  
Less than 12 Months, Fair Value 29,124
Less than 12 Months, Gross Unrealized Losses (83)
12 Months or Longer, Fair value 12,123
12 Months or Longer, Gross Unrealized Losses (370)
Total, Fair value 41,247
Total, Gross Unrealized Loses (453)
Municipal Bonds [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Less than 12 Months, Fair Value 4,951
Less than 12 Months, Gross Unrealized Losses (31)
12 Months or Longer, Fair value 4,771
12 Months or Longer, Gross Unrealized Losses (182)
Total, Fair value 9,722
Total, Gross Unrealized Loses (213)
Corporate Notes and Bonds [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Less than 12 Months, Fair Value 91,968
Less than 12 Months, Gross Unrealized Losses (1,237)
12 Months or Longer, Fair value 138,518
12 Months or Longer, Gross Unrealized Losses (3,524)
Total, Fair value 230,486
Total, Gross Unrealized Loses (4,761)
Commercial Paper [Member]  
Debt Securities, Available-for-Sale [Line Items]  
Less than 12 Months, Fair Value 75,326
Less than 12 Months, Gross Unrealized Losses (198)
12 Months or Longer, Fair value 0
12 Months or Longer, Gross Unrealized Losses 0
Total, Fair value 75,326
Total, Gross Unrealized Loses $ (198)
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Summary of fair value measurements on a recurring basis and the level of inputs (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Assets:    
Total Assets $ 527,513  
Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents 53,901 $ 46,367
Total Assets 527,513 539,798
Liabilities:    
Public warrants 7,429 3,819
Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 335,966 311,430
Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments 137,646 182,001
Cash and money market funds [Member] | Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents [1] 51,012 46,367
Commercial Paper [Member] | Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents 2,889  
Commercial Paper [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 118,066 129,698
Municipal Bonds [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 9,722 4,911
Municipal Bonds [Member] | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments   4,721
Corporate Notes And Bonds [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 148,350 120,447
Corporate Notes And Bonds [Member] | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments 110,871 150,763
US government and agency | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 59,828 56,374
US government and agency | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments 26,775 26,517
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents 51,012 46,367
Total Assets 51,012 46,367
Liabilities:    
Public warrants 7,429 3,819
Quoted Prices in Active Markets (Level 1) [Member] | Cash and money market funds [Member] | Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents [1] 51,012 46,367
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents 2,889 0
Total Assets 476,501 493,431
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 335,966 311,430
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments 137,646 182,001
Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member] | Fair Value, Recurring [Member]    
Assets:    
Cash and cash equivalents 2,889  
Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 118,066 129,698
Significant Other Observable Inputs (Level 2) [Member] | Municipal Bonds [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 9,722 4,911
Significant Other Observable Inputs (Level 2) [Member] | Municipal Bonds [Member] | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments   4,721
Significant Other Observable Inputs (Level 2) [Member] | Corporate Notes And Bonds [Member] | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 148,350 120,447
Significant Other Observable Inputs (Level 2) [Member] | Corporate Notes And Bonds [Member] | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments 110,871 150,763
Significant Other Observable Inputs (Level 2) [Member] | US government and agency | Fair Value, Recurring [Member] | Short-term Investments [Member]    
Assets:    
Investments 59,828 56,374
Significant Other Observable Inputs (Level 2) [Member] | US government and agency | Fair Value, Recurring [Member] | Other Long-term Investments [Member]    
Assets:    
Investments $ 26,775 $ 26,517
[1] Includes money market funds associated with the Company’s overnight investment sweep account and collateralizing letters of credit.
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Additional Information (Detail)
Mar. 31, 2023
$ / shares
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]  
Class of warrants, exercise price per share $ 1.38
Public Warrants [Member]  
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]  
Class of warrants, exercise price per share $ 1.42
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Property And Equipment, Net - Summary Of Property And Equipment (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Gross property and equipment $ 35,179 $ 33,475
Less: accumulated depreciation (8,691) (7,461)
Property and equipment, net 26,488 26,014
Computer equipment and acquired computer software    
Property, Plant and Equipment [Line Items]    
Gross property and equipment 2,707 2,407
Machinery, equipment, furniture, and fixtures    
Property, Plant and Equipment [Line Items]    
Gross property and equipment 7,747 7,506
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Gross property and equipment 1,193 1,132
Quantum computing systems [Member]    
Property, Plant and Equipment [Line Items]    
Gross property and equipment $ 23,532 $ 22,430
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Property And Equipment, Net - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation $ 1.2 $ 1.0
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Agreements With University Of Maryland And Duke University - Additional information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 01, 2021
Jul. 31, 2016
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2020
Dec. 31, 2016
Agreement Disclosure [Line Items]            
Research and development expense     $ 16,233 $ 7,338    
Option Agreement [Member]            
Agreement Disclosure [Line Items]            
Agreement, option to extend     extend another year      
Option Agreement [Member] | University Of Maryland [Member]            
Agreement Disclosure [Line Items]            
Agreement term           5 years
Common stock, capital shares reserved for future issuance           642,995
Option Agreement [Member] | Duke [Member]            
Agreement Disclosure [Line Items]            
Research and development expense     $ 100 $ 100    
Option Agreement [Member] | University Of Maryland And Duke [Member] | Patents [Member] | Initial Patents Received [Member]            
Agreement Disclosure [Line Items]            
Stock issued during the period purchase of assets   142,886        
Amended License Agreement [Member] | University Of Maryland [Member]            
Agreement Disclosure [Line Items]            
Option agreement indexed to equity, shares available for issuance, fair value $ 1,600          
Amended License Agreement [Member] | University Of Maryland [Member] | Common Stock [Member]            
Agreement Disclosure [Line Items]            
Stock issued during the period purchase of assets 257,198          
Amended Option Agreement [Member] | Duke [Member] | Common Stock [Member]            
Agreement Disclosure [Line Items]            
Option agreement, remaining number of shares available for issuance         1,214,317  
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Other Balance Sheet Accounts - Summary of accrued expenses (Detail) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued salaries and other payroll liabilities $ 6,597 $ 4,935
Accrued professional services 1,283 678
Accrued equipment and services liabilities for research and development 611 489
Accrued expenses—other 923 553
Total accrued expenses $ 9,414 $ 6,655
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Warrant Transaction Agreement - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
Mar. 31, 2023
Aug. 31, 2020
Nov. 30, 2019
Warrant Transaction Agreement [Abstract]      
Class of warrant or right, number of securities called by warrants or rights 8,301,202    
Percent of warrant shares will vest and be immediately exercisable   6.50%  
Class of warrant or right, exercise price of warrants or rights $ 1.38    
Fair value of the warrant shares     $ 8.7
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Warrant Liabilities - Additional Information (Detail) - $ / shares
3 Months Ended
Mar. 31, 2023
Sep. 30, 2021
Warrant issue price $ 11.5  
Public Warrants [Member]    
Number of warrants or rights outstanding 5,231,486 7,500,000
Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering  
Public warrant for redemption price at a price of $0.01 per warrant  
Public warrants expire date upon a minimum of 30 days’ prior written notice of redemption  
Class of warrant redeemed 0  
Common Class A [Member] | Public Warrants [Member] | Redemption Price One [Member]    
Redemption price of warrants per unit $ 0.01  
Number of consecutive trading days for which the stock price is to be maintained 20 days  
Number of trading days 30 days  
Common Class A [Member] | Public Warrants [Member] | Redemption Price Two [Member]    
Redemption price of warrants per unit $ 0.1  
Number of consecutive trading days for which the stock price is to be maintained 20 days  
Number of trading days 30 days  
Common Class A [Member] | Public Warrants [Member] | Minimum [Member] | Redemption Price One [Member]    
Share price $ 18  
Common Class A [Member] | Public Warrants [Member] | Minimum [Member] | Redemption Price Two [Member]    
Share price $ 10  
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Summary Of Share Based Payment Award Stock Options Valuation Assumptions (Detail)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]    
Risk-free interest rate 0.00% 1.76%
Expected term (in years)   5 years 7 months 17 days
Expected volatility 0.00% 77.48%
Dividend yield 0.00% 0.00%
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Summary of the Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of Option Shares, Beginning Balance   24,716,270
Number of Option Shares, Granted 0  
Number of Option Shares, Exercised (131,492)  
Number of Option Shares, Cancelled/ Forfeited (296,628)  
Number of Option Shares, Ending Balance 24,288,150  
Number of Option Shares, Exercisable 12,571,954  
Number of Option Shares, Exercisable and expected to vest 24,288,150  
Weighted Average Exercise Price, Beginning Balance   $ 2.19
Weighted Average Exercise Price, Granted $ 0  
Weighted Average Exercise Price, Exercised 0.4  
Weighted Average Exercise Price, Cancelled/ Forfeited 1.58  
Weighted Average Exercise Price, Ending Balance 2.21  
Weighted Average Exercise Price, Exercisable 0.96  
Weighted Average Exercise Price, Exercisable and expected to vest $ 2.21  
Weighted-average Remaining Contractual Term, Outstanding 7 years 1 month 2 days 7 years 3 months 25 days
Weighted-average Remaining Contractual Term, Exercisable 7 years 3 months 7 days  
Weighted-average Remaining Contractual Term, Exercisable and expected to vest 7 years 1 month 2 days  
Aggregate Intrinsic Value, Outstanding $ 108,060 $ 49,690
Aggregate Intrinsic Value, Exercisable 67,930  
Aggregate Intrinsic Value, Exercisable and expected to vest $ 108,060  
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Summary of stock option grants, vesting and exercises (Detail) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]    
Total intrinsic value of options exercised $ 0.8 $ 5.7
Aggregate grant-date fair value of options vested $ 3.3 $ 2.2
Weighted-average grant date fair value per share for options granted $ 0 $ 12.87
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Summary of restricted stock unit ("RSU") activity (Detail) - Restricted Stock Units (RSUs) [Member]
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Number of Option Shares, Beginning Balance 9,320,045  
RSUs, Granted 0  
RSUs, Vested (524,711)  
RSUs, Forfeited (235,613)  
Number of Option Shares, Ending Balance 8,559,721 9,320,045
RSUs, Expected to vest after March 31, 2023 8,518,721  
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares $ 7.02  
Weighted Average Grant Date Fair Value, Granted | $ / shares 0  
Weighted Average Grant Date Fair Value, Vested | $ / shares 8.39  
Weighted Average Grant Date Fair Value, Forfeited | $ / shares 5.04  
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 6.99 $ 7.02
Weighted Average Grant Date Fair Value, Expected to vest 6.96  
Weighted Average Remaining Contractual Term (Years) 2 years 11 months 26 days 3 years 2 months 15 days
Weighted Average Remaining Contractual Term (Years), Expected to vest 3 years 3 days  
Aggregate Fair Value (in millions), Beginning Balance | $ $ 65,380  
Aggregate Fair Value (in millions), Ending Balance | $ 59,790 $ 65,380
Aggregate Fair Value (in millions), Expected to vest | $ $ 59,260  
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense $ 10,887 $ 6,848
Cost of Sales [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 349 104
Research and Development Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 5,280 1,698
Selling and Marketing Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 764 73
General and Administrative Expense [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 3,875 4,797
Stock-based Compensation, Net Of Amounts Capitalized [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 10,268 6,672
Capitalized Stock-based Compensation – Intangibles And Fixed Assets [Member]    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense $ 619 $ 176
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation (Detail)
$ in Millions
3 Months Ended
Mar. 31, 2023
USD ($)
Restricted Stock Units (RSUs) [Member]  
Schedule Of Share Based Compensation Arrangements By Share Based Paymen tAward [Line Items]  
Unrecognized Expense $ 54.7
Weighted- Average Amortization Period (Years) 1 year 6 months
Share-based Payment Arrangement, Option [Member]  
Schedule Of Share Based Compensation Arrangements By Share Based Paymen tAward [Line Items]  
Unrecognized Expense $ 40.6
Weighted- Average Amortization Period (Years) 1 year 6 months
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Aug. 31, 2021
Mar. 31, 2023
Dec. 31, 2022
Jan. 01, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Weighted-average remaining contractual term outstanding   7 years 1 month 2 days 7 years 3 months 25 days  
Stock subject to repurchase related to stock options early exercised and unvested   779,787 905,128  
Stock repurchase program, remaining authorized repurchase amount   $ 1.7 $ 2.0  
Minimum [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share based compensation by share based award vesting term   1 year    
2015 Equity Incentive Plan [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Weighted-average remaining contractual term outstanding   10 years    
Share based compensation arrangement by share based payment award cumulative annual increase percentage   5.00%    
2021 Equity Incentive Plan [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Shares reserved for issuances        13,587,593
Number of Shares Available for Grant   37,279,201    
2021 Equity Incentive Plan [Member] | Maximum [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share based compensation by share based award vesting term   4 years    
Employee Stock Purchase Plan [Member]        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Shares reserved for issuances  5,354,000      
Number of shares issued under share based compensation   0    
Share Based Compensation Arrangement, Cumulative Annual Increase,Shares 10,708,000      
Share Based Compensation Arrangement, Cumulative Annual Increase Percentage Of fully Diluted Shares Of Common stock outstanding 1.00%      
Percentage of discount to the lower of closing price on that day or the closing price on the first day of the offering period 15.00%      
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Line Items]    
Provision for income taxes $ 0 $ 0
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Summary Of Components Of Lease Cost (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Lease, Cost [Abstract]    
Fixed lease cost $ 360 $ 191
Short-term lease cost 43 6
Total operating lease cost $ 403 $ 197
XML 69 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Summary Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Line Items]    
Lease, Cost $ 403 $ 197
Cost of revenue    
Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Line Items]    
Lease, Cost 14 14
Research and development    
Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Line Items]    
Lease, Cost 172 146
Sales and marketing    
Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Line Items]    
Lease, Cost 13 7
General and administrative    
Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Line Items]    
Lease, Cost $ 204 $ 30
XML 70 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Summary Of Supplemental Cash Flow And Other Information Related To Operating Leases (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Leases [Abstract]    
Cash payments included in the measurement of operating lease liabilities $ 166 $ 161
XML 71 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Summary Of Maturities Of Operating Lease Liabilities (Detail)
$ in Thousands
Mar. 31, 2023
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
2023 $ 559
2024 1,831
2025 2,309
2026 2,378
2027 2,449
Thereafter 6,385
Total lease payments 15,911
Less: imputed interest (4,795)
Less: lease incentives (4,882)
Present value of operating lease liabilities $ 6,234
XML 72 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Additional Information (Detail)
Mar. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
weighted-average remaining lease term 7 years 3 months 18 days 7 years 10 months 24 days
weighted-average discount rate 9.80% 11.90%
XML 73 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Schedule of Related Party Transactions (Detail) - UMD and Duke [Member] - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]      
Revenue $ 992 $ 992  
Cost of revenue 13 14  
Research and development 275 271  
Sales and marketing 20 32  
General and administrative 47 $ 29  
Assets      
Prepaid expenses and other current assets 525   $ 529
Operating lease right-of-use asset 3,680   3,753
Other noncurrent assets 1,195   1,325
Liabilities      
Accounts payable 81   29
Accrued expenses 88   0
Current operating lease liabilities 610   591
Unearned revenue 2,448   3,514
Non-current operating lease liabilities $ 3,393   $ 3,459
XML 74 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Schedule of Related Party Transactions (Parenthetical) (Detail) - Duke [Member] - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]      
Prepaid expenses and other current assets $ 520   $ 520
Other noncurrent assets 1,195   $ 1,325
Sales and marketing 10 $ 0  
Research and development $ 130 $ 130  
XML 75 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jul. 31, 2022
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]          
Related party transaction, Term   3 years      
Future minimum lease liability payment due     $ 15,911    
Operating lease payments     166 $ 161  
Operating lease cost     $ 360 191  
UMD and Duke [Member]          
Related Party Transaction [Line Items]          
Operating lease, discount rate     11.90%    
Operating lease term     7 years 8 months 12 days   7 years 10 months 24 days
Future minimum lease liability payment due     $ 6,200    
Operating lease payments     200 200  
Operating lease cost     200 $ 200  
UMD [Member]          
Related Party Transaction [Line Items]          
Related party transaction, amounts of transaction   $ 14,000      
Related party transaction, estimated price     $ 12,600    
Transaction price $ 700        
Contractual obligation   1,400      
Contractual obligation including pledge to establish endowed professorship contribution   $ 1,000      
XML 76 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Geographic Information - Additional Information (Detail)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
UNITED STATES | Geographic Concentration Risk [Member] | Revenue Benchmark [Member]    
Revenue From Contract With Customer Percentage 86.00% 87.00%
XML 77 d246263d10q_htm.xml IDEA: XBRL DOCUMENT 0001824920 2023-01-01 2023-03-31 0001824920 2022-01-01 2022-03-31 0001824920 2023-03-31 0001824920 2020-08-31 0001824920 2019-11-30 0001824920 2022-12-31 0001824920 2022-01-01 2022-12-31 0001824920 2023-05-04 0001824920 2021-09-01 2021-09-30 0001824920 2021-12-31 0001824920 2022-03-31 0001824920 ionq:BilledAccountsReceivableMember 2023-03-31 0001824920 ionq:UnbilledAccountsReceivableMember 2023-03-31 0001824920 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001824920 ionq:QuantumComputingSystemMember 2023-03-31 0001824920 ionq:MachineryEquipmentFurnitureAndFixturesMember 2023-03-31 0001824920 us-gaap:ComputerEquipmentMember 2023-03-31 0001824920 ionq:UMDAndDukeMember 2023-03-31 0001824920 ionq:PublicWarrantsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 ionq:AccountingStandardsCodification606Member 2023-03-31 0001824920 ionq:TwoThousandsAndTwentyOneEquityIncentivePlanMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001824920 srt:MinimumMember ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceTwoMember 2023-03-31 0001824920 srt:MinimumMember ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceOneMember 2023-03-31 0001824920 ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceTwoMember 2023-03-31 0001824920 ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceOneMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2023-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0001824920 us-gaap:MunicipalBondsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember 2023-03-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-03-31 0001824920 us-gaap:MunicipalBondsMember 2023-03-31 0001824920 ionq:CorporateNotesAndBondsMember 2023-03-31 0001824920 us-gaap:CommercialPaperMember 2023-03-31 0001824920 ionq:CashAndMoneyMarketFundsMember 2023-03-31 0001824920 ionq:CapitalizedCommissionsMember 2023-03-31 0001824920 ionq:DukeMember 2023-03-31 0001824920 ionq:BilledAccountsReceivableMember 2022-12-31 0001824920 ionq:UnbilledAccountsReceivableMember 2022-12-31 0001824920 ionq:MachineryEquipmentFurnitureAndFixturesMember 2022-12-31 0001824920 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001824920 ionq:QuantumComputingSystemMember 2022-12-31 0001824920 us-gaap:ComputerEquipmentMember 2022-12-31 0001824920 ionq:UMDAndDukeMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 ionq:CashAndMoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2022-12-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 ionq:CorporateNotesAndBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherLongTermInvestmentsMember 2022-12-31 0001824920 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2022-12-31 0001824920 us-gaap:MunicipalBondsMember 2022-12-31 0001824920 ionq:CorporateNotesAndBondsMember 2022-12-31 0001824920 us-gaap:CommercialPaperMember 2022-12-31 0001824920 ionq:CashAndMoneyMarketFundsMember 2022-12-31 0001824920 ionq:CapitalizedCommissionsMember 2022-12-31 0001824920 ionq:DukeMember 2022-12-31 0001824920 ionq:UMDAndDukeMember 2023-01-01 2023-03-31 0001824920 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001824920 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001824920 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001824920 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001824920 ionq:PublicWarrantsMember 2023-01-01 2023-03-31 0001824920 ionq:UnvestedCommonStockMember 2023-01-01 2023-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001824920 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001824920 ionq:TwoThousandsAndFifteenEquityIncentivePlanMember 2023-01-01 2023-03-31 0001824920 ionq:CapitalizedStockbasedCompensationIntangiblesAndFixedAssetsMember 2023-01-01 2023-03-31 0001824920 ionq:StockbasedCompensationNetOfAmountsCapitalizedMember 2023-01-01 2023-03-31 0001824920 ionq:QuantumComputingSystemMember 2023-01-01 2023-03-31 0001824920 srt:MaximumMember ionq:MachineryEquipmentFurnitureAndFixturesMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember ionq:MachineryEquipmentFurnitureAndFixturesMember 2023-01-01 2023-03-31 0001824920 srt:MaximumMember us-gaap:ComputerEquipmentMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember us-gaap:ComputerEquipmentMember 2023-01-01 2023-03-31 0001824920 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-03-31 0001824920 ionq:OptionAgreementMember 2023-01-01 2023-03-31 0001824920 ionq:OptionAgreementMember ionq:DukeMember 2023-01-01 2023-03-31 0001824920 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001824920 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2023-01-01 2023-03-31 0001824920 ionq:InternallyDevelopedSoftwareCostsMember 2023-01-01 2023-03-31 0001824920 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-01-01 2023-03-31 0001824920 srt:MinimumMember ionq:NonConvertibleDebtSecuritiesMember 2023-01-01 2023-03-31 0001824920 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001824920 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001824920 ionq:EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001824920 ionq:PublicWarrantsMember 2023-01-01 2023-03-31 0001824920 ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceTwoMember 2023-01-01 2023-03-31 0001824920 ionq:PublicWarrantsMember us-gaap:CommonClassAMember ionq:RedemptionPriceOneMember 2023-01-01 2023-03-31 0001824920 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001824920 us-gaap:SalesRevenueNetMember 2023-01-01 2023-03-31 0001824920 ionq:UMDMember 2023-01-01 2023-03-31 0001824920 ionq:CapitalizedCommissionsMember 2023-01-01 2023-03-31 0001824920 ionq:DukeMember 2023-01-01 2023-03-31 0001824920 ionq:AccountingStandardsCodification606Member 2023-01-01 2023-03-31 0001824920 srt:MaximumMember ionq:TwoThousandsAndTwentyOneEquityIncentivePlanMember 2023-01-01 2023-03-31 0001824920 ionq:UMDAndDukeMember 2022-01-01 2022-03-31 0001824920 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001824920 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001824920 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001824920 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001824920 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001824920 ionq:PublicWarrantsMember 2022-01-01 2022-03-31 0001824920 ionq:UnvestedCommonStockMember 2022-01-01 2022-03-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001824920 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001824920 ionq:CapitalizedStockbasedCompensationIntangiblesAndFixedAssetsMember 2022-01-01 2022-03-31 0001824920 ionq:StockbasedCompensationNetOfAmountsCapitalizedMember 2022-01-01 2022-03-31 0001824920 ionq:OptionAgreementMember ionq:DukeMember 2022-01-01 2022-03-31 0001824920 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001824920 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001824920 ionq:InternallyDevelopedSoftwareCostsMember 2022-01-01 2022-03-31 0001824920 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-03-31 0001824920 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001824920 ionq:QuantumComputerSystemsMember 2022-01-01 2022-03-31 0001824920 us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0001824920 ionq:CapitalizedCommissionsMember 2022-01-01 2022-03-31 0001824920 ionq:DukeMember 2022-01-01 2022-03-31 0001824920 us-gaap:CommonStockMember ionq:AmendedLicenseAgreementMember ionq:UniversityOfMarylandMember 2021-02-01 2021-02-01 0001824920 ionq:AmendedLicenseAgreementMember ionq:UniversityOfMarylandMember 2021-02-01 0001824920 us-gaap:CommonStockMember ionq:AmendedOptionAgreementMember ionq:DukeMember 2020-01-01 2020-12-31 0001824920 ionq:PublicWarrantsMember 2021-09-30 0001824920 ionq:UMDMember 2021-09-30 0001824920 ionq:TwoThousandsAndTwentyOneEquityIncentivePlanMember 2023-01-01 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001824920 ionq:EmployeeStockPurchasePlanMember 2021-08-31 0001824920 ionq:EmployeeStockPurchasePlanMember 2021-08-31 2021-08-31 0001824920 ionq:UMDMember 2022-07-31 2022-07-31 0001824920 ionq:OptionAgreementMember ionq:UniversityOfMarylandMember 2016-01-01 2016-12-31 0001824920 ionq:OptionAgreementMember ionq:UniversityOfMarylandMember 2016-12-31 0001824920 us-gaap:PatentsMember ionq:OptionAgreementMember ionq:InitialPatentsReceivedMember ionq:UniversityOfMarylandAndDukeMember 2016-07-01 2016-07-31 0001824920 ionq:UMDMember 2021-09-01 2021-09-30 0001824920 us-gaap:CommonStockMember 2022-12-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001824920 us-gaap:RetainedEarningsMember 2022-12-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001824920 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001824920 us-gaap:CommonStockMember 2023-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001824920 us-gaap:RetainedEarningsMember 2023-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001824920 us-gaap:CommonStockMember 2021-12-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001824920 us-gaap:RetainedEarningsMember 2021-12-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001824920 us-gaap:CommonStockMember 2022-03-31 0001824920 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001824920 us-gaap:RetainedEarningsMember 2022-03-31 0001824920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 iso4217:USD shares pure utr:Year utr:Day iso4217:USD shares ionq:Segment ionq:Customers false Q1 0001824920 --12-31 MD 10-Q true 2023-03-31 2023 false 001-39694 IONQ, INC. DE 85-2992192 4505 Campus Drive College Park 20740 301 298-7997 Common stock, par value $0.0001 per share Warrants, each exercisable for one share of common stock for $11.50 per share IONQ IONQ WS NYSE NYSE Yes Yes Non-accelerated Filer true true false false 201028320 P1Y 51901000 44367000 335966000 311430000 1837000 3292000 12638000 12539000 402342000 371628000 137646000 182001000 26488000 26014000 5796000 3753000 10051000 8944000 742000 742000 4857000 4910000 587922000 597992000 3597000 3055000 9414000 6655000 610000 591000 6294000 8729000 945000 1130000 20860000 20160000 5624000 3459000 954000 1201000 741000 839000 7429000 3819000 77000 303000 35685000 29781000 0.0001 0.0001 1000000000 1000000000 200122686 200122686 199862123 199862123 20000 20000 779286000 769848000 -221640000 -194302000 -5429000 -7355000 552237000 568211000 587922000 597992000 4285000 1953000 1036000 568000 16233000 7338000 2667000 1871000 10581000 9194000 1791000 1266000 32308000 20237000 -28023000 -18284000 3610000 -13448000 4231000 608000 64000 1000 -27338000 -4227000 0 0 -27338000 -4227000 -0.14 -0.14 -0.02 -0.02 200112855 200112855 196183247 196183247 -27338000 -4227000 1926000 -4540000 1926000 -4540000 -25412000 -8767000 199862123 20000 769848000 -194302000 -7355000 568211000 -27338000 -27338000 1926000 1926000 131492 52000 52000 125341 282000 282000 3730 9104000 9104000 200122686 20000 779286000 -221640000 -5429000 552237000 195630975 19000 737150000 -145791000 -148000 591230000 -4227000 -4227000 -4540000 -4540000 453225 1000 131000 132000 139511 316000 316000 168750 6848000 6848000 1487 24000 24000 196393948 20000 744469000 -150018000 -4688000 589783000 -27338000 -4227000 1791000 1266000 130000 130000 10268000 6672000 3610000 -13448000 1570000 490000 -2044000 -138000 939000 -1516000 728000 -291000 920000 1571000 -3271000 -1058000 188000 103000 -13815000 -8324000 1185000 2672000 843000 457000 318000 134000 64430000 311235000 88091000 10400000 21315000 -304098000 52000 132000 -18000 16000 34000 148000 7534000 -312274000 46367000 399025000 53901000 86751000 153000 1007000 216000 86000 2239000 0 0 8000 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. DESCRIPTION OF BUSINESS </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IonQ, Inc. (“IonQ” or “the Company”), formerly known as dMY Technology Group, Inc. III (“dMY”), was incorporated in the state of Delaware in September 2020 and formed as a special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. IonQ Quantum, Inc. (formerly known as IonQ, Inc., and referred to as “Legacy IonQ” herein), was incorporated in the state of Delaware in September 2015 and is headquartered in College Park, Maryland. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 7, 2021, Legacy IonQ entered into an Agreement and Plan of Merger (the “Merger Agreement”) with dMY and Ion Trap Acquisition Inc. (“Merger Sub”), a direct, wholly owned subsidiary of dMY. Pursuant to the Merger Agreement, on September 30, 2021 (“the Closing Date”), the Merger Sub was merged with and into Legacy IonQ with Legacy IonQ continuing as the surviving corporation following the Merger, becoming a wholly owned subsidiary of dMY and the separate corporate existence of the Merger Sub ceased (the “Business Combination”). Commensurate with the Business Combination, dMY changed its name to IonQ, Inc. and Legacy IonQ changed its name to IonQ Quantum, Inc. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> to the “Company” and “IonQ” refer to the consolidated operations of IonQ, Inc. subsequent to the Business Combination. References to “dMY” refer to the company prior to the consummation of the Business Combination and references to “Legacy IonQ” refer to IonQ, Inc. prior to the consummation of the Business Combination. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IonQ is engaged in quantum computing and develops general-purpose quantum computing systems designed to solve some of the world’s most complex problems, and transform business, society, and the planet for the better. To operate the quantum computing systems, the Company has developed custom hardware, custom firmware, and an operating system to orchestrate the quantum computers. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Business Combination </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the legal acquirer in the Merger Agreement is dMY, for financial accounting and reporting purposes under accounting principles generally accepted in the United States of America (“U.S. GAAP”), Legacy IonQ is the accounting acquirer and the merger is accounted for as a “reverse recapitalization” (i.e., a capital transaction involving the issuance of stock by dMY for the stock of Legacy IonQ). </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For accounting purposes, the Business Combination was treated as the equivalent of Legacy IonQ issuing stock for the net assets of dMY, accompanied by a recapitalization. The net assets of dMY are stated at historical cost, and no goodwill or other intangible assets were recorded. Because Legacy IonQ was deemed the accounting acquirer in the Business Combination, the historical financial statements of Legacy IonQ are the historical financial statements of the Company upon the consummation of the Business Combination. As a result, the condensed consolidated financial statements included in this report reflect: (i) the historical operating results of Legacy IonQ prior to the Business Combination; (ii) the combined results of dMY and Legacy IonQ following the close of the Business Combination on September 30, 2021; and (iii) the assets and liabilities of Legacy IonQ stated at their historical cost. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with guidance applicable to these circumstances, the equity structure has been retroactively restated in all comparative periods to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Legacy IonQ’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy IonQ convertible redeemable preferred stock and warrants and Legacy IonQ common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination. Legacy IonQ’s convertible redeemable preferred stock and warrants previously classified as mezzanine equity were retroactively adjusted, converted into common stock, and reclassified to permanent equity because of the reverse recapitalization. All exercise prices for stock options and customer warrants have similarly been retroactively restated to reflect the exchange ratio established in the Business Combination. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Segment Reporting </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates as <div style="letter-spacing: 0px; top: 0px;;display:inline;">one</div> operating segment as its chief executive officer, who is the chief operating decision maker, reviews financial information on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. </div> 0.0001 0.0001 1 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Significant Accounting Policies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022, and the notes thereto are included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Preparation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP as determined by the Financial Accounting Standards Board (“FASB”). Such condensed consolidated financial statements include the accounts of IonQ and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Unaudited Interim Financial Information </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated financial statements included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared by the Company and are unaudited, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> comply with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for a quarterly report and are adequate to make the information presented not misleading. The interim condensed consolidated financial statements included herein reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022, included in the Annual Report. The condensed consolidated statements of operations and the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2023, are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023, or thereafter. All references to March 31, 2023 and 2022, in the notes to the condensed consolidated financial statements are unaudited. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Emerging Growth Company </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company remains an emerging growth company until the earliest of (i) December 31, 2025, (ii) the last day of the fiscal year in which the Company has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the Company is deemed to be a large accelerated filer, which means the market value of the Company’s common stock that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700.0 million as of the prior June 30th or (iv) the date on which the Company has issued more than $1.0 billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities during the prior three-year period. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP and the rules and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant estimates and judgments are inherent in the analysis and measurement of items including, but not limited to: revenue recognition, capitalization of internally developed software and quantum computing costs, useful lives of long-lived assets, and fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. Management bases its estimates and assumptions on historical experience, expectations, forecasts, and on various other factors that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ and be affected by changes in those estimates. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates the fair value of certain assets and liabilities using the fair value hierarchy. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 1—Observable inputs, which include quoted prices in active markets; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 2—Observable inputs other than the quoted prices in active markets that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs such as broker quotes, benchmark yield curves, credit spreads and market interest rates for similar securities that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 3—Unobservable inputs that are supported by little or no market activity and that are based on management’s assumptions, including fair value measurements determined using pricing models, discounted cash flow methodologies or similar techniques. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For assets that are measured using quoted prices in active markets, the total fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Assets and liabilities that are measured at fair value on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> basis include property and equipment, intangible assets, and goodwill. The Company recognizes these items at fair value when they are considered to be impaired or upon initial recognition when acquired through a business combination or an asset acquisition. The fair value of these assets and liabilities are determined with valuation techniques using the best information available and may include quoted market prices, market comparables and discounted cash flow models. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Due to their short-term nature, the carrying amounts reported in the Company’s condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash in banks, checking deposits, money market funds, and commercial paper. The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Restricted cash collateralizing letters of credit is included in other noncurrent assets in the condensed consolidated balance sheets. The Company issues letters of credits in the ordinary course of business, including for lease arrangements. As of both March 31, 2023 and December 31, 2022, letters of credit totaling </div>$2.0 million were outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:6%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:6%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Allowance for Credit Losses </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Accounts receivable are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and represent amounts billed and currently due from customers at the gross invoiced amount as well as unbilled amounts related to unconditional rights for consideration to be received for services performed but not yet invoiced. A receivable is recorded when the Company has an unconditional right to receive payment. Accounts receivable consists of the following at (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Billed accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unbilled accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,142</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,837</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,292</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance for credit losses. This assessment is based on management’s evaluation of relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the receivable. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Materials and Supplies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Materials and supplies are carried at average cost and recorded in prepaid expenses and other current assets in the condensed consolidated balance sheets. Materials and supplies used in the production of quantum computing systems to be made commercially available are capitalized to property and equipment when installed. Materials and supplies used for maintenance or research and development efforts are expensed when consumed. The Company capitalized $0.8 million of materials and supplies to property and equipment for the three months ended March 31, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Investments </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">Management determines the appropriate classification of investments at the time of purchase based upon management’s intent with regard to such investments. The Company primarily invests in debt securities and classifies its investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at the time of purchase if they are available to support either current or future operations. This classification is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> at each balance sheet date. Investments not considered cash equivalents, with remaining contractual maturities of one year or less from the balance sheet date are classified as short-term investments, and those with remaining contractual maturities greater than one year from the balance sheet date are classified as long-term investments. All investments are recorded at their estimated fair value, and any unrealized gains and losses are recorded in accumulated other comprehensive loss. Realized gains and losses on sales and maturities of investments are determined based on the specific identification method and are recognized in the condensed consolidated statements of operations in other income (expense), net. Accrued interest receivable on available-for-sale investments is recorded in the condensed consolidated balance sheet in prepaid expenses and other current assets. As of <div style="display:inline;">March 31, 2023</div> and December 31, 2022, accrued interest receivable was $1.8 million and $1.7 million, respectively. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company performs periodic evaluations to determine whether any declines in the fair value of investments below amortized cost are credit losses or impairments. The evaluation consists of qualitative and quantitative factors regarding the severity of the unrealized loss, as well as the Company’s ability and intent to hold the investments until a forecasted recovery occurs. Declines in fair value are considered to be credit losses if they are related to deterioration in credit risk or are considered impairments if it is likely that the underlying securities will be sold prior to a full recovery of their cost basis. Credit losses and impairments are determined based on the specific identification method and <div style="letter-spacing: 0px; top: 0px;;display:inline;">are</div> reported in other income (expense), net in the condensed consolidated statements of operations.</div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Property and Equipment, Net </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net is stated at cost less accumulated depreciation. Historical cost of fixed assets is the cost as of the date acquired. Hardware and labor costs associated with the building of quantum computing systems are capitalized. Costs <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> maintain quantum computing systems are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:51%"/> <td style="vertical-align:bottom;width:1%"/> <td style="width:48%"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Computer equipment and acquired computer software</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">3 – 5 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Machinery, equipment, furniture and fixtures</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">5 – 7 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Quantum computing systems</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">3 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Leasehold improvements</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">Shorter of the lease term or the estimated useful life of the related asset</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective October 1, 2022, the Company revised the accounting useful life of quantum computing systems, which was determined to be a change in accounting estimate and is being applied prospectively. This change in accounting estimate is not material for the three months ended March 31, 2023. The estimated useful life for quantum computing systems was previously 2 years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (“ROU”) assets and current operating lease liabilities and operating lease liabilities, net of current portion on the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has no financing lease arrangements. The Company recognizes lease expense for its operating leases on a straight-line basis over the term of the lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records a ROU asset and lease liability in connection with its operating leases. The Company’s lease portfolio is comprised primarily of real estate leases, which are accounted for as operating leases. The Company elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for all leases. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future minimum lease payments, including the impact of any lease incentives, as applicable, over the lease term. Amendments to a lease are assessed to determine if it represents a lease modification or a separate contract. Lease modifications are reassessed as of the effective date of the modification using an incremental borrowing rate based on the information available at the commencement date. For modified leases the Company also reassesses the lease classification as of the effective date of the modification. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate, because the interest rate implicit in the Company’s leases is not readily determinable. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s lease terms include periods under options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company considers contractual-based factors such as the nature and terms of the renewal or termination, asset-based factors such as physical location of the asset and entity-based factors such as the importance of the leased asset to the Company’s operations to determine the lease term. The Company generally uses the base <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> lease term when determining the ROU assets and lease liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Capitalized Internally Developed Software </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="null;text-indent: 0px;;display:inline;">Capitalized internally developed software, which is included in intangible assets, net, consists of costs to purchase and develop internal-use software, which the Company primarily uses to provide services to its customers. The costs to purchase and develop internal-use software are capitalized from the time that the preliminary project stage is completed, and it is considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Any costs incurred during subsequent efforts to upgrade and enhance the functionality of the software are also capitalized. Once this software is ready for its intended use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is typically assessed to be three years. During the three months ended March 31, 2023 and 2022, the Company capitalized $</div>1.3 million and $0.5 million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">internal-use</div> software costs, respectively. The Company amortized $0.5 million and $0.3 million of capitalized internally developed software costs during the three months ended March 31, 2023 and 2022, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Impairment of Long-Lived Assets </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets, such as property and equipment and other long-term assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent the carrying amount of the underlying asset exceeds its fair value. No impairment loss was recognized for the three months ended March 31, 2023 or 2022. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Warrant Liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">is then re-valued</div> upon exercise or at each reporting date for the unexercised warrants, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The warrants of dMY assumed in the Business Combination are classified as liabilities and remeasured at each reporting period (as more fully described in Note 10). The determination of the fair value of the warrant liabilities may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">classified as non-current liabilities as</div> their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company derives revenue from providing access to its quantum-computing-as-a-service (“QCaaS”), consulting services related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-developing</div> algorithms on the quantum computing systems, and from contracts associated with the design, development, and construction of specialized quantum computing systems together with related services. The Company applies the provisions of the FASB Accounting Standards Update (“ASU”), Revenue from Contracts with Customers (“ASC 606”), and all related applicable guidance. The core principle of ASC 606 is that an entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support this core principle, the Company applies the following five step approach: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">1.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identify the contract with the customer </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">2.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identify the performance obligations </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">3.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Determine the transaction price </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">4.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Allocate the transaction price to the performance obligations </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">5.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Recognize revenue when (or as) the entity satisfies a performance obligation </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has determined that its QCaaS contracts represent a combined, stand-ready performance obligation to provide access to its quantum computing systems together with related maintenance and support. The transaction price may consist of a variable fee based on usage of its quantum computing systems or a fixed fee for a minimum volume of usage to be made available over a defined period of access. Fixed fee arrangements may also include a variable component whereby customers pay an amount for usage over contractual minimums contained in the contracts. The Company has determined that contracts that contain consulting services related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to co-developing quantum</div> computing algorithms and the ability to use its quantum computing systems to run such algorithms represent a combined performance obligation that is satisfied over-time with revenue recognized based on the efforts incurred to date relative to the total expected effort. For contracts with a fixed transaction price, the fixed fee is recognized on a straight-line basis over the access period or associated measure of progress for the Company’s consulting services contracts. For contracts without fixed fees, variable usage fees are billed and recognized during the period of such usage. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the Company’s contracts contain multiple performance obligations, most commonly in contracts for specialized quantum computing systems together with related maintenance and support. Such contracts may also include access to the Company’s QCaaS. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. When there are multiple performance obligations in a contract, the Company allocates the transaction price to each performance obligation based on its standalone selling price when available. We determine standalone selling price based on the observable price of a product or service when we sell the products or services separately in similar circumstances and to similar customers. When the standalone selling price is not known, due to it being either highly variable or uncertain, the Company allocates the transaction price using the residual approach. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance obligations are satisfied over time if the customer receives the benefits as we perform the work, if the customer controls the asset as it is being produced (continuous transfer of control), or if the product being produced for the customer has no alternative use and we have a contractual right to payment for performance to date. Revenue is recognized on performance obligations satisfied over time based on the efforts incurred to date relative to the total expected effort. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2023 and 2022, all of the revenue recognized by the Company was recognized based on transfer of service over time. There were no revenues recognized at a point in time. In arrangements with cloud service providers, the cloud service provider is considered the customer and IonQ does not have any contractual relationships with the cloud service providers’ end users. For these arrangements, revenue is recognized at the amount charged to the cloud service provider and does not reflect any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> to the end user. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into multiple contracts with a single counterparty at or near the same time. The Company will combine contracts and account for them as a single contract when one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) consideration to be paid in one contract depends on the price or performance of the other contract; and (iii) goods or services promised are a single performance obligation. Consideration payable to a customer includes cash amounts that an entity pays, or expects to pay, to the customer. For arrangements that contain consideration payable to a customer, the Company uses judgment in determining whether such payments are a reduction of the transaction price or a payment to the customer for a distinct good or service. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variable fees associated with the QCaaS are generally billed a month in arrears. Customers also have the ability to make advance payments. If a contract exists under ASC 606, advance payments are recorded as a contract liability until services are delivered or obligations are met and revenue is earned. Contract liabilities to be recognized in the succeeding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period are classified as current and the remaining amounts are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities in the Company’s condensed consolidated balance sheets. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, approximately $30.4 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> contracts, including both funded (firm orders for which funding has been both authorized and appropriated by the customer) and unfunded (firm orders for which funding has not been appropriated) orders. The Company expects approximately 60% of the remaining performance obligations to be recognized as revenue within the next twelve months. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:89%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,930</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue recognized</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,446</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">New deferrals, net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">764</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,248</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For contractual arrangements where consideration is paid <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front,</div> the transfer of the quantum computing services is completed at the discretion of the customer as the customer chooses to use the services starting from the date of contract inception. As such, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of consideration does not represent a significant financing component. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets Recognized from Costs to Obtain a Contract</div></div> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales commissions paid to employees and third parties are considered incremental costs to obtain a contract with a customer. These costs are capitalized in the period a customer contract is executed and are amortized as an expense consistent with the transfer of the goods or services to the customer. Capitalized costs are recorded in prepaid expenses and other current assets and other noncurrent assets in the condensed consolidated balance sheets. Applying the practical expedient, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets is one year or less. As of March 31, 2023 and December 31, 2022, total capitalized costs were $0.9 million and $1.0 million, respectively. Amortization expense was $0.1 million and zero for the three months ended March 31, 2023 and 2022, respectively. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures and records the expense related to stock-based awards based on the fair value of those awards as determined on the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes-Merton (“Black- Scholes”) option-pricing model to determine the fair value of stock awards and the estimated fair value for stock options. The Black-Scholes option- pricing model requires the use of subjective assumptions, which determine the fair value of share-based awards, including the fair value of the Company’s common stock, the option’s expected term, the price volatility of the underlying common stock, risk-free interest rates, and the expected dividend yield of the common stock. The assumptions used to determine the fair value of the stock awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. The Company records forfeitures as they occur. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation cost for restricted stock units is measured based on the fair value of the Company’s common stock on the grant date. For awards with a performance-based vesting condition, the Company records stock-based compensation cost if it is probable that the performance condition will be achieved. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records stock-based compensation expense for incentive compensation liabilities based on estimated payments to employees for which the Company expects to settle the liability by granting restricted stock units. For these awards, stock-based compensation expense is accrued commencing at the service inception date, which generally precedes the grant date, through the end of the requisite service period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company obtained third-party valuations to estimate the fair value of its common stock for awards granted prior to the Business Combination, for purposes of measuring stock-based compensation expense. The third-party valuations were prepared using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants (“AICPA”) Accounting &amp;Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, investments, and trade accounts receivable. The Company maintains the majority of its cash, cash equivalents, restricted cash and investments with two financial institutions. The Company’s deposits routinely exceed amounts guaranteed by the Federal Deposit Insurance Corporation. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to limited credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s accounts receivable are derived from customers primarily located in the U.S. The Company performs periodic evaluations of its customers’ financial condition and generally does not require its customers to provide collateral or other security to support accounts receivable and maintains an allowance for credit losses. Credit losses historically have not been material. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant customers are those that represent more than 10% of the Company’s total revenue. The Company’s revenue was primarily from three significant customers for the three months ended March 31, 2023, and from two significant customers for the three months ended March 31, 2022. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div/><div> <div style="background-color:white;display: inline;"> </div> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Earnings (Loss) Per Share </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock during the period, plus common stock equivalents, outstanding during the period. If the Company reports a net loss, the computation of diluted loss per share excludes the effect of dilutive common stock equivalents, as their effect would be antidilutive. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:70%"/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:8%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Numerator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,338</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,227</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Denominator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200,112,855</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196,183,247</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders—basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.02</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted stock units, unvested common stock (including unvested restricted common stock) and warrants are excluded and diluted loss per share is equal to basic loss per share. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:74%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options outstanding</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,499,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,108,390</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301,202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301,202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,231,486</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,232,471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,077,343</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,310,471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842,454</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351,261</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47,952,453</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37,303,795</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Adopted Accounting Standards </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments—Credit Losses, along with various updates and improvements. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the first quarter of 2023, and it did not have a material effect on the condensed consolidated financial statements and related disclosures. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Issued Accounting Standards Not Yet Adopted </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt, Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its consolidated financial statements and related disclosures. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Significant Accounting Policies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s significant accounting policies, which are disclosed in the audited financial statements for the year ended December 31, 2022, and the notes thereto are included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the “Annual Report”) that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2023. Since the date of that filing, there have been no material changes to the Company’s significant accounting policies except as noted below. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Preparation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP as determined by the Financial Accounting Standards Board (“FASB”). Such condensed consolidated financial statements include the accounts of IonQ and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Unaudited Interim Financial Information </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated financial statements included in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared by the Company and are unaudited, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> comply with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for a quarterly report and are adequate to make the information presented not misleading. The interim condensed consolidated financial statements included herein reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. These interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2022, included in the Annual Report. The condensed consolidated statements of operations and the condensed consolidated statements of comprehensive loss for the three months ended March 31, 2023, are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2023, or thereafter. All references to March 31, 2023 and 2022, in the notes to the condensed consolidated financial statements are unaudited. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Emerging Growth Company </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, the Company’s condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company remains an emerging growth company until the earliest of (i) December 31, 2025, (ii) the last day of the fiscal year in which the Company has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the Company is deemed to be a large accelerated filer, which means the market value of the Company’s common stock that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700.0 million as of the prior June 30th or (iv) the date on which the Company has issued more than $1.0 billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities during the prior three-year period. </div> 1235000000 700000000 1000000000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP and the rules and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant estimates and judgments are inherent in the analysis and measurement of items including, but not limited to: revenue recognition, capitalization of internally developed software and quantum computing costs, useful lives of long-lived assets, and fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. Management bases its estimates and assumptions on historical experience, expectations, forecasts, and on various other factors that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ and be affected by changes in those estimates. </div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates the fair value of certain assets and liabilities using the fair value hierarchy. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 1—Observable inputs, which include quoted prices in active markets; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 2—Observable inputs other than the quoted prices in active markets that are observable either directly or indirectly, such as quoted prices in markets that are not active, or other inputs such as broker quotes, benchmark yield curves, credit spreads and market interest rates for similar securities that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level 3—Unobservable inputs that are supported by little or no market activity and that are based on management’s assumptions, including fair value measurements determined using pricing models, discounted cash flow methodologies or similar techniques. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s assessment of the significance of a particular input to the fair value measurements requires judgment and may affect the valuation of the assets and liabilities being measured and their placement within the fair value hierarchy. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For assets that are measured using quoted prices in active markets, the total fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are primarily valued by reference to quoted prices of similar assets or liabilities in active markets, adjusted for any terms specific to that asset or liability. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Assets and liabilities that are measured at fair value on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> basis include property and equipment, intangible assets, and goodwill. The Company recognizes these items at fair value when they are considered to be impaired or upon initial recognition when acquired through a business combination or an asset acquisition. The fair value of these assets and liabilities are determined with valuation techniques using the best information available and may include quoted market prices, market comparables and discounted cash flow models. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Due to their short-term nature, the carrying amounts reported in the Company’s condensed consolidated financial statements approximate the fair value for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Cash, Cash Equivalents and Restricted Cash </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash in banks, checking deposits, money market funds, and commercial paper. The Company considers all short-term highly liquid investments with an original maturity at the date of purchase of three months or less to be cash equivalents. Restricted cash collateralizing letters of credit is included in other noncurrent assets in the condensed consolidated balance sheets. The Company issues letters of credits in the ordinary course of business, including for lease arrangements. As of both March 31, 2023 and December 31, 2022, letters of credit totaling </div>$2.0 million were outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:6%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:6%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 2000000 2000000 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The following table provides a reconciliation of cash and restricted cash included in the condensed consolidated balance sheets to the amounts included in the condensed consolidated statements of cash flows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:6%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:6%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 51901000 44367000 2000000 2000000 53901000 46367000 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Allowance for Credit Losses </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Accounts receivable are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and represent amounts billed and currently due from customers at the gross invoiced amount as well as unbilled amounts related to unconditional rights for consideration to be received for services performed but not yet invoiced. A receivable is recorded when the Company has an unconditional right to receive payment. Accounts receivable consists of the following at (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Billed accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unbilled accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,142</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,837</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,292</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance for credit losses. This assessment is based on management’s evaluation of relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the receivable. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022. </div> Accounts receivable consists of the following at (in thousands): <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Billed accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unbilled accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">836</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,142</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accounts receivable</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,837</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,292</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 1001000 1150000 836000 2142000 1837000 3292000 0 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Materials and Supplies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Materials and supplies are carried at average cost and recorded in prepaid expenses and other current assets in the condensed consolidated balance sheets. Materials and supplies used in the production of quantum computing systems to be made commercially available are capitalized to property and equipment when installed. Materials and supplies used for maintenance or research and development efforts are expensed when consumed. The Company capitalized $0.8 million of materials and supplies to property and equipment for the three months ended March 31, 2023. </div> 800000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Investments </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">Management determines the appropriate classification of investments at the time of purchase based upon management’s intent with regard to such investments. The Company primarily invests in debt securities and classifies its investments as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> at the time of purchase if they are available to support either current or future operations. This classification is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> at each balance sheet date. Investments not considered cash equivalents, with remaining contractual maturities of one year or less from the balance sheet date are classified as short-term investments, and those with remaining contractual maturities greater than one year from the balance sheet date are classified as long-term investments. All investments are recorded at their estimated fair value, and any unrealized gains and losses are recorded in accumulated other comprehensive loss. Realized gains and losses on sales and maturities of investments are determined based on the specific identification method and are recognized in the condensed consolidated statements of operations in other income (expense), net. Accrued interest receivable on available-for-sale investments is recorded in the condensed consolidated balance sheet in prepaid expenses and other current assets. As of <div style="display:inline;">March 31, 2023</div> and December 31, 2022, accrued interest receivable was $1.8 million and $1.7 million, respectively. </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company performs periodic evaluations to determine whether any declines in the fair value of investments below amortized cost are credit losses or impairments. The evaluation consists of qualitative and quantitative factors regarding the severity of the unrealized loss, as well as the Company’s ability and intent to hold the investments until a forecasted recovery occurs. Declines in fair value are considered to be credit losses if they are related to deterioration in credit risk or are considered impairments if it is likely that the underlying securities will be sold prior to a full recovery of their cost basis. Credit losses and impairments are determined based on the specific identification method and <div style="letter-spacing: 0px; top: 0px;;display:inline;">are</div> reported in other income (expense), net in the condensed consolidated statements of operations.</div> 1800000 1700000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Property and Equipment, Net </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net is stated at cost less accumulated depreciation. Historical cost of fixed assets is the cost as of the date acquired. Hardware and labor costs associated with the building of quantum computing systems are capitalized. Costs <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> maintain quantum computing systems are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:51%"/> <td style="vertical-align:bottom;width:1%"/> <td style="width:48%"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Computer equipment and acquired computer software</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">3 – 5 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Machinery, equipment, furniture and fixtures</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">5 – 7 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Quantum computing systems</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">3 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Leasehold improvements</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">Shorter of the lease term or the estimated useful life of the related asset</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective October 1, 2022, the Company revised the accounting useful life of quantum computing systems, which was determined to be a change in accounting estimate and is being applied prospectively. This change in accounting estimate is not material for the three months ended March 31, 2023. The estimated useful life for quantum computing systems was previously 2 years. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:51%"/> <td style="vertical-align:bottom;width:1%"/> <td style="width:48%"/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Computer equipment and acquired computer software</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">3 – 5 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Machinery, equipment, furniture and fixtures</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">5 – 7 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Quantum computing systems</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">3 years</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top">Leasehold improvements</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap">Shorter of the lease term or the estimated useful life of the related asset</td></tr></table> P3Y P5Y P5Y P7Y P3Y Shorter of the lease term or the estimated useful life of the related asset P2Y <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (“ROU”) assets and current operating lease liabilities and operating lease liabilities, net of current portion on the Company’s condensed consolidated balance sheets. As of March 31, 2023, the Company has no financing lease arrangements. The Company recognizes lease expense for its operating leases on a straight-line basis over the term of the lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records a ROU asset and lease liability in connection with its operating leases. The Company’s lease portfolio is comprised primarily of real estate leases, which are accounted for as operating leases. The Company elected the practical expedient to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for all leases. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future minimum lease payments, including the impact of any lease incentives, as applicable, over the lease term. Amendments to a lease are assessed to determine if it represents a lease modification or a separate contract. Lease modifications are reassessed as of the effective date of the modification using an incremental borrowing rate based on the information available at the commencement date. For modified leases the Company also reassesses the lease classification as of the effective date of the modification. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate used to determine the present value of the future lease payments is the Company’s incremental borrowing rate, because the interest rate implicit in the Company’s leases is not readily determinable. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s lease terms include periods under options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company considers contractual-based factors such as the nature and terms of the renewal or termination, asset-based factors such as physical location of the asset and entity-based factors such as the importance of the leased asset to the Company’s operations to determine the lease term. The Company generally uses the base <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> lease term when determining the ROU assets and lease liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Capitalized Internally Developed Software </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="null;text-indent: 0px;;display:inline;">Capitalized internally developed software, which is included in intangible assets, net, consists of costs to purchase and develop internal-use software, which the Company primarily uses to provide services to its customers. The costs to purchase and develop internal-use software are capitalized from the time that the preliminary project stage is completed, and it is considered probable that the software will be used to perform the function intended, until the time the software is placed in service for its intended use. Any costs incurred during subsequent efforts to upgrade and enhance the functionality of the software are also capitalized. Once this software is ready for its intended use, these costs are amortized on a straight-line basis over the estimated useful life of the software, which is typically assessed to be three years. During the three months ended March 31, 2023 and 2022, the Company capitalized $</div>1.3 million and $0.5 million in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">internal-use</div> software costs, respectively. The Company amortized $0.5 million and $0.3 million of capitalized internally developed software costs during the three months ended March 31, 2023 and 2022, respectively. </div> P3Y 1300000 500000 500000 300000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Impairment of Long-Lived Assets </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets, such as property and equipment and other long-term assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent the carrying amount of the underlying asset exceeds its fair value. No impairment loss was recognized for the three months ended March 31, 2023 or 2022. </div> 0 0 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Warrant Liabilities </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">is then re-valued</div> upon exercise or at each reporting date for the unexercised warrants, with changes in the fair value reported in the condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. The warrants of dMY assumed in the Business Combination are classified as liabilities and remeasured at each reporting period (as more fully described in Note 10). The determination of the fair value of the warrant liabilities may be subject to change as more current information becomes available and accordingly the actual results could differ significantly. Derivative warrant liabilities are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">classified as non-current liabilities as</div> their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Revenue Recognition </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company derives revenue from providing access to its quantum-computing-as-a-service (“QCaaS”), consulting services related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-developing</div> algorithms on the quantum computing systems, and from contracts associated with the design, development, and construction of specialized quantum computing systems together with related services. The Company applies the provisions of the FASB Accounting Standards Update (“ASU”), Revenue from Contracts with Customers (“ASC 606”), and all related applicable guidance. The core principle of ASC 606 is that an entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support this core principle, the Company applies the following five step approach: </div> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">1.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identify the contract with the customer </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">2.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Identify the performance obligations </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">3.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Determine the transaction price </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">4.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Allocate the transaction price to the performance obligations </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">5.</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Recognize revenue when (or as) the entity satisfies a performance obligation </div> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has determined that its QCaaS contracts represent a combined, stand-ready performance obligation to provide access to its quantum computing systems together with related maintenance and support. The transaction price may consist of a variable fee based on usage of its quantum computing systems or a fixed fee for a minimum volume of usage to be made available over a defined period of access. Fixed fee arrangements may also include a variable component whereby customers pay an amount for usage over contractual minimums contained in the contracts. The Company has determined that contracts that contain consulting services related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to co-developing quantum</div> computing algorithms and the ability to use its quantum computing systems to run such algorithms represent a combined performance obligation that is satisfied over-time with revenue recognized based on the efforts incurred to date relative to the total expected effort. For contracts with a fixed transaction price, the fixed fee is recognized on a straight-line basis over the access period or associated measure of progress for the Company’s consulting services contracts. For contracts without fixed fees, variable usage fees are billed and recognized during the period of such usage. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the Company’s contracts contain multiple performance obligations, most commonly in contracts for specialized quantum computing systems together with related maintenance and support. Such contracts may also include access to the Company’s QCaaS. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when or as the performance obligation is satisfied. When there are multiple performance obligations in a contract, the Company allocates the transaction price to each performance obligation based on its standalone selling price when available. We determine standalone selling price based on the observable price of a product or service when we sell the products or services separately in similar circumstances and to similar customers. When the standalone selling price is not known, due to it being either highly variable or uncertain, the Company allocates the transaction price using the residual approach. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance obligations are satisfied over time if the customer receives the benefits as we perform the work, if the customer controls the asset as it is being produced (continuous transfer of control), or if the product being produced for the customer has no alternative use and we have a contractual right to payment for performance to date. Revenue is recognized on performance obligations satisfied over time based on the efforts incurred to date relative to the total expected effort. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2023 and 2022, all of the revenue recognized by the Company was recognized based on transfer of service over time. There were no revenues recognized at a point in time. In arrangements with cloud service providers, the cloud service provider is considered the customer and IonQ does not have any contractual relationships with the cloud service providers’ end users. For these arrangements, revenue is recognized at the amount charged to the cloud service provider and does not reflect any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-up</div> to the end user. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter into multiple contracts with a single counterparty at or near the same time. The Company will combine contracts and account for them as a single contract when one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) consideration to be paid in one contract depends on the price or performance of the other contract; and (iii) goods or services promised are a single performance obligation. Consideration payable to a customer includes cash amounts that an entity pays, or expects to pay, to the customer. For arrangements that contain consideration payable to a customer, the Company uses judgment in determining whether such payments are a reduction of the transaction price or a payment to the customer for a distinct good or service. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The variable fees associated with the QCaaS are generally billed a month in arrears. Customers also have the ability to make advance payments. If a contract exists under ASC 606, advance payments are recorded as a contract liability until services are delivered or obligations are met and revenue is earned. Contract liabilities to be recognized in the succeeding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period are classified as current and the remaining amounts are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities in the Company’s condensed consolidated balance sheets. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, approximately $30.4 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> contracts, including both funded (firm orders for which funding has been both authorized and appropriated by the customer) and unfunded (firm orders for which funding has not been appropriated) orders. The Company expects approximately 60% of the remaining performance obligations to be recognized as revenue within the next twelve months. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:89%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,930</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue recognized</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,446</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">New deferrals, net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">764</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,248</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For contractual arrangements where consideration is paid <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front,</div> the transfer of the quantum computing services is completed at the discretion of the customer as the customer chooses to use the services starting from the date of contract inception. As such, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of consideration does not represent a significant financing component. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assets Recognized from Costs to Obtain a Contract</div></div> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales commissions paid to employees and third parties are considered incremental costs to obtain a contract with a customer. These costs are capitalized in the period a customer contract is executed and are amortized as an expense consistent with the transfer of the goods or services to the customer. Capitalized costs are recorded in prepaid expenses and other current assets and other noncurrent assets in the condensed consolidated balance sheets. Applying the practical expedient, the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets is one year or less. As of March 31, 2023 and December 31, 2022, total capitalized costs were $0.9 million and $1.0 million, respectively. Amortization expense was $0.1 million and zero for the three months ended March 31, 2023 and 2022, respectively. </div> 30400000 0.60 twelve months <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in unearned revenue for the three months ended March 31, 2023 (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:89%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,930</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue recognized</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,446</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">New deferrals, net</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">764</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,248</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 9930000 3446000 764000 7248000 900000 1000000 100000 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures and records the expense related to stock-based awards based on the fair value of those awards as determined on the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes-Merton (“Black- Scholes”) option-pricing model to determine the fair value of stock awards and the estimated fair value for stock options. The Black-Scholes option- pricing model requires the use of subjective assumptions, which determine the fair value of share-based awards, including the fair value of the Company’s common stock, the option’s expected term, the price volatility of the underlying common stock, risk-free interest rates, and the expected dividend yield of the common stock. The assumptions used to determine the fair value of the stock awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. The Company records forfeitures as they occur. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation cost for restricted stock units is measured based on the fair value of the Company’s common stock on the grant date. For awards with a performance-based vesting condition, the Company records stock-based compensation cost if it is probable that the performance condition will be achieved. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records stock-based compensation expense for incentive compensation liabilities based on estimated payments to employees for which the Company expects to settle the liability by granting restricted stock units. For these awards, stock-based compensation expense is accrued commencing at the service inception date, which generally precedes the grant date, through the end of the requisite service period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company obtained third-party valuations to estimate the fair value of its common stock for awards granted prior to the Business Combination, for purposes of measuring stock-based compensation expense. The third-party valuations were prepared using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants (“AICPA”) Accounting &amp;Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, investments, and trade accounts receivable. The Company maintains the majority of its cash, cash equivalents, restricted cash and investments with two financial institutions. The Company’s deposits routinely exceed amounts guaranteed by the Federal Deposit Insurance Corporation. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to limited credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s accounts receivable are derived from customers primarily located in the U.S. The Company performs periodic evaluations of its customers’ financial condition and generally does not require its customers to provide collateral or other security to support accounts receivable and maintains an allowance for credit losses. Credit losses historically have not been material. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant customers are those that represent more than 10% of the Company’s total revenue. The Company’s revenue was primarily from three significant customers for the three months ended March 31, 2023, and from two significant customers for the three months ended March 31, 2022. </div> 0.10 3 2 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Earnings (Loss) Per Share </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock during the period, plus common stock equivalents, outstanding during the period. If the Company reports a net loss, the computation of diluted loss per share excludes the effect of dilutive common stock equivalents, as their effect would be antidilutive. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:70%"/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:8%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Numerator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,338</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,227</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Denominator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200,112,855</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196,183,247</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders—basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.02</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In periods with a reported net loss, the effect of anti-dilutive stock options, unvested restricted stock units, unvested common stock (including unvested restricted common stock) and warrants are excluded and diluted loss per share is equal to basic loss per share. The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:74%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options outstanding</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,499,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,108,390</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301,202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301,202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,231,486</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,232,471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,077,343</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,310,471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842,454</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351,261</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47,952,453</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37,303,795</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted loss per share attributable to common stockholders (in thousands, except share and per share data): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:70%"/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:8%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Numerator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27,338</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,227</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Denominator:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200,112,855</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">196,183,247</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders—basic and diluted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.02</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> </table> -27338000 -4227000 200112855 200112855 196183247 196183247 -0.14 -0.14 -0.02 -0.02 The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:74%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options outstanding</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,499,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,108,390</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301,202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301,202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,231,486</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,232,471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,077,343</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,310,471</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842,454</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351,261</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">47,952,453</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">37,303,795</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 24499968 21108390 8301202 8301202 5231486 5232471 9077343 1310471 842454 1351261 47952453 37303795 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Adopted Accounting Standards </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> Financial Instruments—Credit Losses, along with various updates and improvements. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the first quarter of 2023, and it did not have a material effect on the condensed consolidated financial statements and related disclosures. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recently Issued Accounting Standards Not Yet Adopted </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt, Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its consolidated financial statements and related disclosures. </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. CASH, CASH EQUIVALENTS, RESTRICTED CASH AND INVESTMENTS </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company’s unrealized gains and losses and estimated fair value of cash, cash equivalents, restricted cash and investments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities recorded in the condensed consolidated balance sheets (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:44%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AS OF MARCH 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AS OF DECEMBER 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121,151</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(198</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,955</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,141</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(443</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">263,876</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,761</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,221</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277,184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,993</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271,210</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,935</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,905</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(273</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,632</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(453</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,556</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(688</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82,891</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash, cash equivalents, restricted cash and investments</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">532,942</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,625</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">527,513</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">547,153</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,397</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">539,798</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized losses related to investments were primarily a result of interest rate fluctuations. The following table presents information about the Company’s investments in available-for-sale securities with gross unrealized losses and the length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2023 (in thousands).</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 43%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March 31, 2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12 Months or Longer</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Unrealized<br/>Losses</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Unrealized<br/>Losses</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Unrealized<br/>Loses</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,326</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(198</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,326</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(198</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">91,968</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,237</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">138,518</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,524</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">230,486</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,761</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal bonds</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,951</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(31</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,771</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(182</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,722</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(213</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US government and agency</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,124</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(83</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,123</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(370</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,247</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(453</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">201,369</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,549</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">155,412</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,076</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">356,781</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,625</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no securities in a gross unrealized loss position for greater than 12 months as of December 31, 2022. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company did not have any allowance for credit losses as of either March 31, 2023 or December 31, 2022. The Company does not intend or believe it is more likely than not, that it will be required to sell the investments in an unrealized loss position before the recovery of the associated amortized cost basis. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the Company’s cash, cash equivalents, restricted cash and investments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities as of March 31, 2023, aggregated by investment category and classified by contractual maturity date, is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 84%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:70%"/> <td style="vertical-align:bottom;width:3%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:3%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:3%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1 Year<br/> or Less</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1 Year<br/> or Greater</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,955</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,955</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,871</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,221</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,775</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">387,867</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,646</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">527,513</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company’s unrealized gains and losses and estimated fair value of cash, cash equivalents, restricted cash and investments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities recorded in the condensed consolidated balance sheets (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:44%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AS OF MARCH 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">AS OF DECEMBER 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121,151</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(198</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,955</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130,141</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(443</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">263,876</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">106</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,761</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,221</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277,184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,993</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271,210</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,935</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(213</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,905</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(273</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,632</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,968</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(453</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,556</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(688</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82,891</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total cash, cash equivalents, restricted cash and investments</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">532,942</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">196</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,625</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">527,513</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">547,153</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">42</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,397</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">539,798</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 51012000 0 0 51012000 46367000 0 0 46367000 121151000 2000 198000 120955000 130141000 0 443000 129698000 263876000 106000 4761000 259221000 277184000 19000 5993000 271210000 9935000 0 213000 9722000 9905000 0 273000 9632000 86968000 88000 453000 86603000 83556000 23000 688000 82891000 532942000 196000 5625000 527513000 547153000 42000 7397000 539798000 The following table presents information about the Company’s investments in available-for-sale securities with gross unrealized losses and the length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2023 (in thousands).<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 43%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="22" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March 31, 2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less than 12 Months</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12 Months or Longer</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Unrealized<br/>Losses</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Unrealized<br/>Losses</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross Unrealized<br/>Loses</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial paper</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,326</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(198</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,326</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(198</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">91,968</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1,237</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">138,518</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3,524</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">230,486</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4,761</div></td> <td style="vertical-align: bottom; white-space: nowrap;">)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal bonds</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,951</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(31</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4,771</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(182</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9,722</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(213</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">US government and agency</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,124</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(83</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">12,123</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(370</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">41,247</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(453</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">201,369</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,549</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">155,412</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,076</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">356,781</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,625</div></div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> 75326000 198000 0 0 75326000 198000 91968000 1237000 138518000 3524000 230486000 4761000 4951000 31000 4771000 182000 9722000 213000 29124000 83000 12123000 370000 41247000 453000 201369000 1549000 155412000 4076000 356781000 5625000 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The estimated fair value of the Company’s cash, cash equivalents, restricted cash and investments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities as of March 31, 2023, aggregated by investment category and classified by contractual maturity date, is as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 84%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:70%"/> <td style="vertical-align:bottom;width:3%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:3%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:3%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1 Year<br/> or Less</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1 Year<br/> or Greater</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and money market funds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,955</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,955</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,871</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259,221</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,775</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">387,867</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,646</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">527,513</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 49012000 2000000 51012000 120955000 0 120955000 148350000 110871000 259221000 9722000 0 9722000 59828000 26775000 86603000 387867000 139646000 527513000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. FAIR VALUE MEASUREMENTS </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:72%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of<br/> March 31, 2023:</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Cash and money market funds<div style="font-size: 10px; vertical-align: top;;display:inline;">(1)</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118,066</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118,066</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">335,966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">335,966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,871</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,871</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,775</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,775</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,646</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,646</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">476,501</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">527,513</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,429</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,429</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:72%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of<br/> December 31, 2022:</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Cash and money market funds<div style="font-size: 10px; vertical-align: top;;display:inline;">(1)</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,447</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,447</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,911</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,911</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">311,430</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">311,430</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,517</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,517</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">493,431</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">539,798</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,819</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,819</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes money market funds associated with the Company’s overnight investment sweep account and collateralized letter of credit. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2 and 3 are r<div style="letter-spacing: 0px; top: 0px;;display:inline;">ec</div>ognized at the beginning of the reporting period. There were no transfers between levels during the period. On March 31, 2023, the closing trading price of the public warrants was $1.42 per warrant. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:72%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of<br/> March 31, 2023:</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Cash and money market funds<div style="font-size: 10px; vertical-align: top;;display:inline;">(1)</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,889</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,901</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118,066</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118,066</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148,350</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,722</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,828</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">335,966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">335,966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,871</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,871</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,775</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,775</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,646</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,646</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,012</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">476,501</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">527,513</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,429</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,429</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:72%"/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:2%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measured as of<br/> December 31, 2022:</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Cash and money market funds<div style="font-size: 10px; vertical-align: top;;display:inline;">(1)</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents and restricted cash</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,447</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120,447</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,911</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,911</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56,374</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">311,430</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">311,430</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term investments:</div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate notes and bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">150,763</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Municipal bonds</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">US government and agency</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,517</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,517</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term investments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">182,001</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,367</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">493,431</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">539,798</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,819</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,819</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes money market funds associated with the Company’s overnight investment sweep account and collateralized letter of credit. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> 51012000 51012000 2889000 2889000 51012000 2889000 53901000 118066000 118066000 148350000 148350000 9722000 9722000 59828000 59828000 335966000 335966000 110871000 110871000 26775000 26775000 137646000 137646000 51012000 476501000 527513000 7429000 7429000 46367000 46367000 46367000 0 46367000 129698000 129698000 120447000 120447000 4911000 4911000 56374000 56374000 311430000 311430000 150763000 150763000 4721000 4721000 26517000 26517000 182001000 182001000 46367000 493431000 539798000 3819000 3819000 1.42 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. PROPERTY AND EQUIPMENT, NET </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net is composed of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment and acquired computer software</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,707</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,407</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery, equipment, furniture and fixtures</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,747</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,506</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,193</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Quantum computing systems</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,532</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,430</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Gross property and equipment</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35,179</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,475</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,691</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,461</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Property and equipment, net</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,488</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,014</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"/> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.2 million and $1.0 million, respectively. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net is composed of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment and acquired computer software</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,707</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,407</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery, equipment, furniture and fixtures</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,747</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,506</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,193</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,132</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Quantum computing systems</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,532</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,430</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Gross property and equipment</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35,179</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">33,475</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,691</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,461</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Property and equipment, net</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,488</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">26,014</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear:both;max-height:0pt;"/> 2707000 2407000 7747000 7506000 1193000 1132000 23532000 22430000 35179000 33475000 8691000 7461000 26488000 26014000 1200000 1000000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">6. AGREEMENTS WITH UNIVERSITY OF MARYLAND AND DUKE UNIVERSITY </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive License Agreement</div></div> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company entered into an exclusive license agreement (“License Agreement”) in July 2016 with the University of Maryland (“UMD”) and Duke University (“Duke”). The License Agreement grants to the Company an exclusive, perpetual license (“Initial Patents”) to certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and other intellectual property utilized in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trapped-ion</div> quantum computing systems. The license granted to the Company is exclusive for all patents (and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> for other types of intellectual property), subject to certain governmental rights and retained rights by UMD and Duke and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> institutions to use and practice the Licensed Patents (as defined below) and technology for internal research and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> purposes. In exchange for the Initial Patents, UMD and Duke received an aggregate of 142,886<div style="letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock after giving effect to the recapitalization. </div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">On February 1, 2021, the Company and UMD executed two amendments to the License Agreement granting exclusive rights to license additional intellectual property in exchange for a total of </div>257,198<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock after giving effect to the recapitalization. Management evaluated the amendments and concluded that the arrangements qualify as equity-classified instruments and recorded an intangible asset and additional paid-in capital based on the fair value of the shares at the date the amendments were executed of $</div>1.6 million. The shares for each executed amendment were issued during the year ended December 31, 2021. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Option Agreements</div></div> </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company also entered into an exclusive option agreement (“Option Agreement”) with each of UMD and Duke in 2016 whereby on the anniversary of the effective date of the License Agreement for a period of 5<div style="letter-spacing: 0px; top: 0px;;display:inline;"> years, the Company has the right to exclusively license additional intellectual property developed by UMD and Duke (the “Additional Patents” and together with the Initial Patents, the “Licensed Patents”) by exercising an annual option and issuing shares of common stock each to Duke and UMD in consideration for the Additional Patents. The amount issued to UMD and Duke pursuant to the option over the 5-year term was equal to an aggregate of </div>642,995<div style="letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock to each university after giving effect to the recapitalization. The Company may elect not to exercise the option if there was not a minimum number of intellectual property developed in a given year and then the Option Agreement would </div>extend another year. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In December 2020, the Company amended its option agreement with Duke, and under this amendment, the Company issued 1,214,317<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock after giving effect to the recapitalization, to Duke in consideration for research and development services through July 15, 2026. Under the terms of the amended Option Agreement, the issuance of shares is a nonrefundable upfront payment in exchange for research and development services by Duke whereby the Company will obtain rights to any potential future intellectual property developed during the term. As such, the fair value of the shares of common stock was recorded as a prepaid expense and is being amortized over the term of the arrangement as services are received. The Company recognized $</div>0.1 million of research and development expense related to the agreement with Duke during each of the three months ended March 31, 2023 and 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The useful life of the Licensed Patents derived from the License Agreement and the Option Agreement is the remaining legal life at the time of acquisition. The value of the Licensed Patents is based on the fair value of the common stock given as consideration on the effective date of each agreement and exercise of option. The asset is amortized over the useful life of the Licensed Patents. </div> 142886 257198 1600000 P5Y 642995 extend another year 1214317 100000 100000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. OTHER BALANCE SHEET ACCOUNTS </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses are composed of the following (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued salaries and other payroll liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,597</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,935</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional services</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,283</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">678</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued equipment and services liabilities for research and development</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">611</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">489</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses—other</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">923</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">553</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total accrued expenses</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,414</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,655</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses are composed of the following (in thousands): </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:7%"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued salaries and other payroll liabilities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,597</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,935</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional services</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,283</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">678</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued equipment and services liabilities for research and development</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">611</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">489</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses—other</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">923</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">553</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total accrued expenses</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9,414</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align:bottom;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,655</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 6597000 4935000 1283000 678000 611000 489000 923000 553000 9414000 6655000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. COMMITMENTS AND CONTINGENCIES </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warranties and Indemnification</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s commercial services are typically warranted to perform in a manner consistent with general industry standards that are reasonably applicable and materially in accordance with the Company’s documentation under normal use and circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s arrangements generally include certain provisions for indemnifying customers against liabilities if its products or services infringe third-party intellectual property rights. To date, the Company has not incurred any material costs as a result of such obligations and has not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stockholder Lawsuit</div></div> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In May 2022, a securities class action complaint captioned<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Leacock v. IonQ, Inc. et al</div></div>., Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8:22-cv-01306,</div></div> was filed by a stockholder of the Company in the United States District Court for the District of Maryland (the “Leacock Litigation”) against the Company and certain of the Company’s current officers. In June 2022, a securities class action complaint captioned<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Fisher v. IonQ, Inc</div></div>., Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8:22-cv-01306-DLB</div></div></div> (the “Fisher Litigation”) was filed by a stockholder against the Company and certain of the Company’s current officers (“IonQ Defendants”). Both the Leacock Litigation and Fisher Litigation, which have been consolidated into a single action, allege violations of Section 10(b) of the Exchange Act, and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5</div> promulgated thereunder, and Section 20(a) of the Exchange Act and seek damages. In September 2022, the Court appointed lead plaintiffs and counsel for lead plaintiffs, and ordered lead plaintiffs to file a consolidated amended complaint. The consolidated amended complaint was filed on November 22, 2022. As part of the consolidated amended complaint, certain members of the Company’s board of directors as well as other dMY-related defendants (“Additional Defendants”) have been added as defendants to the case. On February 7, 2023, the IonQ Defendants and the Additional Defendants each filed a motion to dismiss the consolidated amended complaint. Both the IonQ Defendants and Additional Defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the associated suit. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Glatt Litigation</div></div> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January 12, 2021, dMY Technology Group, Inc. II, dMY Sponsor II, LLC, dMY, and dMY Sponsor III, LLC (“Sponsor”) accepted service of a lawsuit where they were named as counterclaim defendants in an underlying action by and between GTY Technology Holdings, Inc. (“GTY”), dMY Technology Holdings Inc., dMY Sponsor, LLC, dMY Sponsor II, LLC, dMY Technology Group Inc. II, dMY and Sponsor (collectively “dMY Defendants”) and Carter Glatt (“Glatt”) and Captains Neck Holdings LLC (“Captains Neck”), an entity of which Mr. Glatt is a member. The underlying lawsuit, filed by dMY Technology Group, Inc. and dMY Sponsor, LLC, seeks a declaratory judgment that Glatt and Captains Neck are not entitled to membership units of dMY Sponsor LLC, which was formed by Harry L. You, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> and former President and Chief Financial Officer of GTY when Glatt was still working at GTY. The underlying lawsuit contains claims arising from Glatt’s termination of employment from GTY, including theft and misappropriation of confidential GTY information, breach of contract, breach of the duties of loyalty and fiduciary duty and conversion. Glatt responded to the underlying lawsuit by adding members of the Sponsor and officers of dMY as additional counterclaim defendants (collectively with the dMY Defendants Glatt and Captains Neck, the “Counterclaim Defendants”) and adding Dune Acquisition Holdings LLC, a newly formed special purpose acquisition company, as a counterclaimant and asserting claims for breach of contract, fraudulent misrepresentation, negligent misrepresentation, tortious interference with business relations, quantum meruit and unjust enrichment. dMY, and now the Company, has never employed Glatt and has no business agreements with him. The Counterclaim Defendants have denied the claims against them and have filed a motion to dismiss the suit. Although the outcome of this matter cannot be predicted with certainty and the impact of the final resolution of this matter on the Company’s results of operations in a particular subsequent reporting period is not known, management does not believe that the resolution of this matter will have a material adverse effect on the Company’s future consolidated financial position, future results of operations or cash flows. </div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. WARRANT TRANSACTION AGREEMENT </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2019, contemporaneously with a revenue arrangement, the Company entered into a contract, pursuant to which the Company agreed to issue to a customer warrants to acquire shares of Legacy IonQ Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock (the “Warrant Shares”), subject to certain vesting events. Upon closing of the Business Combination, these warrants exercisable for Legacy IonQ Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> preferred stock were assumed by the Company and converted into a warrant to purchase shares of common stock. Except as specifically provided in the Merger Agreement, the Warrant Shares will have the same terms and be subject to the same conditions (including applicable vesting conditions) as set forth in the Legacy IonQ warrant agreement. As of March 31, 2023, the contract allows for the customer to acquire up to 8,301,202 shares of common stock in the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Warrant Shares were issued in connection with an existing commercial agreement with a customer, the value of the Warrant Shares was determined to be consideration payable to the customer and consequently is treated as a reduction to revenue recognized under the corresponding revenue arrangement. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Approximately 6.5% of the Warrant Shares vested and became immediately exercisable in August 2020. The fair value of the vested Warrant Shares was amortized over time as the related customer revenue was earned and was fully amortized as of December 31, 2021. The remaining Warrant Shares will vest and become exercisable upon satisfaction of certain milestones based on revenue generated under the commercial agreement with the customer, to the extent certain prepayments are made by the customer. The exercise price <div style="letter-spacing: 0px; top: 0px;;display:inline;">for</div> the Warrant Shares is $1.38 per share and the warrant is exercisable through November 2029. The fair value of the Warrant Shares at the date of issuance was determined to be $8.7 million. </div> 8301202 0.065 1.38 8700000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">10. WARRANT LIABILITIES </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company assumed 7,500,000 public warrants on September 30, 2021 as part of the Business Combination. As of March 31, 2023, there were 5,231,486 public warrants to purchase common stock outstanding. Each warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per share. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The public warrants may be exercised on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering of dMY; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the public warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their public warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The public warrants became exercisable on November 17, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants when the price per share of common stock equals or exceeds $18.00: </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at a price of $0.01 per warrant; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">upon a minimum of 30 days’ prior written notice of redemption; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the closing price of common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a 30-trading day</div> period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants for when the price per share of common stock equals or exceeds $10.00: </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Once the warrants become exercisable, the Company may redeem the outstanding warrants: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value (as defined within the warrant agreement) of the common stock except as otherwise described within the warrant agreement; and upon a minimum of 30 days’ prior written notice of redemption; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:5%"> </td> <td style="width:3%;vertical-align:top;text-align:left;">•</td> <td style="width:1%;vertical-align:top"> </td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the closing price of common stock equals or exceeds $10.00 per public share (as adjusted) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the 30-trading day</div> period ending three trading days before the Company sends notice of redemption to the warrant holders. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">No<div style="letter-spacing: 0px; top: 0px;;display:inline;"> public warrants had been redeemed by the Company as of March 31, 2023. </div> </div> 7500000 5231486 11.5 on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering 18 at a price of $0.01 per warrant 0.01 upon a minimum of 30 days’ prior written notice of redemption 18 P20D P30D 10 0.1 10 P20D P30D 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">11. STOCK-BASED COMPENSATION </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Equity Incentive Plans </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company has a 2015 Equity Incentive Plan (the “2015 Plan”), which provided for the grant of share-based compensation to certain officers, directors, employees, consultants, and advisors. Upon the closing of the Business Combination, no further awards were made pursuant to the 2015 Plan and all outstanding Legacy IonQ stock options under the 2015 Plan were assumed by the Company. Each Legacy IonQ stock option issued and outstanding immediately prior to the Business Combination was converted into an option to purchase shares of common stock of the Company equal to the product of (a) the number of shares of Legacy IonQ common stock subject to such Legacy IonQ stock option agreement immediately prior to the Business Combination and (b) the exchange ratio at an exercise price equal to the (i) the exercise price per share of such Legacy IonQ stock option divided by (ii) the exchange ratio. Such stock options will continue to be governed by the terms of the 2015 Plan and the stock option agreements thereunder, until such outstanding options are exercised or until they terminate or expire by their terms. For awards granted under the 2015 Plan, vesting generally occurs over four to five years from the date of grant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In August 2021, the Company’s board of directors adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which was subsequently approved by the Company’s stockholders in September 2021, and became effective upon the closing of the Business Combination. The 2021 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards (“RSU”), performance awards and other forms of awards to employees, directors, and consultants. The number of shares of the Company’s common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each year, beginning on January 1, 2022, and continuing through and including January 1, 2031, by 5% of the Fully Diluted Common Stock (as defined in the 2021 Plan) outstanding on December 31 of the preceding year, or a lesser number of shares </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt;text-indent: 0px;"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"/> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">determined by the Company’s board of directors prior to such increase. As of January 1, 2023, the number of shares reserved for issuance under the 2021 Plan increased by 13,587,593. For awards granted under the 2021 Plan, vesting terms range from <span style="-sec-ix-hidden:hidden78956467">one</span> to four years from the date of grant. As of March 31, 2023, the Company had <div style="letter-spacing: 0px; top: 0px;;display:inline;">37,279,201</div> shares available for grant under the 2021 Plan. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under both equity incentive plans, all options granted have a contractual term of 10 years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock Options </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option- pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility</div></div>—As the Company was privately held until 2021 and there has been limited history of a public market for its common stock prior to closing the Business Combination, the expected volatility is based on the average historical stock price volatility of comparable publicly-traded companies in its industry peer group, financial, and market capitalization data. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term</div></div>—The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has estimated the expected term of its employee awards using the SAB Topic 14 Simplified Method allowed by the FASB and SEC, for calculating expected term as it has limited historical exercise data to provide a reasonable basis upon which to otherwise estimate expected term. Certain of the Company’s options began vesting prior to the grant date, in which case the Company uses the remaining vesting term at the grant date in the expected term calculation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-Free Interest Rate</div></div>—The Company estimates its risk-free interest rate by using the yield on actively traded <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-inflation-indexed</div> U.S. treasury securities with contract maturities equal to the expected term. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Yield</div></div>—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Underlying Common Stock</div></div>—For options granted under the 2015 Plan, because the Company’s common stock was not yet publicly traded on the date of grant, the Company estimated the fair value of common stock prior to closing the Business Combination. The board of directors considered numerous objective and subjective factors to determine the fair value of the Company’s common stock at each meeting in which awards were approved. The factors considered included, but were not limited to: (i) the results of contemporaneous independent third-party valuations of the Company’s common stock; (ii) the prices, rights, preferences, and privileges of Legacy IonQ’s previously Convertible Redeemable Preferred Stock relative to those of its common stock; (iii) the lack of marketability of the Company’s common stock; (iv) actual operating and financial results; (v) current business conditions and projections; (vi) the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company, given prevailing market conditions; and (vii) precedent transactions involving the Company’s shares. For options granted under the 2021 Plan, the Company utilizes the closing stock price on the date of grant as the fair value of the common stock underlying such options. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions used to estimate the fair value of stock options granted during the three months ended March 31, 2023 and 2022, are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.76</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.63</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77.48</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock option activity is summarized in the following table: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:61%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Option<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,716,270</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49.69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131,492</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancelled/ Forfeited</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(296,628</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.58</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,288,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.09</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108.06</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,571,954</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.96</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67.93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable and expected to vest as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,288,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.09</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108.06</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes additional information on stock option grants, vesting and exercises (in millions, except per share amounts): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intrinsic value of options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Aggregate grant-date fair value of options vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average grant date fair value per share for options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.87</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Early Exercised Stock Options </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 31, 2023 and December 31, 2022, there were 779,787 and 905,128 shares, respectively, subject to repurchase related to stock options early exercised and unvested. As of March 31, 2023 and December 31, 2022, the Company recorded a liability related to these shares subject to repurchase in the amount of $1.7 million and $2.0 million, respectively, in its condensed consolidated balance sheets. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Restricted Stock Units </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RSU activity is summarized in the following table: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:63%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> RSUs</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Fair Value<br/> (in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,320,045</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.02</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65.38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(524,711</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.39</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(235,613</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.04</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,559,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.99</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.99</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59.79</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected to vest after March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,518,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.96</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.01</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense for stock option awards and RSU awards, which are included in the condensed consolidated financial statements, is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:81%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">349</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,280</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">764</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,875</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation, net of amounts capitalized</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,672</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized stock-based compensation—Intangibles and fixed assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">619</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,887</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,848</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Unrecognized Stock-Based Compensation </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of our remaining unrecognized compensation expense and the weighted-average remaining amortization period as of March 31, 2023, related to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options and RSU awards is presented below (in millions, except time period amounts): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:73%"/> <td style="vertical-align:bottom;width:10%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:10%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrecognized<br/> Expense</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Amortization<br/> Period (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40.6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Employee Stock Purchase Plan </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2021, the Company’s board of directors adopted the Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders in September 2021, and became effective upon the closing of the Business Combination. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The number of shares of common stock initially reserved for issuance under the ESPP was 5,354,000 shares. The ESPP provides for an annual increase on January 1 of each year, beginning on January 1, 2022, and continuing through and including January 1, 2031, equal to the lesser of (i) 1% of the fully diluted shares of common stock outstanding on the last day of the prior fiscal year, (ii) 10,708,000 shares, or (iii) a lesser number of shares determined by the Company’s board of directors prior to such increase. The board of directors elected not to approve the annual increase of ESPP shares on January 1, 2023. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Under the terms of the ESPP, eligible employees can elect to acquire shares of the Company’s common stock through periodic payroll deductions during a series of offering periods. Purchases under the ESPP are affected on the last business day of each offering period at a 15% discount to the lower of closing price on that day or the closing price on the first day of the offering period. As of March 31, 2023, no shares of common stock had been issued under the ESPP and no offering period had been set by the board of directors. </div> 0.05 13587593 P4Y 37279201 P10Y <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions used to estimate the fair value of stock options granted during the three months ended March 31, 2023 and 2022, are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.76</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.63</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">77.48</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> 0 0.0176 P5Y7M17D 0 0.7748 0 0 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock option activity is summarized in the following table: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:61%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Option<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,716,270</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.19</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49.69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(131,492</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.40</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancelled/ Forfeited</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(296,628</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.58</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,288,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.09</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108.06</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,571,954</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.96</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67.93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable and expected to vest as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,288,150</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.09</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108.06</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 24716270 2.19 P7Y3M25D 49690000 0 0 131492 0.4 296628 1.58 24288150 2.21 P7Y1M2D 108060000.00 12571954 0.96 P7Y3M7D 67930000 24288150 2.21 P7Y1M2D 108060000.00 <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes additional information on stock option grants, vesting and exercises (in millions, except per share amounts): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total intrinsic value of options exercised</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Aggregate grant-date fair value of options vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.3</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average grant date fair value per share for options granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.87</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 800000 5700000 3300000 2200000 0 12.87 779787 905128 1700000 2000000 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RSU activity is summarized in the following table: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:63%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> RSUs</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Fair Value<br/> (in millions)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,320,045</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.02</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.21</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65.38</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(524,711</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.39</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(235,613</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.04</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,559,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.99</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.99</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59.79</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected to vest after March 31, 2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,518,721</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.96</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.01</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59.26</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 9320045 7.02 P3Y2M15D 65380000 0 0 524711 8.39 235613 5.04 8559721 6.99 P2Y11M26D 59790000 8518721 6.96 P3Y3D 59260000 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense for stock option awards and RSU awards, which are included in the condensed consolidated financial statements, is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:81%"/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:4%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">349</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,280</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,698</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">764</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,875</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation, net of amounts capitalized</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,672</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized stock-based compensation—Intangibles and fixed assets</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">619</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,887</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,848</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 349000 104000 5280000 1698000 764000 73000 3875000 4797000 10268000 6672000 619000 176000 10887000 6848000 <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of our remaining unrecognized compensation expense and the weighted-average remaining amortization period as of March 31, 2023, related to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options and RSU awards is presented below (in millions, except time period amounts): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:73%"/> <td style="vertical-align:bottom;width:10%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:10%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrecognized<br/> Expense</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Amortization<br/> Period (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock units</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">54.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock options</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40.6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 54700000 P1Y6M 40600000 P1Y6M 5354000 0.01 10708000 0.15 0 <div style="margin-top: 15pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">12. INCOME TAXES </div></div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company had no provision for income taxes in any period presented. The effective tax rate for each period differs from the statutory rate primarily as a result of not recognizing a deferred tax asset for losses due to having a full valuation allowance against deferred tax assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The realization of tax benefits of deferred tax assets is dependent upon future levels of taxable income, of an appropriate character, in the periods the items are expected to be deductible or taxable. Based on the available objective evidence, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets as of March 31, 2023, and December 31, 2022. The Company intends to maintain the remaining valuation allowance until sufficient positive evidence exists to support a reversal of, or decrease in, the valuation allowance. </div> 0 0 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">13. LEASES </div></div> <div style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company has two operating leases for its facilities in College Park, Maryland, and Bothell, Washington. The College Park, Maryland facility is used for research and development and corporate functions and is leased from UMD. Refer to Note 14 for further information. The Bothell, Washington, facility is used for manufacturing, research and development and general office space. Both leases expire in 2030. As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term was 7.3 years and 7.9<div style="letter-spacing: 0px; top: 0px;;display:inline;"> years, respectively, and the weighted-average discount rate </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">was 9.8% </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and </div>11.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, </div> <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively.</div></div></div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Bothell, Washington facility lease includes a landlord-provided tenant improvement allowance to offset a portion of the costs of the construction of leasehold improvements. The Company determined that the leasehold improvements will be Company-owned, and as such, reflected the lease incentive as a reduction of lease payments used to measure the operating lease liability and ROU asset as of the lease commencement date.</div></div></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The components of lease cost were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating lease cost<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed lease cost</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term cost</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; padding-bottom: 0.5px;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease cost</div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;">$</td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;;text-align:right;">403</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;">$</td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;;text-align:right;">197</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.5px;"> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The lease costs are reflected in the condensed consolidated statements of operations as follows (in thousands): </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">204</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">197</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Supplemental cash flow and other information related to operating leases was as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash payments included in the measurement of operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2023, maturities of operating lease liabilities are as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td> <td style="vertical-align: bottom; padding: 0px 0px 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December 31,</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">559</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,831</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,309</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,378</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,449</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,385</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,911</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,795)</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: lease incentives</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,882)</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,234</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> P7Y3M18D P7Y10M24D 0.098 0.119 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The components of lease cost were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating lease cost<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed lease cost</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">360</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term cost</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; padding-bottom: 0.5px;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease cost</div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;">$</td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;;text-align:right;">403</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.5px;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5px;">  </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;">$</td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 1px solid black;;text-align:right;">197</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0.5px;"> </td> </tr> </table> 360000 191000 43000 6000 403000 197000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;;text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(1)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The lease costs are reflected in the condensed consolidated statements of operations as follows (in thousands): </div> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">146</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">204</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">197</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 14000 14000 172000 146000 13000 7000 204000 30000 403000 197000 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Supplemental cash flow and other information related to operating leases was as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 8pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash payments included in the measurement of operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 166000 161000 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2023, maturities of operating lease liabilities are as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td> <td style="vertical-align: bottom; padding: 0px 0px 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December 31,</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">559</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,831</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,309</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,378</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,449</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,385</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,911</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,795)</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: lease incentives</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,882)</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,234</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> 559000 1831000 2309000 2378000 2449000 6385000 15911000 4795000 4882000 6234000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. RELATED PARTY TRANSACTIONS </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Transactions with UMD and Duke </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 6, the Company entered into a License Agreement and Option Agreement with UMD and Duke whereby the Company, in the normal course of business, has licensed certain intellectual property and, in the case of the amendments to the Option Agreements, has purchased research and development services. The Company considers these agreements to be related party transactions because the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-founder</div> and Chief Technology Officer serves as a professor at Duke and the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-founder</div> and Chief Scientist served as a professor at UMD. During 2021, the Company’s Chief Scientist moved to Duke and each, in their role as professors at Duke, are leading the research subject to the License Agreement and Option Agreement with Duke as of March 31, 2023. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the Company has an operating lease for office space with UMD, which expires in 2030. Under the lease, for each of the three months ended March 31, 2023 and 2022, the Company incurred fixed lease costs of $0.2 million and made lease payments of $0.2 million. Future minimum lease payments as of March 31, 2023, are $6.2 million. As of March 31, 2023 and December 31, 2022, the remaining lease term was 7.7 years and 7.9 years, respectively. As of both March 31, 2023, and December 31, 2022, the weighted-average discount rate was 11.9%. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2021, the Company entered into a contract with UMD to provide certain quantum computing services and facility access (the “UMD Quantum Agreement”) related to the National Quantum Lab at UMD in exchange for payments totaling $14.0 million over three years. Over the term of the contract, the Company estimates that it will make payments to UMD of approximately $1.4 million, including a contribution of $1.0 million to establish the IonQ Endowed Professorship in the College of Computer, Mathematical and Natural Sciences at UMD. The pledge and other estimated payments to UMD will not be an exchange for distinct goods or services under the provisions of ASC 606 and therefore are considered a reduction of the transaction price for the UMD Quantum Agreement. The transaction price is currently estimated at $12.6 million, reflecting this reduction. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2022, the Company entered into an agreement to provide customized quantum computing hardware to UMD for a transaction price of $0.7 million. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s results from transactions with related parties, as reflected in the condensed consolidated statements of operations are detailed below. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">992</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">992</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development ($130 and $130 attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing ($10 and zero attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following balances related to transactions with related parties, as reflected in the condensed consolidated balance sheets. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets ($520 and $520 attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">529</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,680</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other noncurrent assets ($1,195 and $1,325 attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,325</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">610</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">591</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unearned revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,448</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,514</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,393</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,459</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 200000 200000 200000 200000 6200000 P7Y8M12D P7Y10M24D 0.119 14000000 P3Y 1400000 1000000 12600000 700000 <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company’s results from transactions with related parties, as reflected in the condensed consolidated statements of operations are detailed below. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:84%"/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:5%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">992</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">992</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development ($130 and $130 attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing ($10 and zero attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">20</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following balances related to transactions with related parties, as reflected in the condensed consolidated balance sheets. Except as noted below, all transactions in the table below relate to the Company’s arrangements with UMD (in thousands):</div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width:76%"/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> <td style="vertical-align:bottom;width:9%"/> <td/> <td/> <td/> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets ($520 and $520 attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">525</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">529</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,680</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other noncurrent assets ($1,195 and $1,325 attributable to Duke)</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,325</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities</div></div> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">29</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">610</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">591</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unearned revenue</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,448</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,514</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> operating lease liabilities</div> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,393</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,459</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> </table> 992000 992000 13000 14000 130000 130000 275000 271000 10000 0 20000 32000 47000 29000 520000 520000 525000 529000 3680000 3753000 1195000 1325000 1195000 1325000 81000 29000 88000 0 610000 591000 2448000 3514000 3393000 3459000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. GEOGRAPHIC INFORMATION </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue generated for customers located in the United States was approximately 86% and 87% of revenue for the three months ended March 31, 2023 and 2022, respectively.</div> 0.86 0.87 Includes money market funds associated with the Company’s overnight investment sweep account and collateralizing letters of credit. EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

O;<#VJS;;[*:\/'\JP<(7\ '@.S(D'@BYT6S@O+"P#-W6/2H/D5C3 MMD'X(-=$J\'(H*5L5$%?D*5?HS-QV.TH"@4VM#D%.D&0!F"[6PS*1+-!T3J( MZ($6N$,6W% J4#*'6['B1@I.#MT1 @+'^A9_/GR6N".R>;N'C^#F*F]H;@\38M$6SX M_6=?(_E(%@RG#.2\F"GF^0#N8@QN4F-JA-O@77X%KI@H('/M(>F"8.1@\+*N MI,"CJ.QO*4=SX+;V0._!1$/!ZZ4(A%$3/"V455M_AD\)&%!EI:ML@X"278$. M(^O;&_P\@TP*=$5*06RJ6%[)K" G6Q>8&3!.X-! 0^!U5LU#^\3H4%4M29I.L0:\ !$3Y>5W6UTC[@".=SC95 =E#')"% MV$$*%.827O4RMNIBH/I2M59G[])(XWVW=8,B/;O0-;/1%T\5,'%HXE>:-L_P M#NZV_D!8+'T%6HG=6*]9]E4O@B F+;HDDC0(] MB;-%*_^ %UCZ@#F;XGI3HF$&9) )X*DZIB;E&11O%9!< M@M\I$,=>>K )2U M@DU01E(IC&RV7,1&0<-J$"=HPSU/0_+0EQD$6@"SQ9 ;-UWJKD.4,6IEWUG$ MI2]6.Y!"%$&RBBS,(DLCLB/%O(1: (.LF@I$9G]E!Q.B3R!&BQ3M6][S2JI> MD2^BO2-10.!5Q0Z,; R] 8@G;]"4NMH\\?! S7B?!F0R<8V/46S:D8A*/81K M'[#KC')4FW-:\6L'A!^6G[^)<-9G64W^1B"!OEJ4T-^:Y &]5_<&,#0/GQUY M^H1D.2)B(6V.QK7I?G(R3Y_.YO##\7&Z?'QZ-!2U13J;S?C?HX_D@S)2XSU0 MA\GUMS8(6"TM5H\)JS-K83XXLT,+GB%3B=0H1Q?,]]D(F#WDSF094[_ST]F1Y^JU?C#3Y:/@8KSXX50<0S@D^4I_+], M%T\71^_0=7#]#GS3"OL7:5B4\-DKZMTAB$@C%]5A:5]SQE!;^:><,B*B*$]) M1$2=+Z)(#7Z[*^+446S5:LBX%%4??"E?K3#.:+",A;6$+C('L%H'=A0K6N@X MV@)]?YI8LX625/AN ^0'IJY\YL81-/T.ZVD0J6Z_,(/&$WZVN;*$@)YHL9W+ MP=AC:D,E8OS@#FI)<5)2JH'9@H?WK-84'L*>AI+L]@HV@.7'PLS. M4*F)W=U6Y3IPRECF]ODX;5B*2UPJ . @%Y(%H0%J.!#?Z K6!YN"*G@WFL@X MK EWNN), PO/1A._6&.H8K657@"(%)->2)GS8DBE?HMK1?%#@.W]V?1)LN42 M+E)B>QBG\4W9;FD4+'"%/Y:N:7(9!"1OO(D(E)]<$ 9^$#]3^Z($_E-<[HMV M'H:$+M3("4,75GXJK!Q0?Z(I9T587<76)1:O>BI^.. QQ7S8SX^00.9ZU84I M/7DO05CL782M.50!;/7$FL@AP6(,=(OFR7A;Z\T8L<=1T5E0,@TZ*XFR^PG@ M@)@K'%!!_]]V)!BLL"C;D?G V@M@5+0!E0*#2J&I86\)2@76B_I"OIIJ/UA# MVE.W1CA@JW,&I+H-+%Y?@?ED0<7UJ6EY2V5&CY M_7(_13DCK-DTP?JP>@9,AD3\^XI*J&2TO##>@DHC6@;W3I5- M7%]Q<A)7EI+4F:O(4DZ/U!*Y,FE:;-4SQ&CH4PIHP$@HI^VS.-A^VNBR^N2&_K$RSJKK]"J9#*J$@#EO,7D$_7$0#MK9E:%''4N!0:6]LC M7/5%2=)\IU,9N P@.0$$!KT(\$?T /5,MN:+^1# *IRVFJ!P6N(B0[D]Z&K? MPRZ%+R--L:WEOZ/=&>(T9&:DVB"=$ MBA*F7V$Z[+O;G+=Q-724/FOM0RPF-A=77KJ>[3NP5A@5N50N[%[:CG PLH(( M#\"/BH,MO=_&LS>V$PH^#5)..[4CL.TF6#UM&5 U7$4#XN.[P5#/ MOW/>_WN\^L=1FB*0<27 [39(.L@2P9XMF*W3A/@:M\""" ',(*8#/@^GYHA- MSS&*SW3#VO^NH1(AU1X(Y' XJXX? "N,2E6O)SC+$;?G,6;%=3Z\^R2R0=: M7HMZ6F"]*YFX)*. 46T#\RO)^A(6"8BQ&VL0F+\1_HF08;GA;A<+=8Y+*OSFJF -DL4F!=&/_ M8O/M=9/":IF=8-L;^13I0L8-_G5/-@1$HMB"< GIU&X[S-7(Z\-&>7()]\O/ MHIA4J!\<4Y#B9%PI=(;4FXYI<@:0Q9:HHRR(3H<,$!6('K4D=*MY=Q4/EMA/HW78=2B,.#+N0@"+5]ACHFI3 MNT?T*!?VF8Y-3@<,XPX"KZASJVVAA81\HO;8FY#[<83_/=N:^HD[VVYSS5K/ MB:_)4"P[-B08*N_AIB Y*'PZANLN&@RAMK?+&36)3>VOE$_PZV M1*Y:_XG1:HU-\/PND\>KV:(YYS>&PUJ<'K,)#@^.D1=G\G3!BI);TY*N MXK)S\Q$N6+8"2>&Q_H+IO)'IM[KQ0K5?:;?*"3G-A%7%9C"V<4Q]*^5B&]Z5 M"RLJ?0O,"Y"GH10BTPB\9K,S9(N)A,-.(,?'F$_M[L '!!"+3=*JW../%'V' M;!&'L9=8#HUB2*EKV&%+E9'>*CBBQ>-4B ";D(N@]'#IYV]>N/F;*QM1AD_> M.:GC)A?BJC6\ R$"C7#9D1S((=(H0\ULV.U*!T%IQ:U*X.9YA;QJ__ RB)$#-?: MQA4EL#47M>[X0Y=WP@LK'HJTX-SR-J^TAE;J$F)1JTP26Y[Q3(.I14$O 5K M4I.:V"64HIB%*R2Z"U4&@4H]]2F#Z5];!L-AW.:Z5;D6)=F0 M H08JK"L&I&6/%64F[WCES'Y##!'8[T[B&WJ1NB,I,N^J$+V-T[?V/S>E;WY M[.2 R'>[!HT$5B2#0&1E(W>)J5\PL;XIHB>B[2DX9^0.%Q5]'9@FZRA]@!6ICLPX!ML.[%C M%CA3VS?$).TZ_4T-<1!-&[CMQ Q8%ZWI9&*9YKD/3;H8BMSM3#JLP':YLZ,5 MX=Q B(NU3S$%:'LCE"%G\)4=NL#&$8PTH!I!WK:/,%#U/"5E,!C M^[+3*'N9:I RLNP'L#P$]O2%3+RY?A(=8#"#L18$I_KU0JDK>[*&PQ<S @%(T MP@0\:4H=FQ=E.SW1(,(:20\VJN'$0F6;9T=S, M@^3='M2<3,PXXW$.AR\UH' M-8/>8&1)\_EWH43U#J[ X^ND]:Z(?4E"(J3E#NX)@>'$#.B MRC1YY:"'LSH\78FAG4TS@YT@GG4EX4.KP4^Z,!WS7XH!V+4@PK)5Q"/(">TN MC+7 T>@,FDG&FQAT\26A=W:N%6BEI:8&D@U?L=W.JJET+3F5SA" M?MMM;6#.92MFW%C2!D?PM9<81.U9G:?^ES9JI$Q3&=@T&I44HKZ/B[YGA^XC2)'0V/]\#1Y/R(5 M-*AOA4HR2TR^BW7DG.W9'2G60)ZP+GA,X59':3W>*Y'NO4UB5YZF? M /H\"149:&KND!_EDB8G70$),=RF8K:-\N+$@X^I'B3X(6)'0FXK$ZYX(6NQ M^4/=N#8EU6DD##G\Y*%I%XH%T MH!L#\EJ;>#@N$@HM9RLW16."^/4P,N(\D/(H;&@QA#.#T>#4D;P84H.TA:.) M;(-G7%U*.[))J@C:3;1ZC>TZV@=.C4\@R0Z#"G2/&DLS?#3-.1#O0'D0/$&[ M0I]C_M7B"1::!,>S/'A(EVR@VFK/Y[AR+K%K -<> NW]2-B6.FM^*9LED&.L MR"QN,2&Q_1B7=&1M06UH.;+0/:-CSE$LQ5.R^KKN"NG7TT&<[#,&9\,]NEGZ M>O4']Y2>\PGI^" )!YPTD%@PA@[G7#? =.-[D@6/Y$46@;PF+C(R'RS0W9]R536[@ M54,VEPV-$:N8.DD4:'(R*-35O;CT*PC%[H[*X^[4$XW0<;1 UR'(V!J5.5P_ MCBD#^NV'-0^[2LHEK&T?;$0R#1?,(2<"1K" AYG-X>$>SN80(]_ML./4;)4I M(@,+3T77"Y=%4,1*!HC47Z8%['EME=\0K^V>J>KFG1<>RC6=;8AA7>;Q['&Z M]Y;KL7,QQ(00_(2"W']A!9 K2%C!0PN*1R('<<16VZE=9\]@+R9,J[#0PD6ALU,(/7]Y6QZ',ZJADC%5<^P>(V;"3 ) MR]WV)]LX^#!@HQN3>[?B8^]>"*\4WIB MKXPACAJ3Y_K;5/6.VT#_TW1YLQ4 M.ZP>S%L&?7;7FZOM6G&=2P5F\N.@X9-%O4N;_V&E0@T": 1'XJNSGOR8C$CZ MEI&2@_DTUFUK,6Z V=G"M1]YV_W8];*YZM/_>:+[_XI^>W3H+#^H?F$4: M3MV)<-C3^D/> 3F8=W)GEHT<(H+*3+[$Y9*$"/55>#E-? P76W:57!$F)^.F M!XW8V%&P3LXI#?E P?3]V?2I,W0(X/Y\.K,?8' 93O>=A++7T#,2D/CJ/ M9 ([B3>0C@\ MN6KM\5%-T]MP/KY$@'OC=Z(,F9>.!&XX,S@4N;OO M%&+#Q)C[8V8N) $\TB!ON*DQZ2RC8PZN5QF#Q7,!X!+U8([+^.L'W2HD@IB9 M\CT5 CD$Q]0.[P,Z/"VWO_>(Q;Z'<>!PS0I1=)?]6,_H;_\I*MC]37#GCRN, MN2,T9&5Y'M-&_ <6LEG$OGHCCB!I:UUP!Y0+L'*HPUJO VI/IP#6?,[*GA#E MC?,=!&#RW?'Y.\W35^Z?VNM*2IK%U)78(@A3!5=K.]SQPGUOB.^/6C7:GCM$ MLC_A$P;&;@TW[H/#_! WYH?)_5532F,:=N0V?B2ZS,*2U9L/E]Y$D1S"VY_# M"M)9<-)=*1-K+OE9[9CJ-#QYD,E104<,PUB/-R=S7] [[I)A!'/]H"7LG7.>)SXVY(P#[ MHDP3(:'HKKV<$HHZ.%I$+L=>&7E!]2$9@XCL)/&TP'O^4H_ M.;5-%U)9AWIV>?'^S/G1X)K4_U';YOEO[H#/0^#<_CB4?CJ;W]4^+309FSH J4O0'P MC]H>&N0AIF]:7B::!W=D=+?U8&P%Y< '*T/3;N_R2$!+@=]8I^!!(U=\N^X5 MZ8JONK_2F .7>-@+WT5IZULRO!@7F$!B'0EB"8SQ7U6_G?MA$[SI;?^&2+H& MZX[+3WS9V2,"&-?VB%0@7/;6OE"D(HLBDZK4DOP.XGDK"=EF;S^!O7'+%+Q< MQ9>2=70@DD9D.XZCL&\B3*W;$:8?O,; #F/98D4P1."4P[:7)2^FBQ]#P;[[ ME*^5;PO8]B.\O'K'C;SQWB5H(/!T8@0GG"[QAP/\#6ERK'3'YZ1YGFCL)@>O MFE^[M2$^9NHO52AW7"KE:4NZ!Y /I<4W2GKL%1T]J.T$U M(P^Q49Q<8]MYVP[,^6F[XF@9"FL^S6QO7=\YNY4($FD3U! "OPIT= M:2AK/M)&3TM0/8(E)T 0V,E;[O).#(7M^]/#Y6O-LSVV+QICNB)IH@;E89Q5 M!PYWU7?!!INIC-TOE\D3XY.4GF3Q^G\R?+='%\ZG?XGUD&]CV;SH^9 M K/I; $_7=KZI\M,W1UOL1![B42IFCBQC.H]>![D1LM="X?RK^"!2)X?^.K, M(0CALP]Y!H3GK^V=*'(LZ Y1Q2*\+=4Q:>('AOI!IXZ-_P,:!TW.F$XZPQ=< MV#!B2WSIU3'"7P?/?[O [LZ=!!HQ*)%46M0V=)SD3A/AF/D5W;N(S+RD6>&V M%L?I\=.GZ=/'3Y+%/)W/GJ3+I[.CWRVKPG-0$>7@N=D\A37\3T>2BCD^GZ0+ M<(#'3Q[33XOT^'1^].EN84N>IK-34/KC93)/E_-9_$Z,P3% /#G&YTY@_<=S MN2'K^#1]>H)?+9,E0)HMT].G)TWCHC\L\"O[*#MY13W]+R/ ("?_!'?>I^W-%9_Q7 M>OSC_+>.(&"YQA"QU&MX=38]/;G'\UGVEZYNZ&_VK.H.PA_Z<:,A-6SQ ?A^ M74.X+K_@ NZ/./WT?U!+ P04 " !-@JM6_PNX1# & 4#P &0 'AL M+W=O>7?/G7CRH/27 M9B6$(7]79=V3IJU%KQP0E4Y8;X? M3RHNZ_'9B=O[J,].5&M*68N/FC1M57']>"Y*]7 ZIN/-QHUI&JIIHL3@=3^GK\]#R.X;/4CPT.VMB3S)7ZHO]N"I. MQ[YU2)0B-U8#Q^M>7(BRM(K@QM=>YW@P:05WUQOM;]W9<98Y;\2%*G^7A5F= MCM,Q*<2"MZ6Y40_O1'^>R.K+5=FX)WGH>*-X3/*V,:KJA>%!)>ONS?_NX[ C MD/K/"+!>@#F_.T/.RTMN^-F)5@]$6VYHLPMW5"<-YV1MDW)K-*@2 M,120:U6;54-F=2&*;^4G<'KPG&T\/V<'%5YS?4P"ZA'FL^" OF"(1.#T!0T_Y_9.VAH_S%(<$PNIK?O//OI]]N+N%![/;NYNKB[O9 M94>3@"G("RXU03!:0=2"Y"Y(]DG$;I#T M-DCY)O=R&R2L";_GLK2^O4+[>]5 _T%?7K1UD5#7I*(>CYE6+@0 ML3??K 9B&'M!G#S#U1%'"'4E="YY2=9\+32AC'HTHH21(YJEY&=L^%X6180& MOD=#.J@X"L/ D3,OSE(HTFNEX3NIE>GS,E?6718'7IK$A/HQA+PDIA!C4>8Q M!C-)XM$T)#0C1Y&7958E2ZC'J#^Z;FN9RS5Z%KFUNG5L8.77^2-+8R^*4I"F\BBP_-F(_(&G@15%,D-RC M.+412)F79G1TIPQ<^:\UA;P$S,M"FQB:Q7CBO#&+H!\DEG@1CH-5B'A$=N4X MCQ(OR)*.)\!1$>A/6S#T$-"B=#5EU#<6'X069*VE15;Y2+AU$1/+ D/61EB' MB4O8HFQSTW([*YOCO?ATR.^0T?T-N+$ZQZC?B]/TBS(DM7 M_NV3H]DH6@L(\A)L2^+%DG94;?B]X+,A:B=99)C],BZ5>T3 M[62M&MD=I+&*,57RU1;81Q W*\C!A>;GX]%T#]/HO6ALQ^(U8+"95_Y'V%+\O21)Y 7,%U@%X/_Z_XSJ WXPZG!P! ME($M11JD*%9L "@#W"'V)W% TM\P=SHO"S 6!1I$7NKX(/WWT([L9 M1+&7I'0'C2/4/W#CP%.KWEA ('BT 8]5 755<-795=BEQ4BD&8 A],H@!_H^ZY\P?PC4PHJK"W; M#!!L2,Q%*04,PX1LX#="4,HO LW#G07,7@\] ]B62*] 4T$7U%WWP2]WZ>#Z M?0.HGX_87"RL'2NE16[S_^A@CF_>- J5;5L;'\9EKM"V\#W40/SRVPZR?S,SS?7\8U?N&<#=S-W#MOP^ E(:I%T0^H=3' ML*6;^;IGAEK$;?2ZK^>!!QTI2S' @=FH'X\#R((T\5+W>T$QF>(PWLZQ??^W MDYV;"@Z[=/DN+=+7MW7T2I+^U?8"D6$/6/DVA,='<' MZSZ,6KM[SUP9W*+<&ULS5=- M;^,V$+WK5PR\Q6(78&-]V9*=Q$"2)ML 21'$R?90]$#+M,V&$K4D%6_ZZSND M%,56[22+7GJ1-.+,XYO1/&ETM);J0:\8,_ ]%X4^[JV,**T;D+RD4_]/UA/Z>\Z$V.W+T;-3F2E1&\8#<*=)7G5#V= M,B'7Q[V@]WSCEB]7QM[H3XY*NF139N[+&X56OT69\YP5FLL"%%L<]TZ"\6EL M_9W#5\[6>N,:;"8S*1^L<3D_[OF6$!,L,Q:!XNF1G3$A+!#2^-9@]MHM;>#F M]3/ZAJXE_9@SA:T$N96KG]E33X#BY=)H=T1UK5O@LY9 MI8W,FV!DD/.B/M/O31TV E)_3T#8!(2.=[V18_D+-71RI.0:E/5&-'OA4G71 M2(X7]J%,C<)5CG%F?%G,VWX_M(JF46/C,[#5\%O*;J ** 0.B'T2MX49MIY/"B-S,E<$H% M+3(&4]?W7Y2L2EXL"5SP N]S*F!JJ'&E@#-:VO[1\,<5(L(EWM9_[JI/O7V\ M>WLKKK$N:<:.>Z@>S=0CZTT^?@B&_N$KR<5MF,"VXXT_@*F/V%L@0C86&9/SKF^09SL(I%U6>54OAHK/)XC6-P0\$>F0"Y M %Z4%3I7FLT!WU (G*VV<=9,,:2!JP)?0!H^\0(A9*412W\>>_^NW-RZRX5W MY38)H#Z'S3F".VFH\$Y<9F/OC.H5@0R/P+Y5'#-QVUJF6#^C>&80T:[7OFXE MEP5[0AFK!VR_185,X%/P&7Z"04#\(,0+5\OP<.NJ7O2PVCE3KKPE+9EJ/4*2 MIJ-MRW-DW?;O(_G,8!MK$)&1'WC3E53F9\-4CH5_Q$!7XO%^1D&0$G\X[-H8 MH$JI4&%02,-J(C-IR]!ZQBF)!G[7]JZK@F>\Q)VV_4@YW,#]^.B M"D=D.$J[]GMZ+?1)'"==>Z^H8C(*@OKX#E%A.DG<,=\IJB @<>1W[?\@JH%/ MDF'4M5])- F#;>M= AP$2<=\GP#3D/A^T+6[ FR;,1Y%6(^. "-\V>%3?T. M$4F#?0)T:YYM_,LB$]4<2[E#&/@)E]B%MIO7W*S<][?[P7=ULO/O1KJ@UXR5 M.'9GLFH*B,.J0"!%!?\;X00S:-C/>(:JY^8 [I"V7C"E<3+H+Y3,:]%KL&.@ M@XB XO=< B=N[[1_%23U(O[C7OR,X?BXY3GV" M+3#4/T@&/5#UB%\;1I9NK)Y)@T.ZNUSA7Q%3U@'7%Q*;LS'L!NU_UN0?4$L# M!!0 ( $V"JU9&SA; 40, !0' 9 >&PO=V]R:W-H965T(,9\Z3S%99B-W<"Y^"XY]M"&X>WF#5LBU]1?VO6DBRO1\EXA;7BH@:)^=Q9!M.K MV,3;@#\Y[M31&DPG&R%^&.-C-G=\0PA+3+5!8/1ZQ&LL2P-$-'[N,9V^I$D\ M7A_0W]G>J9<-4W@MRK]XIHNY,W$@PYRUI;X7NP^X[V=D\%)1*ON$71<;4\6T M55I4^V2R*UYW;_:T/X>CA(G_FX1PGQ!:WETAR_*&:;:82;$#::()S2QLJS:; MR/':#.6KEK3+*4\OUI+F*_4S+.L,5C];WM"):Q?N4,\\305,F)?NP:XZL/ W M8!'LUL".FX9_EANE)7TGWT^UWB''IY'-W9FJAJ4X=^AR*)2/Z"S>O K&_A]G M>,<][_@<^O^=TEFPTU1A-(3U_>?UZO[A;UC>W<#JR[>/Z]O5W0-563U S\ < M&;XPJ$DWN()45(U0F('(01<(N2CINO-Z"Q>\)H]H%26JM],!C30M[$QO,,5J M@](8 S-@,^5P<$U0K29W7\769"F9DBJDAWTEP.7\R:P5)&X2)_0<^>/!)Z3[78@R UXU4CRBR500N,%E M9)Y1./C2TG?35GL6ID'UK#16"L+('44AA,0A\@?OI5 *FI.G!M'(#9)+B"(W M3D945:DI]9>V55LR32UF2(-).;.Z=3%QQYD5!7*K=5C\_FTM>Y$J_?VDK_LE.XEO/M? M$,\MKQ64F%.J/TQ&#LA.@SM#B\;JWD9H4E&[+.BWA=($T'XNA#X8ID#_(US\ M E!+ P04 " !-@JM6:Y%V_W4& !:$0 &0 'AL+W=OI0EX8LE6>"W/_5F9Z?M@;]9H/EVJ6.OXP.#HHQ4Q>27=37AB\#5HKL>.[A,A97O=/9%Q2X][+WJ42P3467N4L\_R)K/ M'MN+=&;];YJ'N7M_]"BJK--YO1@(T@9*\V=[!T]_VVT/WRS >YN"W=WD_5?[+N- M>SW,A/:W:?+GY/DTS'Q MS_'-WR?=\9/O45998**/*D*>2UHXX#J5]$[GI2CN">_2R)A4X32)@F2[+JO7 MB7;=B^>_O1J/AV_6+/KOHS>_PPK]567WB)G1/I(-NKFTJPWICG:-N9NSX]: M6->SG[Y% M!7.1- YEF,HPU*?;0L^W4@05XKB6Q()'$$S=:>*&BLLIDC21?. MQ+)GG0P_+WT3[I2L;H:+S.H-::[#XO4L7[7:9H//:RFBE'%PD+5)"\8A\U-L M-KUO"(LB)#-':\TX>)CW]VSKK^OA&(('0:6TI[U']U(8NQSL*?SG X4#E:.F M98=2]-,Q&TO,QW-,0+Y$ZP4;KU69+,PL5PD_W>F9Q&2SJ'TK)24 7ZZC\5J] M 0#XVD3*07I:EK(RM4"V:/*W1:;C:O^]ML:\(@9?3/*08-@CQ)V9P M\:QV_2,8)/A2JO M+3;WQF]_ 4%N=]&VH,1QD<: M8>!(!E@+Y;'S201J&^]U!6&];3F)&CGG)3Z[H:SU6&9)WZ \.B M>_)(J3F]N" DE>,3\%/A%%>&'="(@#.AQ24O2ON;6\FJ-SFB%PV,]A/OJB0E/I2TZNC5,_N-7<=5S0>F#11-E8JPFVYETDHC]>SC_>>U9XB\_\ M0&7A##Z!):O5ORV'4,&P)8*K\D?Z0YU=ZXFEZI8@^?+,E#*4FWJ_NL\Z7(!Y M;Q&A]UNU*!I+@JZA8I$VM_,EY4,I@$K+B5$O7N^#ON2))8)MK<)P* !U>?9' M#Y_J:^[Z"7VWZ:%[TJ!SW\VEF?E;/:-')PA7W_9K^X^#2;@O+Z:'_SK@I#_# M*0K2)U@ZW'ZYUPOIT+PX7?K;\U0[W,7]8RH%-.()&$\TTJ5^X0W:?Z<<_0=0 M2P,$% @ 38*K5E+UG?[^ @ ;08 !D !X;"]W;W)K&ULE551;]HP$'[G5YS2JMHD1$@"%%I DK526N+2KL]3'LPR4&L M)G9JF]+NU^_L0-95%&TOV#[???=]=^;2WTCUJ%-$ R]Y)O3 2XTISGQ?QRGF M3#=D@8)NEE+ES-!1K7Q=*&2)"\HS/VPV.W[.N/"&?6>;J6%?KDW&! M,_4ZQDQN!E[@[0QW?)4::_"'_8*M<([FH9@I.OD52L)S%)I+ 0J7 V\4G(U; MUM\Y?..XT6_V8)4LI'RTAR_)P&M:0IAA;"P"H^49)YAE%HAH/&TQO2JE#7R[ MWZ%?.NVD9<$T3F3VG2T1N>' 6=YOD!>:U*7NL0^G]W\R#:?JYPVH#;^ZOI M'8Q'7TQA-)K)RZEE]@C/F"]-"A9OMO'T%8V^%K4JFXQ:>^ M22>\8*^*@"'C;,$S;NSM,73J[=XIK:UZ+VI7X8622]1VME!SK38>DW=0#[L1 M=$Z[E1\^K7EA^^[R5(YO4]!H!%L?Q]QZ)?A,TZZ,Z@0!M+J]VONRG!QUPR \ M+XGW2%R['=7NI2$V['T%CZ%7;P4MIZ73;N][*/Z;$9"C6KE!I\&UOIP&E;6: MI:-RA/QQ+PZ7 M4IK=P2:HOC##WU!+ P04 " !-@JM6EJNZP0P% #W"@ &0 'AL+W=O MD9#6FG;.SU. M[S[[TV/71J,M?_84VKI6?G7&QBU/>J/>^L47O:BBO!B<'C=JP;<<_VH^>ZP& MFRBEKMD&[2QYGI_TWH^.S@[$/AG\K7D9MIY)F,R>!S-D8" <:_79DMQW'Y>1_^0N(/+3 4^=^:K+F-UTCOL4NKG6$RC&0LB6=.QNU7; M M-(?C0<068C@HNG!G.=SX)^$.:(H 5:!+6W*YZS\ M V^\1K?V?C%@%/E^W0P MVJ/Q<'SP0KR##=^#%._W_XOOB^&D98Y"HPH^Z:$G OL'[IW289_./TVGD[OI MY/3V7: "P-D76AF2;70AOIXIKAJX&;.B90[*)45'#7OI6-(H?-2+M>P1 M KT4(KBCR&)%8,T>\;0M46A^12$"C?)EH%BIF,*CT8.S:H;XJFD,MIH93J#1 M$>QUVEDV*0KG2V4+SK'C,Q1*5[2B?";9@K0G*ZUEJ TY:*$]; 0'^/6?%2*Q M7'!.84/6@9'8$@A'!,$J^0[*ZOV"/8 K8ADM%JIHU. M&=%ST@B- &5;X '>&\6UG7LI%_#3OMQOE(^R=<14P9AIP01NT!YOO"H MA%1[VY)0I0*H1T'=>H^4R4BS.Z#*YS[5%1E+M(7M9^S[= M1E?<5\Y('J_5,K0ZHI1IJE;2K>,]P \,?AE*850(:0HC^;*E@?21"M7(&VQR MS:I 0'KHT\39/_<0J^@3SB5L>W@T'N\7#_O#T<'PS1Y]T)AX?L=RUV3_XOJ, M1L/9_FNZ@@*1K@$B$Z=/EOY0ML411*-Q&BP8+^7T&]UQ45EGW&)%5]ZU38=@ M,LF?;QN1Q*?U]?5Y>KF7LK#[-7^F5U*QX^&[[D-:C=[])GIS(Z)V126Y560Z M_9;@)=7%Z&=YLJJ6M$K_MR@S#Q5U+<<.HU.E Z3WNF8R*86=PK-5@C;CN&2V M='6WP^\CL@;CT%%<8X75&N<32=8NR6-'D404;TC(Z@>S1F9"H!M&?6V(;&=IQ^11 TB+6M=H M9V1I66FTT!0'4MY02X/67,_8YU&UE84NGWMH'8,$(ALO5-@/-=1)%YCO98>2 MD72OHD/!_M.6"^F^/* SC*<,97#+5$C036[_C#-4N@%,F6\@M)VQM&5FN%1I M9M89]T<,W!5=]^F;:_,0*]S^W"6NSQW(@ZW+"&;L(EVYNOK-]Y+-V\VM[GV^ MS#R:YRLA#O^%D#(\A^NP__9U+X_5]2*Z)EUM9BYBH*?'"C=3]F* [W/GXGHA M&VSNNJ?_ 5!+ P04 " !-@JM68LS MN8# #Y" &0 'AL+W=OF=.R4:ISVYPFRVBD2-$):76(7#\[>B:RM(! M@<9+BQGU(9WCZ_<._2>O'5HVW-"U*I]%9HM%]"%B&6UY4]JUVO]"K9X+AY>J MTO@GVP?;&2*FC;&J:ITQKH0,__S0YN&5PX?1.PZ3UF'B>8= GN4G;OERKM6> M:6<--/?BI7IOD!/2%>71:JP*^-GE,]>:2\N>\#0\9"K)-1$2;^>Q10AG&*<3UDT_& 34:3Z1F\::]W MZO&F_TMZS<^C_O4YGX4Z391^'[#E9KY/[)_:$YV-R_73[VSU+?E[?W-S=8/96LGNU MHVI#&@49?QRP%.6FJE:@1:HQY1']:PO&L6%W)!MBGG?N:0Z8+8A=JZKF\L@P M09HR)J15L'= +O,#5C?:-$XKYO>%2(LW;MR)SMR:, ;XP=EO%)#:AS09/YV^ M-$(3,P6'1*:V[%?*>7IDMTK^SAY)"\RNOA_[7V)\E"[-C\%G#X8ACN/I.,KV M- DJ):.#,%;('&L5"*2"EX&B[Z/'M.XIV9#P#L-M0RBOD M$XG*1'"D@\N9\8*0X*3)(>*6T]4K0HA""N\,) M=TZ:2I^'/EF=)N='7,N6H1MNFQ+$OH!QWSJ?* UMWYY%X\!/D[OX7):^)B3* MTG/ME"/L&[4-TLL,2FJV[79&E)2T!1X.^A*N2@+(73E0)'O*.4G7"E\5[+WF M>]TB@ZYGZ&"=01<-)P":ROD@B6CXBF?$-L/K7 M\FI)T!UK=*V6[@ O1?.\M_ 5!+ P04 " !-@JM6$Z(6=$\% M !E#@ &0 'AL+W=O]7 M#+S%(@%<6[9S0RX&G.T6#;"7(-EV411]H*2QQ88BM205)7_?&5)6Y,1)MS>@ M+XE%-H8>^,*1 ]WI=+N;%!X7QV/QRXKL!1N9"K4M+,TMA2>'NUJ M["J+(@]&I1I/D^1@7 JI!_/3L'9IYZ>F]DIJO+3@ZK(4]OXN%* MK@K/"^/Y:256>(W^I^K2TM.X0\EEB=I)H\'B\FRPF!R?[_'Y<.!GB8WK_0:. M)#7FAA\N\K-!PH108>890="_6WR#2C$0T?C28@XZEVS8_[U&_R'$3K&DPN$; MHS[+W!=G@Z,!Y+@4M?)7IOD1VWCV&2\SRH6_T,2S,_*8UYRU(.<19/H,R S>&^T+!V]UCOFF_9@(=:RF M:U;GTQI_QF19?@(9^W M" W_V1].:7WOZ.")5V]HB>RH!R$S94DLJ#VR&Z!9X[S0N=2K$;P5A-S: &HO MO:)D,R&+*^D\^O;R62T3Y*0>3@^ M@LM'/%G+Q]Q+<0\I MZAS:0C!H3.G)0@0@R[(W9)2)AZ5PC"^ MZ(S8JBD8"SOI+DRF4,8N7%I31G-EZ/QJG9$+3;4DU)KPQ^42;;N=O__EA&(T MMY(:&*0&9!DS%L87)(#OU0?)!8).D'D8J:VP-K*A3%!AD/!0Z[P-XQJSVL:N M6V2>HKJ-CGDOB.B>B"ZI"$6J$.J*UM:ZK2-Y+"\EG]0A)Y8=4QRN(FZU(VJD M<'!EV+ D7!"W0JJ O6/L1F24U%(27"R/4'&=9SHG[;9.$"Q3H3@K]'J0D8RK MHWQQO0.1X7=9^9BC#>&>DVMWM+6B4LQ$V554"(= /I"TH2LGA[$K1W"%.7ML M:ZBS;PJ,)1@KNZOG)YG +[50CJL,[S+$W%$+'(V2Y!@^ZBSHLD'*;)(:;@C, M;4#]AQCKL]>X#QCTH1&4._[F]:NCZ?3@A,NQH91@4%8;SPL\:4ZZ$X]:-!DE MDQ!1"_IP,%23X!>I+.N2#[=-QP8?93WY[[+^%Y--&9XD_0S_&XE]F']AY*V'0".5XMD=6NSI1'AQ%$2G M9-3SPG%9S) G9W"DZ]"QQ*6=A3EZ'D2:F*2L'(UI#*(;GKMB99$Y!C[\0=J] M3'I.2 MVH'")9DFH\/] =AXJ8D/WE3A(I$:3]>2\+.@>R!:/D#[2V/\^H$==#?+^1]0 M2P,$% @ 38*K5I)>E27E# [B, !D !X;"]W;W)K&ULU5I9<]O($7[GKYC2VBFY"H((WO2A*DF6-T[6:T64O)5*Y6$( M#,F)08"+ 41S?WV^[L'@D$AIG4IM*B\2CIZ>/K_N:?#M-LV^FI52N?BVCA/S M[FB5YYO7IZ+-)L+7/<9LM3L\F4C'C1.C[M=;NCT[74R='9 M6WYVG9V]38L\UHFZSH0IUFN9[2Y4G&[?'05'[L&-7JYR>G!Z]G8CEVJF\KO- M=8:[TXI+I-.%^G!:C_\1-8BH^Y6IM_[C.0W7^P?W]* MK]=F(T/U[@CY8U1VKX[._O1#,.J^>4*[0:7=X"GNW^7()SGMEU,$@2]FMY\O M_WIR<3Z[>B\N/W^ZOOIY=G[[\?//XNK70N<[\3$)84ADF;B.96+$[4JQ+#+9 MB94T0L*5P7 _M3C.0?VG'R:]7O<-D]%3O@_>O/+$=J7#E=ADZ;U&> G D: % M2_@O%^E"F(9WPX;^(D]%J+(<^ 2RA<:U\42D,\!"2I=JO8G3G5*X#-/$()O! M$3<4!#*ZUP94OKC;$"ML&,:IT1$ILB,P4)#<&(0Z6KW3&.!;#30(B(MOE)+64(6Z7)WX0A%XMT M0WL842#-L@<<>!=I@+"PPGS';TL'^.)*PH"'^ F-567H-_?7:[#2,E?Q#L;7 M9/7TH.)B"R?#B/>P-WCI!+20JMP!-] ]1" HZRU#1H2OUGA9RK)HBBS4KX6, MW89P?52$[.MC^8H?)<5Z#ALX[S._IH(MWJ:8_PL^)W:F>,H29(JA0>3.H0RE6V-LXY[7BE)_NM9^A= MICA,/41KKF.K03.\G!2DH5,= 9B5]."PX]W)QHJ>JV\;I&XIF,ZL:+Y A7:9 MQH@ )GORPQ/WRN2T[U(E*D.N[40:ADA(01H#5 IV\8) ::0B!:4Z$- 4:JZ@4JQ?\+BP$V3XL MI&1#4!O$$=9"%;DA>'R4^94\[*=5&L,N!LDI9@JR< 99'Z4'*+&,$& MJD>6CI0%B,-QORZYMKKZWO]C\?O&D[$WG/:? MA:UR?0U;%HBY9;7(E*(?[8^]WGCJ >7$'2^>(Z*INA"PZ I8-M22>;;!*%'7 M[;F2>"\Y(#(A:(/1+UWXNES9;.Q(.T:D8\<5" I;O95RH1XDN M2BAI8:DHC U!8$HLTW9(1'S;! M3IZHK- EK3.X1N%TP.-BH[;0[/Q"W*8;'8I@(&8:='JAL?J3RES"\[IV=6EQV$* D+$A3\VEM#,L G"1CKM>:HT% U(\RINQ)X3G(C9Y$= M04.!G29R'BLZ'6MC"X8U) @97+>TU.G=WM<7EU5SOC=Y7>@ SY!)+A%:W9@- M(PHJC^#&[AU2F]EL)@M3!FBF:%A!7)II13U:FYF#KK:=*@N2]V^T^7KR 0T/ M"CC>@IVXX=A.3G2RL%2XBF"_"%!))H,W_JY5'(D/%%I?7&AQYL8[DJ8%I10] MC1 E+2*N3TA\=J>UA6=U@7.VK"9.VQSS)2%@@\4B!V* M+/.Z<\MKFR?]#J\@Z@Z;8T$$VIDC(QG9F;TWXJ4(_/%(O.QY5;,:C_W!!+PJL^[8K#5!?77[J$FEW&=X-.4XBL[YSN%66;86 MQ?7KSL\5]/_"4QZ05A?G2S2\2VC9^=RH:Y+1IE':;.$5O8$W#D; ZZYX(7I^ M,!5CO]_#]6#JCZ:='TMG.='+_["$:XV/ _ :3'OBE>CZ@V[GDHI.'*OHE(K) M0G'F'O>F(V_4FX H\(>3/9(]\#?$ZDTF7C"T8J'NC/WN%-=!=^)W1VY_SO*] M#(*>-QP'WG0XP**N/QV!06^,Z]'8G_;;Z^&J.J523L+_2"IVZP-?U=ZD7CO2 MY&W@%Y*11WCD^_JP:6.!$\34-=;*9^UM.#;7."+9^H#S%'KFQJE,\F#(O'HF M,6[3G*5 PYH8@'>5JRY+Z[,/F6^"OT-_W*EBRPIYPJC43G;'@*3GU7V_;ZW5 M<2%Z@NJ>R64+VAI,:F6H0#R$C1=5+,+L/7\R%E<2."7JB&SW!>?['$DF?90+ MGCT?VIG%& W,&,R)@&"U[99W.AO;+&.=U[S&)^I:IZ0J5B6\=2&/\72 MUN:E#8K$6LO_7FFK6H(V,LT(-]&6:CFWT-20 ;3UD&._Q"76V B*5X &UVH ML0PO>G[7/7AH!:RF1@$=6V1'EG0B26,=L01S&7,ORF-AM&XW]5')>NLNH=64 M/S@@_>_0<.KU>UVO.Q@BN)#:/00ODAR@,?3[DX-@^,6&^O&0P30 R$W\_K33 MA+_^T!L%?;P9^MW!\_ W\89#Q)_=VY].D3Y3PIGAU!]/&\7*@=4"96L/CV!2 M\QA!EVY@>?1&XM!TULV2!D<%A#R&B6 0]X@.-10-3%G[$0;69AL-NSD'>9&@[K3-TKFBP!F086NP<= MQ*-BZY'8$0CB=,,#MR$ OXMCUV@ZZ"@0&--Q9W; FIY(%,M6HC=ZNFK6#_F\WF@B4#_'4*+Q MXI!ORK!$ XACF9X[H1>:>CZT;LA ,4*A#\:CSC->)NMXDPG736\RF'3N$D*: M9<("'(RA<_=)C0M"D34ZW*+)8&]$N2'>]F&UJ)G 3%FN?[/K4"XTG33VY)'7 MA$"2(T'W:Z&VK4E5F3HW^X8XAM)F #1$\V*=6,$Y&J6N/Z(7XLH=DBS%M0-6 M/G'_%\9S3_)O#NBN9M?7_R^S.9*5LIKZ#07E:.Y0]]:VF,XYB<-]8>[>@Y' MI^R%-C0#L#KQIP6@U+@[:=B+1W1XA7=_T*"._+.'G+_V8X,DY7ZKS#K;:3UT MW,(ZV)GGH8OZ?CE.>_0%A);!$[%FN*_'Q*@CB96 ]PYY /4] V$7 Q9C<4[8 MR%V&X@O3T: \V MWM^H\V?6 \&]D@27JOJL^= ,"87((_VJ52C:+D8?!YDO]GVN/VW\!F.MLB7_ MTH3\"S/9GV-43ZL?LYS;WW#4Y/:7,% 3P&&02 LL[?KCX9']'.)N\G3#O^B8 MIWF>KOERI20T) *\7Z1I[FYH@^HG/F?_!E!+ P04 " !-@JM68/$+8HT# M "]!P &0 'AL+W=O M/,X,EP?GGT/#'.FE-3:LLB;&[BK/0]EPJ\+4=6SQI7:^51%;O\M#YUE5R:DU M>3&;_9RW2MMLO4QG#WZ]='TTVO*#I]"WK?*O&S;NL,KFV?'@L]XU40[R];)3 M.W[D^&?WX+'+3RB5;MD&[2QYKE?9]?QJLQ#[9/"7YD,X6Y-DLG7N639WU2J; M"2$V7$9!4/C;\PT;(T"@\>^(F9U"BN/Y^HC^:\H=N6Q5X!MG_M95;%;9QXPJ MKE5OXF=W^(W'?#X(7NE,2+]T&&SGBXS*/D37CLY@T&H[_*N748 ^!$LM/*JKUTKL#>;$&FBQ2JLD;Y+252WF,'E\U_.+ZSI:N97I2+QR6 M>02BG.?EZ+T9O(OO>"_HWMG8!+JU%5=O_7,P.=$ICG0VQ;N ]\I/:3&?4#$K M%N_@+4[I+1+>3_\SO7>]I2&N0J=*7F6H^,!^S]F:YL64[GZ_^>/^EIZNO]P^ MTE/#=./:3ME7:E1%UE'GW5ZGPD7?D!Y81&&!#8EAQUZ[BA*NC5Q-$PS7-:Q*M[/ZJ[8[?$/ULO="N)0WXF0?>P] MD^$]FS#"J*WA4=V)'"G0ZJ ]-! IRD9YM#W[B:@N6@T:AK36D5LH!$Q^Z:"Z M$' @AL!5CTL0;*@QAIG2!LU?D1N U%YID\*[[3_CE?%>@VX)*O&L(BH'+47[ M+1L-\H@KV;5.DM'/C(N*#8B+"18Q.5N^*">& ^Y@>U(T\;HN2^'#:+M MH"\JMX;K;/K+AXS\\%@,F^BZ-*"W+F+?P-0 M2P,$% @ 38*K5DW=;1U)!0 R0P !D !X;"]W;W)K&ULK5?;;ALW$'W75PS4I(B!M:2]Z.;:!GQ)V@))8UA)@Z+H [4[ MTA+F+KYO#,F>&0.E]I\V!S1 =/A2KM13=WKCKK M]VV:8R%L3U=8TLQ"FT(XZIIEWU8&1<9&A>I'@\&H7PA9=B_/>>S.7)[KVBE9 MXIT!6Q>%,.MK5'IUT0V[FX%[N+7\X+?):[L7AN\)W.M'WSGU^RB._"$4&'J/(*@GT>\0:4\$-'X MN\7L;K?TAOOM#?H']IU\F0N+-UI]DYG++[J3+F2X$+5R]WKU"[;^##U>JI7E M+ZR:M2$M3FOK=-$:$X-"ELVO>&IUV#.8#%XQB%J#B'DW&S'+6^'$Y;G1*S!^ M-:'Y!KO*UD1.ECXH,V=H5I*=N_R(Y)(][SO"\B/]M+6[;NRB5^QB^*1+EUMX M7V:8/;?O$XS:TS%/N_ M#OG80"2'(?QY.+.52/&B2PEOT3QB]_+''\+1X*08^A'EC]H=9@5A MW(./[Z]F[V?P)4>XT44ERC7DPH);::!#;(23Y1)4HPL=9Y".?D4JE722AF1) M9DKA$N%.F(< *"1K),M M/6%ATIP1,WRDHE#1$7?<3[6I--%$6-0E'UK+XP3 K G"Z *^?KKMP3TNT(#3 M\)NF]6'"Z(O:$$=RK&RJE=Q0/, ].$RP$&5-$ZXVM"PXSG>)):FJ0"\6,D7@ MH/1XKXW*^%1)@U[9:! />G!E:;&7B! WN]&-9$M5%LW)LV/?:@0BY]:MT$\B!P)FVJ:W*, M]?>(T][D+:]_^QSD545W@C;<9)FJ.B,5!/B$4-IDIY71CY(*!A$O!>TF"S^" MC:2*;@A1DI(45M+4TI4D@#*"RS?IYHFGVCJ[ZY1TN.MTLX#WS;7*]G%M[]F) MR-!K1F?*"R$<=N5O0<$V9XD%>G%504LP;7?W.]Y^_$BQKL]6A69?J@D#3 M1LR,PM@X3L.5+GFW[?Y>1W+6^9(;Q&=E?I>Y M'[:;)ID-[L6"/>'\R.C]@!EGBE;2JY*!=?13;!1IM^-B M\Y_%N/%<"=10J2AK](03_G3N7ZLDX3BB^5%G)A0VIY=>1P_( H0QC#L_MV6& M\RZCU)7^1N/\B@8)Q(-6MWV)9G55*?:1)E(ZHK @MQA"ORR11%:Q+N[ />$K MP?\@BV>P3?JV,&S#U"8_J[$+R+_RW]]1Y-UHQ-_P8#$-2#Q?NWGQ=[#$\?2_ M*GP][/Q!4?.>>8S]*MUX]P:&PZEO)A &DSCTS2%$03S@T9%OCB>^.:9FDDQ) M,3IV8D&9#Z,@G@S;X+VH"^$PF(9AYR-:>^:+4MUD-5FA/UU),)X.3]KI%T7' M^NG))#KIW/G;BS1]%(I2\;O*CH(H3@X];/I[S\L"S9(?T1;XOFA>FMO1[3O] MJGF>[I8WCWR*UE*6_CY?D.F@-QYVP30/YZ;C=,6/U;EV]/3E9D[_-=#X!32_ MT'3?MQV_P?;?R^4_4$L#!!0 ( $V"JU:;;^'(.0< (81 9 >&PO M=V]R:W-H965TW%QT0=:HFTBDJB25!SWU_?,2);EQ E0H$ ?XD@RY\R9F3-# MRJ*G76/C_E9[?V_-04/M&9NK7"%6DJ[?JS2LSJK!VT-P_N]&+IZ4'O M_#27"W6O_/?\UN*N5Z/$.E69TR835LW/VM/@T^<%_]%JY1K7@B*9&?-( M-Y?Q6;M/A%2B(D\($O^>U(5*$@("C=\KS';MD@R;UQOTGSEVQ#*33EV8Y+\Z M]LNS]G%;Q&HNB\3?F=6_517/B/ BDSC^%*MR[6#2%E'AO$DK8S!(=5;^E\]5 M'AH&Q_TW#,+*(&3>I2-F^45Z>7YJS4I86@TTNN!0V1KD=$9%N?<6WVK8^?,[ ME4BO8G$KK5^+!RLS)SE?[K3G@4^K>E&%];G$"M_ &HAO)O-+)[YFL8IW[7O@ M59,+-^0^A^\"?I.V*P9!1X3]1.FNC,YRR3ZI]_M,/P;A_\@[K8O%P>7-]O^,2\O1+\?W;%R&S6'PI'I68.K2! MBZR>@:3.Q+7Q2HP[PB^5N#!I+K.U4)E7EK_V1DAQI2/T-4P75BFTN&>TFYQK ML7WXVM=J"9C9NHG=(9]TGU&7)B(RA06TF8M9X1"^8X*.]@X[KBH9&C".G5L;*.T.%8UL#D<:: 5PHA9R'X9E5F*I(%;!IY M^>F'XS X.G&X/YR; BUIFY>7F(AQK,E\MU04@\P$I4-ZG2U$HB@-F/](Q1RT M!0NH+DX'1=$(4CWG&A%3[L+^H-\5W]D/03-"AR&4Q-(JI7Z) $5:S@Q%,T-\ MXWQM6IX3AXMPEZ'.HL*2FN;Z&9\EO\@X) K(!_UNB$F9)#ST 9#*N** S*W+ MA+Y8UQ4_%[ZPBB:L3HOTY7+)%KOD.D+"X&#<1)GN65>*5T4JG2$=U=,J(JMH MW]PF&4V2BA6\'76/Q!KB<6Q]U)V4=QW25*YX)TO6&W\S@TJ\(O>VUQ5O52H^ ME$^H\4*)6#MT#82)BBOV'P3=R8]=$LF]RGT) H#@W:Z&@"'*J-&W>(S&>H*J MZZ[[O9"91X8C8!2LKTTW,.6YC'2BJ0\C/'+B _DC*8?]$T+\M3*ONXZ_"TX^ MUMU1=>>U)&FCLS<65W(FI&=:H*&>T:39HM1U76=OO$R(TP%&8K]6D7EB(9-: MN0Q=!<@HRXVFLR1?5@!JA"\AH84P,@=NM0HIZI+"L',\^,)[> M7XAQ?\RNR;,"CN+^W Q5<)"02%Q$FX1Q]1I'@-S2;","],U>K95AOC;23O!$ MRGRR;@2-W!P$87>\+2"(\7$4%?1+6-6$N-5^*6#^>MSM=EFVW1=VVHN/BOH/ MK'O=84MIXQ5EH\H^!2GWQ%%.Q:/M/'O8LYU@ N'$Z\35)T25YLQ#$VB8[:!9+VJ!W2U Q$R<8\5Y@<4!LG@3:(KOCY'&$T$ M#QUM'L,=A+7#JG))W:#*117'S:1X&:"TEK18\JA'V0?&,86#QMS'3ZT''@?- M V^+ISW5KW6'S3XKL#N(R20L/UL7V* H+%M]%PQP[L+*-\X('PZ"09^?EA>^ M[':. L3I-/11A$YE4\Q-O5H^*BPZ TOX/919T)S ?ZLN*@^"7W/OFQ>G,THY^:.:'= @<=,;'*&SG:#1HW;"[S&2O/ :=8#*J!-89 'F_UW(9 MKVA=:3FCW1GU:TTC/C(X&NUL<1Q *O38%JH1\_$Q;]]!>-*ZJ"B\/%HF6U@Q MAFA'DZ#U/4-;9'R(+MLE[ R'QPAJA*:Y-MGA)IY!9S 9X',XFHA]+UN]QKMQ MJNR"?P%P@LF7K\GUT_I'AFGY;KU=7OY"@;HO-&25J#E,,2A'[3+QFQMO04 !D !X;"]W;W)K&ULE511;]HP$/XK MITS=4T4@4(HZB 2L[7AHB^BZ/4Q[,,DEL>K8F6T:^N]W=D+&I)9I+XG/ON^[ M[\YWGM9*/YL"T<*^%-+,@L+:ZBH,35)@R4Q/52CI)%.Z9)9,G8>FTLA2#RI% M&/7[X[!D7 ;QU.^M=3Q5.RNXQ+4&LRM+IE\7*%0]"P;!86/#\\*ZC3">5BS' M1[1/U5J3%78L*2]1&JXD:,QFP7QPM1@Y?^_PC6-MCM;@,MDJ]>R,53H+^DX0 M"DRL8V#T>\$E"N&(2,:OEC/H0CK@\?K ?N-SIURVS.!2B>\\M<4LF 208L9V MPFY4_07;?"X<7Z*$\5^H&]]Q%$"R,U:5+9@4E%PV?[9OZW $F/3? 40M(/*Z MFT!>Y6=F63S5J@;MO(G-+7RJ'DWBN'27\F@UG7+"V?@65:Y95? $5K*Y8RK6 M-+3$[3S"I.59-#S1.SQ#N%/2%@:N98KIW_B0-'7"HH.P1722\([I'@P'YQ#U MH^$)OF&7Z-#S#?^=Z)RZUYS#!E]0[M! IE4)UWN+6C(!2U]TU 9^S+?&:NJ; MGV_5HPDW>CN M)'?6HZ5- S4SP*I*JSTG:2A>83(^ R93F%R>@$-17Z81:OO;>*&1Z- VG-_= ;2-1.VF8RNMWN79DWX_3' MO7F42$3.)66+&4'[O6':ZLL%<8O"WH;43L'.L^4L@?#!>A> MV_@W4$L#!!0 ( $V"JU9,R@TK>B, .%V 9 >&PO=V]R:W-H965T MUVDBI9MF]\)XD=*TYJ M'D&@*2(& 00-2%:^?L[6&PA LG)?;$D$ND^??6U^=ULU7_16J3;ZNBM*_?V3 M;=O6+U^\T.E6[1(]KVI5PB>;JMDE+?S:7+_0=:.2C%[:%2]6B\7)BUV2ET]^ M^([^]K'YX;NJ:XN\5!^;2'>[7=+WVOLYPJ.LJ^H+ M_O(^^_[) B%2A4I;7"*!_V[4I2H*7 G@^$L6?6+WQ!?]G\WJ[^CP<)AUHM5E M5?R19^WV^R=G3Z),;9*N:#]5MS\J.= QKI=6A:9_HUM^]OCH291VNJUV\C) ML,M+_C_Y*HCP7CA;C+RPDA=6!#=O1%"^2=KDA^^:ZC9J\&E8#7^@H]+; %Q> M(E6NV@8^S>&]]H1U]K(H\S96.GIF? MGG_WHH6M<8$7J6SSFK=9C6QS&/UU61V_+3&7A^R\ 9 OWRL#]>C6YX,]) M,X\.EW&T6JP.)]8[M'@XI/6.QO P??BA$T\NB-+T4M=)JKY_ N*B57.CGOQP M+XY_VZKHLMK527GW/_]UMEJ>OM*1]MY)W#NUO!-'M]L\W49)HZ(LUVE1:95% M>1FUL%;297D+OV[R,BG3/"DBW2:M K%J=00R30_=J:2)%!(F>J-2M5NKQJ!V M%4=)F=%39=4"@/!3H]J*=LO+M.@RMUD?\(NR[&#'3ZJNFC8"$40YBI:+V?]. M$.S($NQHDF"O$YUK9-N/C:J3)D$9'Z+2Y"HC5!I:FTB#Z*#?"R/NJ_)58(H??;[=548#NN$4@=;?6>98G#?#D/+HH"E@#3B ( MB]HF*75"JEC3 NNDP)/[N%%%#@(^@ MY3L/I>]+-G$C;#2Y\ @;/7 [XJQ::^2\?\&+P+0B]4-(FUQH!&DCR_N:, M#4F.:*9_=[L:$ <8^= UT>M.PX=:H^PT;5>#IDI;9.[58KF*GN$+(D3__O#Z M"C]T@O09R,-:TWP6CP""ZAQT-H!2)'=1DE4UR6L)C@KHW4;=Y$AE3Z%K*\FY MUIU(E/JK UI'H'%Q3U6"!"'Q$=H0"%P$N /EO 6W"9'0;L$4>,LF=0VL 4O5 M37X#7.0 G0?HW<*[Y#8!#/!TIQ6SE_K:LI4@6[G)S0DS1%#N01Y.#[ MO$7>1L_RY\@W914557D-#XUS$(+]+(?GD\TF)R&]48 XTGH-G*=*DS6JO1I5 M8F=I,8&>NJENB0 M1>A@2C&9R+2/D@H +^'G5#9(R 8(-0RV>@0+>:E1&!I,R>L>_31A%.G5]T:. M8Z8+/ELD\%R6W!GL;\#U 6R0+P-89I^H[7%U6[7P3,)^"8 !.@ .K^L21]6>+P8??INAQ(?0 MX.;MW9ZK)?YMTQ6*/9-&77=%PIZ*X/WJ[27\^:\N!R"!,"4$K#O1R[OD"W"N M!1472$!_[VI>@(B2D(BP,[5C7ZHA"VU5@E;?="+:Q7=&R3N?!_%%"-.?778M M[Y+KOF5M:^*$,BGN=,Z/ @OJKE'&SH 'LS/.!FP51VO0>:AFT%MC&_'2BE&C MT@I :$ENTJ3.0>#RORW5R,V!O4#[9/!&4=5HYZI->XM0X>9_=0![MR/MT+7L M9^L6HAPP0YNN@$UO%)$%U?@,?R-\*WP$W]\D>>-D)KE)\@*UX RH/]/))-N? M6;8_FV3[=[C%[[3%SPY5@]P_N= (]X\L'ZA5A2=,)"#KG3D% 4\PNB"L$%) M X R ZJ@N=2(U-YK6S";29-N[^:\/?]5_*RO8#[![*9(78*3;8/C9F;RVZI# MO4,\H(@N(!U:%:AP&1@T,G62TP=D)#=HARUT=Q03 9\T&3FQ7L@ R[:W&"*( M4@1-T$+T"[C $[)D^6R+HM,_BI$'THWD"UE$0!A3W>)O%@]&'<.YJP80][>@ M.B^!*Q&)?#S9TTTD(L/["]5?26NVD+/T\@_J('EH>=EP?DSYZ\BGZB=9=D3E:O/JR1!6D] M/J9!@@D&_^HJ1!_Q@N8 ENP^$T6_ZJV[&ELWJC"-@,?@4]ZSKNA00'/E5E(Y MK9&!1D[;@GRVO#2_Q>P(@\7?6WIO3=1DO%^,BS!H J=99=U47^"OM!A@9:W* M=(L+17)U%<^B< MZ%@G);MT35.MJ\:PL/>0[ )]I1# MGX*'0L'/9;5'0PNL[FHQ90 4K-,RU&5EP"+LHGBSJ9774"(RC%"=.;5NC6= M8V=Y1M@Y2)6P=D-RX_^["J(O6 +S8JBHT+8F>AMM0*Y@"0B0LJJHKA'W'D5: ME6[+' *OT)?UH8/HT0_#G.BE;'9$075%TAB9G9)([9P+8Z>%>^Y\WX&5OIA2 MCXA]%;]6='A>/S,>#FQ<%PF[\K[:&3$#@!!9WI+,KLA8OD=L.9YAEWL3:&+\ M.P41>JNLB+"%@8 ) @(0HAU$1'D-X8!-?Y4=Q0)P='R W=R8#H)!&/I,$&(Y M!]&W'N1"8+ UB*ZQ\_D*E=7"OA3@:P YG"$'2:,3$L"-HG VI? K1!3 9CAM M4 B',)ED?W::O$$D"Z;3@.%!/]4J10B9N_ 4QLQ:F_H-IX;??4\"H*"8H4$% MU2!"WG1*^!B>TEL0^AFIE#)I88%8S%O3D&$=<73_48 +5KNIOI(5[[,N92!0 MMO&<] -*%'R&+\8NA\G."9+0^V.=W%DS"G]LD(CJ:XU@Z=&4F[C@&J*HA.M8)"'>8'3!""W"!>?(X:IM? M;PNT)@ ,<@Z8UY99@*(W&3>0LCZ4I0!%EF@)G=$=VW$) M"J4#LW\E!G]56\6*QX'\/?B/#F9(8[RTUC*Y''1"@.C10 MG2!4$^INN7!EY<6DPKLPJO63U;<$] 4R!I$+>?&2>>>G"CVJP:KRY"XCJN\1 M>[MW&N\=B@[*F7'>[Z?]Z[PH7 (U6.QIM 2R+NG_Y?'BX'.Y'G_X[/ $N&!Y MM!(N&%OP[/ 4_C^,5^>K@P]HKSG?# [!&DN8L9^JV41#F)I233H<,614;LH";DK.$)0IJO2AII(%_F,"6)-,ECNVI77AX3^M..B)+K^%C.2F9 M/Z,M WO,2+D"+!0C#0[3"XT(W_#RO3]K\V<4,?08T_,K0CH'5>&P7P?]:EAE'W4Y3Z3E.2E%V*79(IS_'!TI%+ MU-"!)2W*.218''A7PF-4\C5':%M5POZ@MU%-3(.)S(5UEE:5'()B,4X3#O34!:*M?/&*A#Q4:VR ,:D M2-+EP=T:XK=2U=;W6UES4BIP0'<2L3F.QX(%MGY@NK6C=)U=/"2E"U3Y$9*4 M3*U;/PE%KHL +,8B@%8/)-4!@IFQ+WU*AA"H!G6[=H;*V0#B&XM%:WY(KZJT M(,SNIRQZR%QCGR$Z?TU+',N:!(4NT+V8+02(\L;#DF>-*"[1["J!M(/JIR*P M*U"8/VP@4*\:+10P^60-XM9XYJ(KP?:P!.'^U*%P2XEQ/1@2&VM#%6>F,Z!F M6Q69Y*#=>;EXFE@+IEAGPOZP>PI$A<.]\;#G88ZP(@&8K4^&:,H)_CMZ%,QS M(AT!1*2\DEP+5M?XK2;77Q"UO94]3..*'# 5^1=%N4EA_ZZDI#]I4\>,MZ!K M$"R-9Z= M*[><,.0D03-52%JZKL/E=-OA1U]-OC5J,HY^4>V@OGI,S^'$'N%GRGU6*B(2 M!0UDF0FS%#:#Y]CM.N:%#.M!:2X=6C\Z=XP>![)L\J^V/FV& A:IF*JDEM9X59HK4SCPKK+"Y*Z2:OZ A-$FW %YS%_MDW'1-F6-NCDNC M^5?\6<-+YO53>?W74>0=RA,_8=J 5!"($80#$DM>8<[&M=QP\N/LH,I:MV&/9:F/0-L;WFM M3'>FK&T.P6K$)-B3FO/3@ Y4&=PF)$'0]#+4B-1:]^E;W*+?1G&*BXP+ 1ZW M1M15G0:]NV*R3KM9KA=W.=V,2\PQ[&$]IO^6EPLC*^==@0G!.-0EL*@4:O): M&#ZFJF:-]*&F@@ E[6C)?MMR%3X %@P%O=K,L.DM[&/"0 3W^?3AL_ K:2AZ M+:A@@^4K9>: %!5Z4+U]1@I+O!A&I: ;\HHT$CS2$+L[YXUB98QY23W+BGX; MN+"<*1?-(?\ MS2;%Z0N*E:3)C.U!8(^EYR#LA-ITI-> )?(=,+R@+KG;]9,$Y#'!0;G%$\_+ MSR*;E"BS[(^1,*=<%[#*W:FS>70!*V>L],@%,7E4)0D/SS4B_Y4]'=LQX5AT M!WZOBP6P <)B%EBG10+,602"1PT*[6[.A(8=>.:OP3YLSA+TUE*N.0*)UUA1 MIC1MLX?T( GCPE>3%>D1C.N%O*/*C+3Y6AN"Q,I!KWWJA]'1MQQK[GJG37'= MMF8X2MS'0R'O&#>E+YSCB,.&@#3A-MD^-,!Y.*9A&ZT&15X;@X!] WGAM)W+ M,$V0+6AM0=;L%GHZ5?8\I)-J3S>S52;.#;4'!)@FZT)#KG#ECP+1D_K[2@) M$]K2IOKN;#>4#30,0U)HH;YBCD9+FW!5.Z;:+U$9X81X<,:B8J(_TR9"5>K$ M^EM\*NOJE.H6B.KMG29=3"CLU_W99\=8]&X"'F! S')*8\(> M?:1:TB>+&(R]H+RO%'U,7<,)&TIW=4; $2SN.T4 2(5,^1MNCF,Y/6D MWKN6PC>VI?!*/.5!E^0QLQP/WC%X <>1%2-> Z/V'\O\[EI MJIU+?%GQ!)SS%%"#\%5_8B(>_)QK9;RA I@Q$V74\A]MI@%>6'//NUG.;F\R M"<8\2"9*[$"92BJ#6_ACKRE=P/.6@CVID8;()9@B3XMS93(% !N!TT :A#-M ME*0&+'742^$-=YB,+,Y:U-=-DBD1[2V)K0]AXEAWIODTIXV)^P*?DG:G[EMIM!!?28N:A[ M]N&_A.W0UHP,Y^)=^81:J2EHMYW4Y&K>Y.I6@@B7.R,[BPE.*H=&BH_# M\F$QNC3$ !UO!#-D;N\YH74=+<)(6LL1X$UE&$,!1U-2##8X,]-F7SGU/ Z; ME[1ED-375*F,JP8NU3R/?JG\W3 G2PD);\\'IT#P_/>70]T(RW)ZAN4/2B2T MT4\N5AV4V-P#G,FFJ3C./#;DJ:+/ MNU$))_R()ZF0L4%]&V%A.M>'!A(OKBZC'ZK0%%'9\OCV$Q%OO%>0B7R MH\IPKFLN4Y(4"KJ%Q\YEV@_WDA5>UH"%TUO+KXX1*0D%&IDD M5V9*EGU5[-^E8HYXDE[]**UFXBM2PUAE>C'86P%*4D\M\$Q=J% _)Z;"'#29 M;9 U0,G7'/LFZ?;EP1+T*I=O[DPS $5OKGA@?-J#5>]1<0TY9EH7^35'0@>' M6$KS(R&_Q9B:>P^.:/*]2DUDNO>$T:UC>QS/#=W^5I9"%-D^(^G@,42.^B(- M+VFJTB8C"^[-]?H9[ZT("Q'/(DB[G!5E"G9K?#KFJ=T9NX\CF_F=0D-<--@Q M<KPX''_LX1;]!PB/NOK^!J(8;>Y27UNHTAA$TT38%$J7D MN'"%KY-6LGG&FZKHN$[/JWD='RY+1DYQ8H?090@8(2.LS*-W=G6_#Y/;_=&/ M-YD0[R0(9U6*_]4H<#1L3(8I&G*BV#8CP')4A,-+6YA3:&,A@K9(IO[^*'B? M91RCV%\3N:[AP3)OL'\IV9G1\5:SE=E%Q@)&!0@[D=F# Q>B,/EX681&8["X M*^' ?XPMS?4:LL\^':TT#)V2Y \4AUW!?K+/ZCFU2G-&C5)BH.QPO 6@!]TV M(I>FD\KDWG6H6=CLCFLEJ@2+JH&X\@]\IZ5T'XT/W$,1\BOLT7KJ7(ZBQY4E M'7 $+BO9*-!\JP!XRXJ&#LT8D)S1"B? [U7^Q]\*DN'>W =_RC,^W!5&HT-B M#VFO6U[+[QS3WD/:YON9/TW*-0QQ*(%8N0]= L;@?QQV"0F^E-5M&4<93VWD MK90MI>-06NRM@D&M44JV]-NHY$KE8#;R#!6-LE 'FPGR3( G[M$ P5-]4>R MHYQUYZC50R&& U1O,5Y>&+GQE1.#"!]"=L#D)@UE,U6R%ZL_A%WT%X]TV1B8 MW^,*T+B >Z4"FKE X;AP.F M4'(;P3:OM>>_#@,CQ@,QC\R&&D,HTQO[B"W*\SXV2%K8FTBW>%^%S0F,')+2 MO^80C=I@19G.@1-!LZX.G HTCPKS<#PK;0V(,Z \Y!.A7J&_8WS8X$@E3?G@ M<"E>N$$Z,-DI1^>PN".^J[>NN3;!N$FPPHZ*OVXK$R6082Q)+>XP(#$E0QMT MI$U.W1LR0]>^I"M+ E^*)PC4==7FTN9"DZ'I%W3.^F>T[[BVT[" MR49V.*D1.F<(+&,FX"\+":P=XJ'UHS6$<5<\OWXA9I&?V121W.")0FN(%7->E<5C1:M&)L M.5%6DU%57U;W_-)[ K-'=5"[!@N=:0$AXAF,']R&:X)XZC.83(%>3,J EK9?+(0,-3AOW21A'D ML9("(O&7AA9SPTF2W1"MS9DI;>F,%]X2H5M3L\6\TX, 6*&A1G]'M^Q$Z9:0&KS^!P);?Z]5:7_O1U8&@D" *B8OH2 MZ;Q10C-MPF MS;K2F?-G=*M&(YDP[Y/GQ%%A^75P/(^O9+5W7'C9_*YD1+IDT8.-?']PCB:9 M#E[+\ 5W>>S-N$1/H_/X_'!Q\&G?&WAV&!\=G43/#WY1MQA;*Q#Y@JNCT>G) M46_I'C1/H]-X=71V\*X*(^+0QI.G$"H,+/:ALNWJ&1 )ZP7F)U-Y^=0CH^TN M_;#F>U@<$UXE>,<0ZOI<:Z*HN0Y%[>JBNE/&\=_F3<9$-4,R7CNUUPIB"[&5 MV2O,FORM5]U+@T*UB?\P4Y'T'&A1?&J*(-),-@NNHMEOI@KIP??X&7K( MQ72NLZ)WW04_+?UQ#'D J $AO ['735#%5R^+$!W)N@([][A=HU)D"$^5 '# M]9MO^RPW?8LAJT^&W T*6\<)X(B]Z.:FPM"X"&:M;$DZ7!:'D\!PJUY#I'8W M7-M=B 4Q?N;KG61E?SG&MG_/WW#;Z?[9 Q*[2LO A-\:0;27^!G[[6[URTLX M_8UWEY]-W]DY/K(%W-ALXI*!C4RLLR_>""-PVD;E7$?F-+%,ELU%>PV(/8WX M;'@*U=Q1P ?GJWO ,-E;9R;5TSTW7N[5=B489.R*!^0YTP*KT1UV0'S?9N/[ MHUJ-CFYA.]!P4@>\VVP8W?>J4NK&,;WKX2/!'5 &K4Y]V" L M\#=QO?W60"_H!E>B+:3UTX9HZSO&.G4A#Q(Y2#N)8KCW<+FV]^](CSF5I*67 M3RR&'? @DALEY>P$SG2I3!2FQ#F?<38J M'%ZU\SW[K$R-/S[K;AR?$HC*FV\DDV,NJ;ZD+)9T"_-ER$U=:9XQ8RGB2Y6G M42NUTV'8R9^S-]-S/C^X'BVV&7VC,'W=-^3O7X +CU=G1>]+P$K;L1N!]3[N ML?C(EPC+O1MTCZ,QJ!?O+S]>6#OJW77_/\FN?O6[G=+]5P=:.HY^]R^1^,C7 M0Q=WLQ]!=<\,\7#L$8Y\Y29+W_,=VXD._*Y)OW'E;C]93=]^ @$?"JAIH<:# M\S3J)S!"0\[C]'IC/^UW=05THKS!6+Y ^&G]Z\DF??RQCFE],SUR']69LB:V^H>M+U,,?0NE&IO MJUZ?$K*L\ZOZ5LA"K#AKY/RBQ6YJ]]?N^X=O,MU__ILNNARXJ8PE\=W@ #$E1G5])C+ M7!SLLU2@_*3/FVJ\WX \I] A?._,7^!L7(,&@USRM:,M#9!3@WG++A\6HH2H M53-"],$[%T95CA,O5X2#73WM,_8T['8\%)K!WU"XT:5F=WQ7.F*/@% EHO_'G,C.;,A6B<2GI8PM M8!RA!^%Z<.I"[JNF]6ZK?[C:=#OLRMT.M)J^'>AMTF F"HPQ7HSU',OWT=5V M9))F>JVQ+_@8VX&^=B>ES#U_7M#G>",H!9EF *231FN*TO@K-6CH%Q!FWA&E M<4O?R:6RF;E7R%TA2BO*+(T?4'0M=568R_)<4G0>O0%-2O5N ^!_ ++HP9!E M;A*" 8JCNNAZ3F5@^/RS[+UMN\Y=_%'SM4 $-%]38E1QUUKUF@D2J(7;(0", M'U?TI)% \;0M/2UAR@B4'%*"JRQOV5O$,;@P[\^'RQ:*>[I,/3R$=$W<1(7I M89B3%OR"===Z7Y)A8<2+#E#\@B)&3#:^;LW[9>:MAGKA? MP D#2U4U+P]^$20_"(JGT;/5:7QX>!8]QY^/XM7J-'I^\$;A'&;)"_[1YRCA M(W.-E>MQ,_3]-E3(3=#[6%TM%O%RN8K/CH^CY?E)O#P[C%='I^Z$_YEMX-R+ M^?*(,;"8+U;PTWN3][:QOKUL-F1BQY'(53/+ED$>^;I1*+27XR:L('^O)!%R)H]]5^@RIG3":M MXO/NX1G1)2[E;@GAOM*'O]++G,Z.^XTHE( K#6A;FAF;5!&6F/?(WF6@YB5P M]8^U.HJ/SL_C\Y.S:+6,EXNS^/!\\A+AE]G1XOD4RMQ-3ZOIFYXLU :B(; 'M!LBY=]=J?![ MST[&4+(\F2T/XR$4O/"^=12_VHF^6U5SMQ9_ :G]J_W^U@O^UE+W.'_Y*[BR MUQ@\%&H#KR[FI\=/N!72_-)6-7V'Z;IJP3&F'[&ULK5A;;]LV%'[WKR"\8F@!-=;-MRP)D%NQ =V6->WZ M3$M41%0B/9**D_[Z?8>2?$D=-QWV8E$4S_T[%_IDIV17@J%+X4V-7=X-7';B]V[,V8EN M7"65N#',-G7-S>.%J/3J=!@-^XT/\JYTM#$Z.UGR.W$KW*?EC<';:,TEE[50 M5FK%C"A.A^?1\<6,SOL#?TNQLEMK1I8LM/Y"+[_EI\.0%!*5R!QQX'C&LI)14&Y=09?)>C>7?L<+?Q:,LP\BTRJ3E>0>-]B[Y+9D MYRK')^N,S)S(_=X^3QP41"EV;)<\$Z=#Y) 5YEX,S]C'4K!"5T@0',]$_-/(>UYYQJ_8. KF881%F@;)9#KX\,3B. C#L/T= M?-2.5WX[^);5?G?])P.A5=)K-2&M#D P74,P?1$$(>F]YJK5]YU4B!.! J 4 M, 7(V >ZPZR[9+8$I(Z)-U3:UC*W S_N?CR %[*JX#"^1] K%B$VD7]&XW#P M22V>/SQ+)@AEE,9=*)]C.$NF>"9!/(\/N'Z\=OWXI:Z_,6AWQCVRF\J70<3@ M&AA:$@K8)RN*IF+O9;$W" >%/)/Y5P(O69?8T@)D5=94'GV-]<4 L0%F.367 MM\23U0*AR9F^1Q3H*R MZX["ZU>AS:WCRJU%AA_UNK??N*$/7!2U\O& M@9]8VTKHXQE>C<^*[KO5A5L1=<)^_FD61]$O;,P>!3<6&,E*J&<>@PV7@!6- M4=(U) \,"_E :PNBGGS:D?_5P-]-W8DBR^VC1?99B&I/O!=HOJ6N4)9J*HY= M9MZ6VI!JG;T5G6+8J)E^UC^%Z(\;T3K;N^D E"9K*$U>"J7+DJL[0=64?5*P M0 GJ'_="-7O15-Y.%S#.7"C M93>PX;8$R@-VP:W,/'2O9(4,R/=%[J"('XD PI50&A-N MR_"S'ZN!\"B,L3H Z-D:T+.7UI]SC.]>&DH^NQ598Z2C M,?[ZH9ON"J-K=KF+LF^38!_B#^NPBVU)$ZS=J$707CT-[K;G=H:VOD39C?ZX M66(P4SDQS['9-4F 8RG\%8\B)'5.]0^S3 D9;"&$(K1O&;XGQ?K8[""J5ZTM M"-Q758E.6120ABMG@X:TH.QQ\FWO[N_DS>6VM7I)XG?-BM,@G:-V3F8LQM04 MSH)D'@X^UN4\7"*A$T3C%Y)%.[2[&J0@N,XI7,8W.-)U UR MZ328C^E3PA)P"I-@.A_OP_MHZRJ+ZG+G+^R8BV@,;&^UZ]WU?P+G[55X<[S] M0P%=XT["LY4H0!H>33&@F?:2WKXXO?07XX5VN&;[92DXTI8.X'NAM>M?2,#Z MGY*S?P%02P,$% @ 38*K5C6=('BH!0 U0X !D !X;"]W;W)K&ULK5?;;MLX$'WW5PS<8N$";"Q2]S8QX%RZ+=!@@[CM M8K'8!UJB;:&2Z(J4T^S7[Y"29:51G*+8%XF7F>$,.6<.>7HGJZ]J(X2&[T5> MJK/Q1NOMF^E4)1M1<'4BMZ+$F96L"JZQ6ZVG:EL)GEJE(I\RQPFF!<_*\>S4 MCMU4LU-9ZSPKQ4T%JBX*7MV?BUS>G8WI>#]PFZTWV@Q,9Z=;OA8+H3]O;RKL M33LK:5:(4F6RA$JLSL9S^N8\,/)6X$LF[E2O#2:2I91?3>=#>C9VC$,B%XDV M%CC^=N)"Y+DQA&Y\:VV.NR6-8K^]M_[.QHZQ++D2%S+_,TOUYFPO1=M/+ZQE\ARTDG=0&6FT9AHV5*N-SF6E.92%KG V0ST]N^!J0\!\X>I;G>UX+DJM M"-P*I:LLT2)M)N=E"A_*'8X61@ FG_@R%^K5Z52C%\;6-&E7/&]69$^LZ,*U M+/5&P569BO2A_A2][T)@^Q#.V5&#U[PZ 9<28 YSC]ASNRUQK3WWR)8 +]-' MNP)_SY>X*YA(_PR%W5CUAJT:<+U16YZ(LS&B1XEJ)\:SWU[0P'E[Q&>O\]D[ M9GVV:# %<@6?2P1GGOV+)_<[@E+94#Y*I433O%(ZPVS&Z7<\J^ +SVMA]!Y% MRQ\>^5#(1YT:#AD^;02L9([5("O7H$T:M24!?5:@WO_V(F(T?*N@ M/H2T[D+*#R&)+J25"6FW#RFQR6V^(/K)71V2.]D?=M9+[@RKQ8YGN?'M-1:^ MUPHU1_,%_/$.KN>W%^^[=(-F\/+JXNKZ_.IV/\Y&\T)6NCF$"AUMOX>]?V9^ MU"5A(4MQCXBOOF*%7M5EJN E^)0XE&'#;A%[^Z#537H!<8/P":EF!N@ZA'NU,3#S/M=,Q">((#55;6:'O M4$K=GLM2&G=9X)(H#( Z 2J1,*"HQOR8,(;+A"&AD0\'@(<["2*S Q$C44Q'GZ1&5WXUI_!<7$9B MSQP,C0/\8KP!\]$^3K&0^!@.MCS<#]^TK.0D)&X<-C(NAAI'1XJ%WQ4+_WBQ M0&9/Z[Q!/=9B4]%J#.V:Z[K*]#U&'0F'@,W\ GP5JPD(DQGHF M!BO)48^/5)*GH#]41O[?TP!!&Q&+$+\D#/T6'2T*7H(;A22R MU85B8@9><$CC(RD:="D:_"R?78JE[B4/&<@MTB<]0W5P(U5F;GVD1W)#:7?< MBR&JLOG79$5S);9WRR7>=P=S[MD\ M6%AE<_O8&U98(>Y?6(SJR 2;M&,9/C M>#O&(:[1*-*-@>. MFZ"ZWJ >NJ!>G8SF T*CCT(9\N8E9NO^AG=HR0K/I5R+/5!Z5X^&^7H'^(MS MCV'T$D*?N,S6VH;+AJGP!ZDC,(NII8P)\I-KJC)U(TQX'$#*8)ZA+B1)+SKP MW", >@ADBO*& U$&H3JA$>MXK"&UIR&)9$MQH4G44"]V\'C/%4.XLV##Q-H;2YSN5BAJG,2(@=4S2.JZ6BYM0^7I=3X M#++-#;X[164$<'XE\7C:CEF@>\G._@-02P,$% @ 38*K5E,$F["7! M; T !D !X;"]W;W)K&ULS5=-;^,V$+WK5Q#: M8I$ ;*PO6[;C&$C2I@V0 ,$ZNST4/= R;;.A2"U)V9O^^@XI6;%5V_&B/?0B M:<29QWFC>=)HM);J12\I->A;SH6^\I?&%,-.1V=+FA-](0LJ8&4N54X,F&K1 MT86B9.:"ND:6 MR53*%VOH-\Y[L!E2C2] ME?PW-C/+*[_OHQF=DY*;3W+]*ZWY="U>)KEV1[2N?0,?9:4V,J^#(8.I, MOM5U."4@J@,BEW>UD*3D&BGK#6CVPE%UT9 <$_:A3(R"509Q9GQ' MF$)?""\I>J1$EXI"Q0TZ>R933O7YJ&-@$^O:R6K FPHP.@ 8HT/8X<7O,L;HAG B,HHFKO]_ M4;(LF%A@=,<$W&>$HXDAIBK)+2EL'VGT^P,@HGNXK?_85Y]J^V3_]E9D0UV0 MC%[YH")-U8KZXX\?PEYP>816Y/WXH1^%Z:5& M\Z;&1&MJJAPX(U/&F6%4PWMB^B=H%QGYGW!!I:8S!*\Q ,Z6NSAKJBBD :L< MWE(:G3$!$++4@*7/A]X_53*S[G+N/;A-0E2=H_HN';.A=TOT$J,, MCHA^+1DP<=O:3*%(1K', *)=KWS=2BX%?06MJQ?HS7D)F:"S\!S]@+HA#L(( M+EPMH\N=JVK1@VKG5+GR%J2@JO&(<+\_V+4\EZS;_K0D-QGL8G5C/ A";[*4 MROQHJ,JA\"L(="4>'LXH#/LXZ/7:-@2H0BJ0'Q+2T"J1J;1E:#R3/HZ[0=OV M'DO!,E; 3KO^ YQ&477T/D_00JZH$D[<%AN^02)[?:,SP/VHWS+K4NF]'!O? M..[BP1:CVO8>I%CLKS%*<3>,O8$B ;LVSC7\O,E[.H)1[A &?< E= M:+MYSDUI ;-Y)LNZ@##1<@!2A+._ (Y3 X;]C&>@ M>F8NT+XQJ;,U 8,@%F[.U\BA5L-P<[?YE;BN)N@W]^H_!.;-!8,QC],YA 87 M:=='JIKM*\/(PLW34VE@.G>72_@=HLHZP/I<0L/5AMV@^<$:_PU02P,$% M @ 38*K5IF=F38) P CP8 !D !X;"]W;W)K&ULA55M;^,V#/Z>7T%XP] "1OV:.,V2 &WO;ANPV[+KO7P8]D&QZ5@X2_)) M\BTVEDE0\2;93&\2P2C,M@O?2VC5XO56];+G&CP?1",/URCZW: MKX(D.!H^\%UCG2%:+SNVPT>TG[J-)BT:42HN4!JN)&BL5\%=LKC/G;]W^,QQ M;TYD<)5LE?KJE-^J51 [0MAB:1T"H^4)'[!M'1#1^'; #,:4+O!4/J*_\[53 M+5MF\$&U7WAEFU4P#Z#"FO6M_:#VO^*AGJG#*U5K_!?V@V].&6"4.P:0+ M+H>5/1_.X21@'G\G(#T$I)[WD,BS?,,L6R^UVH-VWH3F!%^JCR9R7+JF/%I- MNYSB['JCJ;_:OL"=K.#MMYYW=.(VA#_H/EQ]9-L6S?4RLI3)^4?E ?5^0$V_ M@YK!>R5M8^"MK+#Z;WQ$#$>:Z9'F?7H1\#W3-Y E(:1QFEW R\:R,X^7_4_9 M(6Q:)BVPT^KA[[NML9HNS#_G2A^0\_/([A$M3,=*7 7T2@SJ)PS6/_V0S.*? M+_#.1][Y)?3UX_!VX,\:+G3N'.N+N.=9OZ9PQX.O*21=#FZ@5*)3!BM0-=@& MH58MO7$N=W#%)5E4;RC07"\FU+ZR\?U[@R6*+6JG3%PS74?3R0-!]9;,8Q:? MDY6D:LI0'O>-JNV>:80?(0V+N/!K'A>4HFRH*$TM/6%:]UIRVY._@ZOYLY,- M%&&1%_2=QK/)[TB/NE%M!5QT6CVABS20A,EMYKY9.OFKISO2BP,+5Z!Y,1:% M@30+IUD**7'(XLDO6AD#W=E3@VP:)L4M9%F8%U/*:LR"ZBM[T;?,4HD5TLF7 MG/EA=34/9[<)7,-5$>8S$B:7>D%G, OS^7P0XB0_=].BDR$A4._\*'1-[*4= MYL5H':?MW3!D7MV'44WMW'%IH,6:0N.;8AJ 'L;?H%C5^9&S598&F!<;^F.@ M=@ZT7RMECXI+,/Z#UO\"4$L#!!0 ( $V"JU:KW6UK\0( %4& 9 M>&PO=V]R:W-H965TJI 9%M?9UI8!FSJGD?MCK]?V2,N%- MQTZW4-.QK UG A:*Z+HLJ7J= Y>;B1=X.\4]6Q?&*OSIN*)K6(+Y7BT42GZ+ MDK$2A&92$ 7YQ)L%HWEL[9W!#P8;O70_66:*B3?P2 8YK;FYEYLOL,TG ML7BIY-K]DLW6MN>1M-9&EEMG9% RT7SIR_8=_L28L$59&H6W#/W,])LI0)$YY52D0):N#V9I*FMA-#E[H"L. M^GSL&PQE'?QT"SMO8,,/8"-R)X4I-/DL,LC>^OM(L>49[GC.PZ. =U1=D"CH MDK 71D?PHC;OR.%%'^6MUE2P/]2V1I=<2Z$E9QEM.D5D9*% @S"-0N;DE@E\ M(48Y6:(2L"WQ?7[-5MHH;*S?AUZH(1 ?)F"';:0KFL+$JVPL]0S>]/0DZ/>N MCJ07M^G%Q]"GRV;&+'.:IJJ&C, +#K(&?8CJ4;##5&V7O,$E5 %)95E)C5H, MC)U%0 KE"KL0A8XMKZUQV-GA:^Q- MQ2P^ED6Z=JWHJT)@PAE=,(G?N#N,DM:]4C(';7<(ULYR9RE: M!]UP$)'^Y:"U@Z>:5;:L+DYKN!\"5R"Q^3OFUBJ#9]QJC5<_"$@\&';>/\OI MR2 ,PJN&^!"32Y*H\R -LGE?&>0^[,9!['+I)\FA/O#W1KT$M78+31,WL,W4 MM]IV9\Z:5?'/O%FX6($U$Y@BY.C:N[A,/**:)=8(1E9N<:RDP37DC@7N?5#6 M .]S*TV2'IY6.P#+=$V$4GTDK2=].MWAI1E)[658%\6"&)*FAF>F3DS0^EL M+>2=FC.FR7U=->I\,-=Z<3H\8=>2J&5=4_EPR2JQ/A\$@\V-&SZ;:[PQ')\M MZ(S=,OUM<2WA:MA9*7G-&L5%0R2;G@\N@M/+'.6-P'?.UFIG3="3B1!W>/&I M/!_X"(A5K-!H@<+/BEVQJD)# ..?UN:@VQ(5=]<;Z[\9W\&7"57L2E0_>*GG MYX-L0$HVI=,CG.97L9&)\OJ8/0#%-+J2D MS8SAVB4?[C$.\)0V$!6ZX)I6_"CSKM1G_7QK2TO(J;$.$HN'SNZIK(D M)NWDRP)3K]N\^OWIWW^T6^SAFA6[-DB6BT($QI#E7%B :! M*>62K &0]S*H!.MP@PRHT&G7$K>S(RXGDO&2&UIQI!F!$A2S#N6F,S!(G0) MAH J,A45-"!UZGPUNKL4=8P&2CLW7-V=3%& PY[@A"82,;Y]E85!^(Z\(8&7 M)N2-@Q0I$!5(U>2(-^2!4:F..\G82Z*MU$I4$."*ZX<=4VGJC3*P]9ZO> E> MD ?.JG)'8+OJX47<\2)^*2\PA+L,(!?8&P'RGC")4'^8M@JBW>)B-I-L!DEQOBRUTI!H5(0,@_1[ M5C"CV?(@).'(38/$#5.?O":A%^0D]:(0UJ/<2W+G8\NM3:3;7T@60P%B8,H[J1V&>N$F8@5#@Q=D>9$_H";#"+'.# MV,(* X#EY[ ._,SSD\W^&(W]!H+0C=/ S>,1*/E>GH"!,(5UDGIY]%@?F,4Z MN@JR0E;_%U1]+$PZ%B8O[DYF]$Q^'3UM^\6:E4\Z%?KRK4$/K!*T "NQC[F] M2 XQ5T"OM]QMH16[T)B%9I ])CBV58OOYO9;>^F2]9Q#@+$%\::HEN66\X6 MUM/8#1HE*EY2]&G*&R 8-QC@!K9L, -5LVUAIMOHN5@JV$T=/]/1K@1D&Z(M MV8HUT%Y?DVAD4SIR;L!MPP"$78) )19F2,3 Y\$;I)GSBV%8X"1@,3=,8V< M3I,122/G(VN8!*CXD)9P.N%*0[N$8Q:)W"R-"11?GCJW!Z+IDH89;-1,546* M[:@%?&Z89 3**@4G=AX(\DV6, MCIMEIIS<;)3U\#[M>)^^E/>/>&.&&V08*6VZA2E6VWSVCN#>;7K:\9,>N^W" M$*:RY @&0L(;>\Y':/#W0-L7/L=4F!F8O MC'K%B^V18',88%UCQK:7P?_82YUN)EB0)UA+3\X4&P-M[X R\"+;Y9S-:#FA M*Z#SK#5"GAK9.H/5__1T\KJ;(<">T /R]+ FZUB3O90U>!:1W/1PFY5EPS4Y M&D"W&1QW\W4?8WJWZ&&,Z6/_U]S.W2CT77\40SAA"(60+AA'4(^Q%V4'Q_9W MF]RCV(S] ,9QYD6YLSNHH]A-@@B>Q!YTP&<'=>;&<>ZF=F\OSX$P.;;/./?2 M?.<4N!FK4S@/[K$19%L;"?CB!]9&V#M4\XXF>3]-.I9\:R0KQ*PQ63KT;K>/ M)+T;'"#)Q>95WM374@)'\3, QG*YBV/O!,7N@1Q:/RV^K1'H&5+SGU8/JH^+ M@@_V MYFNX\P)>,SDSGQE@GF'/L^_BW=WN2\:%?8'?BMO/(.#:#'H?J=@45'TOA?.W MM)\6[(46"_,Z/Q%:B]HLYXR63*( /)\*H3<7N$'W?6?\+U!+ P04 " !- M@JM6S\,CJQ0$ !*"P &0 'AL+W=O]&K9SFP#2;IN U(TB+,-P[ /M'2VB%"D2E)Q^N][ MI&3%&1PUP/I%)GF\AP_ON3MSL9?J09< ACQ57.BE7QI37P2!SDNHJ#Z7-0BT M;*6JJ,&IV@6Z5D +YU3Q( [#+*@H$_YJX=9NU6HA&\.9@%M%=%-55'VY B[W M2S_R#PMW;%<:NQ"L%C7=P1K,'_6MPEG0HQ2L J&9%$3!=NE?1A=74[O?;?B3 MP5X?C8F]R4;*!SOYO5CZH24$'')C$2C^/,(U<&Z!D,;G#M/OC[2.Q^,#^@=W M=[S+AFJXEOPO5IARZ<]\4L"6-MS29-W]W3#08\6@4%0:PKR#N"J!8A? 4C(1RE,J,G3#,;F6VI!_+C?:*,R$?T]=M,5) M3^/8ZKC0-18KY@83!!3RD934>C1A7=?*H 7 MDA,4+"^M8IY5S,H6>Y]J4-0PL3O&?A>-O _L"5V.%L](DH7XC>:1MRZE,C\9 M4%5K2Q.2>??24$[D*< SDH:)\YV2 0TFO0:3MVKP?(@F%"."K<+V$:3NX@%D M;:B!ZA# [KI2X&Y1. 45E+9U/0*YD5J?TFZ8# ;+*?5-)KE$%83&!1QIR5E! MK56_("B/"/YO<5TI(:B"1Q -6 %2]_'N,,F<@XU"@68N:\N!1-,8[9FWIMAE MG!4C_0!.T"@A4^]7$,B0.Q,ML-$Q6ZBV8^.9*4G"+@^.)!]0/.L5S]ZJ^+JI M:^X"AJ?D5)=DBS%R?"2&66&XV[_ ]M^(NR ;^=_$/*GT((E7JO1[\2%[^ETT MMPQJ^J7-*"9RWA3/.5CA48UR;(^RK2]6SNB&<688TD'ILLQ]HZ&:G?8*3M^J M(,:B4>TAPQQ.231XRBL27;J#^FBY/ZSQVVFXWUA15AB+\1YR MJ#8H?B_.&9E,YG:8DF@\2R([G)!XG(1N-;/#Z;K'+DFR< MS"9=8;7T>H6CR7@>1=X-:'U!6%4W;<=!+["=/!U/YY-19VY=,2?0$PM66_-L M%H^\6QLK3(E'RK%-?#,QLG&;ECB8Q>4W8#VK93F M,+$'],_GU5=02P,$% @ 38*K5@OXM5P!! @@D !D !X;"]W;W)K M&ULQ5;;;N,V$'W75PRTP2(!G,B2K-A.; .Y;-L% M-MT@E_:AZ ,MC2TB%*DEJ3CIUW=(R5YGZQ@H4* /DGB9.7/F1FJR4OK)E(@6 M7BHAS30LK:W/HLCD)5;,G*@:)>TLE*Z8I:E>1J;6R JO5(DHZ?=/HXIQ&%*@L;%-+R(SRX'3MX+_,9Q9;;&X#R9*_7D)I^+:=AWA%!@;AT"H\\S M7J$0#HAH?.LPPXU)I[@]7J/_Y'TG7^;,X)42O_/"EM-P%$*!"]8(>Z=6OV#G M3^;P2-L:KJE(E!Q67[92]='+841OUW%)).(?&\6T.>Y36S M;#;1:@7:21.:&WA7O3:1X](EY=YJVN6D9V=W*)C% FZ9MJ_PH)DTS,?+P.$# MFPLT1Y/(DB$G'N4=Z&4+FKP#FL*-DK8T\$D66+S5CXC@AF6R9GF9[ 6\8?H$ MTK@'23])]^"E&Z]3CY?^6Z_ACR\D"I\M5N;/78ZWN(/=N*Z#SDS-W-VLX:%$N%)5S>3K MQP^C)!Z>&^I"0]5N8*%5!7:[6%;. *TU5G$MSA,\H&X0#&XZ1]!U?*6.>6[O;B%.(!21ID.B^!8,G%9^)7.\MP M>!"G?;_:#JS5?-ZT7A#QZ^8)CR 99O3$P3VC)O7"=*H^H>5RZ0!:_;]0J_?T M^Y FP<\H*=+""[."#AANK(O\,\)@",EXNPR@I("[J"V4H% Z0W,FF,S1;%+O MXOJ?UD5G ?P19_[WU-_XA+FCZ!ISK.:HW60K_1?&$,_@5F/-> 'X4CNGV@0I MLJOI5-?:99EY2QQ\;7N#HB^0[B/0[N(Y5HOCAB9I M[W1$B>T-LS3XZLU))?]A,>[%XZPKL%Y*R+NMMF)>(OC"V9P+[O(77.2Y:ER8 M:O;J-48QE8I;U@UN^3P:@0]O.U/VDO':?T'F1CV'6^1EOW8H5ZZ6]_ YY\>T5N5C<_&!?M MO?I=O/T[H;PO.965P 6I]D^&6=@&?CVQJO:W[%Q9NK/]L*2?)-1.@/87BLJU MFS@#F]^NV=]02P,$% @ 38*K5B"Z9LF@ @ M@8 !D !X;"]W;W)K M&ULK55M;],P$/XKIX 02*-)DW9#(XW4%Q"3&*LV M 1\0']SDDEB+[6 [[4#[\=A.&MJI+4+B2^*S[WGNN;-]CC="WJL24<,#J[B: M>*76]:7OJ[1$1M1 U,C-2BXD(]J8LO!5+9%D#L0J/PR"SL?6WSE\H;A1.V.PF:R$N+?&53;Q BL(*TRU92#FM\8Y5I4E,C)^ M=)Q>']("=\=;]O% M3>M[;B*FC=*"=6!C,\K;/WGHZK #B*(C@+ #A$\ X?@((.H D4NT5>;26A!- MDEB*#4CK;=CLP-7&H4TVE-M=O-/2K%*#T\D"52II[4HJ9]L1& M?:4C1QT=H;Z1!>'T5UO$OLY3GL&,**K@)H>EB60R:%V^?30><*61J>^':MU& M&QV.9B__I:I)BA.OMJQRC5[RXMGP/'A[J"K_B6RO,*.^,*-3[,E<,&;R-4<] MO3^#FDA8DZI!>#R]D[.6]<*QVF:U3H)!$ 3#V%_OIO97MSW1XU[T^*3H3PU; MH;17QC14:7:,%Z"Z _BX/8J'5+>TXQTY3P6?#/RO>^'OM :&LG =4T$J&J[; M+M'/]DUYZGJ1_\>][>CFMA64*Z@P-]!@<&&$RK9+MH86M6LT*Z%-VW+#TCPL M**V#6<^%T%O#!NB?JN0W4$L#!!0 ( $V"JU;_'Z$,_P( .D) 9 M>&PO=V]R:W-H965TAE$ MH@W3]C -E79[F/9@$H=8=6QJ&^C^_8Z=D$*3(BKQ@F_G^W+.=P[''JR%?%0% M(1H]EXRKH5-HO;AV7946I,3J7"P(AY-$B?70Z3F;C3LZ+[39<./! L_)E.B'Q43" MRFU8,EH2KJC@2))\Z(QZU^/(V%N#7Y2LU=8*HYG>:3!K@]W[!_M;%#+#.LR*U@OVFFBZ%SZ:",Y'C)])U8 M?R-U/-;!5#!E?]&ZMO48:C=)4++FF?(XF@M&4$H4^HXWQSQQA=$=2P5/**+89A[U; MK HTXAD<*2UIJDE6[9TF1&/*/@'%PS1!IR>?T FB'-T78JDPS]3 U1"+\4Y"GIGR/?\H -^NQ^>D+2!^QWPY/"O=\''AW^]MPMW(7]- M$OTFB;[E"][@LR*#CI7:XZE0<5LMH6NFT5AD'_8MO6>Q4\$MF.@F&C8+A7P:UF8C3L MTJTBB+84@6O2>R7;(4;)7E?>J]J1R'94BQK5HKVJW0N-F17LK%5ZMA[EKJRF M'>N"(.CI&;P"S*[@"EI_AHV)TC"4%@PWA07D\,3HK.*H7<5!NXK;5F&_7<5M MJ\O^1?2*:]RV"JZN/#]JS"H)W:UKTCR"H(O/*5>(D1R WOD%\,CJ85$MM%C8 MFW,F--S#=EK 6XQ(8P#GN1!ZLS"7&PO=V]R:W-H965TSD MGI-SS[U.[V3/Q;U, 11ZR"B34R=5*C]S71FGD&%YRG-@^LF:BPPKO14;5^8" M<%* ,NH&GC=P,TR8$TV*>PL13?A64<)@(9#<9AD6OR^ \OW4\9W'&[=DDRIS MPXTF.=[ $M1=OA!ZYUJ6A&3 ).$,"5A/G7/_;#8V\47 -P)[65LCD\F*\WNS MN4JFCF<$ 858&0:L+SN8 :6&2,OX57$Z]I4&6%\_LE\6N>M<5EC"C-/O)%'I MU!DY*($UWE)UR_>?H@>"L5SRJP5I 15E[Q0^5##>#W M7@ $%2#X5T!8 <(BT5)9D=8<*QQ-!-\C8:(UFUD4WA1HG0UAIHI+)?13HG$J M6I;50WR-EF3#R)K$F"ET'L=\RQ1A&[3@E,0$)/J(:L'7'#.),$O0)6&8Q2;R M%F(@.[RB@([GH#"A'S3H;CE'QT M4'J#Q2D*_1,4>$'8 I\=AL\AMO"@"7>U9]:XP!H7%'SA"WR50_($?>$*].4O MCORXU@3H2D$F?[8E7[ZMU_XVIS8J.R!K& MA-:8\!"[-4:?\Q_.@,!@'-JBAKV?U]0[J MNR"40H*LS'J-;B!;@6BMST'2U]:G([)&_GV;?_]-&[??I3$=D36,&5AC!ETT M;DG2KS>NY_E/&KY!VM=6J".RA@,CZ\#H35MW MU*4Q'9$UC!E;8\9=M.[XV>=T% Z>=.[SF,#O/?WDNK6!PPQ[^K]Y0W0E**PU MS#L=ZLX7Y0!5;A3/BQEDQ96>:(IEJF=.$"9 /U]S7=!J8\8:.\5&?P!02P,$ M% @ 38*K5A3Y>U21 P ZQ !D !X;"]W;W)K&ULM5C;;N,V$/T50@46+9!&HIS826H;2+()&B &O&ML^[#H R.-+&)Y MT9)4G #]^)*4+'D!AVZ=ZL4F*'N>(M^[X.WP3P1#;>2_4ES4\ZBBPCE4)":F<]R\SNT 9T[O$PR[3_1IMV; M1"BKM9&\-;8,.!7--WEI$[%C,!F_89"V!JGGW3CR+#\20^93)3=(N=T6S0U\ MJ-[:DJ/"GT9'Z_R-'=]YI6]L ,^J*AJ!EZI 6@GS^"(93],HV-I>NI$' !5&G:(1/4)JDHP#>J,O= MR..=O8%W*WE5&U [D7]= '\"]1?Z&RVHH+SFW=*^! 3QW0_R2ETQ"T)YH.H9Y_<>>$'1][ GU%Q:,A MY3-$/<5]0<7!JO=>^83!)X?ET]=/'"YRGVI+SPJA*5'N)6_UJFU6P\H(8AZ; MW+Z:XO&0RABBEN*^F.)@Q7NO,L+@AU]9<%\[<;C /8+M<$K)60NABB6J9]M4R#!>V0+NZTH;;QA+Q7R#/H?7$<\+,JI7*O MHK9Q,R4@YDX9V06.I/(KT'FJ&T_,]6[M=@7,/R):@]D7=[S3?W)0:]]E:^1; MR*85[5:[3OZZZ5_[[4EWP'3-SD7%59Z*PI7[@3@S#I5U/4]+W0K M3)B3Q/9L+9*8UXH2!FN!9%U56/Q: N6'N3-QC@?WI"B5.7"3>(<+V(!ZV*V% MWKD=2D8J8))PA@3DZ&R*I< M88636/ #$L9:HYF%#=5Z:W&$F:)LE-"W1/NI9-,4 _$<;4C!2$Y2S!1:I"FO MF2*L0&M.24I H@O4,[XM,2OT(6'H@0$6##)T#WM@-:#3%2A,Z!DZ,==?2EY+ MS#(9NTH+-K1NVHI;-N+\5\0%Z(XS54KTGF60_>OOZD"[:/UCM$M_%/ .BTL4 M3,Z1[_D!>MBLT.G)V0ANT&4QL+C!*[@KR$&(7@J^+[92"?WD?@Q%W8!-A\%, M&][('4YA[N@^DR#VX"1OWTQ"[]V(U&DG=3J&GBRA((R9PFXQQ2R%(8$-1&@A M3%OOD^OKP(O=_0#QK".>C1(?4R,@Y?JA_7Y>T(:YP9CUF"^"Z30#IDM$:;R'#%00]3A"^HHG X31QUQ-$JLW^U_,AV]R'3D3Z^>L;J]_JY M%':*261;M&GU[K0;E(MF/OPU;Z:L[@!=?XDHY-K5NXQTO**97,U&\9V=%ENN M].RQRU(/>Q#&0-_GG*OCQA!T?Q_)'U!+ P04 " !-@JM6R:Z^Y$T# ": M"@ &0 'AL+W=O7F>ZE>M0%I09^EESHF5<84]WZOLX*6A)](RLJ\,U&JI(8'*JMKRM%2>Y M)?>C(!CY)6'"2Z=N;JG2J:P-9X(N%>BZ+(GZ:TZYW,^\T#M,?&/;PM@)/YU6 M9$M7U#Q42X4COV/)64F%9E* HIN9=Q?>WD]LO OX@]&]/GH&JV0MY:,=_)[/ MO, F1#G-C&4@^+>C]Y1S2X1I_-ER>MTG+?#X^<#^V6E'+6NBZ;WD/UANBIF7 M>)#3#:FY^2;WO]%6S]#R99)K]PO[-C;P(*NUD64+Q@Q*)II_\K.MPQ$ >?H! M40N(G@,&)P!Q"XB=T"8S)VM!#$FG2NY!V6ADLP^N-@Z-:IBP+JZ,PK<,<29= M->Z!W,"*;07;L(P( W=9)FMAF-C"4G*6,:KA&E:XAO*:4QO]B2B!KS4LJ8)5 M012]@CG1+ ,B Q/P()C15SB) MS]\+66M$ZZEO4)I-T,]:&?-&1G1"1@Q?I#"%AD\BI_E3O(\EZ>H2'>HRC\X2 M?B'J!N+P"J(@BGORN;\<'IU))^YLBAU??(+O:UU218Q4MWVU:;"#?JP]!VYU M13(Z\W"C:ZIVU$O?O0E'P<<^8:]$]D3FH),Y.,>>?L5CBTNM@1BCV+HV9(VK MS4C(9%GBIL?MD#T6DN=4]2Z2AGWDV.WYM4NOHW$<)U-_=RRQ)VP01>,NZDGN MPR[WX5F+%E1(W* G31J^IDFO1/9$Z*@3.CIKT@]W-.+F)CM_HR\A\\G71EF/PWGIZ1-;G(U=ZH%Z[Z1]<\7@=;U_UH<#=U<[-U MLUV#=>?ZBF?S&]M65" Z<;I QNQEAFU71"S<#(RC43:VFP M-7&/!3:/5-D ?+^1TAP&]@-=.YK^#5!+ P04 " !-@JM6M;-38!P$ #> M%0 &0 'AL+W=OJ\]\_Y&6A 8:+^2Q-+]H7]HZ%@ISJ7A2.D,$"4N+?_)2 M"G'D #CM#F[IX)XZ^!<A2+\B)K8"6#LX.2PJ/!07W @4//?%4;>'>*=RXZ6^#')4F[D&31[<3 M\(F(.^3AM\AU7*\EGOG/N[L=X7A5BCR#YUW ZTOJ;W\#,/JD:"+_;5.YB,)O MCT(_3NYE1D(ZM>!Y(:G846OV^V]XZ+QKDZ@GL(9@?B68WX7>%$S6@M&&8&%3 M,'H0+ /!S%9\BTBBBZ!-JR* @0E /REW,W\4#%Q_ /ME=ZS#N:$W\AP/C"O# M!L=!Q7'0R1'2G4#@\'P(GQ'/- N)X#$M%4DCX-$6="?BM0GN":Q!?EB1']Y$ M10S[%*PGL(9@HTJPT:^NB-'91G=]/PB"X?BD(EH,,7;&7N"T5\2XXCCNY/B5 M" &O+HD41UDNPBV\W#6EJDS:HNZ$O#;#/8$UV <5^^ F2B+H4[">P!J"8:?N M?)Q?711E!,>;?>PY&!J#DZ+X"<,FRZ/^#G>R7.0KZ-]051W?GFBRHJ(UN=U0 MUV:W+[0F<;I6$W](Q[< M1FGTVG'VA=84K>XY<6>']BJE,3S;\8$S&GG^Z5=%BR'VL'.Y-.I&$7=WBE5I M_%_GU(US=6Y[0FNRKEM'/+Z-@NBUW^P+K2E:W7'BSO[L50HB.&^+?/C*]D_K MX=P.>P/L#D_KP3Z:E"54;,P 42(S["H&1-5J-:1\,*.YD_5'/;PT$[@:IIA\ M/A&Q8? Q'M,U0#IW(XA*%,/$XD3QS,SC5EPIGIC#+241%=H KJ\Y5X<3?8-J MI#O[ 5!+ P04 " !-@JM6V?9[V<<' "E,P &0 'AL+W=OY.A29#KF*3Q(HK(D8?+Y!F+Q=-7S>YL;CWRQU.9&?W2Y8@N8@/YC]2#Q MJE^AS'@"J>(B)1+F5[UK_T,X\$R!_(T_.3RIK=_$F#(5XK.YN)U=]3S3(H@A MT@:"X;\UC"&.#1*VXTL)VJOJ- 6W?V_0/^7&HS%3IF LXK_X3"^O>N<],H,Y MRV+]*)Y^AM*@4X,7B5CE?\E3^:[7(U&FM$C*PMB"A*?%?_:U)&*K0$!?*$#+ M O2U!8*R0+!3@+Y48% 6&.3,%*;D/(1,L]&E%$]$FK<1S?S(R$I^7XI,L72F+OL:&VBJZ4=E8VZ*QM 7&A.0>Y'J MI2(?TQG,FN7[:%AE'=U8=T.M@/=,OB>!?T*H1P/RQR0D/WS[(QGGM(+L:N'X M]8#T58"A'3"$J UHL3RH^C7(<8.7^G5/9_Y]AP7(K89$_=/5407ZH!O=.*,/ M:L4BN.JAMU$@U] ;??>-/_1^ZN+4)5CH"*S!ZJ!B=6!#'UW'Z"=9&@'!T4]F M(IOJ>1:C\\H)[ASQ!> P!S1.>#WR+OOK;7:L51[*CJVZALFGE+B?6-ATZ,#IJ//->&!MG%2UG5EK&;,4UB_F_2 W& I"2@.&38/*E M-')DW#%+C-_H(NF\11)FXA MF8+LC#Q6Q$,CCTNPT!%8@TG?JQ,U[Z@1O81W1*Q3M- 56I/:K1S8?_4PC3 # ME:A&\(?JG)DEUO9$N6C-3'N%!]/CMZ*C_^+<]&EM-GV;V<8O2BNR>19F7ED]5-V MS(/GD],P];[/U:L=?)6E'!Q7::\GZXRYE30>$*K;DV6BL* M:DVK-X-M+UOD(V: D<8L\7>>F->0X0D^47,6;9YC,'J1V3W-T$\0KX$D^=)O MYY*L4ZWA"JU)>JTUJ%UKW"/3">::MMACASC403I%"UVA->FK-0NE1XT]U)'2 M**EUB1:Z0FM26ZL@:E=!]TQ^!DW6+$:?(.9$+R%71"Q]_EZA+DQPAA*E1?2Y MD]B@%73./*^]9F5OQ,&4'4/HT%KH4/M^0.E!.YG:*$KM":U MM7ZA]FV+7S(S(/,E^FV223)M!K _UGW=V]H>S\CV)WA[5?H MS@J8O''?N.]U#<8H6ND)KGHJH-4]@%QO-<2MQW)YLICQJQ\Z3 M$%Z'+O1W9KB]UH./.!Q#H@2U1 GL$F4BYOJ)2<@7%ZN+$+U +/)U1IS]2MM7 MQ^U5''R Q*F$<876I+>6,,%Q)4S@5,(X10M=H36IW3KT9)RZY!/&7PTD MS@_J\!U2]NX2[ $/7ES7']M+'CR8CB%E@EK*!'M./IG#/BF+X^>-[X,M=VAU M?DYEC5.TT!5:D]1:U@3'E36!4UGC%"UTA=:DMI8U@5W67&]OVJ.XV9WWG>JE MQ+1ZLW''2RV_&-I;]U;K:P43V!7,+V@T)G):G0SLZN1!B@A@I@JI?:M4 M5FS[S?/AW'F\V.L\&M1>9;37?/ Q8Z<*I;_U_4("R05/%8EACI#>^S,,@[+X)J2XT&*5?R4Q M%5J+)/^Y!#8#:5[ YW,A].;"5%!]F3/Z'U!+ P04 " !-@JM6*GRXP80% M ""'@ &0 'AL+W=O.7 MZ)_SY$4RCV%&9C3^)UKR]84UML"2K,)MS._I_D]2).3*> L:9_DOV!>VM@46 MVXS3I' 6")(H/?R'/XI"U!R@T^& "@=TK ,N''">Z %9GM95R,/IA-$]8-): M1),'>6UR;Y%-E,K7..=,W(V$'Y_.PFQ] N0O^/1]&^W"F*0\.P'W).,L6G"R M/-R\3)?@)MV)JXDT *=@?GCQ@*[ 0RI&4!S])XROQ"9T8SK4CWX>[F_Y*7=U,4H<$3]=_4D M-&:.#UU8 M>#J KO+P4]=#;@NBQLK'@:]'Z94H/2-*'07H('K*PUWDNQ"W,&K,!,1@K ?I MER!](\AR,B8T)3\%S;)G(:2KK2 :\.V6)(^$::>B,6K?J3A0L$8!QF4!QF_$ M1N,A2S!0L$8)@K($P2^R4:"./6C#-AFI5HZ'O8Y9!.U*KNV!V*@(5$=@MS : M39H :^L).!0=%9&,"$TF3825XD*CFAU-1468UUZTQLSTIBM5A&99G-$D(6P1 MA3&X"S>$&1G('*OO_!LJ6C/S2G"A\T8L!(U2WKL, T5KEJ'2=6@6]M>9"*I2 M#1&$+FP/48T=MJ$#.\9H)>K0K.H]V$A5;&4BJ29=<[T2=&A6]#YLY*OK'EA; M410@-5:.T['$A)7N0J.F'<])8\T;MP.WO8;3V@5>UP()5NH(S?(XHVQ#F4 * M_J)R+_Q(7UL@F8/VGI<#16LV;)4$(_NM6C:CMO?NV0:*UBQ#)?3(+/2O MTQ-2Q1MY>.RW>R*=G>_#L:,?K*C66YN5_GAZ0JJ(0UO!J3$*.C!6,H_,,M^# MH8I(3>[QO3;;Z\S<(.C@*%3),C(WPL=R%%)[7.0&""DX-7:^T*\.TD>5<"*S M<-YNTV@1;<3"Z75F,H?J/24'BM9,O))CY+T5,QEUOG<9!HK6+$,E^L@L^D

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

,"2*['MPYWT4KMY3X?K_E\-G4$L#!!0 ( $V"JU:7BKL

-8?20$3;8T.P6BP^0"X99K>]9!:G+G*CRW(VFG8K[H5Q,O^E>=%" MWO$'&UHF_\31KU2YL+F1==O.])*=-58J82V .T3@#FGA%DU5.S?-<-\I) 'F$0!X17V9NUWNL_61__=/()U[Z[>T>NQ76&9G#3GR"]>(3 M6LQ/7!IVS\M&L"O!;6/:+L?!"SU%)4-L&9\VU%[J+VRNBA#'NMUACWT1#B)B MBID2.V:^,J(+&OLFW9I]53Z!,-8G,>QZR:X@)B:9*;%EKMW:YP\;/8>$9_/$ M]*XVYI@IN62J2KHNEER%#M+Y?$NH7(H>).:8*;%DOG%CVN[FSG]:'E):]G8/ M0$C,,5-BR6P@+R4/"?6[^&%FF1*K9>%T_KA_QCL#5OY(-FP$^3"Y3(GM-LS@^>@1XAI(R+6QF>A M5X;7:YFS"]4=H7^'1>B@A-@8:/[2RZ4CS!@1L3%P3)A-1Y@T(FII8(E6/YJ8 M-B)B;6Q/M-@?=]QSV \0$Q-'1"P.).%J62$F)I&(6")8-N,Y(2;FDHAZI++# M=:^7'6)B>HE^BUZVW8LQYIEX,,\$5(B)R28FELV.L3)C^VQ>%' X&F/6B0>U M#JP[Q&@Q;%#KI! 3LTY,;!T<,X.8F'5B8NO@F <0$[-.3&P='/,08F+6B:F' M+BCF$<3$K!,/6!_['JI-;YB8=>(A*V2]_#+!+)006PC'A/UF@EDHH9Z/03%A MOYE@%DJ(+;2CWNA=&>Y:B(E9*"&VT&[,5NFPS).@DS+$%L*R=1]1B(E9*"&V M$(XYAYB8A1)B"Z&5W-Y(,L$LE PY]MF',Z\)9J&$V$)HG93M0TS,0@FQA;94 M2C=/N=\4=D@I9J&4V$([1Y)=QPDQ,0NEQ!9",?O3Q)B%4NJQ$(H)4X\4LU!* M/19",6'JD6(62JG'0B@F3#U2].4 ZK$0B@F';"EFH91Z++0;\UTY(<4LE!); M"$Z3P ZS["KN$!.S4$ILH=?2UFMZ:<*<;!M5K8+G(29FH?3W5.!ZF*'-P]K> M!&V&62@CMM VS$53UV60.I1EAEDH([;0-LPK[AK3Z1UB8A;*B"WTAOG^X?EE MNBK#+)016P@IP_H(PS=9,LQ"&;&%4,Q>ZI%A%LJ(+81BS@N(B;ZD1FRA[3.H M;_'3?P%02P,$% @ 38*K5LA!-T#(HPS=1Y +Z1 ITA@\%3$D>/E7'X@AGWZ50SONNU/=[?NZ M^#@>3G75[,:Q_Y%27>_*L:UW75].YRN;;CBVXWDY;%/?KM_;;4FZ7.8TW,YH MGI]N9RY>/_OR/Q.[S6:_+C^[]>]C.8W_&)S^=,-[W94R-HO7=MB6<=6DC\/U M=$V7@]R=)S>+E[=5,[R\29/F#E((TOF##()L_B"'()\_*" HY@_*$)3G#[J' MH/OY@QX@Z&'^H$<(>IP_2)8HXY(@:8(U@=:"7 N!UX)@"X'8@F0+@=F": N! MVH)L"X';@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!WCIYV2;06U%O)=!;46\E MT%M1;R706U%O)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;)ILE M!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z.^KM M!'H[ZNT$>OMDLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.] O8- [T"] M@T#O0+V#0.] O8- [T"]@T#OF'RL)- [4.\@T#M0[R#0.U#O(- [4.\@T#NC MWIE [XQZ9P*],^J="?3.J' M2KWV?*WQ^=])]7B^MUP??UE^G9RP<\$YW5;4Y[]02P,$% @ 38*K5N(A M,D+Q 0 &2< !, !;0V]N=&5N=%]4>7!E&ULS=K+3L,P$ 707ZFR M18WK)P_1;H ML. '3#*E49/8LETH?X^3 A((*E"1N)M&K>VY$X]T5CV_>_84 M)]NN[>.\6*7DSQB+U8HZ&TOGJ<\K2QTM)LV3:ZV^>?8N'Y>!&IC,;G8;1RRYH7UOFTJF_(Z>^SK3RG3UX0R MGQSWQ%7CXU'>4+ O$X:5[P->S]T\4@A-39-;&]*U[?(NMFU93,\MQ7)_B2]Z M=,ME4U'MJDV7CY31![)U7!&EKBUW18_V)Z=\P[3[Y ?GCV7V!>:=M\'YF"<6 MZ/=Q;R,93D]]+D0A-?M?\3TQES[X_6B8=DWU#[/S]3ZYL![G$=GX./R./\[X MO?XO^Q @?4B0/A1('QJD#P/2QS%('R<@?9R"],%G*(V@B,I12.4HIG(45#F* MJAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)*%%DE MBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR*A19 M%8JL"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM&D56CR&I09#4HLAH4 M60V*K 9%5H,BJT&1U?RGK/?.K?\X?GR6G6WZMWPV_B-N\0)02P$"% ,4 M" !-@JM6!T%-8H$ "Q $ @ $ 9&]C4')O<',O M87!P+GAM;%!+ 0(4 Q0 ( $V"JU9!=N(H[@ "L" 1 M " :\ !D;V-0&UL M4$L! A0#% @ 38*K5M^93AJ3!@ @28 !@ ("!#0@ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K M5B_9OESC! %1( !@ ("!-!@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ 38*K5MFG%1E&!P =A\ !@ M ("!?"< 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ 38*K5O\+N$0P!@ % \ !D ("!AED M 'AL+W=O&PO=V]R:W-H965T-D !X;"]W;W)K&UL4$L! A0#% @ M38*K5FN1=O]U!@ 6A$ !D ("!:V@ 'AL+W=OP >&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K5F#Q"V*- P O0< !D M ("!3HX 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 38*K5BK:7+B" @ >04 !D ("! I\ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K M5C6=('BH!0 U0X !D ("!&LP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K5JO=;6OQ @ 508 M !D ("!!]H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K5@OXM5P!! @@D !D M ("!/>@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 38*K5O'K6TS4 @ T0H !D ("!@O( 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K5LFN MON1- P F@H !D ("!*/P 'AL+W=O%0 &0 M @(&L_P >&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K5BI\N,&$!0 @AX !D M ("!_0L! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 38*K5G"--$.U"0 $E0 !D ("! M1QL! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 38*K5G]0\T9F @ P04 !D ("!WRL! 'AL+W=O&PO=V]R:W-H965T9 0!X;"]W;W)K&UL4$L! A0#% @ 38*K5K);#B?F! %1@ !D M ("!_T,! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 38*K5H]_;^9S! RQ< !D ("!)%$! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M38*K5H@;<\A> @ N 4 !D ("!%6 ! 'AL+W=O@%?4" "+" &0 @($= M; $ >&PO=V]R:W-H965T&UL4$L! A0#% @ 38*K5HE"C<*%! S10 !D M ("!T'$! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 38*K5J$F-CIY @ ] 4 !D ("!>W\! 'AL M+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " !-@JM6XB$R0O$! 9)P $P @ $5 LC@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 2P!+ (04 WD $ ! end XML 79 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 199 337 1 true 75 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://www.ionq.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.ionq.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Description of Business Sheet http://www.ionq.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 1009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments Sheet http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestments Cash, Cash Equivalents, Restricted Cash And Investments Notes 10 false false R11.htm 1011 - Disclosure - Fair Value Measurements Sheet http://www.ionq.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 1012 - Disclosure - Property And Equipment, Net Sheet http://www.ionq.com/role/PropertyAndEquipmentNet Property And Equipment, Net Notes 12 false false R13.htm 1013 - Disclosure - Agreements With University Of Maryland And Duke University Sheet http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversity Agreements With University Of Maryland And Duke University Notes 13 false false R14.htm 1014 - Disclosure - Other Balance Sheet Accounts Sheet http://www.ionq.com/role/OtherBalanceSheetAccounts Other Balance Sheet Accounts Notes 14 false false R15.htm 1015 - Disclosure - Commitments and Contingencies Sheet http://www.ionq.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Warrant Transaction Agreement Sheet http://www.ionq.com/role/WarrantTransactionAgreement Warrant Transaction Agreement Notes 16 false false R17.htm 1017 - Disclosure - Warrant Liabilities Sheet http://www.ionq.com/role/WarrantLiabilities Warrant Liabilities Notes 17 false false R18.htm 1018 - Disclosure - Stock-Based Compensation Sheet http://www.ionq.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 1019 - Disclosure - Income Taxes Sheet http://www.ionq.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 1020 - Disclosure - Leases Sheet http://www.ionq.com/role/Leases Leases Notes 20 false false R21.htm 1021 - Disclosure - Related Party Transactions Sheet http://www.ionq.com/role/RelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 1022 - Disclosure - Geographic Information Sheet http://www.ionq.com/role/GeographicInformation Geographic Information Notes 22 false false R23.htm 1023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 1025 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments (Tables) Sheet http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsTables Cash, Cash Equivalents, Restricted Cash And Investments (Tables) Tables http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestments 25 false false R26.htm 1026 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.ionq.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.ionq.com/role/FairValueMeasurements 26 false false R27.htm 1027 - Disclosure - Property And Equipment, Net (Tables) Sheet http://www.ionq.com/role/PropertyAndEquipmentNetTables Property And Equipment, Net (Tables) Tables http://www.ionq.com/role/PropertyAndEquipmentNet 27 false false R28.htm 1028 - Disclosure - Other Balance Sheet Accounts (Tables) Sheet http://www.ionq.com/role/OtherBalanceSheetAccountsTables Other Balance Sheet Accounts (Tables) Tables http://www.ionq.com/role/OtherBalanceSheetAccounts 28 false false R29.htm 1029 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.ionq.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.ionq.com/role/StockBasedCompensation 29 false false R30.htm 1030 - Disclosure - Leases (Tables) Sheet http://www.ionq.com/role/LeasesTables Leases (Tables) Tables http://www.ionq.com/role/Leases 30 false false R31.htm 1031 - Disclosure - Related Party Transactions (Tables) Sheet http://www.ionq.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.ionq.com/role/RelatedPartyTransactions 31 false false R32.htm 1032 - Disclosure - Description of Business - Additional Information (Detail) Sheet http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail Description of Business - Additional Information (Detail) Details 32 false false R33.htm 1033 - Disclosure - Summary of Significant Accounting Policies - Summary Of a Reconciliation Of Cash And Restricted Cash (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail Summary of Significant Accounting Policies - Summary Of a Reconciliation Of Cash And Restricted Cash (Detail) Details 33 false false R34.htm 1034 - Disclosure - Summary of Significant Accounting Policies - Summary of Loans and Financing Receivable (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail Summary of Significant Accounting Policies - Summary of Loans and Financing Receivable (Detail) Details 34 false false R35.htm 1035 - Disclosure - Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail) Details 35 false false R36.htm 1036 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Unearned Revenue (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInUnearnedRevenueDetail Summary of Significant Accounting Policies - Summary of Changes in Unearned Revenue (Detail) Details 36 false false R37.htm 1037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Detail) Details 37 false false R38.htm 1038 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Details 38 false false R39.htm 1039 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 39 false false R40.htm 1040 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments (Detail) Sheet http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments (Detail) Details 40 false false R41.htm 1041 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities (Detail) Sheet http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail Cash, Cash Equivalents, Restricted Cash And Investments - Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities (Detail) Details 41 false false R42.htm 1042 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Detail) Sheet http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Detail) Details 42 false false R43.htm 1043 - Disclosure - Fair Value Measurements - Summary of fair value measurements on a recurring basis and the level of inputs (Detail) Sheet http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail Fair Value Measurements - Summary of fair value measurements on a recurring basis and the level of inputs (Detail) Details 43 false false R44.htm 1044 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 44 false false R45.htm 1045 - Disclosure - Property And Equipment, Net - Summary Of Property And Equipment (Detail) Sheet http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail Property And Equipment, Net - Summary Of Property And Equipment (Detail) Details 45 false false R46.htm 1046 - Disclosure - Property And Equipment, Net - Additional Information (Detail) Sheet http://www.ionq.com/role/PropertyAndEquipmentNetAdditionalInformationDetail Property And Equipment, Net - Additional Information (Detail) Details 46 false false R47.htm 1047 - Disclosure - Agreements With University Of Maryland And Duke University - Additional information (Detail) Sheet http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail Agreements With University Of Maryland And Duke University - Additional information (Detail) Details 47 false false R48.htm 1048 - Disclosure - Other Balance Sheet Accounts - Summary of accrued expenses (Detail) Sheet http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail Other Balance Sheet Accounts - Summary of accrued expenses (Detail) Details 48 false false R49.htm 1049 - Disclosure - Warrant Transaction Agreement - Additional Information (Detail) Sheet http://www.ionq.com/role/WarrantTransactionAgreementAdditionalInformationDetail Warrant Transaction Agreement - Additional Information (Detail) Details 49 false false R50.htm 1050 - Disclosure - Warrant Liabilities - Additional Information (Detail) Sheet http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail Warrant Liabilities - Additional Information (Detail) Details 50 false false R51.htm 1051 - Disclosure - Stock-Based Compensation - Summary Of Share Based Payment Award Stock Options Valuation Assumptions (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetail Stock-Based Compensation - Summary Of Share Based Payment Award Stock Options Valuation Assumptions (Detail) Details 51 false false R52.htm 1052 - Disclosure - Stock-Based Compensation - Summary of the Stock Option Activity (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail Stock-Based Compensation - Summary of the Stock Option Activity (Detail) Details 52 false false R53.htm 1053 - Disclosure - Stock-Based Compensation - Summary of stock option grants, vesting and exercises (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationSummaryOfStockOptionGrantsVestingAndExercisesDetail Stock-Based Compensation - Summary of stock option grants, vesting and exercises (Detail) Details 53 false false R54.htm 1054 - Disclosure - Stock-Based Compensation - Summary of restricted stock unit ("RSU") activity (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail Stock-Based Compensation - Summary of restricted stock unit ("RSU") activity (Detail) Details 54 false false R55.htm 1055 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail Stock-Based Compensation - Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock (Detail) Details 55 false false R56.htm 1056 - Disclosure - Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation (Detail) Details 56 false false R57.htm 1057 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 57 false false R58.htm 1058 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 58 false false R59.htm 1059 - Disclosure - Leases - Summary Of Components Of Lease Cost (Detail) Sheet http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail Leases - Summary Of Components Of Lease Cost (Detail) Details 59 false false R60.htm 1060 - Disclosure - Leases - Summary Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss (Detail) Sheet http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail Leases - Summary Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss (Detail) Details 60 false false R61.htm 1061 - Disclosure - Leases - Summary Of Supplemental Cash Flow And Other Information Related To Operating Leases (Detail) Sheet http://www.ionq.com/role/LeasesSummaryOfSupplementalCashFlowAndOtherInformationRelatedToOperatingLeasesDetail Leases - Summary Of Supplemental Cash Flow And Other Information Related To Operating Leases (Detail) Details 61 false false R62.htm 1062 - Disclosure - Leases - Summary Of Maturities Of Operating Lease Liabilities (Detail) Sheet http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail Leases - Summary Of Maturities Of Operating Lease Liabilities (Detail) Details 62 false false R63.htm 1063 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.ionq.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 63 false false R64.htm 1064 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Detail) Sheet http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail Related Party Transactions - Schedule of Related Party Transactions (Detail) Details 64 false false R65.htm 1065 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Parenthetical) (Detail) Sheet http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail Related Party Transactions - Schedule of Related Party Transactions (Parenthetical) (Detail) Details 65 false false R66.htm 1066 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 66 false false R67.htm 1067 - Disclosure - Geographic Information - Additional Information (Detail) Sheet http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail Geographic Information - Additional Information (Detail) Details 67 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d246263d10q.htm 2391 [dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d246263d10q.htm 5627, 5631 [dq-0542-Deprecated-Concept] Concept RelatedPartyCosts in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d246263d10q.htm 5637, 5641 [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d246263d10q.htm 5754, 5758 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - d246263d10q.htm 9, 245 d246263d10q.htm d246263dex311.htm d246263dex312.htm d246263dex321.htm ionq-20230331.xsd ionq-20230331_cal.xml ionq-20230331_def.xml ionq-20230331_lab.xml ionq-20230331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d246263d10q.htm": { "axisCustom": 3, "axisStandard": 25, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 637, "http://xbrl.sec.gov/dei/2022": 33 }, "contextCount": 199, "dts": { "calculationLink": { "local": [ "ionq-20230331_cal.xml" ] }, "definitionLink": { "local": [ "ionq-20230331_def.xml" ] }, "inline": { "local": [ "d246263d10q.htm" ] }, "labelLink": { "local": [ "ionq-20230331_lab.xml" ] }, "presentationLink": { "local": [ "ionq-20230331_pre.xml" ] }, "schema": { "local": [ "ionq-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 553, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 63, "keyStandard": 274, "memberCustom": 29, "memberStandard": 30, "nsprefix": "ionq", "nsuri": "http://www.ionq.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.ionq.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments", "menuCat": "Notes", "order": "10", "role": "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestments", "shortName": "Cash, Cash Equivalents, Restricted Cash And Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://www.ionq.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Property And Equipment, Net", "menuCat": "Notes", "order": "12", "role": "http://www.ionq.com/role/PropertyAndEquipmentNet", "shortName": "Property And Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:AgreementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Agreements With University Of Maryland And Duke University", "menuCat": "Notes", "order": "13", "role": "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversity", "shortName": "Agreements With University Of Maryland And Duke University", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:AgreementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Other Balance Sheet Accounts", "menuCat": "Notes", "order": "14", "role": "http://www.ionq.com/role/OtherBalanceSheetAccounts", "shortName": "Other Balance Sheet Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "15", "role": "http://www.ionq.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:WarrantTransactionAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Warrant Transaction Agreement", "menuCat": "Notes", "order": "16", "role": "http://www.ionq.com/role/WarrantTransactionAgreement", "shortName": "Warrant Transaction Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:WarrantTransactionAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:WarrantLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Warrant Liabilities", "menuCat": "Notes", "order": "17", "role": "http://www.ionq.com/role/WarrantLiabilities", "shortName": "Warrant Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:WarrantLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "18", "role": "http://www.ionq.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "19", "role": "http://www.ionq.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Leases", "menuCat": "Notes", "order": "20", "role": "http://www.ionq.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "21", "role": "http://www.ionq.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:GeographicAreasRevenuesFromExternalCustomersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Geographic Information", "menuCat": "Notes", "order": "22", "role": "http://www.ionq.com/role/GeographicInformation", "shortName": "Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:GeographicAreasRevenuesFromExternalCustomersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:SignificantAccountingPoliciesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:SignificantAccountingPoliciesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:ScheduleOnReconciliationOfCashAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:ScheduleOnReconciliationOfCashAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsTables", "shortName": "Cash, Cash Equivalents, Restricted Cash And Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Fair Value Measurement (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.ionq.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Property And Equipment, Net (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.ionq.com/role/PropertyAndEquipmentNetTables", "shortName": "Property And Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Other Balance Sheet Accounts (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.ionq.com/role/OtherBalanceSheetAccountsTables", "shortName": "Other Balance Sheet Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.ionq.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.ionq.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Related Party Transactions (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.ionq.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Description of Business - Additional Information (Detail)", "menuCat": "Details", "order": "32", "role": "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "shortName": "Description of Business - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "0", "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Summary of Significant Accounting Policies - Summary Of a Reconciliation Of Cash And Restricted Cash (Detail)", "menuCat": "Details", "order": "33", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail", "shortName": "Summary of Significant Accounting Policies - Summary Of a Reconciliation Of Cash And Restricted Cash (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ionq:ScheduleOnReconciliationOfCashAndRestrictedCashTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Summary of Significant Accounting Policies - Summary of Loans and Financing Receivable (Detail)", "menuCat": "Details", "order": "34", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Loans and Financing Receivable (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_BilledAccountsReceivableMemberusgaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ionq:DisclosureOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail)", "menuCat": "Details", "order": "35", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Property Plant And Equipment Useful Life (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ionq:DisclosureOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ionq:SummaryOfChangesInUnearnedRevenueTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Unearned Revenue (Detail)", "menuCat": "Details", "order": "36", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInUnearnedRevenueDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Changes in Unearned Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ionq:SummaryOfChangesInUnearnedRevenueTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Detail)", "menuCat": "Details", "order": "37", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)", "menuCat": "Details", "order": "38", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "menuCat": "Details", "order": "39", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments (Detail)", "menuCat": "Details", "order": "40", "role": "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "shortName": "Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ionq:ScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "ionq:DebtSecuritiesAvailableForSaleContractualMaturityLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities (Detail)", "menuCat": "Details", "order": "41", "role": "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "shortName": "Cash, Cash Equivalents, Restricted Cash And Investments - Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ionq:ScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "ionq:DebtSecuritiesAvailableForSaleContractualMaturityLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Detail)", "menuCat": "Details", "order": "42", "role": "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "shortName": "Cash, Cash Equivalents, Restricted Cash And Investments - Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "ix:continuation", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "ionq:ScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesTableTextBlock", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Fair Value Measurements - Summary of fair value measurements on a recurring basis and the level of inputs (Detail)", "menuCat": "Details", "order": "43", "role": "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail", "shortName": "Fair Value Measurements - Summary of fair value measurements on a recurring basis and the level of inputs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "menuCat": "Details", "order": "44", "role": "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "2", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Property And Equipment, Net - Summary Of Property And Equipment (Detail)", "menuCat": "Details", "order": "45", "role": "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "shortName": "Property And Equipment, Net - Summary Of Property And Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Property And Equipment, Net - Additional Information (Detail)", "menuCat": "Details", "order": "46", "role": "http://www.ionq.com/role/PropertyAndEquipmentNetAdditionalInformationDetail", "shortName": "Property And Equipment, Net - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Agreements With University Of Maryland And Duke University - Additional information (Detail)", "menuCat": "Details", "order": "47", "role": "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "shortName": "Agreements With University Of Maryland And Duke University - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ionq:AgreementDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_OptionAgreementMemberIONQAgreementAxis", "decimals": null, "lang": "en-US", "name": "ionq:AgreementOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Other Balance Sheet Accounts - Summary of accrued expenses (Detail)", "menuCat": "Details", "order": "48", "role": "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail", "shortName": "Other Balance Sheet Accounts - Summary of accrued expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "div", "ionq:WarrantTransactionAgreementTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Warrant Transaction Agreement - Additional Information (Detail)", "menuCat": "Details", "order": "49", "role": "http://www.ionq.com/role/WarrantTransactionAgreementAdditionalInformationDetail", "shortName": "Warrant Transaction Agreement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ionq:WarrantTransactionAgreementTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "ionq:WarrantLiabilitiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "2", "first": true, "lang": null, "name": "ionq:ClassOfWarrantOrRightIssuePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Warrant Liabilities - Additional Information (Detail)", "menuCat": "Details", "order": "50", "role": "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail", "shortName": "Warrant Liabilities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ionq:WarrantLiabilitiesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "2", "first": true, "lang": null, "name": "ionq:ClassOfWarrantOrRightIssuePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Stock-Based Compensation - Summary Of Share Based Payment Award Stock Options Valuation Assumptions (Detail)", "menuCat": "Details", "order": "51", "role": "http://www.ionq.com/role/StockBasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetail", "shortName": "Stock-Based Compensation - Summary Of Share Based Payment Award Stock Options Valuation Assumptions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Stock-Based Compensation - Summary of the Stock Option Activity (Detail)", "menuCat": "Details", "order": "52", "role": "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail", "shortName": "Stock-Based Compensation - Summary of the Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Stock-Based Compensation - Summary of stock option grants, vesting and exercises (Detail)", "menuCat": "Details", "order": "53", "role": "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockOptionGrantsVestingAndExercisesDetail", "shortName": "Stock-Based Compensation - Summary of stock option grants, vesting and exercises (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Stock-Based Compensation - Summary of restricted stock unit (\"RSU\") activity (Detail)", "menuCat": "Details", "order": "54", "role": "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail", "shortName": "Stock-Based Compensation - Summary of restricted stock unit (\"RSU\") activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock (Detail)", "menuCat": "Details", "order": "55", "role": "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail", "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation (Detail)", "menuCat": "Details", "order": "56", "role": "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail", "shortName": "Stock-Based Compensation - Summary of Unrecognized Stock-Based Compensation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "57", "role": "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "0", "lang": null, "name": "us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "58", "role": "http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1059 - Disclosure - Leases - Summary Of Components Of Lease Cost (Detail)", "menuCat": "Details", "order": "59", "role": "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail", "shortName": "Leases - Summary Of Components Of Lease Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1060 - Disclosure - Leases - Summary Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss (Detail)", "menuCat": "Details", "order": "60", "role": "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "shortName": "Leases - Summary Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ionq:DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ionq:DisclosureOfSupplementalCashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1061 - Disclosure - Leases - Summary Of Supplemental Cash Flow And Other Information Related To Operating Leases (Detail)", "menuCat": "Details", "order": "61", "role": "http://www.ionq.com/role/LeasesSummaryOfSupplementalCashFlowAndOtherInformationRelatedToOperatingLeasesDetail", "shortName": "Leases - Summary Of Supplemental Cash Flow And Other Information Related To Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1062 - Disclosure - Leases - Summary Of Maturities Of Operating Lease Liabilities (Detail)", "menuCat": "Details", "order": "62", "role": "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail", "shortName": "Leases - Summary Of Maturities Of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1063 - Disclosure - Leases - Additional Information (Detail)", "menuCat": "Details", "order": "63", "role": "http://www.ionq.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_UMDAndDukeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1064 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Detail)", "menuCat": "Details", "order": "64", "role": "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "shortName": "Related Party Transactions - Schedule of Related Party Transactions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_UMDAndDukeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_DukeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "-3", "first": true, "lang": null, "name": "ionq:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1065 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Parenthetical) (Detail)", "menuCat": "Details", "order": "65", "role": "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail", "shortName": "Related Party Transactions - Schedule of Related Party Transactions (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "PAsOn03_31_2023_DukeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "-3", "first": true, "lang": null, "name": "ionq:PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P09_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:RelatedPartyTransactionTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1066 - Disclosure - Related Party Transactions - Additional Information (Detail)", "menuCat": "Details", "order": "66", "role": "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P09_01_2021To09_30_2021", "decimals": null, "first": true, "lang": "en-US", "name": "ionq:RelatedPartyTransactionTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "div", "ionq:GeographicAreasRevenuesFromExternalCustomersTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_USsrtStatementGeographicalAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1067 - Disclosure - Geographic Information - Additional Information (Detail)", "menuCat": "Details", "order": "67", "role": "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "shortName": "Geographic Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ionq:GeographicAreasRevenuesFromExternalCustomersTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_USsrtStatementGeographicalAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Description of Business", "menuCat": "Notes", "order": "8", "role": "http://www.ionq.com/role/DescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d246263d10q.htm", "contextRef": "P01_01_2023To03_31_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 75, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CommitmentsAndContingencies", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/DescriptionOfBusiness", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementTables", "http://www.ionq.com/role/FairValueMeasurements", "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail", "http://www.ionq.com/role/IncomeTaxes", "http://www.ionq.com/role/RelatedPartyTransactions", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsTables", "http://www.ionq.com/role/StockBasedCompensation", "http://www.ionq.com/role/StockBasedCompensationTables", "http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CommitmentsAndContingencies", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/DescriptionOfBusiness", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementTables", "http://www.ionq.com/role/FairValueMeasurements", "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail", "http://www.ionq.com/role/IncomeTaxes", "http://www.ionq.com/role/RelatedPartyTransactions", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsTables", "http://www.ionq.com/role/StockBasedCompensation", "http://www.ionq.com/role/StockBasedCompensationTables", "http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r627" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ionq.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ionq_AccountingStandardsCodification606Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Codification 606.", "label": "Accounting Standards Codification 606 [Member]", "terseLabel": "ASC 606 [Member]" } } }, "localname": "AccountingStandardsCodification606Member", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_AccruedEquipmentAndServicesLiabilitiesForResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued equipment and services liabilities for research and development current.", "label": "Accrued Equipment And Services Liabilities For Research And Development Current", "terseLabel": "Accrued equipment and services liabilities for research and development" } } }, "localname": "AccruedEquipmentAndServicesLiabilitiesForResearchAndDevelopmentCurrent", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "ionq_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_AgreementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement disclosure.", "label": "Agreement Disclosure [Abstract]" } } }, "localname": "AgreementDisclosureAbstract", "nsuri": "http://www.ionq.com/20230331", "xbrltype": "stringItemType" }, "ionq_AgreementDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement disclosure.", "label": "Agreement Disclosure [Line Items]" } } }, "localname": "AgreementDisclosureLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_AgreementDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement disclosure.", "label": "Agreement Disclosure [Table]" } } }, "localname": "AgreementDisclosureTable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_AgreementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement disclosure.", "label": "Agreement Disclosure [Text Block]", "terseLabel": "Agreements With University Of Maryland And Duke University" } } }, "localname": "AgreementDisclosureTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversity" ], "xbrltype": "textBlockItemType" }, "ionq_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement", "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_AgreementOptionToExtend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement option to extend.", "label": "Agreement Option To Extend", "terseLabel": "Agreement, option to extend" } } }, "localname": "AgreementOptionToExtend", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_AgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement term.", "label": "Agreement Term", "terseLabel": "Agreement term" } } }, "localname": "AgreementTerm", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "ionq_AmendedLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended license agreement.", "label": "Amended License Agreement [Member]", "terseLabel": "Amended License Agreement [Member]" } } }, "localname": "AmendedLicenseAgreementMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_AmendedOptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended option agreement.", "label": "Amended Option Agreement [Member]", "terseLabel": "Amended Option Agreement [Member]" } } }, "localname": "AmendedOptionAgreementMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_BilledAccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Billed accounts receivable [Member].", "label": "Billed Accounts Receivable [Member]", "terseLabel": "Billed Accounts Receivable [Member]" } } }, "localname": "BilledAccountsReceivableMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "domainItemType" }, "ionq_CapitalizedCommissionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capitalized Commissions [Member]" } } }, "localname": "CapitalizedCommissionsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_CapitalizedMaterialsAndSuppliesToPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of capitalized materials and supplies to property and equipment.", "label": "Capitalized Materials And Supplies To Property And Equipment", "terseLabel": "Capitalized materials and supplies" } } }, "localname": "CapitalizedMaterialsAndSuppliesToPropertyAndEquipment", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_CapitalizedStockbasedCompensationIntangiblesAndFixedAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capitalized StockBased Compensation Intangibles And Fixed Assets [Member]", "terseLabel": "Capitalized Stock-based Compensation \u2013 Intangibles And Fixed Assets [Member]" } } }, "localname": "CapitalizedStockbasedCompensationIntangiblesAndFixedAssetsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "ionq_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and money market funds [Member].", "label": "Cash And Money Market Funds [Member]", "verboseLabel": "Cash and money market funds [Member]" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "ionq_ClassOfWarrantOrRightExercisableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Exercisable Description.", "label": "Class Of Warrant Or Right Exercisable Description", "terseLabel": "Public Warrants will become exercisable" } } }, "localname": "ClassOfWarrantOrRightExercisableDescription", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_ClassOfWarrantOrRightIssuePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right Issue Price", "label": "Class Of Warrant Or Right Issue Price", "terseLabel": "Warrant issue price" } } }, "localname": "ClassOfWarrantOrRightIssuePrice", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "ionq_ClassOfWarrantRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant redeemed.", "label": "Class of warrant redeemed" } } }, "localname": "ClassOfWarrantRedeemed", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "ionq_ContractualObligationIncludingPledgeToEstablishEndowedProfessorshipContribution": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual obligation including pledge to establish endowed professorship contribution.", "label": "Contractual Obligation Including Pledge To Establish Endowed Professorship Contribution", "terseLabel": "Contractual obligation including pledge to establish endowed professorship contribution" } } }, "localname": "ContractualObligationIncludingPledgeToEstablishEndowedProfessorshipContribution", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_CorporateNotesAndBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate notes and bonds.", "label": "Corporate Notes And Bonds [Member]", "terseLabel": "Corporate Notes and Bonds [Member]" } } }, "localname": "CorporateNotesAndBondsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "ionq_CurrentPortionOfStockOptionEarlyExerciseLiabilities": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of stock option early exercise liabilities.", "label": "Current Portion Of Stock Option Early Exercise Liabilities", "terseLabel": "Current portion of stock option early exercise liabilities" } } }, "localname": "CurrentPortionOfStockOptionEarlyExerciseLiabilities", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ionq_DebtSecuritiesAvailableForSaleContractualMaturityGreaterThan12Months": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt securities available for sale contractual maturity greater than 12 months.", "label": "Debt Securities Available For Sale Contractual Maturity Greater Than 12 Months", "terseLabel": "1 Year or Greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContractualMaturityGreaterThan12Months", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "ionq_DebtSecuritiesAvailableForSaleContractualMaturityLessThan12Months": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt securities available for sale contractual maturity less than 12 months.", "label": "Debt Securities Available For Sale Contractual Maturity Less than 12 Months", "terseLabel": "1 Year or Less" } } }, "localname": "DebtSecuritiesAvailableForSaleContractualMaturityLessThan12Months", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "ionq_DetailsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Details.", "label": "Details [Axis]", "terseLabel": "Details [Axis]" } } }, "localname": "DetailsAxis", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "ionq_DetailsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Details.", "label": "Details [Domain]", "terseLabel": "Details [Domain]" } } }, "localname": "DetailsDomain", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "ionq_DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of lease costs are reflected in the Statements of Operations and comprehensive loss.", "label": "Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Line Items]" } } }, "localname": "DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "ionq_DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of lease costs are reflected in the statements of operations and comprehensive loss.", "label": "Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Table]" } } }, "localname": "DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossTable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "ionq_DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of lease costs are reflected in the statements of operations and comprehensive loss.", "label": "Disclosure Of Lease Costs Are Reflected In The Statements Of Operations And Comprehensive Loss [Table Text Block]", "terseLabel": "Summary of lease costs are reflected in the Statements of Operations and Comprehensive Loss" } } }, "localname": "DisclosureOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossTableTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ionq_DisclosureOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of property plant and equipment useful life.", "label": "Disclosure Of Property Plant And Equipment Useful Life [Table Text Block]", "verboseLabel": "Summary of Property Plant And Equipment Useful Life" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ionq_DisclosureOfSupplementalCashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of supplemental cash flow and other information related to operating leases.", "label": "Disclosure Of Supplemental Cash Flow And Other Information Related To Operating Leases [Table Text Block]", "terseLabel": "Summary of Supplemental cash flow and other information related to operating leases" } } }, "localname": "DisclosureOfSupplementalCashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ionq_DukeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duke.", "label": "Duke [Member]", "terseLabel": "Duke [Member]" } } }, "localname": "DukeMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "domainItemType" }, "ionq_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for emerging growth company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ionq_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_EventAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Event [Axis]" } } }, "localname": "EventAxis", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "ionq_EventDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Event [Domain]" } } }, "localname": "EventDomain", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "ionq_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value assets and liabilities measured on recurring basis line items.", "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "ionq_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value assets and liabilities measured on recurring basis table.", "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "ionq_FairValueOfTheWarrantShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the warrant shares.", "label": "Fair Value Of The Warrant Shares", "verboseLabel": "Fair value of the warrant shares" } } }, "localname": "FairValueOfTheWarrantShares", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantTransactionAgreementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_GeneralAndAdministrativeExpensesRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "General and administrative expenses related parties.", "label": "General and Administrative Expenses Related Parties", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpensesRelatedParties", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "ionq_GeographicAreasRevenuesFromExternalCustomersTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Geographic areas revenues from external customers.", "label": "Geographic Areas Revenues From External Customers [Text Block]", "terseLabel": "Geographic Information" } } }, "localname": "GeographicAreasRevenuesFromExternalCustomersTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/GeographicInformation" ], "xbrltype": "textBlockItemType" }, "ionq_IncomeTaxDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax disclosure.", "label": "Income Tax Disclosure [Line Items]" } } }, "localname": "IncomeTaxDisclosureLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_IncomeTaxDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax disclosure.", "label": "Income Tax Disclosure [Table]" } } }, "localname": "IncomeTaxDisclosureTable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_InitialPatentsReceivedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial patents received.", "label": "Initial Patents Received [Member]", "terseLabel": "Initial Patents Received [Member]" } } }, "localname": "InitialPatentsReceivedMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_IntangibleAssetPurchasesInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intangible asset purchases in accounts payable and accrued expenses.", "label": "Intangible Asset Purchases In Accounts Payable And Accrued Expenses", "terseLabel": "Intangible asset purchases in accounts payable and accrued expenses" } } }, "localname": "IntangibleAssetPurchasesInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ionq_InternallyDevelopedSoftwareCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Internally Developed Software Costs [Member]", "terseLabel": "Internally Developed Software [Member]" } } }, "localname": "InternallyDevelopedSoftwareCostsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_MachineryEquipmentFurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Machinery equipment furniture and fixtures.", "label": "Machinery Equipment Furniture And Fixtures [Member]", "terseLabel": "Machinery, equipment, furniture, and fixtures" } } }, "localname": "MachineryEquipmentFurnitureAndFixturesMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "domainItemType" }, "ionq_MarketValueOfTheCompanysCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Market value of the company's common stock.", "label": "Market Value Of The Companys Common Stock", "terseLabel": "Market value of the Company's common stock" } } }, "localname": "MarketValueOfTheCompanysCommonStock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_MaterialsAndSuppliesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for materials and supplies.", "label": "Materials And Supplies [Policy Text Block]", "terseLabel": "Materials and Supplies" } } }, "localname": "MaterialsAndSuppliesPolicyTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ionq_NonCashReclassificationOfWarrantLiabilitiesToEquityUponExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash Reclassification Of warrant liabilities to equity upon exercise.", "label": "Non cash Reclassification Of Warrant Liabilities To Equity Upon Exercise", "terseLabel": "Noncash reclassification of warrant liabilities to equity upon exercise" } } }, "localname": "NonCashReclassificationOfWarrantLiabilitiesToEquityUponExercise", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ionq_NonCashResearchAndDevelopmentArrangements": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash research and development arrangements.", "label": "Non Cash Research And Development Arrangements", "terseLabel": "Non-cash\u00a0research and development arrangements" } } }, "localname": "NonCashResearchAndDevelopmentArrangements", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ionq_NonConvertibleDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non convertible debt securities.", "label": "Non Convertible Debt Securities [Member]", "terseLabel": "Non Convertible Debt Securities [Member]" } } }, "localname": "NonConvertibleDebtSecuritiesMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_NumberOfConsecutiveTradingDaysForWhichTheStockPriceIsToBeMaintained": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days for which the stock price is to be maintained.", "label": "Number Of Consecutive Trading Days For Which The Stock Price Is To Be Maintained", "terseLabel": "Number of consecutive trading days for which the stock price is to be maintained" } } }, "localname": "NumberOfConsecutiveTradingDaysForWhichTheStockPriceIsToBeMaintained", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "ionq_NumberOfCustomersOverTenPercentBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of customers over ten percent benchmark.", "label": "Number Of Customers Over Ten Percent Benchmark", "verboseLabel": "Number of customers over ten percent benchmark" } } }, "localname": "NumberOfCustomersOverTenPercentBenchmark", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "ionq_NumberOfTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days.", "label": "Number Of Trading Days", "terseLabel": "Number of trading days" } } }, "localname": "NumberOfTradingDays", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "ionq_OperatingLeaseLiabilitiesRelatedPartiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Liabilities Related Parties Current.", "label": "Operating Lease Liabilities Related Parties Current", "verboseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilitiesRelatedPartiesCurrent", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "ionq_OperatingLeaseLiabilitiesRelatedPartiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Liabilities Related Parties Noncurrent.", "label": "Operating Lease Liabilities Related Parties Noncurrent", "verboseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilitiesRelatedPartiesNoncurrent", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "ionq_OperatingLeaseRightOfUseAssetsRelatedPartiesNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Right Of Use Assets Related Parties Noncurrent.", "label": "Operating Lease Right Of Use Assets Related Parties Noncurrent", "verboseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetsRelatedPartiesNoncurrent", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "ionq_OperatingLeaseRightOfUseAssetsSubjectToLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease right of use assets subject to lease liability.", "label": "Operating Lease Right Of Use Assets Subject To Lease Liability", "terseLabel": "Operating lease\u00a0right-of-use\u00a0assets subject to lease liability" } } }, "localname": "OperatingLeaseRightOfUseAssetsSubjectToLeaseLiability", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ionq_OptionAgreementIndexedToEquitySharesAvailableForIssuanceFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option agreement indexed to equity shares available for issuance fair value.", "label": "Option Agreement Indexed To Equity Shares Available For Issuance Fair Value", "terseLabel": "Option agreement indexed to equity, shares available for issuance, fair value" } } }, "localname": "OptionAgreementIndexedToEquitySharesAvailableForIssuanceFairValue", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_OptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option agreement.", "label": "Option Agreement [Member]", "terseLabel": "Option Agreement [Member]" } } }, "localname": "OptionAgreementMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_OptionAgreementRemainingNumberOfSharesAvailableForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option agreement, remaining number of shares available for issuance.", "label": "Option Agreement, Remaining Number Of Shares Available For Issuance", "terseLabel": "Option agreement, remaining number of shares available for issuance" } } }, "localname": "OptionAgreementRemainingNumberOfSharesAvailableForIssuance", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "ionq_OrganizationBusinessAndBasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Business And Basis Of Presentation [Line Items]", "terseLabel": "Organization Business And Basis Of Presentation [Line Items]" } } }, "localname": "OrganizationBusinessAndBasisOfPresentationLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_OtherAssetsNoncurrentRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Assets Noncurrent Related parties.", "label": "Other Assets Noncurrent Related parties", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrentRelatedParties", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "ionq_PercentOfWarrantSharesWillVestAndBeImmediatelyExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent of warrant Shares will vest and be immediately exercisable", "label": "Percent of warrant Shares will vest and be immediately exercisable", "verboseLabel": "Percent of warrant shares will vest and be immediately exercisable" } } }, "localname": "PercentOfWarrantSharesWillVestAndBeImmediatelyExercisable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantTransactionAgreementAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ionq_PercentageOfDiscountToTheLowerOfClosingPriceOnThatDayOrTheClosingPriceOnTheFirstDayOfTheOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to the lower of closing price on that day or the closing price on the first day of the offering period.", "label": "Percentage Of Discount To The Lower Of Closing Price On That Day Or The Closing Price On The First Day Of The Offering Period", "terseLabel": "Percentage of discount to the lower of closing price on that day or the closing price on the first day of the offering period" } } }, "localname": "PercentageOfDiscountToTheLowerOfClosingPriceOnThatDayOrTheClosingPriceOnTheFirstDayOfTheOfferingPeriod", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ionq_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses And Other Assets Related Parties Current.", "label": "Prepaid Expenses And Other Assets Related Parties Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "ionq_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_QuantumComputerSystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quantum computer systems.", "label": "Quantum Computer Systems [Member]" } } }, "localname": "QuantumComputerSystemsMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_QuantumComputingSystemMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quantum computing system.", "label": "Quantum Computing System [Member]", "terseLabel": "Quantum computing systems [Member]" } } }, "localname": "QuantumComputingSystemMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "domainItemType" }, "ionq_RecentlyAdoptedAccountingStandardsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recently adopted accounting standards.", "label": "Recently Adopted Accounting Standards [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards" } } }, "localname": "RecentlyAdoptedAccountingStandardsPolicyTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ionq_RedemptionPriceOfWarrantsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Price Of Warrants [Axis]" } } }, "localname": "RedemptionPriceOfWarrantsAxis", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_RedemptionPriceOfWarrantsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Price Of Warrants [Domain]" } } }, "localname": "RedemptionPriceOfWarrantsDomain", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_RedemptionPriceOfWarrantsPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price of warrants per unit.", "label": "Redemption Price Of Warrants Per Unit", "terseLabel": "Redemption price of warrants per unit" } } }, "localname": "RedemptionPriceOfWarrantsPerUnit", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "ionq_RedemptionPriceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Price One [Member]", "terseLabel": "Redemption Price One [Member]" } } }, "localname": "RedemptionPriceOneMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_RedemptionPriceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Price Two [Member]", "terseLabel": "Redemption Price Two [Member]" } } }, "localname": "RedemptionPriceTwoMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_RelatedPartyTransactionEstimatedPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party transaction, estimated price.", "label": "Related party transaction, estimated price", "terseLabel": "Related party transaction, estimated price" } } }, "localname": "RelatedPartyTransactionEstimatedPrice", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_RelatedPartyTransactionPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party transaction price.", "label": "Related Party Transaction Price", "terseLabel": "Transaction price" } } }, "localname": "RelatedPartyTransactionPrice", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ionq_RelatedPartyTransactionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party transaction term.", "label": "Related Party Transaction Term", "terseLabel": "Related party transaction, Term" } } }, "localname": "RelatedPartyTransactionTerm", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "ionq_ResearchAndDevelopmentExpensesRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expenses related parties.", "label": "Research and Development Expenses Related Parties", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpensesRelatedParties", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "ionq_SalesAndMarketingExpensesRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales and marketing expenses related parties.", "label": "Sales and Marketing Expenses Related Parties", "terseLabel": "Sales and marketing" } } }, "localname": "SalesAndMarketingExpensesRelatedParties", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "ionq_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities [Table]" } } }, "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_ScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual maturity date of cash cash equivalents restricted cash and investments in available for sale securities.", "label": "Schedule Of Contractual Maturity Date Of Cash Cash Equivalents Restricted Cash And Investments In Available For Sale Securities [Table Text Block]", "terseLabel": "Schedule of Contractual Maturity Date of Cash Cash Equivalents, Restricted Cash and Investments in Available-for-Sale Securities" } } }, "localname": "ScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesTableTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "ionq_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymenTawardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Arrangements By Share Based Paymen tAward [Line Items]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymenTawardLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail" ], "xbrltype": "stringItemType" }, "ionq_ScheduleOnReconciliationOfCashAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule on reconciliation of cash and restricted cash.", "label": "Schedule On Reconciliation Of Cash And Restricted Cash [Table Text Block]", "terseLabel": "Summary Of a Reconciliation Of Cash And Restricted Cash" } } }, "localname": "ScheduleOnReconciliationOfCashAndRestrictedCashTableTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ionq_ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreasePercentageOfFullyDilutedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase percentage.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Cumulative Annual Increase Percentage of Fully Diluted Common Stock", "verboseLabel": "Share based compensation arrangement by share based payment award cumulative annual increase percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreasePercentageOfFullyDilutedCommonStock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ionq_ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreasePercentageOfFullyDilutedSharesOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase percentage of fully diluted shares of common stock outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Cumulative Annual Increase Percentage Of Fully Diluted Shares Of Common Stock Outstanding", "terseLabel": "Share Based Compensation Arrangement, Cumulative Annual Increase Percentage Of fully Diluted Shares Of Common stock outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreasePercentageOfFullyDilutedSharesOfCommonStockOutstanding", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ionq_ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award cumulative annual increase shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Cumulative Annual Increase Shares", "terseLabel": "Share Based Compensation Arrangement, Cumulative Annual Increase,Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCumulativeAnnualIncreaseShares", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "ionq_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expected to vest.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest", "terseLabel": "Aggregate Fair Value (in millions), Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVest", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "monetaryItemType" }, "ionq_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expected to vest outstanding weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Outstanding Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingWeightedAverageGrantDateFairValue", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "decimalItemType" }, "ionq_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpectedToVest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based award equity instruments other than options expected to vest.", "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Expected To Vest", "verboseLabel": "RSUs, Expected to vest after March 31, 2023" } } }, "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpectedToVest", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "ionq_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based award equity instruments other than options expected to vest weighted average remaining contractual term.", "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Expected To Vest Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (Years), Expected to vest" } } }, "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "durationItemType" }, "ionq_ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsOutstandingAggregateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based award equity instruments other than options outstanding aggregate fair value.", "label": "Share Based Compensation By Share Based Award Equity Instruments Other Than Options Outstanding Aggregate Fair Value", "periodEndLabel": "Aggregate Fair Value (in millions), Ending Balance", "periodStartLabel": "Aggregate Fair Value (in millions), Beginning Balance" } } }, "localname": "ShareBasedCompensationByShareBasedAwardEquityInstrumentsOtherThanOptionsOutstandingAggregateFairValue", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "monetaryItemType" }, "ionq_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ionq_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_StockOptionEarlyExerciseLiabilitiesNetOfCurrentPortion": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock option early exercise liabilities net of current portion.", "label": "Stock Option Early Exercise Liabilities Net Of Current Portion", "terseLabel": "Stock option early exercise liabilities, net of current portion" } } }, "localname": "StockOptionEarlyExerciseLiabilitiesNetOfCurrentPortion", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ionq_StockbasedCompensationNetOfAmountsCapitalizedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockBased Compensation, Net Of Amounts Capitalized [Member]", "terseLabel": "Stock-based Compensation, Net Of Amounts Capitalized [Member]" } } }, "localname": "StockbasedCompensationNetOfAmountsCapitalizedMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "ionq_SummaryOfChangesInUnearnedRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of changes in unearned revenue.", "label": "Summary Of Changes In Unearned Revenue [Table Text Block]", "terseLabel": "Summary of Changes in Unearned Revenue" } } }, "localname": "SummaryOfChangesInUnearnedRevenueTableTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ionq_TwoThousandsAndFifteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Equity incentive plan.", "label": "Two Thousands And Fifteen Equity Incentive Plan [Member]", "terseLabel": "2015 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandsAndFifteenEquityIncentivePlanMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_TwoThousandsAndTwentyOneEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Thousands And Twenty One Equity Incentive Plan [Member]", "terseLabel": "2021 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandsAndTwentyOneEquityIncentivePlanMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_UMDAndDukeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMD and Duke.", "label": "U M D And Duke [Member]", "terseLabel": "UMD and Duke [Member]" } } }, "localname": "UMDAndDukeMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "domainItemType" }, "ionq_UMDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U M D.", "label": "U M D [Member]", "terseLabel": "UMD [Member]" } } }, "localname": "UMDMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_UnauditedInterimFinancialInformationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaudited interim financial information [policy text block].", "label": "Unaudited Interim Financial Information [Policy Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "UnauditedInterimFinancialInformationPolicyTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ionq_UnbilledAccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unbilled accounts receivable [Member].", "label": "Unbilled Accounts Receivable [Member]", "terseLabel": "Unbilled Accounts Receivable [Member]" } } }, "localname": "UnbilledAccountsReceivableMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "domainItemType" }, "ionq_UnearnedRevenueAttributableToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unearned revenue attributable to related parties.", "label": "Unearned Revenue Attributable To Related Parties", "verboseLabel": "Unearned revenue" } } }, "localname": "UnearnedRevenueAttributableToRelatedParties", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "ionq_UniversityOfMarylandAndDukeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "University of Maryland and Duke.", "label": "University Of Maryland And Duke [Member]", "terseLabel": "University Of Maryland And Duke [Member]" } } }, "localname": "UniversityOfMarylandAndDukeMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_UniversityOfMarylandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "University of maryland.", "label": "University Of Maryland [Member]", "terseLabel": "University Of Maryland [Member]" } } }, "localname": "UniversityOfMarylandMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ionq_UnvestedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested common stock [Member].", "label": "Unvested Common Stock [Member]", "terseLabel": "Unvested common stock" } } }, "localname": "UnvestedCommonStockMember", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "ionq_WarrantLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liabilities.", "label": "Warrant Liabilities [Abstract]" } } }, "localname": "WarrantLiabilitiesAbstract", "nsuri": "http://www.ionq.com/20230331", "xbrltype": "stringItemType" }, "ionq_WarrantLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liabilities.", "label": "Warrant Liabilities [Text Block]", "terseLabel": "Warrant Liabilities" } } }, "localname": "WarrantLiabilitiesTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilities" ], "xbrltype": "textBlockItemType" }, "ionq_WarrantRedemptionPriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Redemption Price, Description.", "label": "Warrant Redemption Price Description", "terseLabel": "Public warrant for redemption price" } } }, "localname": "WarrantRedemptionPriceDescription", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ionq_WarrantTransactionAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant transaction agreement.", "label": "Warrant Transaction Agreement [Abstract]" } } }, "localname": "WarrantTransactionAgreementAbstract", "nsuri": "http://www.ionq.com/20230331", "xbrltype": "stringItemType" }, "ionq_WarrantTransactionAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant transaction agreement.", "label": "Warrant Transaction Agreement [Text Block]", "verboseLabel": "Warrant Transaction Agreement" } } }, "localname": "WarrantTransactionAgreementTextBlock", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantTransactionAgreement" ], "xbrltype": "textBlockItemType" }, "ionq_WarrantsExpireDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Expire Date.", "label": "Warrants Expire Date", "terseLabel": "Public warrants expire date" } } }, "localname": "WarrantsExpireDate", "nsuri": "http://www.ionq.com/20230331", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r165", "r211", "r218", "r224", "r275", "r391", "r392", "r393", "r401", "r402", "r425", "r428", "r430", "r431", "r478" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r165", "r211", "r218", "r224", "r275", "r391", "r392", "r393", "r401", "r402", "r425", "r428", "r430", "r431", "r478" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r302", "r303", "r304", "r305", "r355", "r518", "r549", "r593", "r594", "r610", "r617", "r625", "r679", "r718", "r719", "r720", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r302", "r303", "r304", "r305", "r355", "r518", "r549", "r593", "r594", "r610", "r617", "r625", "r679", "r718", "r719", "r720", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r302", "r303", "r304", "r305", "r347", "r355", "r382", "r383", "r384", "r494", "r518", "r549", "r593", "r594", "r610", "r617", "r625", "r675", "r679", "r719", "r720", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r302", "r303", "r304", "r305", "r347", "r355", "r382", "r383", "r384", "r494", "r518", "r549", "r593", "r594", "r610", "r617", "r625", "r675", "r679", "r719", "r720", "r721", "r722", "r723" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r256", "r257", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r611", "r624", "r681" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r256", "r257", "r578", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r611", "r624", "r681" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableClassifiedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current and Noncurrent [Abstract]" } } }, "localname": "AccountsNotesAndLoansReceivableClassifiedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r623" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r11", "r130", "r131", "r654" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r259", "r260" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r139", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r79", "r174" ], "calculation": { "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r23", "r24", "r181", "r544", "r557", "r561" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r21", "r24", "r113", "r480", "r552", "r553", "r642", "r643", "r644", "r655", "r656", "r657" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r623" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r391", "r392", "r393", "r655", "r656", "r657", "r709" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r212", "r213", "r214", "r215", "r224", "r261", "r262", "r272", "r273", "r274", "r275", "r276", "r277", "r391", "r392", "r393", "r399", "r400", "r401", "r402", "r411", "r412", "r413", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r457", "r458", "r460", "r461", "r462", "r463", "r475", "r476", "r477", "r478", "r479", "r480", "r521", "r522", "r523", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r102", "r103", "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "auth_ref": [ "r662" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r40", "r66", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r133", "r147", "r177", "r203", "r246", "r249", "r253", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r415", "r419", "r440", "r623", "r677", "r678", "r716" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r169", "r182", "r203", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r415", "r419", "r440", "r623", "r677", "r678", "r716" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r120" ], "calculation": { "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total Assets", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r63", "r263", "r283", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r410", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r106", "r107", "r410", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r44", "r45", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "terseLabel": "Capitalized contract cost amortization expense" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAxis": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Axis]" } } }, "localname": "CapitalizedContractCostAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedContractCostDomain": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.", "label": "Capitalized Contract Cost [Domain]" } } }, "localname": "CapitalizedContractCostDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Net", "terseLabel": "Capitalized contract cost" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r42", "r171", "r596" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.", "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash And Investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r37", "r42", "r47" ], "calculation": { "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r37", "r129" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing transactions:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r178", "r179", "r180", "r203", "r227", "r228", "r230", "r232", "r236", "r237", "r271", "r306", "r309", "r310", "r311", "r315", "r316", "r334", "r335", "r336", "r337", "r339", "r440", "r595", "r634", "r651", "r658" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/CoverPage", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "disclosureGuidance": "Class of warrants, exercise price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Class of warrant or right, exercise price of warrants or rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.ionq.com/role/WarrantTransactionAgreementAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Class of warrant or right, number of securities called by warrants or rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/WarrantTransactionAgreementAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Number of warrants or rights outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r140", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies (see Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r83", "r300", "r301", "r580", "r676" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "definitionGuidance": "Shares reserved for issuances", "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Common stock, capital shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r655", "r656", "r709" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r89" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r623" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock $0.0001 par value; 1,000,000,000 shares authorized; 200,122,686 and 199,862,123 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r25", "r188", "r190", "r196", "r540", "r546" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment and acquired computer software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r55", "r56", "r127", "r128", "r258", "r579" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r55", "r56", "r127", "r128", "r258", "r562", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r55", "r56", "r127", "r128", "r258", "r579", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r144", "r240" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r55", "r56", "r127", "r128", "r258" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage", "verboseLabel": "Revenue From Contract With Customer Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r55", "r56", "r127", "r128", "r258", "r579" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual obligation" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r645", "r646" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of revenue (excluding depreciation and amortization)" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]", "verboseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r134", "r135", "r145", "r207", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r459", "r605", "r606", "r607", "r608", "r609", "r652" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r15", "r207", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r459", "r605", "r606", "r607", "r608", "r609", "r652" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "auth_ref": [ "r665" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "terseLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain": { "auth_ref": [ "r663", "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss": { "auth_ref": [ "r664", "r667" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative unrecognized loss on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r269", "r288", "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "verboseLabel": "12 Months or Longer, Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r269", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "12 Months or Longer, Gross Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r269", "r288", "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Less than 12 Months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r269", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Less than 12 Months, Gross Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r267", "r285", "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Total, Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r268", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "negatedLabel": "Total, Gross Unrealized Loses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": { "auth_ref": [ "r284", "r603" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r266", "r603", "r672" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]" } } }, "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInUnearnedRevenueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Abstract]" } } }, "localname": "DeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInUnearnedRevenueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue, Additions", "terseLabel": "New deferrals, net" } } }, "localname": "DeferredRevenueAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInUnearnedRevenueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r636" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "verboseLabel": "Unearned revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r637" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Unearned revenue, net of current portion" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "negatedLabel": "Revenue recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInUnearnedRevenueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r40", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r40", "r77" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r183" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "positiveLabel": "Warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r115", "r116", "r117", "r118", "r119", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Warrant Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r359", "r387", "r388", "r390", "r394", "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r93", "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of the Stock Option Activity" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r197", "r216", "r217", "r218", "r219", "r220", "r225", "r227", "r230", "r231", "r232", "r234", "r431", "r432", "r541", "r547", "r600" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders - Basic", "verboseLabel": "Net loss per share attributable to common stockholders\u2014basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r197", "r216", "r217", "r218", "r219", "r220", "r227", "r230", "r231", "r232", "r234", "r431", "r432", "r541", "r547", "r600" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders - Diluted", "verboseLabel": "Net loss per share attributable to common stockholders\u2014diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Accrued salaries and other payroll liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensation", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail", "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted- Average Amortization Period (Years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Common stock options outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r89", "r165", "r191", "r192", "r193", "r208", "r209", "r210", "r213", "r221", "r223", "r235", "r275", "r341", "r391", "r392", "r393", "r401", "r402", "r430", "r449", "r450", "r451", "r452", "r453", "r455", "r480", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of equity interests that are issued or issuable in a business combination.", "label": "Equity Interest Type [Axis]", "terseLabel": "Equity Interest Type [Axis]" } } }, "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.", "label": "Equity Interest Issued or Issuable, Type [Domain]", "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]" } } }, "localname": "EquityInterestIssuedOrIssuableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r40", "r85" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r120", "r121", "r122", "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Summary of fair value measurements on a recurring basis and the level of inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementTables", "http://www.ionq.com/role/FairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r120", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementTables", "http://www.ionq.com/role/FairValueMeasurements" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r325", "r348", "r349", "r350", "r351", "r352", "r353", "r435", "r491", "r492", "r493", "r606", "r607", "r612", "r613", "r614" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r434", "r435", "r436", "r437", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r325", "r348", "r353", "r435", "r491", "r612", "r613", "r614" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted\u00a0Prices\u00a0in Active Markets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r325", "r348", "r353", "r435", "r492", "r606", "r607", "r612", "r613", "r614" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable\u00a0Inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r325", "r348", "r349", "r350", "r351", "r352", "r353", "r491", "r492", "r493", "r606", "r607", "r612", "r613", "r614" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r264", "r265", "r278", "r279", "r280", "r281", "r282", "r287", "r289", "r290", "r333", "r338", "r421", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r603", "r668", "r669", "r670", "r731", "r732", "r733", "r734", "r735", "r736", "r737" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Finite lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r294", "r295", "r296", "r297", "r520", "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of capitalized costs incurred in the period to renew or extend the term of a recognized finite-lived (amortizing and amortizable) intangible asset.", "label": "Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend", "terseLabel": "Intangible asset capitalized during period" } } }, "localname": "FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "verboseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographic Areas, Revenues from External Customers [Abstract]" } } }, "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r54", "r579" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r175", "r293", "r537", "r604", "r623", "r673", "r674" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r40", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "verboseLabel": "Impairment of Long-Lived Assets to be Disposed of" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r74", "r81" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncentiveFromLessor": { "auth_ref": [ "r159", "r160", "r161", "r711" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of incentive received by lessee from lessor.", "label": "Incentive from Lessor", "negatedLabel": "Less: lease incentives" } } }, "localname": "IncentiveFromLessor", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r27", "r132", "r141", "r154", "r246", "r248", "r252", "r254", "r542", "r602" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before benefit for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r204", "r396", "r397", "r398", "r403", "r405", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r205", "r222", "r223", "r245", "r395", "r404", "r406", "r548" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Benefit for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r39" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r39" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r39" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r597" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Unearned revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r39" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r39" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r65", "r68" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r143" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r638" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Accrued interest receivable on available-for-sale investments" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalUseSoftwarePolicy": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.", "label": "Internal Use Software, Policy [Policy Text Block]", "terseLabel": "Capitalized Internally Developed Software" } } }, "localname": "InternalUseSoftwarePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r270", "r728" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r473", "r622" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost", "totalLabel": "Total operating lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail", "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Components of lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Operating lease, discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of maturities of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Future minimum lease liability payment due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "verboseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r474" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "verboseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r203", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r416", "r419", "r420", "r440", "r601", "r677", "r716", "r717" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r136", "r149", "r623", "r653", "r671", "r710" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r170", "r203", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r416", "r419", "r420", "r440", "r623", "r677", "r716", "r717" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r172" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r38", "r41" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r41", "r142", "r153", "r168", "r186", "r189", "r193", "r203", "r212", "r216", "r217", "r218", "r219", "r222", "r223", "r229", "r246", "r248", "r252", "r254", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r432", "r440", "r602", "r677" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "verboseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncatastrophicEventAxis": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Axis]" } } }, "localname": "NoncatastrophicEventAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NoncatastrophicEventDomain": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Noncatastrophic event causing change in the insurer's provision.", "label": "Noncatastrophic Event [Domain]" } } }, "localname": "NoncatastrophicEventDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r246", "r248", "r252", "r254", "r602" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r468", "r622" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Fixed lease cost", "verboseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r465" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r465" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r466", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash payments included in the measurement of operating lease liabilities", "verboseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfSupplementalCashFlowAndOtherInformationRelatedToOperatingLeasesDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r464" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r472", "r622" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r471", "r622" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r114" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Accrued expenses\u2014other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/OtherBalanceSheetAccountsSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r176" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r89", "r187", "r190", "r195", "r449", "r454", "r455", "r539", "r545", "r642", "r643" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of reclassification adjustments:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r110", "r111", "r112", "r187", "r190" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r184", "r185" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Change in unrealized gain (loss) on available-for-sale securities, net" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 13.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r34", "r62", "r198" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r35" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Intangible asset acquisition costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r35" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopSoftware": { "auth_ref": [ "r35" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Develop Software", "negatedLabel": "Capitalized software development costs" } } }, "localname": "PaymentsToDevelopSoftware", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r640" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r647" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from Issuance of Debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r62", "r198", "r199" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Maturities and sales of available-for-sale securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r648", "r649" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r36", "r100" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r168", "r186", "r189", "r200", "r203", "r212", "r222", "r223", "r246", "r248", "r252", "r254", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r414", "r417", "r418", "r432", "r440", "r542", "r602", "r619", "r620", "r644", "r677" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r82", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property And Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r78", "r173" ], "calculation": { "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Gross property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r80", "r150", "r543", "r623" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r80", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary Of Property And Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Credit Losses" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyCosts": { "auth_ref": [ "r31", "r308", "r309", "r310", "r314", "r315", "r316", "r654" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.", "label": "Related Party Costs", "verboseLabel": "Cost of revenue" } } }, "localname": "RelatedPartyCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r354", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r131", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transaction, amounts of transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r158", "r483", "r484", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactions", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail", "http://www.ionq.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r354", "r483", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r481", "r482", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r104", "r157", "r724" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "verboseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r635", "r650", "r725", "r727" ], "calculation": { "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAReconciliationOfCashAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Unvested restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r90", "r148", "r556", "r561", "r623" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r165", "r208", "r209", "r210", "r213", "r221", "r223", "r275", "r391", "r392", "r393", "r401", "r402", "r430", "r552", "r554" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r243", "r244", "r247", "r250", "r251", "r255", "r256", "r258", "r345", "r346", "r519" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r30", "r156", "r308", "r309", "r310", "r314", "r315", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromRightsConcentrationRiskMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that license fee or royalty revenues during the period from other parties from use of a specified patent, trademark, or other form of right granted to such parties are to a specified benchmark, such as total license fees, total revenues, segment revenues or product line revenues. May also reflect the percentage contribution the revenue made to operating results. Risk is materially adverse effects of a loss of such revenues, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Revenue from Rights Concentration Risk [Member]" } } }, "localname": "RevenueFromRightsConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r598", "r599" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, remaining performance obligation, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation", "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r680" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Percentage Of Remaining Performance Obligation" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r194", "r203", "r243", "r244", "r247", "r250", "r251", "r255", "r256", "r258", "r271", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r440", "r542", "r677" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r258", "r660" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfLoansAndFinancingReceivableDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Summary of Loans and Financing Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Summary of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/OtherBalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of Unrealized Gains and Losses and Estimated Fair Value of Cash Equivalents and Investments" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of Stock-based Compensation Expenses for Stock Options and Unvested Common Stock" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r49", "r52", "r227", "r228", "r230" ], "lang": { "en-us": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r98", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensation", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail", "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Smmary of Unrecognized Stock-Based Compensation" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyPlantAndEquipmentUsefulLifeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactions", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsDetail", "http://www.ionq.com/role/RelatedPartyTransactionsScheduleOfRelatedPartyTransactionsParentheticalDetail", "http://www.ionq.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Related Party Transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]", "terseLabel": "Summary of stock option grants, vesting and exercises" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]", "verboseLabel": "Summary of restricted stock unit (\"RSU\") activity" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r356", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Share Based Payment Award Stock Options Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": { "auth_ref": [ "r86", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Represents settlement terms for the group of mandatorily redeemable securities, including the description and the details of all terms for each outstanding financial instrument and each settlement option.", "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]" } } }, "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Selling and Marketing Expense [Member]", "verboseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfLeaseCostsAreReflectedInTheStatementsOfOperationsAndComprehensiveLossDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpensesForStockOptionsAndUnvestedCommonStockDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r39" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Share based compensation by share based award vesting term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "RSUs, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "RSUs, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "presentationGuidance": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Option Shares, Ending Balance", "periodStartLabel": "Number of Option Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Term (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Option Shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockOptionGrantsVestingAndExercisesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Option Shares, Cancelled/ Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Option Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average grant date fair value per share for options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockOptionGrantsVestingAndExercisesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic\u00a0Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Option Shares, Ending Balance", "periodStartLabel": "Number of Option Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic\u00a0Value, Exercisable and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Option Shares, Exercisable and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Number of shares issued under share based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfUnrecognizedStockBasedCompensationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Cancelled/ Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in\u00a0years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic\u00a0Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Term, Outstanding", "verboseLabel": "Weighted-average remaining contractual term outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "verboseLabel": "Aggregate grant-date fair value of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationSummaryOfStockOptionGrantsVestingAndExercisesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": { "auth_ref": [ "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur.", "label": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]" } } }, "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r137", "r138", "r146", "r639" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r575", "r576", "r577", "r626" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r469", "r622" ], "calculation": { "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/LeasesSummaryOfComponentsOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r178", "r179", "r180", "r203", "r227", "r228", "r230", "r232", "r236", "r237", "r271", "r306", "r309", "r310", "r311", "r315", "r316", "r334", "r335", "r336", "r337", "r339", "r440", "r595", "r634", "r651", "r658" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/CoverPage", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r19", "r89", "r165", "r191", "r192", "r193", "r208", "r209", "r210", "r213", "r221", "r223", "r235", "r275", "r341", "r391", "r392", "r393", "r401", "r402", "r430", "r449", "r450", "r451", "r452", "r453", "r455", "r480", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CommitmentsAndContingencies", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/DescriptionOfBusiness", "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/IncomeTaxes", "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r208", "r209", "r210", "r235", "r519" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CommitmentsAndContingencies", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/DescriptionOfBusiness", "http://www.ionq.com/role/GeographicInformationAdditionalInformationDetail", "http://www.ionq.com/role/IncomeTaxes", "http://www.ionq.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitRsuActivityDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesTables", "http://www.ionq.com/role/WarrantLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "presentationGuidance": "Issuance of common stock from the settlement of restricted stock units shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Warrants exercised shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Stock issued during the period purchase of assets" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/AgreementsWithUniversityOfMarylandAndDukeUniversityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "verboseLabel": "Vesting of restricted common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r89", "r90", "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Option Shares, Exercised", "verboseLabel": "Stock options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.ionq.com/role/StockBasedCompensationSummaryOfTheStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Warrants exercised" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r4", "r5", "r89", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "verboseLabel": "Vesting of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r19", "r89", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "verboseLabel": "Stock repurchase program, remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased", "verboseLabel": "Stock subject to repurchase related to stock options early exercised and unvested" } } }, "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r61", "r623", "r653", "r671", "r710" ], "calculation": { "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r456", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r456", "r487" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.ionq.com/role/DescriptionOfBusinessAdditionalInformationDetail", "http://www.ionq.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Other Balance Sheet Accounts" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/OtherBalanceSheetAccounts" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r264", "r265", "r333", "r338", "r421", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r668", "r669", "r670", "r731", "r732", "r733", "r734", "r735", "r736", "r737" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r212", "r213", "r214", "r215", "r224", "r261", "r262", "r272", "r273", "r274", "r275", "r276", "r277", "r391", "r392", "r393", "r399", "r400", "r401", "r402", "r411", "r412", "r413", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r457", "r458", "r460", "r461", "r462", "r463", "r475", "r476", "r477", "r478", "r479", "r480", "r521", "r522", "r523", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "US government and agency", "verboseLabel": "US government and agency [Member]" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsScheduleOfContractualMaturityDateOfCashCashEquivalentsRestrictedCashAndInvestmentsInAvailableForSaleSecuritiesDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfDebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueDetail", "http://www.ionq.com/role/CashCashEquivalentsRestrictedCashAndInvestmentsSummaryOfUnrealizedGainsAndLossesAndEstimatedFairValueOfCashEquivalentsAndInvestmentsDetail", "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r57", "r58", "r59", "r238", "r239", "r241", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CoverPage", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Public warrants" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/FairValueMeasurementsSummaryOfFairValueMeasurementsOnARecurringBasisAndTheLevelOfInputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r226", "r232" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders \u2013 Diluted", "verboseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders\u2014diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r225", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders \u2013 Basic", "verboseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders\u2014basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ionq.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.ionq.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareBasicAndDilutedDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123386226&loc=d3e41620-112719", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org/topic&trid=2208923", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r628": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r629": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r631": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r632": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r633": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=118255708&loc=SL5909891-110878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 85 0001193125-23-142049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-142049-xbrl.zip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s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

O.8507Q'B M$"5PTF*I(IJTJ6[VW;PWI"BY$YEE16R',&YTLR,=JKE0/!Q6EB.IZ)AT+K0V M3 $#>-WCZ4,I\T&@1""4"&<46^KZ&H[)Z("DONG2QK+*]+"/$ NG_L@O/>') M;7'P09%3=<.12<\GQW6[$[J+[6R, 41:"DZM]= /!AD!#W@(7G6B.HE^1S9Y MO/@920F7AYI-*-]Y>7#+-O<$2N0I CW-Q9_WY]) \3G_,CVC:$+[]S9S7YS; M@?-K\Z.I-*8L)LWY58110W_7!@H F? A4>___UGN^.;6[?> X8=^1GJ;$J[1%Z MXY]-D0&?<8U,5GA[C!B!_K/[H @9"&<$8M6'2(ANSD<_FX%T\#WPQI\X ZE8 M#G3 ;DKA[6Q8"(0>O?^*M>/ MM)OBOW "EPK7J95UY650%#A.N4U[;U)R[H)FCT&!#8HNL=AF.9$I@]J7 ML>=C_4TVE"M&:JCR1BM +"2$I] MJ=P@Q2(+$J]V[25SL'QC%]$B&XHI5141XH5'-&,E/\PN[%-+_X[K^_^>+BDS\:AIG^/XHP09_%5B5% M+8:-]0=6)\J>J0CWL&MO-^VM2>Q.WI,.)J_+ ^]E>\7.8ZOGQ(BYH -4:-PV ML4!23-E5K7(CHP!3/J:RR*L?CA2/EQ<_O>(YZPIC#=>"T!9TRME;UNO.W7G= M9W,@R+Q,'3B['1$6]7 V6FDP7NN#Z%>S-AN6M:FZJY/= ?<&4],OLR.5*A[) MZ!Q!&9D@RGH8]#G>GS9"*Q,?CA"XI!_>UH-\]NGJ2_M[7^Y$9PJBO/*A/D6P MH\;DF.?BW,[9F% T9W0);>'1>OI<1H/48F*HYFH0R@9 7E?I*?IL8)_>_U5U MXOE)@AN+@..XW*A;ZWO9W@UP$C,QOWM+:YBJ%P<_ M4Y^DZL8;0:;[-RJRF[0YSWAEL@2T_\/RMA'BX]46*<"9]HI-I.40,A C9"#V M6;A41?Q%7 &CLV2LX_F!ULT_6>KF'Y;F;N8).)+0 MK)\WM;L^#-G95+LHF(,'R\(HRYZRB;E0LEN7+.U()R]GD+34VM",GI:_(4WA M(K&-K#E!W@9K\G< M:_4R5=V%*,%V+Z/CX'!G>H"46Q:2LISTL8S-A-$-Y9H<"E>4A,]!BMKBIX_T M*-^2Q7.F*BO_JCK)45O;"B?6E)I=Y' XXKTHWKIFE?8;S1;)B3$)J!^U$I/8 MX9JI8#1'IKLY=ODJC\"X'N6M9A3)Y65R-Y;1L]Q!2-A9]N92A:=#L!?EY#3? M3$Q$#AS<38+$0L8%K'C8&?+I5"19+Y,L1.QSRH>>)5-Y#_/3KP,3 MV#H=1V'0)(%A!XJ=MEOM2&/66':#_=HI=$"BG>Q1X"B ]L_9(EZ0?91* M0)"8J'4Y77XN#*5BT4-:)1Z,9X842HFONHSE/;>-G\_&H]==Z^:N /JQJF6H M+Z?Z\IXYH!MDECU(U)1&KC MJ%%^873;].E[K0SP&Q0^"SIV;7):/H.9%"5-MI]% (L.JLN@V)[1/"C[2454 M<,Z%.+KD.E5?IP:$'I9Z^>+\GDIEMUPY2^]/PTQ?"OYT,SKME'H_N\%"G]6O MGFPZH/_>+L:5OD* SMC,1,6]<+G.((->+IKM54T-!>!OXNVC(&17&MB[H<8K M2\$=?H-UTTE.,7!HO$%53!\'B.!)XVOLHZ17\AYZZN=AY*= #ZQGIE&X7-$V MON(=[-K8&@[YOQC&];H^V Z/:,.LC,@=+U&GG*8ED7P ?4:D-(_EN?^F(#0* M",EU;2P31OA+A WZL/0CIC[404V98VKG7C-[,W$OFV&=3;[RZZBKZI7 ML6T]"N)".#T/J--( C_H'T99#=V>5')W'1+K_F!/@%,HWAV1H3C;GF"IH_;"P@^?F2FYLUT!PI[^&2'RUR3+198]]G[-+)\[<)0B3R?*;FP36EGSJD M'-7\- =#8G+&BN%&2FF!ZL<%<,[]N -G)"D;D,-(JM'3<(1>[G-Z4[3E5T^4 M(PH$3%\_?_Z]L^;%CGJYOJZK&UW;0%3J54Q-76;OW->&[O,XI3\MK+D,5:'4 MNM5!2OV6CE!BBGO6XJVSRFO;L##P7K(?J5Q'_? M):-^^\/SUXTY/E<\LF0V,GZQJ1C0CV,-7J:8B:(J?LZ-)NEU7(*QWKQC#?IC MS_NEMLDBF1U+8_.(W[-+O0>]3*XPR%D(RB(=$&BYQ%$YZDKB$W=C<^Z (G$Z M:S>:%W[3=V6E9Q77@W!U6=(J\C[Q.GU-!Q[M)VQPV=03?B]Y%T9[-K=\?'X$ M$"O>-EY=SC.E$]WK2I\AF^#+K^T-4=FK 8#'UVN$SU=6B1'HM*)_)^_2;VH; MU.1S-00(^=4KWT8.8#*_T^G8XU"^LKB&?]S^EAUB$:&453^5RLAP@+-+ILQ4 MO2%)Z1'TI+;#.W=3&&#SPX')+,^=#--L3-!(M]'8/$\1N*-L%UWBO&_$!:FK M_D]CW[*PIB^LZ?>SIE/*##H[?+\N/4N_/-++:GKC:]F=C";0M8V9LJ90V0P; MA>)P+D"_\FGA\"&M/C)%7H2Q%ED%4JS[LNRZVN>]>3<9 Y]#9PTJES<9F1.M.M52^HG\P#GYPQ@-(KG\B" O2O#XURP4NI[ZC4U6A1\ M!?DNL'AL8C5YVYXCODT_A]C%?W.1)%IVPL,(&#>)L55"@FU7[BL01 MVX!TO*Q,2&.Q2L^N)A"/-%\9OB/Q>)UZ[9+: M>-N6!PH[YL%OAY)+J4@SM#T?!#^T&9ZZCXLM+[;\(+:<19=DQ4AB@6#3L\TZ M,ZT!;+4YM%C@8H&_JKA>-A 0H%4*L$.D[;'D>#&SQ

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end